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Summary 
 
Cystic fibrosis (CF) is a fatal genetic disease that affects 1/2500 people in the UK.  Mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) cause dehydration of 
mucosal membranes, leading to mucus obstruction of the small airways.  The CF lungs are 
susceptible to recurrent infection promoting chronic neutrophilic inflammation.  Neutrophils 
recruited to the CF lungs become dysfunctional and are ineffective at clearing pathogens, 
perpetuating inflammation.  Neutrophil serine proteases (NSPs) released by neutrophils 
collaterally remodel the airway, reducing lung function and causing mortality. 
 
The complement anaphylatoxins (C5a and C3a) are important mediators of inflammation. C5a 
and C3a are chemotactic for monocytes and granulocytes, they also stimulate degranulation 
and the generation of reactive oxygen species (ROS).  C5a is particularly potent towards 
neutrophils and is critical for orchestrating their response towards pathogens. C5a and C3a 
are elevated in the CF airway.  Furthermore, in addition to complement activation these 
anaphylatoxins can be generated by non-complement proteases including NSPs.  The 
mechanisms by which C5a and C3a promote chronic neutrophilic inflammation in the CF 
airways are not fully understood. 
 
In my study I show that C5a and C3a correlate with markers of neutrophilic inflammation 
(neutrophil count and CXCL8) in bronchoalveolar lavage (BAL) fluid from paediatric CF 
patients.  I further characterise the generation of functionally active C5a-like and C3a-like 
forms by NSPs. Moreover, I demonstrate that atypical C5a production by NSPs cannot be 
prevented by therapeutic complement inhibitors.  I show for the first time that NSP-generated 
C5a-like fragments are resistant to inactivation by carboxypeptidase B, an important regulator 
of C5a activity. 
 
I also further characterise the interaction between C5a and soluble glycosaminoglycans 
(GAGs), these are abundant during chronic neutrophilic inflammation of the CF airway.  
Additionally, I show that GAG interaction influences C5a activity.  In conclusion, the CF airway 
environment modifies C5a function; these mechanisms could promote chronic neutrophilic 
inflammation.
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                                                                                                       Airway hydration in the normal 
airway (left) compared to the CF airway (right). Adapted from Haq et al. 2016 (Haq et al. 2016).  Loss 
of CFTR or reduced activity reduces airway surface liquid volume and accumulation of thick mucus.  
CFTR-inhibition of ENaC is also reduced leading to unregulated absorption of sodium.     
 
 
 
1. Introduction 
 
 Clinical description of CF 
 
CF is the most prevalent fatal genetic disease in Europe and the USA, affecting 1/2500 births 
in the United Kingdom (UK).  CF patients have poor quality of life and despite improved 
disease management, the median age of mortality is 31 years (UK CF registry 2016).  Multiple 
therapeutic avenues are being explored to increase life expectancy yet, we lack understanding 
of the precise mechanisms of how the disease manifests, particularly in the airway.  A 
consequence of the gap in our knowledge is that new therapeutics in CF only marginally 
improve patient health (Elborn 2016).  In this review I will discuss driving factors behind 
neutrophilic inflammation in the CF airway and the rationale behind investigating the role of 
the complement anaphylatoxins in promoting CF pathogenesis.  
 
CF is a recessive autosomal disorder caused by mutation of the CFTR, a chloride channel 
essential for maintaining hydration of mucosal membranes throughout the body (figure 1-1) 
(Haq et al. 2016). 
 
 
Figure 1-1: Diagram of hydration in normal and CF airways.  
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Water homeostasis by epithelial cells is regulated at the apical membrane by absorption of 
Na+ by epithelial Na+ channels (ENaCs) and secretion of Cl- by CFTR (Haq et al. 2016). To 
hydrate mucosal surfaces, Cl- is pumped out of epithelial cells and Na+ is pumped in, 
facilitating the movement of water through gap junctions in the epithelium (Haq et al. 2016).  
As well as a functioning as a Cl- channel, CFTR also regulates ENaCs via an intracellular 
feedback loop (Haq et al. 2016).  Along mucosal membranes of CF patients, reduced Cl- 
secretion by CFTR induces Na+ resorption from the mucosal layer by ENaCs and 
subsequently Na+ secretion across the basolateral membrane (Donaldson and Boucher 
2007).  Consequently, water is drawn from the mucosal layer through cell gap junctions 
causing dehydration of the mucosal surface (Donaldson and Boucher 2007).  Expression of 
Ca2+ activated Cl- channels (CaCC) on the apical surface of epithelial cells, enables CF 
patients, with reduced CFTR activity, to maintain a level of hydration that enables people 
without CFTR-mediated Cl- activity to survive (Donaldson and Boucher 2007).  In support of 
the necessity of CaCC for survival in CF patients, it was shown that there was greater disease 
pathology in mice with genetically reduced CaCC expression (Clarke et al. 1994). 
 
Since 2007, all new-born babies in the UK are genetically screened for CF by heel prick test 
(UK CF registry 2016).  Positive cases from the heel prick test undergo further confirmation 
by a sweat test whereby conductivity of sweat is measured.  Those with defective CFTR have 
a high NaCl concentration due to the inability to resorb Cl- in sweat glands.  The clinical 
threshold for normal sodium concentration in sweat is 30 mM; subjects with >30 mM sodium 
are likely to have CF and those above 60 mM are positive for the disease (LeGrys et al. 2007).  
The cftr alleles for each suspected positive case are sequenced and compared with over 1000 
cftr genotypes that have been genetically characterised (Sosnay et al. 2013).  The phenotypes 
of these mutations have been categorised into six classes, with the severity of CF disease 
being dependent on which alleles a patient has; the different categories have been listed in 
table 1-1 (Elborn 2016). 
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Table 1-1: Cftr mutation classes I-VI and diagrams describing phenotypes                                                                                                                        , adapted from Elborn 2016 (Elborn 2016).    
Molecular impact of each mutation class and effect on CFTR function or expression.  Example of genotypes for each class and 
percentage prevalence of the most common (red) alleles in the UK for each class.  Disease severity decreases from class I (high) 
to class VI (low).  Sweat chloride range for each class set by the UK CF registry (Fogarty et al. 2012) 
14 
 
 
The most common cftr genotype is ∆F508Del; 90.9% people diagnosed carry at least one 
∆F508Del allele and 50.2% are homozygous (UK CF registry 2016). The F508Del allele is 
lacking a phenylalanine at amino acid position 508 of 1480 (of the wild type allele) and causes 
a missense translation of the CFTR.  The phenotype of the ∆F508Del mutation is a misfolded 
CFTR that is targeting for degradation in the endoplasmic reticulum (ER) and, is therefore not 
expressed on the apical membrane of the epithelium (Jensen et al. 1995).  This means that 
the majority of patients have a cftr phenotype that is indicative of severe disease, accounting 
for the low median age of death (figure 1-2).  Consequently, due to the severity of disease in 
these cases, CF is predominantly a paediatric disease; however, patients diagnosed with less 
severe disease alleles live into their 60s or older (figure 1-2)(UK CF registry 2016).    
 
There is no difference in allele distribution between males and females yet, the median 
predicted life expectancy of females is significantly lower (UK CF registry 2016).  For example, 
males and females with CF registered in the UK between 2012-2016 have a median predicted 
survival age of 47.9 and 44.2 years respectively.  This difference in life expectancy has been 
attributed to elevated oestradiol (oestrogen steroid hormone) in women that correlates with 
the presence of biofilm forming strains of Pseudomonas aeruginosa (P. aeruginosa), a 
bacterial pathogen that causes  pulmonary exacerbation in CF patients (Chotirmall et al. 
2012). 
 
 
Figure 1-2:  UK CF population by age                                                             , adapted from UK CF registry 2016.  Proportion of both sexes 
(yellow), females (purple) and males (grey) with CF.  The median age of mortality has been annotated 
by a red dashed line (n=9695).  
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The CFTR is expressed on epithelia throughout the body and therefore the disease affects 
multiple organs (figure 1-3) (Xue et al. 2016).  Expression of CFTR is not limited to epithelial 
tissue and has been demonstrated on immune cells such as monocytes, macrophages, 
alveolar macrophages and neutrophils (Yoshimura et al. 1991).  Due to expression throughout 
epithelial tissues, CF patients can suffer multiple complications including in the gastrointestinal 
(GI) tract.  At birth blockage of the intestines can prevent passage of meconium, known as 
meconium ileus (Xue et al. 2016).   Dehydration and obstruction of the pancreatic and bile 
ducts can also lead to malnutrition, reducing development and causing osteoporosis.  
Consequently, body mass index (BMI) is routinely used as a measure of disease progression 
(Kerem et al. 2014).  In severe cases, reduced function in the pancreas caused by insufficient 
hydration and mucus blockage and consequent insulin deficiency that can induce CF-related 
diabetes (Frost et al. 2018). 
  
 
Figure 1-3: Diagram of different organs where CF pathology manifests 
 
The reproductive organs are also affected by dehydration of mucosal surfaces, causing 
sterility in men and infertility in women (Ahmad et al. 2013).  Despite system-wide 
complications, airway disease in CF is the primary cause of morbidity and mortality, this is due 
                                                                                                                                              
CFTR dysfunction in several organs can lead to well-characterised pathologies in CF patients. 
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to continual exposure of the airway to the external environment. Therefore, reduced lung 
function is the predominant cause of morbidity and mortality in CF patients (Elborn 2016).  In 
the remainder of the introduction I will focus on CF in the airway and the driving forces behind 
pathogenesis. 
 
 Pathogens in the CF airway 
 
The lungs are constantly being exposed to the external environment by inhalation of debris 
and pathogens.  Mucociliary clearance is critical for removing foreign material, keeping the 
airway clear and preventing infection.  In CF, dehydration and depleted airway surface liquid 
volume reduces mucociliary clearance, causing accumulation of viscous mucus that obstructs 
the small airways and harbours pathogens (Hoegger et al. 2014).  Opportunistic bacterial and 
fungal pathogens that would normally be cleared in healthy lungs, establish chronic infection 
in the CF airway and cause pulmonary exacerbations.  Pathogens that have been identified 
in CF airway during pulmonary exacerbation are listed in (table 1-2).  CF Patients are 
frequently hospitalised and intravenous antibiotics are administered to fight the infection.  The 
frequency of hospitalisation increases with patient age, furthermore chronic infection and the 
consequent inflammation can irreversibly remodel the CF airway, reducing lung function that 
eventually leads to mortality (UK CF registry 2016).  
 
Pathogens in the CF airway 
 
  
Bacterial (Gram positive) Bacterial (Gram negative) Fungal Viral 
Staphylococcus aureus  
(inc. methicillin resistant) 
Pseudomonas 
aeruginosa 
Aspergillus 
fumigatus 
Influenza 
Mycobacterium spp.  
(nontuberculous) 
Burkholderia 
cenocepacia complex 
Candida 
albicans 
Adenovirus 
 Stenotrophomonas 
maltophilia 
E. dermatiditis Rhinovirus 
 Achromobacter spp.  Metapneumovirus 
 Haemophilus influenzae   Picornavirus 
Table 1-2: Diversity of pathogens associated with pulmonary infection in the CF airway. 
 
 
Identifying pathogenic microbes is critical for monitoring and preventing pulmonary 
exacerbation by administering the most effective antimicrobial, whilst maintaining a healthy 
lung flora (Chmiel et al. 2013).  Early antibiotic intervention reduces the risk of permanent lung 
function loss and mortality; however, prophylactic administration of antibiotics is controversial, 
with some reports suggesting antibiotic prophylaxis can cause proliferation of bacterial strains 
                                                                                                                                              
Pathogens that have been identified during pulmonary exacerbation in CF patients.  Pathogens in bold 
are reported to be opportunistic pathogens in the CF airway (de Vrankrijker et al. 2010). 
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associated with infection, such as P. aeruginosa (Chmiel et al. 2013; Smyth and Walters 
2014).  This is because some strains of P. aeruginosa can form biofilms protecting them from 
erdication by antibiotics (Parkins and Floto 2015).      
 
Identification of bacterial pathogens has been dramatically improved by sensitive and 
quantitative molecular analysis, such as sequencing 16S rRNA.  A longitudinal study by Stokell 
et al. measured bacterial diversity in CF sputum.  They observed that pulmonary exacerbation 
onset by P. aeruginosa and B. cenocepacia reduced bacterial diversity, suggesting that there 
was proliferation of single strains (Stokell et al. 2015).  P. aeruginosa, B. cenocepacia and S. 
aureus are the most prevalent exacerbating pathogens in CF and correlate with the decline in 
lung function (Parkins and Floto 2015).  In particular, biofilm forming strains of P. aeruginosa 
are notoriously difficult to eradicate and can cause multiple hospitalisations annually in 
individual patients (Parkins and Floto 2015).  Biofilms are an extracellular matrix of 
carbohydrates, protein and DNA that prevent immune cells and their antimicrobial agents from 
reaching the pathogens.  
 
P. aeruginosa can colonise the airways within the first three years of life; however, only 6.4% 
of the UK CF population below 16 years old have chronic infections (UK CF registry 2016).  
The UK CF registry has reported that during adolescence P. aeruginosa infection rates 
dramatically increase (figure 1-4),  with 54.6% of 32 to 35-year olds having a chronic P. 
aeruginosa infection (UK CF registry 2016). 
 
 
Figure 1-4 Bacterial infections in the UK CF population                                                                                         , extracted from UK CF registry 2016.  
Percentage of the UK CF population that had at least one positive pathogen identification in 12 months. 
MRSA – methicillin resistant staphylococcus aureus, NTM – non-tuberculous mycobacteria (n=9695.) 
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Successful colonisation by P. aeruginosa is due to a large genome that possesses survival 
genes enabling host immune evasion (Stover et al. 2000).  It has been hypothesised that P. 
aeruginosa is prolific in the CF airway because of the absence of CFTR in neutrophil 
phagosomes, reducing myeloperoxidase-mediated killing (Painter et al. 2006).  As well as the 
secretion of proteases, haemolysins and exotoxins, P aeruginosa can switch to less motile 
and more mucoid strains in the CF airway preventing eradication by antibiotics (Smith et al. 
2017).  In evidence, 44% of paediatric CF patients (< 5 years) in Australia and New Zealand 
reacquired P. aeruginosa within a median follow-up time of 2.8 years (Kidd et al. 2015).  
Therefore, several anti-pseudomonal therapies are being developed to target biofilm formation 
and are currently undergoing clinical trials (Kidd et al. 2015).      
 
Notably, antibiotics such as tobramycin and ceftazidime that are effective at targeting P. 
aeruginosa have also been reported to enable proliferation of anaerobic Streptococci spp. 
(Tunney et al. 2011).  Although anaerobic bacteria have been found to be pathogenic in other 
lung diseases, such as non-CF bronchiectasis, it is unclear whether their presence is 
detrimental in CF (Tunney et al. 2011).   
 
Pathogen identification in the CF airway can also vary depending on the airway sampling 
technique.  There are three methods for sampling airway fluid for pathogen screening; cough 
swabs, induced sputum and BAL fluid.  Cough swabs are cotton swabs placed in, but not 
touching, the posterior pharynx whilst the patient is encouraged to cough.  Induced sputum is 
performed by inhalation of hypertonic saline and physiotherapy to encourage the production 
of mucus that can be used for analysis.  Finally, BAL is an invasive procedure that requires 
sedation of the patient.  A flexible bronchoscope is inserted into the infected portion of the 
airway (determined by computerised tomography (CT)) and saline is instilled then sucked back 
up for analysis.  These airway sampling procedures and their advantages and disadvantages 
will be discussed in the background to chapter 3.     
 
Fungal pathogens have been isolated from the CF airway during pulmonary exacerbation, yet 
it is not clear whether a particular species, at one time, is responsible for driving pathogenesis 
or whether it is just present (Middleton et al. 2013).  For example, in one clinic, a study of 
Aspergillus fumigatus (A. fumigatus) reported that Candida albicans (C. albicans) and 
bacterial pathogen P. aeruginosa, were also isolated from the same sputum samples (50.5 
and 64.2 % respectively) (Bakare et al. 2003).  C. albicans and A. fumigatus have both been 
shown to co-colonise CF the airway with P. aeruginosa; however, it was unclear whether the 
presence of fungi was a pathogenic factor or a consequence of advancing disease (Chotirmall 
and McElvaney 2014).  If misdiagnosed (e.g. mistaken for S. aureus in a chest X-ray) A. 
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fumigatus can colonise the lungs causing allergic bronchopulmonary aspergillosis (ABPA), a 
hyper-responsiveness to Aspergillus spp. allergens (Chotirmall and McElvaney 2014).  ABPA, 
typically induces wheezing and pulmonary exacerbation, chronic infection can cause 
bronchiectasis, lung fibrosis and mortality through respiratory failure.   
 
A. fumigatus produces small spores called conidia that are ubiquitous in the environment.  In 
healthy lungs these do not pose any risk and are cleared; however, in the compromised CF 
airway conidia germinate producing hyphae and establishing colonies.  Detection rates of A. 
fumigatus in CF patients is between 6 and 60%, but not all patients go on to develop ABPA 
and it is not always a reliable predictor of worsening disease (Singh et al. 2018).  C. albicans 
is a skin commensal but can cause candidiasis in immunocompromised individuals and CF 
patients (Navarro et al. 2001).  Despite the C. albicans detection rate ranging from 35 to 93% 
in CF patients, its detection only correlated with a small reduction of lung function, 5 – 10% 
FEV1  (Navarro et al. 2001; Singh et al. 2018).  FEV1 (forced expiratory volume in one second), 
is the volume of air that can be forcibly expelled in a spirometer in the first second after a deep 
breath.  FEV1 is usually calculated as a percentage predicted according to the median FEV1 
for people of the same gender, height and mass. 
 
Viruses have also been detected in CF patients but a longitudinal study using nasal swabs 
found that there was no difference in prevalence compared to healthy controls; however, acute 
respiratory illnesses lasted longer in CF patients and viral infections may predispose to 
infection by P. aeruginosa, precipitating pulmonary exacerbation (van Ewijk et al. 2008). 
 
The primary response to infection in the airway is inflammation.  I will continue with a general 
overview of inflammation but will continue to focus on inflammation in the airway leading to 
chronic neutrophilic inflammation of the CF airway.   
 
 Inflammation 
 
Inflammation is an evolutionally ancient immune response to trauma; the predominant 
characteristic of inflammation is the recruitment of leukocytes that stop infection, clear affected 
tissue and prevent systemic damage.  It was first described in 30-38 B.C by the Roman, 
Celsus, that four signs of acute injury were: redness, swelling, heat and pain.  A fifth sign, loss 
of function was later described by Galen, 132-200 A.D (Punchard et al. 2004).  Whilst our 
understanding of the mechanisms behind inflammation has progressed significantly, 
inflammation is not a simple process and therefore the immune response varies depending 
on the tissue and type of trauma (i.e. whether this is sterile or non-sterile) (Robb et al. 2016).  
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Furthermore, there is a spectrum of inflammation ranging from acute, lasting a few hours or at 
the other extreme it can be chronic and consequently pathological (such as CF) (Robb et al. 
2016). 
 
Inflammation is the immune response to damage, it is primarily an innate immune response; 
however, both innate and adaptive immune cells are involved (table 1-3 for lung specific cells).  
The complement system also plays a significant part by bridging the innate and adaptive 
immune systems together enabling efficient resolution through the clearance of pathogens 
and dead cells (Ricklin and Lambris 2013).  The complement system will be discussed in 
greater depth in section 1.6. 
 
Cell Role in inflammation References 
Innate Immune cells 
Polymorphonuclear leukocytes 
Neutrophils Phagocytosis of pathogens, release of enzymes, 
ROS and neutrophil extracellular traps. 
(Robb et al. 2016) 
Eosinophils Release eosinophilic granules, eosinophil extra 
cellular traps 
(Felton et al. 2014) 
Basophils Release cytokines, enzymes and histamines (Robb et al. 2016) 
Monocyte/macrophages 
Alveolar macrophages Release pro-inflammatory mediators, suppress 
hyper-responsiveness  
(Hussell and Bell 
2014) 
Macrophages Release pro-inflammatory mediators, ROS and 
protease 
Important for resolution, apoptosis of neutrophils. 
(Shapouri-
Moghaddam et al. 
2018) 
Other innate immune cell 
Mast cells Release histamines, enzymes and cytokines that 
induce mucus release from goblet cells, increase 
endothelial permeability and recruit PMNs. 
(Felton et al. 2014) 
Stromal cells 
Epithelial cells Produce mucus, release pro-inflammatory 
mediators, express adhesion molecules for 
leukocyte transmigration 
(Parkos 2016) 
Endothelial cells Release pro-inflammatory mediators, express 
adhesion molecules for leukocyte transmigration 
(Parkos 2016) 
Adaptive immune cells 
Dendritic cells Phagocytic, relay antigens to lymph nodes, 
stimulate innate lymphoid cell recruitment, 
stimulate B-cell IgE response to allergens (via 
naïve T-cells)  
(Condon et al. 
2011; Felton et al. 
2014) 
NK cells Pro-inflammatory and tissue-protective roles by 
releasing cytokines and cytolytic granules 
(Culley 2009) 
Innate lymphoid cells Pro-inflammatory (TNF, IL-17) and pro-resolution 
(IL-22) roles by releasing cytokines 
(Sonnenberg and 
Artis 2015) 
Naive T-cells Present antigens to B-cells (Felton et al. 2014) 
CD4+ T-helper cells Release pro-inflammatory cytokines (Lloyd and Saglani 
2013) 
Table 1-3: Immune cells and their roles in inflammation 
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Inflammation can be initiated by the recognition of damage-associated molecular patterns 
(DAMPs).  These endogenous factors are released by necrotic or damaged cells following 
trauma (Rock et al. 2011).  Examples of DAMPs are uric acid, heat shock protein 70, fibrinogen 
domain A, fragments of GAGs and CgG-rich deoxyribonucleic acid (DNA) regions (Rock et al. 
2011).  Exogenous factors released by pathogens also stimulate the immune system and 
stromal cells, these have been termed pathogen-associated molecular patterns (PAMPs); 
examples of PAMPs are:  bacterial components such as lipopolysaccharide (LPS), flagellin, 
peptidoglycans and unmethylated DNA (Tang et al. 2012).  DAMPs and PAMPs are 
recognised by pattern-recognition receptors (PRRs) that are expressed on the surface and 
within the cytosol of immune cells such as T-cells, B-cells, NK-cells, dendritic cells, 
macrophages, and polymorphonuclear leukocytes (PMNs)(Tang et al. 2012).   
 
PRRs have distinct functions that orchestrate inflammation through initiation, amplification and 
resolution (Tang et al. 2012). For instance, toll-like receptors (TLRs) such as TLR1, TLR2, 
TLR4 and TLR5 recognise bacterial components and up-regulate the expression and release 
of pro-inflammatory cytokines such as interleukin-1ß  (IL-1ß) and tumor necrosis factor-α 
(TNFα) (Tang et al. 2012).  IL-1ß is a key pro-inflammatory mediator that is released through 
the activation of cytosolic complexes termed “inflammasomes” (Lamkanfi 2011).  
Inflammasomes are centered around NOD (nucleotide-binding oligomerisation domain) -like 
receptors (NLRs), that can be primed and activated through stimulation of PRRs by DAMPs 
and PAMPs (Lamkanfi 2011).  A major process of NLRP activation is the expression of pro-
IL-1ß that undergoes cleavage and activation to IL-1ß by caspase 1.  IL-1ß is an essential 
pro-inflammatory cytokine that, in-turn, stimulates the release of other pro-inflammatory 
mediators, amplifying inflammation (Lamkanfi 2011).  Pro-inflammatory mediators such as 
cytokines (as well as lipid mediators such as leukotrienes) act by recruiting leukocytes to the 
trauma site, activating effector cell functions such as the generation of ROS and upregulating 
phagocytic receptors for phagocytosis of pathogens and debris. 
 
A crucial phase of inflammation is repair and resolution.  Macrophages are a key cell type in 
the resolution of inflammation; they phagocytose cell debris and dead cells and also have a 
critical role in the efferocytosis of neutrophils (Shapouri-Moghaddam et al. 2018).  
Macrophages also release IL-10 and transforming growth factor-ß (TGF-ß), that simulate 
collagen expression in fibroblasts, establishing the extra cellular matrix (ECM), the scaffolding 
that connects tissue structure. (Shapouri-Moghaddam et al. 2018).  IL-10 also suppresses and 
dampens inflammation. Oneway Il-10 achieves this is by inhibiting pro-inflammatory TLRs 
through upregulation of microRNA that target MyD88-dependent signaling, an important 
signaling pathways for TLRs and G-protein coupled receptors (Mittal and Roche 2015).  
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If inflammation is not resolved, it can become chronic and cause permanent tissue damage, 
this is because long term exposure of tissue to proteases and ROS released by PMNs and 
macrophages can collaterally remodel tissue (Braga et al. 2015).  Furthermore, over-
stimulated fibroblasts can lead to fibrosis and the generation of scar tissue, altering the normal 
structure of organs leading to loss of function (Shapouri-Moghaddam et al. 2018).  Examples 
of fibrotic diseases that occur are diabetes mellitus, liver cirrhosis, cardiovascular disease and 
plaque formation, kidney disease and lung diseases, such as bronchiectasis and CF (Braga 
et al. 2015).    
 
Having broadly discussed inflammation, I will continue by focusing on airway inflammation and 
the key cells that are involved. 
 
1.3.1. Inflammation in the normal airway 
 
The airway lining is comprised of different epithelial cells.  The epithelial lining of the smaller 
airways is composed of mucus producing goblet cells and epithelial cells (figure 1-5).  
Epithelial cells are further divided into type I ciliated epithelial cells (pneumocytes) that 
primarily facilitate gas exchange and, type II epithelial cells.  They are also important for 
immune surveillance (Hussell and Bell 2014; Robb et al. 2016).  The mucosal barrier lining 
the lungs is constantly absorbing and clearing debris and pathogens that have been inhaled.  
Mucociliary clearance by epithelial cells removes organic and inorganic particulates from the 
airway to maintain gas exchange and lung function.  If the mucosal barrier is breached, 
pathogens can establish colonies causing infection; this initiates an inflammatory response in 
reaction to the release of DAMPs (by damaged epithelial cells) and PAMPs (by the 
pathogens).  
 
DAMPs and PAMPs are recognised by PPRs expressed on the surface of epithelial cells and 
resident alveolar macrophages.  Alveolar macrophages are unique to the airway.  They are 
essential for the phagocytosis of debris and surveillance of the airway lumen (Hussell and Bell 
2014).  Interestingly, they need to be responsive to pathogens but also suppressive and not 
become over-activated by the multitude of different debris and stimulants they encounter 
(Hussell and Bell 2014).  This dichotomy is facilitated through the normal expression of PRRs 
(in comparison with circulating macrophages) but lower expression of major histocompatibility 
complexes (MHC).  They also release TGFß that suppresses T-cell activation (Roth and Golub 
1993; Hussell and Bell 2014).   Alveolar macrophages also migrate and present antigen in 
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                                                                                    , extracted from Hussel and Bell (Hussell and 
Bell 2014).  The airway is separated into the large airway, small airways, alveolar space (alveolus), 
and the interstitial space.  The epithelial lining comprises of ciliated type I epithelial cells (tan), type II 
epithelial cells (red), goblet cells (blue), clara cells (light purple).  Cells present in the airway are 
alveolar macrophages (orange) and small numbers of T-cells (light red).  The epithelium is covered in 
a layer of mucus (yellow) that prevents infection of the large and small airways by pathogens (green).  
The boxes demonstrate the immuno-suppressive roles that alveolar macrophages have towards A) 
epithelium and B) T-cells.  
draining lymph nodes, although this role is primarily performed by dendritic cells (Kirby et al. 
2009). 
 
 
 
Figure 1-5: Diagram of the normal healthy airway 
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Following the initiation and amplification of an immune response, alveolar macrophages and 
epithelial cells release pro-inflammatory cytokines and chemokines; that facilitate extravasion 
of circulating neutrophils to the airway lumen and site of infection (figure 1-6).  Pro-
inflammatory cytokines up-regulate expression of adhesion molecules on capillary endothelial 
cells that supply the alveoli.  Specifically, E-selectin expressed on endothelial cells bind to 
neutrophils via complementary receptors these are O-glycosylated carbohydrate ligands such 
as cluster of differentiation-44 (CD44), E-selectin ligand-1 and P-selectin glycoprotein ligand-
1 (PSGl-1) (Voisin and Nourshargh 2013).  Neutrophil migration to the airway lumen is also 
enabled by the cytokine-mediated relaxation of epithelial tight-junctions by inducing the 
internalisation and disassociation of junction proteins such as occludin and claudin (Parkos 
2016). 
 
  
Figure 1-6 Diagram of neutrophil transendothelial and transepithelial migration  
 
 
 
Neutrophil migration from the circulation to the airway lumen is a complex step-wise process 
that involves a multitude of adhesion molecules expressed on the surfaces of neutrophils, 
endothelial cells, pericytes and airway epithelial cells (figure 1-6A).  The first step in 
transendothelial migration is to tether circulating neutrophils, slowing fluid-phase movement.   
                                                                                                                                 ,  extracted from 
Zhou et al. (Zhou et al. 2018).  A) Neutrophil transendothelial migration is a multistep process that 
involves capturing and slowing neutrophil movement in blood, by expression of adhesion molecules by 
both neutrophils and endothelial cells.  Firmly arrested neutrophils transmigrate through gap junctions 
in the lumen and pericytes via adhesion of ICAMs and VCAMs expressed on the luminal endothelial 
surface. B) Neutrophil transepithelial migration from the basolateral surface to the apical surface 
(airway lumen) is mediated by array of JAMs, CARs and Fc receptors.  
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Weak interactions between L-selectins on neutrophils surfaces with PSGL-1 on the endothelial 
lumen reduce the movement of neutrophils in the bloodstream  (McEver 2002; Zarbock et al. 
2011). 
 
Further adhesion of neutrophils to the endothelium is mediated via interactions between 
intercellular adhesion molecules (ICAMs) and vascular cell adhesion protein-1 (VCAMs) on 
endothelial cells with lymphocyte function-associated antigen-1 (LFA-1) and very late antigen-
4 (VLA-4) respectively; these molecules reduce neutrophil movement to a slow roll or crawl 
(Zarbock et al. 2011).  Transendothelial migration occurs through gaps between the 
endothelial cells and pericytes, this step requires tight interaction between the neutrophils and 
lumen and is mediated through the expression of junctional adhesion molecules (JAMs) on 
endothelial cells (Voisin and Nourshargh 2013).  Neutrophils undergo actin cytoskeletal 
rearrangement, polarising the cell to produce protrusions (lamellipodia) in order to squeeze 
between gap junctions and migrate through the interstitial space (Voisin and Nourshargh 
2013). 
 
Neutrophil epithelial migration from the basolateral membrane (airway interstitial space) to the 
apical membrane (alveolar space) is a three-step process; adhesion, transmigration and post 
migration (figure 1-6B).  Neutrophil transepithelial migration also involves interaction between 
JAMs and integrins such as CD11b (complement receptor 3) and CD18 as well as coxsackie 
and adenovirus receptors (CARs)  (Parkos 2016).  
 
Upon infiltration into the airway, neutrophils have several effector functions: phagocytosis, 
generation of ROS, release of proteases (and antimicrobial peptides) and neutrophil 
extracellular trap (NET) formation; these functions will be discussed in section 1.4.8.  
Macrophages also have a crucial role in orchestrating and resolving inflammation.  As well as 
the presence of resident alveolar macrophages, circulatory monocytes are recruited into the 
airway where they differentiate into macrophages.  Chemotaxis of macrophages is mediated 
by macrophage chemoattractant protein-1 (MCP-1) and CXCL8 upregulation of adhesion 
molecules expressed on the macrophage surface, allowing firm adhesion to the endothelium 
and transmigration to the airway lumen (Mantovani et al. 2004). 
 
The function of macrophages can be manipulated by their environment and has been broadly 
categorized into two phenotypes: M1 macrophages are proinflammatory and release 
proinflammatory mediators such as TNFα, IL-1ß, IL-6 and chemokines: they can also release 
proteases, generate ROS, and stimulate Th-1 T-cells (Shapouri-Moghaddam et al. 2018).  M2 
macrophages are anti-inflammatory or pro-resolution, they have been further characterised 
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into M2a (tissue remodeling), M2b (immunoregulation), M2c (phagocytosis of apoptotic cells) 
and M2d (angiogenesis) (Shapouri-Moghaddam et al. 2018).  Categorisation of M1 and M2 is 
based on expression of surface and soluble markers: M1 macrophages express IL-1R, TLRs 
(pro-inflammatory TLR2, TLR4) and MHCII but release low levels of IL-10 (Shapouri-
Moghaddam et al. 2018). M2 macrophages (generally across the sub-classes) produce 
arginase-1, an inhibitor of ROS production, they also express macrophage mannose receptor 
(MMR, CD206) (Salam et al. 2011; Shapouri-Moghaddam et al. 2018). MMR is a c-type lectin 
that recognises pathogen-associated carbohydrate structures but are also important for 
removing neutrophil anti-microbial glycoproteins that could damage self-tissue, such as 
myeloperoxidase (MPO), a co-factor for ROS production (Gazi and Martinez-Pomares 2009). 
 
An important step in the resolution of airway inflammation (and inflammation in general) is the 
switching of macrophage phenotype from the pro-inflammatory M1 state to pro-resolution M2 
types.  There are a range of stimulants and receptors that promote macrophage phenotype 
switching, these include: cytokines (IL-4, IL-10, TGF-ß), TLRs (TLR7, TLR8, TLR9) (Tang et 
al. 2012; Shapouri-Moghaddam et al. 2018) 
 
Phenotype switching of macrophages to M2 promotes efferocytosis of neutrophils by 
upregulation of first apoptosis signal ligand (FasL) and phosphatidylserine ligands on 
neutrophils.  The removal of apoptotic neutrophils is essential to prevent damage to tissue by 
factors released by neutrophils such as proteases and ROS (Shapouri-Moghaddam et al. 
2018).  Macrophages present an array of scavenger and apoptotic receptors on their surfaces 
for the clearance neutrophils such as FasR, phosphatidylserine receptor, CD36, CD14, ß-
integrins (complement receptors) and collectins (Vandivier et al. 2002b).  As wells as, 
facilitating uptake of apoptotic neutrophils, ligation of the above receptors stimulates the 
release of pro-resolution cytokines such as IL-10 and TGF-ß; they also suppress expression 
of pro-inflammatory cytokines like CXCL8 and TNF-α (Vandivier et al. 2002b).     
 
Over stimulation of immune cells by pro-inflammatory cytokines or ineffective clearance of 
pathogens can lead to chronic inflammation of the airway.  Chronic inflammation in the lungs 
is particularly detrimental because enzymes released by macrophages and PMNs can 
collaterally degrade and remodel the small airways, reducing lung function (Robb et al. 2016).  
Examples of chronic inflammatory diseases in the airway are asthma, chronic obstructive 
pulmonary disease (COPD) and CF (Robb et al. 2016).  In the next section I will discuss 
inflammation in the CF lung. 
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1.3.2. Inflammation in the CF airway 
 
In CF, the inflammatory response to infection is characterised by an overwhelming influx of 
neutrophils to the airway lumen.  Therefore, neutrophilic inflammation is strongly associated 
with pulmonary exacerbation and decline in lung function (Sagel et al. 2012).  Despite 
neutrophil domination of the CF airway, other innate and adaptive immune cells are also 
elevated and may contribute to disease progression (Table 1-4) and (figure 1-7). 
 
Cell Function Reference 
Lymphocytes 
(sub-epithelial tissue) 
CD4+ Th2 Release pro-inflammatory cytokines (IL-4, IL-5 
and IL-3). Co-ordinate eosinophil activity during 
allergic in asthma and ABPA in CF 
(Knutsen et al. 2004) 
CD4+ Th17 Release IL-17 that stimulates chemokine 
secretion.  IL-17 is reported to be elevated 
during P. aeruginosa infection 
(Bayes et al. 2014) 
CD4+ Th22 Pseudomonal-specific Th22 cells release IL-22 
that in turn induce repair and regeneration of 
epithelial cells 
(Bayes et al. 2014) 
Natural Killer cells  Release interferon-ᵧ , that mediate clearance of 
P. aeruginosa. Impaired function in fibrotic lung 
disease  
(Culley 2009) 
Monocytes 
Macrophages 
(lung parenchyma) 
Excessive neutrophilic inflammation suggests 
efferocytosis may be impaired. Contribute to 
fibrosis.  M1 and M2 phenotypes observed. 
(Vandivier et al. 
2002a; Bruscia and 
Bonfield 2016) 
Alveolar Macrophages 
(airway lumen) 
Upregulation of pro-inflammatory cytokine 
release, impaired function 
(Hussell and Bell 
2014) 
Dendritic cells   
Polymorphonuclear leukocytes and mast cells 
Mast cells Cause bronchoconstriction during allergen 
response.  Source of pro-inflammatory 
cytokines and can induce fibroblast proliferation 
(Andersson et al. 
2011) 
Eosinophils Elevated eosinophil cationic protein and 
myeloperoxidase in CF airway but contribution 
to disease is unclear 
(Koller et al. 1994; 
Eltboli et al. 2014) 
Basophils Basophil activation tests in blood used to 
diagnose ABPA in CF. Source of IL-4 
stimulating CD4+ T-cell differentiation 
(Gernez et al. 2016) 
Neutrophils Most prominent cell type during inflammation of 
the CF airway.  Chronic neutrophilic 
inflammation collaterally causes airway 
remodelling and irreversible loss of lung 
function 
(Sagel et al. 2012) 
Table 1-4 Cell populations observed during chronic inflammation of the CF airway 
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The presence of a sub-set of cells does not necessarily imply a pathogenic role.  In asthma, 
T-helper 2 (Th2), and more recently reported Th17 and Th22 cells, are reported to play an 
important role in hyper-responsiveness through recruitment of eosinophils (Lloyd and Hessel 
2010).  Moreover, it is hypothesised that the multiple-factorial causes of asthma may not be 
based on single sub-set of cells but dysfunctional communication between structural cells and 
cells from adaptive and innate lineages (Lloyd and Saglani 2013).   CF patients also have 
varying degrees of asthma and elevated T-cell populations, particularly Th-17 cells (Bayes et 
al. 2014).  Unlike allergenic (eosinophilic) asthma, the CF airway is dominated by neutrophils.  
Th17 cells in CF are characterised by the release of IL-17, a pro-inflammatory cytokine that 
stimulates the release of neutrophil chemoattractants from macrophages, epithelial cells and 
endothelial cells (figure 1-7) (Tan et al. 2011; Bayes et al. 2014).  It has been reported that IL-
17 is elevated in the CF airway and may contribute to chronic neutrophilic inflammation in the 
CF airway (Tan et al. 2011; Bayes et al. 2014). 
 
 
 
The role of macrophages in promoting CF disease progression has been studied intensely 
(Bruscia and Bonfield 2016).  Elevated macrophage numbers are observed in the CF airway 
and correlate with concentrations of CCL2 (macrophage chemoattractant) in CF BAL fluid 
(Bruscia and Bonfield 2016).  Despite this, characterising macrophage populations in the CF 
airway has been challenging due to dynamic stimulatory environment that could favour both 
M1 and M2 phenotypes (Bruscia and Bonfield 2016). For instance, levels of IL-4 and IL-13 are 
elevated in BAL fluid from CF patients; these cytokines promote polarisation of macrophages 
to the M2 phenotype (Hartl et al. 2006). Contrary to this, pro-inflammatory cytokines that are 
indicative of M1 phenotype polarisation  (IL-6, CXCL8 and TNFα) have also been reported to 
be elevated (Bonfield et al. 1995).  Therefore, it is difficult to attribute disease progression to 
either phenotype.  None the less, there is evidence of over-activation of both; this is supported 
by elevated pro-inflammatory cytokines (M1) and fibrosis (M2) (Bruscia and Bonfield 2016). 
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Figure 1-7 Diagram representing some of roles for the different cell types in the CF airway and 
how they contribute to CF airway pathology. 
 
 
 
 
Phagocytosis of apoptotic and necrotic immune cells by macrophages (efferocytosis) is 
essential for resolution of inflammation and prevents prolonged exposure to proteases that 
are released by dying neutrophils.  Inefficient efferocytosis leads to degradation of structural 
cells and the surrounding ECM, promoting small airway remodelling and consequently 
irreversible loss of lung function (Robb et al. 2016).  Since discovering CFTR expression on 
macrophages it has been hypothesised that the CFTR may be important for clearance of 
pathogens and apoptotic neutrophils (Painter et al. 2006).  Di Pietro et al. have shown that 
TLR4 is dysregulated in the absence of CFTR (Di Pietro et al. 2017). The authors show that 
TLR4 expression is dependent on the heme oxygenase 1/carbon monoxide pathway, a 
process that is interrupted without CFTR (Di Pietro et al. 2017).  They summarise by 
hypothesising that the abundance of LPS during bacterial infection causes the over-activation 
of macrophages (Di Pietro et al. 2017). Moreover, Di et al. have investigated the role of CFTR 
                                                                       , extracted from Nichols et al. (Nichols and Chmiel 
2015).  The interaction of immune and stromal cells in the CF is complex owing to a plethora of 
cytokines, lipid mediators, enzymes and ECM fragments.  The production of pro-inflammatory cytokines 
(TNFα, IL-1ß, IL-18, IL-6) by epithelial cells and macrophages stimulate the release of chemoattractants 
such as CXCL8 (IL-8) by other epithelial cells and macrophages but also T-cells.  Recruitment of 
neutrophil to the interstitial tissue and release of matrix metalloproteases generates N-acetyl-PGP, 
recruiting more neutrophils.  Necrotic neutrophils, not cleared by macrophages, lyse and release DNA, 
protease and ROS that promote airway obstruction and remodel the airway causing a loss of lung 
function.  
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in the acidification of endocytic compartments following phagocytosis of bacteria.  
Autonomous integration of CFTR during endocytosis promotes acidification by accumulating 
Cl-, generating a large enough counterion conductance to maintain H+ gradients (Di et al. 
2006).  Di et al. showed that internalised CFTR be detected in non-CF alveolar macrophages 
ant that macrophages from cftr -/- mice failed to acidify endosome to a bactericidal pH (Di et 
al. 2006). 
 
Another proposed mechanism of macrophage dysfunction is the cleavage of PRRs by 
proteases released by neutrophils; this will be discussed in detail in section 1.5.2.  It is clear 
that delineating the roles of different immune cells in disease progression is complicated due 
to heterogeneity in the airway of CF patients.   
 
Despite elevated numbers of macrophages, Th cells and other PMNs neutrophils make up 
>70% of the cells in the airway during pulmonary exacerbation and are directly responsible for 
irreversible loss of lung function.  Therefore, better understanding of neutrophil dysfunction 
may improve effectiveness of therapeutics targeting inflammation. 
  
  Biology of neutrophils 
 
Neutrophils are the first line of defense during infection.  They are highly responsive to their 
environment and possess an armory of effector functions that allow them to eradicate 
pathogens.  In this section I discuss the mechanisms that enable neutrophils to efficiently clear 
infection and maintain homeostasis.  
 
1.4.1. Differentiation 
 
Neutrophils are released as terminally differentiated cells from the bone-marrow at a steady 
state of 1 – 2 x 1011 cells/day (Borregaard 2010).  Neutrophils start as a common progenitor 
myeloblast, similar to erythrocytes, granulocytes and monocytes.  They differentiate to 
myeloblasts, then  promyelocytes and subsequently neutrophils; this is in response differential 
cues such as CCAAT/ enhancer binding protein a (C/EBPa) and PU.1 (figure 1-8) (Borregaard 
2010).  The release of neutrophils from the bone marrow is mediated by the ligand CXC12 
and the regulated expression of its receptors, CXCR2 (retention in the bone marrow) and 
CXCR4 (release)(Borregaard 2010; Kruger et al. 2015).  
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Figure 1-8: Diagram of neutrophil differentiation and granulopoiesis. 
 
 
 
1.4.2. Effector functions 
 
The primary role of neutrophils is to infiltrate damaged tissue and fight pathogens. If 
neutrophils do not encounter pro-inflammatory signals or signals to prolong life, they undergo 
apoptosis within days of release from the bone marrow (Geering and Simon 2011).    
Neutrophils infiltrate the infected tissue by transmigration through the endothelium and 
epithelium, as described in section 1.3.1.   Arriving at the site of infection, neutrophils have 
four main effector functions that facilitate the clearance of pathogens and promote further 
neutrophil recruitment, these are: phagocytosis, ROS production, degranulation and 
neutrophil extracellular trap (NET) formation (figure 1-9). 
 
                                                                                                             , extracted from Lekstrom-
Himes et al. (Lekstrom-Himes et al. 1999).  Neutrophils differentiate in the marrow and mature through 
stimulation by differential cues.  Neutrophil granules develop sequentially in a process called 
granulopoiesis.   
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Figure 1-9 Neutrophil effector functions 
 
1.4.3. Neutrophil cell surface receptors 
 
For neutrophils to respond to infection appropriately, they possess an array of surface (and 
cytosolic) molecules and receptors that are regulated by the expression of cytokines and other 
stimulatory factors released by other neutrophils and other cells at the infection site.   Important 
cell surface receptors expressed on neutrophils are G-protein-coupled receptors, adhesion 
molecules, cytokine receptors, Fcγ-receptors (FcγRs) and PRRs, I will briefly discuss each of 
these in turn (Futosi et al. 2013). 
 
 
 
G-protein-coupled receptors are critical for neutrophil function during an inflammatory insult; 
they facilitate chemotaxis by responding to ligands released by resident tissue cells.  
Examples of molecules that are chemotactic for neutrophils are: chemokines (via CXCR1, 
CXCR2, CCR1 and CCR2), formyl-peptides released by bacteria (via FPR1, FPRL1 and, 
FPRL2), leukotriene B4 (via BLT1 and BLT2), platelet activating factor (via PAFR) and, 
complement anaphylatoxin C5a (C5aR1).  The biology of these chemoattractants will be 
discussed in section 1.4.4 (Futosi et al. 2013).  As well as mediating chemotaxis, G-protein-
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coupled receptors also have important functions in inducing ROS production, degranulation, 
priming and up-regulation of other receptors. 
 
Upon ligand binding, signal is transduced via pertussis toxin-sensitive heteromeric G-proteins 
(figure 1-10).  The Gα subunit and ß-arrestins disassociate from the G-protein-coupled 
receptor and bind Src-family kinases, a pathway that stimulates neutrophil degranulation 
(Fumagalli et al. 2007).  Specifically, the Src-kinases, Hck, Fgr and Lyn have been shown to 
be essential for neutrophil degranulation (Mocsai et al. 1999; Mocsai et al. 2000; Fumagalli et 
al. 2007).  The Gα subunit (as wells as Gßγ subunits) can also activate phospholipases Cß 
(PLCß1, PLCß2 and PLCß3); these produce inositol 1,4,5-trisphosphate, a signalling mediator 
important for chemotaxis, ROS production and NET release (Smrcka and Sternweis 1993; Li 
et al. 2000; Nguyen et al. 2017).   Along with diaglycerol, inositol 1,4,5-trisphosphates induce 
the release of calcium from the ER by diffusing through the ER membrane and binding to 
inositol 1,4,5-trisphosphate receptors,  ligand-gated calcium channels (Smrcka and Sternweis 
1993; Clemens and Lowell 2015). 
 
  
Figure 1-10: G-protein couple receptor signalling pathways and functions 
 
 
 
 
                                                                                                                             , adapted from Rabiet 
et al. (Rabiet et al. 2007).  Following ligand binding, G-proteins Gßγ and Gα can initiate several 
pathways that trigger neutrophil functions.  Gα subunits bind Scr that induces ROS production and 
upregulation of pro-inflammatory mediators through Ras and p38/ ERK pathways. Src activates Src 
family kinases that induce degranulation.  G-protein subunits also activate phospholipase C and via 
inositol 1,4,5-trisphosphate (IP3) and diaglycerol, inositol 1,4,5-trisphosphates (DAG) induce Ca2+ 
release and protein kinase C (PKC) activation.  PKC phosphorylates p47 and p40 to form facilitate 
formation of NADPH oxidase. 
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Interestingly, secondarily to ER calcium release, further calcium can be pumped into 
neutrophils from the extracellular space via calcium release-activated calcium channel protein 
(ORAI) following stimulation by stromal interact ion molecules (STIM) located in the membrane 
of the ER (Clemens and Lowell 2015).  Calcium mediates calcium-dependent protein kinase 
C phosphorylation of p47phox and p40phox , both are subunits of NADPH oxidase, the catalyst 
for ROS production (see section 1.4.6) (El-Benna et al. 2016; Nguyen et al. 2017).  Intracellular 
calcium also bind calpains, cysteine proteases that aid actin polymerisation and actin-ß-
integrin cross-linking, important for chemotaxis and granule mobilisation (Tian et al. 2004). 
 
G- protein subunits ßγ also bind and activate phosphatidylinositol 3-kinases (PI3K) that in turn 
activate the ERK-Akt pathway and p38 mitogen-activated protein kinase (MAPK) pathways, 
these up-regulate adhesion molecules, enabling neutrophil chemotaxis (Kim and Haynes 
2013). 
 
A crucial part of G-protein-coupled receptor signalling is regulation, this has two steps: 
desensitisation, mediated by ß-arrestins, that uncouple G-proteins by phosphorylating the 
receptors (Magalhaes et al. 2012). The second subsequent step is internalisation or 
endocytosis of the receptors, a process that is facilitated again by ß-arrestins that interact with 
clathrin (figure 1-11) (Magalhaes et al. 2012).  
 
Figure 1-11: Diagram of G-protein coupled receptor internalisation 
 
 
 
                                                                                                                 , extracted from Rabiet et al. 
(Rabiet et al. 2007) Following ligand binding, G-protein coupled receptors are phosphorylated and 
bound by ß-arrestins that form complexes with clathrin and AP2, facilitating internalisation.  They can 
either fuse with lysosomes, degrading the G-protein receptors or be re-phosphorylated and recycle 
to the cell surface. 
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Endosomal compartments can merge with lysosomes whereby G-protein coupled receptors 
are degraded; however, the majority of internalised receptors are desensitised and recycled 
to the cell surface (Magalhaes et al. 2012).  Internalisation is determined by the level of 
phosphorylation of the receptor in the seventh transmembrane domain (Oakley et al. 2000).  
G-protein-coupled receptors that do not internalise are de-phosphorylated and re-sensitised 
(Magalhaes et al. 2012). 
 
Interestingly, the association with ß-arrestins allows cross-desensitisation between CXCRs 
and also heterologous desensitisation by other ß-arrestin-associated G-protein coupled 
receptors on neutrophils such as C5aR1 and formyl-peptide receptor 1 (Heit et al. 2002; 
Sogawa et al. 2011).  This is because the same ß-arrestins that mediate desensitisation are 
used by all of above the receptors.Furthermore, C5a and fMLP desensitisation is not 
reciprocated by CXCLs revealing a hierarchy of desensitisation in response to different 
neutrophils chemoattractants (Heit et al. 2002; Sogawa et al. 2011). 
 
 
 
Neutrophils express L-selectin and integrins on their cell surface to facilitate endothelial and 
epithelial transmigration (Futosi et al. 2013).  They also present glycoproteins, PSGL-1, CD44 
and E-selectin-ligand (ESL-1), as well as glycosphingolipids, that bind E-selectins, expressed 
on endothelial cells to arrest neutrophil movement through blood vessels (Hidalgo et al. 2007; 
Nimrichter et al. 2008). The expression of integrins is also important for neutrophil 
transmigration, specifically neutrophils express LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18; 
CR3(complement receptor 3)), integrin αX (CD11c, CD18, CR4) and, VLA-4 that bind to 
ICAMs or VCAMs on the endothelial luminal surface.  
 
Interestingly, PSGL-1 and integrin binding to endothelial receptors (E-selectin and ICAMs 
respectively) induces intracellular signalling cascades through interaction with co-receptors 
such as immunoreceptor tyrosine-based activation motifs (ITAMs) and FcγR/DAP12 (Mocsai 
et al. 2006).  ITAM-mediated signalling stimulates syk activation and up-regulation of integrins, 
generation of cytokines as well as ROS production.  ROS production via syk signalling is 
triggered through phospholipase C-γ (PLC-γ), that increases intracellular calcium 
concentration and subsequently, ROS production (Berton et al. 2005; Mocsai et al. 2006; 
Nguyen et al. 2017).  Signalling in this manner enables communication between neutrophils 
and the endothelium.   
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The integrin Mac-1 is also known as CR3.  As well as binding to ICAMs, CR3 also recognises 
ß-glucans, the most abundant component of fungal cell walls; however, fungal recognition by 
CR3 does not induce ROS production (Wright and Silverstein 1983; Thornton et al. 1996).  
Furthermore, CR3 also binds to the complement opsonin iC3b (inactivated C3b) and 
consequently CR3 can recognise both opsonised and non-opsonised yeasts (Netea et al. 
2008). CR4, also recognises iC3b, together expression of CR3 and CR4 are important for 
neutrophil phagocytosis of opsonised and non-opsonised pathogens (Ren et al. 2004; Netea 
et al. 2008). 
  
There are two other complement receptors, CR1 and CR2.  Neutrophils do not express CR2, 
but it has important roles in activation of B-cells, acting as a B-cell co-receptor via interaction 
with IgM immunocomplexes and C3d (Boackle et al. 1998). CR1 binds several complement 
proteins, such as C3b (and lesser extent iC3b), C4b, C1q and mannose-binding lectin. 
Therefore, because mannose-binding-lectin and C3b opsonise yeasts (and other pathogens) 
CR1 is an important phagocytic receptor (Li et al. 2012).  CR1 is also a complement regulator, 
it is a co-factor with factor I for inactivation of C3b (to iC3b), iC3b (to C3f and C3d,g) and, C4b 
(to C4c and C4d)(Ross et al. 1983).  The complement system will be described in further detail 
in section 1.6. 
 
 
 
Cytokine receptors are divided into four subsets: type I and type II cytokine receptors, IL-1 
family receptors and the TNF receptor family.  Neutrophils express Type I cytokine receptors 
such as IL-4R, IL-6R, IL-12R, IL-15R, G-CSFR and GM-CSFR (Futosi et al. 2013).  The Type 
II cytokine receptors expressed by neutrophils are interferon receptors (IFNAR (IFN-α/ß, 
IFNGR (IFN-γ)) and IL-10R (Ellis and Beaman 2004; Bazzoni et al. 2010).  Type I and type II 
receptors activate transcription factors via the JAK/STAT pathway.  They are split into two 
classes because Type I cytokine receptors are generally pro-inflammatory, whereas type II 
cytokine receptor are associated with pro-resolution cytokines (figure 1-12)(Futosi et al. 2013).  
The two receptor classes are associated with different isotypes of JAK and STAT so that pro-
inflammatory or pro-resolution genes can be differentially activated (O'Shea and Plenge 
2012). 
 
Neutrophils express receptors for IL-1α and IL-1ß (IL-1RI/IL-1R3) as well as IL-18 (IL-IR5/IL-
1R7(IL18RAP)) (Futosi et al. 2013).  Ten IL-1 family receptors and co-receptors have been 
identified; these are structurally more similar to TLRs than they are to type I and type II cytokine 
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receptors, in that they possess an extracellular immunoglobulin-like domain (O'Neill 2008; 
Dinarello 2018).   IL-1RI is the receptor for IL-1α and IL-1ß, IL-1ß is a potent pro-inflammatory 
cytokine but, despite expression of IL-1RI, the only stimulatory effect on neutrophils is 
promoting survival (Colotta et al. 1993; Mitroulis et al. 2010). IL1-RII, a decoy receptor lacking 
a cytoplasmic signalling domain, it is highly expressed on neutrophils and is thought to be 
important for regulating IL-1ß stimulation of resident cells and macrophages (Futosi et al. 
2013).  IL-18 is a neutrophil stimulant, promoting survival and inducing cytokine release and 
ROS production (Leung et al. 2001).  IL-1ß or IL-18 stimulation of IL-1RI/IL-1R3 and IL-IR5/IL-
1R7 induces signalling via MyD88-IRAK kinase family pathway and activation of transcription 
factors (NF-kB) (Fortin et al. 2009). 
 
Figure 1-12: Cytokine receptor signalling pathways and functions  
 
 
 
Neutrophils also express TNF-family receptors, these can be divided in-two by the possession 
of an intracellular death-domain (Futosi et al. 2013).  For instance, TNFR-1, TRAIL-R2 and, 
Fas receptor are death receptors and promote neutrophil apoptosis (O'Donnell et al. 2015). 
TNFα is a potent activator of neutrophils by inducing ROS production (Dri et al. 1999).  TNF-
family receptors signal via receptor-interacting serine-threonine protein kinase (RIP1) and 
TNF receptor associated factors (TRAF); however, alternative TRAF complexes are used to 
differentiate the pro-inflammatory and pro-resolution signals that these receptors transmit 
(Futosi et al. 2013). 
                                                                                                            , extracted from Futosi et al. 
(Futosi et al. 2013).  Cytokine type I and II receptors signal via JAK / STAT pathways following ligand-
mediated phosphorylation.  IL-1 family receptors signal via MyD88 pathways using TIR located within 
the intracellular domains.  TNF-family receptors signal via RIP and TRAF complexes; however, 
differential TRAF interaction facilitates alternative functions such as MAP kinase activation (pro-
inflammatory gene expression) or caspase activation (apoptosis).     
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Neutrophils express an array of PRRs that trigger activation upon recognising DAMPs and 
PAMPs (Tang et al. 2012).  Humans express 11 TLRs that recognise a range of DAMPs and 
PAMPs, such as bacterial membrane components like peptidoglycans (TLR2), LPS (TLR4) 
or, flagellin (TLR5) (Takeuchi and Akira 2010; Futosi et al. 2013).  They also recognise danger 
cues from host cells such as DNA (TLR5), heat-shock-protein 70 (TLR2), GAG fragments 
(TLR4) (Zhang and Schluesener 2006; Tang et al. 2012).  Neutrophils express all known 
TLRs, except TLR3.  Activation of TLRs upon ligand binding can induce cytokine release and 
promote survival (Hayashi et al. 2003; Koller et al. 2009).  As mentioned, TLRs belong to the 
same family of receptors as IL-1R and therefore, like IL-1R1 signal via MyD88-IRAK pathways, 
leading activation of NF-kB transcription factors (figure 1-13) (O'Neill 2008).  One function of 
TLRs is to induce the generation of proIL-1ß that is cleaved by caspase-1 following 
inflammasome activation via secondary signals such as an increase in intracellular calcium or 
ROS (Lamkanfi 2011). 
 
Neutrophils also express C-type lectins, these are fundamental for recognition of fungal 
pathogens such as Candida albicans and Aspergillus fumigatus (Steele et al. 2005).  C-type 
lectins such as Dectin-1 (CLEC7A), recognise ß-glucans on the surface of A. fumigatus (and 
Candida spp), whereas, Dectin-2 (CLEC2) binds mannose disaccharides and also recognises 
C. albicans (Steele et al. 2005; Feinberg et al. 2017; Griffiths et al. 2018).  Another C-type 
lectin, Mincle (CLEC4E) recognises α-mannose structures on the cell walls of 
Malassezia spp.; these are responsible for causing skin lesions but can also cause sepsis in 
immunocompromised patients (Yamasaki et al. 2009). 
 
Neutrophils also express other C-type lectins such as MDL-1 (CLEC5A) and Mcl (CLEC4D) 
(Futosi et al. 2013).  C-type lectins signal via ITAMs; however, Dectin-1 and Dectin-2 only 
possess half an ITAM (hemITAM) and therefore, it has been suggested that homo-
dimerisation with TLRs is required for signal activation (Hughes et al. 2010). 
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Figure 1-13: Pattern recognition receptor signalling pathways and functions 
 
 
 
As for, PSGL-1 and FcγR signalling, C-type lectin signalling is mediated by interaction with 
co-receptors ITAMs and FcγR/DAP12 that lead to activation of the syk pathway and cytokine 
transcription via NF-kB (Gross et al. 2006). The syk signal pathway also triggers intracellular 
calcium via activation of PLC-γ, the consequent increase in calcium causes ROS production, 
NET release and degranulation (Berton et al. 2005). 
 
 
 
FcγRs bind to the fragment crystallisable (Fc) tail regions of immunoglobulins and facilitate 
the recognition and opsonisation of immunoglobulin targeted pathogens (Karsten and Kohl 
2012).  Seven FcγR subclasses have been identified; each have been reported to have 
different affinities for IgG subclasses. For instance, FcγRI has been reported to have the 
highest affinity for IgG, whereas the other FcγR classes have much lower affinity for IgGs but 
can differentially bind to different IgG subclasses (IgG1-4) (Karsten and Kohl 2012).  There 
are two low-affinity FcγR that are crucial for immunoglobulin recognition by neutrophils, these 
are FcγIIA and FcγIIIB.  Moreover, both are required for receptor activation and signal 
transduction (Futosi et al. 2013).  The current model of activation of these receptors is that 
                                                                                                                             , extracted from 
Futosi et al. (Futosi et al. 2013). Surface expressed TLRs signal via MyD88 and TIR located in 
cytoplasmic domains (like TNF-family receptors (figure 1-12).  TLR activation activates MAP kinases 
and NF-kB transcription factors that upregulate transcription of pro-inflammatory cytokines, 
particularly IL-1ß, this becomes activated by NLRP3 inflammasome.  Dectin-1 and 2 and Mincle 
recognise pathogen surface molecules, these trigger signaling through Syk and, like TLRs, 
stimulates NF-kB and Map kinase transcription factors. 
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FcγIIIB binds first, but because FcγIIIB is glycosylphosphatidylinositol (GPI)-anchored and 
does not possess an intracellular signalling domain it requires FcγIIA to function (Futosi et al. 
2013).  Signalling of FcγRs is mediated via a γ-accessory protein that is associated with ITAMs 
and induces signal via the syk-pathway and subsequent ROS production (Karsten and Kohl 
2012).   
 
Not all FcγR induce a pro-inflammatory signal. FcγRIIB is anti-inflammatory and has been 
shown to associate with dectin-1 when FcγRIIB recognises highly glycosylated 
immunoglobulins (Karsten et al. 2012).  Dectin-1 signalling via syk, promotes phosphorylation 
of Src homology 2 domain–containing inositol phosphatase on FcγRIIB with the downstream 
affects inhibiting complement C5a receptor 1 (C5aR1) stimulation and neutrophil activation 
(Karsten et al. 2012).  
 
In this section I have discussed some of the key molecules and receptors that regulate the 
functions of neutrophils.  Neutrophils are the first line of response during inflammation and 
migrate to the infection site by transmigration following gradients of chemotactic molecules 
that are released by resident cells (and infiltrating neutrophils) upon sensing danger signals.  
In the next section I will discuss the range of molecules with chemotactic activity for 
neutrophils, with particular emphasis on those that have been found elevated in the CF airway. 
 
1.4.4. Neutrophil chemotaxis 
 
Neutrophil chemotaxis requires both neutrophils and tissue cells to display adhesion 
molecules to facilitate transmigration from the circulation through the vascular endothelium to 
the infected tissue.  Furthermore, chemotaxis requires significant changes in neutrophil 
morphology for adherence and migration which I will briefly discuss. 
 
Neutrophils express chemotactic G-protein-coupled receptors that as well as mediating ROS 
production and degranulation also induce neutrophil chemotaxis (Futosi et al. 2013).  There is 
a range of neutrophil chemoattractants that elicit a response via G-protein-coupled receptors.  
A detailed account of several chemoattractants important in the airway will be in the next 
section.  Upon activation of chemotactic G-protein-coupled receptors on neutrophils, G-protein 
subunits, Gα Gßγ, trigger various signalling cascades, such as PI3K activation.  PI3K and its 
products, phosphatidylinositol (3,4,5)-trisphosphate, stimulate Rac GEFs (Guanine nucleotide 
exchange factors) and, in turn, Rac GTPases(Mocsai et al. 2015).  This signalling pathway 
promotes neutrophil polarisation by inducing actin polymerisation and myosin mobilisation that 
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produce lamellipodia, an extension of the neutrophil leading edge (figure 1-14) (Mocsai et al. 
2015). 
 
 
Figure 1-14: Diagram of neutrophil polarisation during chemotaxis 
  
 
 
At the opposite end, the trailing edge, the actin-myosin arrangements are stable and form a 
uropod, a process that involves disassociation of actin with the cellular cytoskeleton (Mocsai 
et al. 2015).  The formation of the uropod is mediated by phosphatidylinositol activation of Rho 
(Ras homolog gene)(Mocsai et al. 2015).  It has been shown that neutrophil polarisation does 
not change distribution of G-protein-coupled receptors and therefore, migration of neutrophils 
is facilitated by dynamic changes in morphology towards the chemotactic gradient (Ku et al. 
2012).  This is because at the leading edge chemotactic receptors will become activated; 
whereas at the trailing edge there will be less receptor activity.  Therefore, the difference in 
receptor activation across the cell, rather than receptor mobility, is important for chemotaxis 
(Ku et al. 2012). 
 
Our understanding of neutrophil homing and accumulation at the inflammation site has been 
improved by the recent development of intravital imaging in mice (Lämmerman et al. 2015).  
Here neutrophils are labelled and their movement is followed through membranous 
                                                                                                            , extracted from Mocsai et 
al. (Mocsai et al. 2015).   Neutrophil polarisation facilitates migration towards chemotactic gradients 
by generation of a leading edge.  The leading edge is formed by dynamic actin polymerisation 
following activation of Rac by PI3K.  At the trailing edge PI3K stimulate Rho-mediated stabilisation 
of actin to form a uropod.      
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translucent tissue; for instance in the GI tract or skin (Lämmerman et al. 2015).  From these 
experiments it has been observed that neutrophils accumulate en masse in a process that is 
called neutrophil swarming (Lämmerman et al. 2015).  Two types of neutrophil swarming 
events have been observed: transient swarms and persistent swarms (Lämmerman et al. 
2015).  Transient swarms are formed by coordinated groups of 10 – 150 neutrophils; these 
typically disperse within 40 minutes and are associated with minor trauma (Lämmerman et al. 
2015).  Persistent swarms are formed by an assembly of greater than 300 neutrophils that 
sustain recruitment for periods longer than 40 minutes (Lämmerman et al. 2015).  
Furthermore, large persistent swarms can form by merging together multiple smaller groups. 
(Lämmerman et al. 2015) 
 
In skin it has been shown that neutrophil swarming is initiated by “pioneer” neutrophils drawn 
in to the tissue by DAMPs, PAMPs and chemotactic molecules released by damaged tissue.  
Neutrophil recruitment and swarming is subsequently amplified by the release of leukotriene 
B4 (LTB4, see section 1.4.4e) by pioneer neutrophils (Lämmerman et al. 2015).  However, 
LTB4 is not solely responsible for neutrophil swarming and other chemotactic molecules may 
also be important for driving neutrophil swarming (Lämmerman et al. 2015).  The process of 
neutrophil swarming also differs on the tissue; the ECM density is a key factor in governing 
the rate of neutrophil swarming (Lämmerman et al. 2015) 
In the following sections I will discuss the range of neutrophil chemoattractants and their 
relative potencies (where investigated). 
 
 
 
There are several different forms of neutrophil chemoattractants, most of which are released 
by host cells following stimulation by DAMPs, PAMPs and cytokines (e.g. chemokines and 
leukotriene B4). However, some are derived from bacterial components (e.g. fMLP), ECM 
components (e.g. Pro-Gly-Pro, PGP) or the complement cascade (C5a).  A similarity between 
them all is that they induce chemotaxis through G-protein coupled receptors (Futosi et al. 
2013).  I will briefly discuss each chemoattractant individually, apart from C5a which will 
discussed in section 1.7. 
 
 
 
PGP and acetyl-PGP are chemotactic peptides released from the ECM following degradation 
of collagen by neutrophil matrix metalloproteases (MMPs), MMP8 and MMP9, during 
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inflammation (Abdul Roda et al. 2015).  PGP is directly generated by collagen degradation, 
but acetyl-PGP is a secondary product following acetylation by acrolein (which is found in 
cigarette smoke and is a by-product of glycerol breakdown during heating) (Abdul Roda et al. 
2015).  It has been shown that PGPs bind and activate CXCR2, inducing ROS production and 
inhibiting neutrophil apoptosis (Kim et al. 2011).  PGPs are degraded during inflammation by 
leukotriene A4 hydrolase; however, in cases of chronic inflammation such as in COPD or CF 
there is an imbalance of ECM degradation / PGP generation and inactivation by leukotriene 
A4 hydrolase (Snelgrove et al. 2010).  Therefore, PGPs are elevated in these diseases and 
could be used as biomarkers of airway inflammation and remodelling (Abdul Roda et al. 2015). 
 
 
 
HMGB1 is a DNA binding molecule that facilitates and interacts with transcription factors and 
histones (Yang et al. 2013).  It is released by necrotic cells during inflammation and therefore 
could be considered a DAMP (Yang et al. 2013).  HMGB1 has three cysteine residues that 
when reduced can modify interaction with cytokines allowing it to bind external receptors and 
induce intracellular signals (Yang et al. 2013).  For examples, partial reduction of HMGB1 
enables interaction with MD-2, an adapter protein for TLR4 that can stimulate TLR4 and 
consequent pro-inflammatory cytokine release (Yang et al. 2013).  If all three cysteine residues 
are reduced however, HMGB1 binds the chemokine CXCL12 modulating chemotactic activity 
via CXCR4 (Venereau et al. 2012).  Of further interest, HMGB1 can also bind complement 
C1q, activating the classical pathway and complement cascade, promoting cell lysis by the 
membrane attack complex, driving further HMGB1 release and generating the neutrophil 
chemoattractant C5a (Kim et al. 2018). 
 
 
 
CXCL8 (also known as IL-8) is a member of the chemokine family; these are categorised by 
conserved N-terminal cysteine residues.  Four sub-families have been established: C, CC, 
CXC and CX3C.  CXC Chemokines have a low molecular weight between 8-9 kDa (Walz et 
al. 1987). They can be further subdivided by the presence of a Glu-Leu-Arg (ELR) binding 
domain located before the above conserved cysteine residues; CXCL8 is ELR-positive 
(Hebert et al. 1991). 
 
In the airway, chemokines can be produced by alveolar macrophages, epithelial, and 
endothelial cells upon stimulation by DAMPs, PAMPs and cytokines (Hartl et al. 2012).  A list 
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of characterised chemokines that have been isolated in the CF lung can be found in Hartl et 
al. but, for the remainder of this review I will focus on CXCL8 (Hartl et al. 2012). Two different 
length forms CXCL8 exist, CXCL8(77) and a more active truncated form, CXCL8(72) 
(Padrines et al. 1994).  CXCL8(77) is released by non-immune cells whereas CXCL8(72) is 
secreted by immune cells (Padrines et al. 1994).  
 
Furthermore, CXCL8(77) is subsequently proteolytically modified by NSPs and other 
proteases to create the more potent CXCL8(72) form (Padrines et al. 1994).  Pre-term infants 
have a higher prevalence of CXCL8(77); however, pre-term infants that went on to develop 
bronchopulmonary dysplasia (an airway condition that can afflict pre-term children) had higher 
expression of the more potent CXCL8(72) form (Chakraborty et al. 2014).  Using patient BAL 
fluid, Chakraborty et al. showed that CXCL8(77) activation was mediated through cleavage by 
neutrophil proteases present in the airway.  The authors also noted that over extended 
periods, CXCL8 was susceptible to degradation beyond the N-terminus resulting in loss of 
function (Chakraborty et al. 2014).  
 
At low concentrations soluble CXCL8 is monomeric; however, oligomerisation of CXCL8 (and 
other chemokines) allows stronger initial chemotactic attraction to high concentrations of 
CXCL8 (Das et al. 2010).  Furthermore, positively charged epitopes located on the C-terminal 
α-helix and proximal loop at residues 18-23, encourage binding to non-sulphated and 
sulphated GAGs such as heparan sulphate (HS) and hyaluronic acid (HA) (Kuschert et al. 
1999).  Soluble GAGs, released by degradation of the ECM during chronic inflammation, can 
inhibit CXCL8 binding to CXCR1 (Pichert et al. 2012b; Schlorke et al. 2012). Conversely, cell 
surface GAGs facilitate ligand binding of dimerized CXCL8 establishing chemotactic gradients 
within tissue and upregulating the production of ROS in neutrophils (Pichert et al. 2012b; 
Schlorke et al. 2012). 
 
CXCL8 binds to receptors via a sterically protected ELR motif adjacent to the N-terminus 
(Gerber et al. 2000).  CXCL8 has been shown to have affinity towards three receptors: 
CXCR1, CXCR2 and the Duffy antigen receptor (Stillie et al. 2009). The latter has been shown 
to facilitate transmigration of neutrophils to sites of infection and is also upregulated in the lung 
during infection by pneumonitis (Lee et al. 2003).  CXCR1 and CXCR2 share 77% homology 
but CXCR1 only binds CXCL6 and CXCL8 (Stillie et al. 2009).  On the other hand, CXCR2 
binds CXCL6 and CXCL8 as well as the remaining CXCL family. This divergence in binding 
of different CXCL chemokines has an important functional role; this is because the signalling 
pathways differ between the two receptors (Stillie et al. 2009).  CXCR1 signalling is mediated 
via phospholipase D1 and induces NADPH oxidase activation and ROS release, whereas both 
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CXCR1 and CXCR2 can signal via phospholipase D2.  This pathway has shown to be 
important for chemotaxis as well as ROS production and degranulation (Lehman et al. 2006). 
 
 
 
Since their characterisation in the 1980s, leukotrienes have been reported to have diverse 
functions beyond leukocyte activation and chemotaxis such as vascular homeostasis and cell 
proliferation. See Brink et al. for an extensive list of functions (Brink et al. 2003).  LTB4 is a 
derivative of leukotriene A4, an eicosanoid metabolite of arachidonic acid break-down that is 
mediated by 5-lipoxygenase, a lipase produced by granulocytes and macrophages (Brink et 
al. 2003). Therefore, LTB4 is generated following recruitment of leukocytes to the site of 
inflammation (Yokomizo 2011; Sadik and Luster 2012).   
 
LTB4 binds to two rhodopsin family G-protein coupled receptors, BLT1R and BLT2R; however, 
LTB4 has higher affinity to BLT1R than BLT2R (Yokomizo et al. 1997; Yokomizo et al. 2000; 
Brink et al. 2003).  They are both highly expressed in leukocyte populations as well as 
endothelial and vascular smooth cells (Brink et al. 2003).  Neutrophil chemotaxis is induced 
upon LTB4 ligand binding to BLT1 R or BLT2R (Yokomizo et al. 1997). Murine models lacking 
BLT1R or BLT2R have revealed that LTB4, more so than the other arachidonic acid derivatives, 
play an important role in the development of inflammatory conditions such as rheumatoid 
arthritis and asthma (Mathis et al. 2010).  
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Figure 1-15: Arachidonic metabolites and their receptors 
 
 
 
A number of arachidonic acid derived lipid mediators compete for BLT1R binding. These 
include: 12(S)-HETE, 12(S)-HpETE and 15(S)-HETE whereas 12(S)-Hydroxyheptadeca-5Z, 
8E, and  10E-trienoic acid(12-HHT), derived through cyclooxygenase, have high affinity for 
BLT2R (figure 1-15) (Okuno et al. 2008).   The relevance of these other lipid competitors is not 
fully understood but it has been shown they may be important macrophage chemoattractants 
and encourage wound healing (Liu et al. 2014). Furthermore, ibuprofen, a cyclooxygenase 
inhibitor, may slow wound healing (Liu et al. 2014).  This is also important for CF because 
some clinics prescribe high doses of ibuprofen as a non-steroidal anti-inflammatory drug. 
 
 
 
During the 1980s Escherichia coli culture filtrates were found to possess chemotactic 
properties.  Chromatography identified heterogeneous peptides specifically formyl-methionyl 
products from N-terminal regions (Marasco et al. 1984).  Formyl-methionyl products are 
generated through bacterial protein synthesis and trafficking (Ye et al. 2009).  Membrane-
bound bacterial proteins that possess transporter signal peptides are cleaved by signal 
peptidases releasing peptide fragments into the extracellular space (Ye et al. 2009).  The 
released peptides are anionic, ranging in molecular weights between 0.15 - 1.5 kDa; 
                                                                                            , adapted from Brink et al. (Brink et al. 
2003).  Leukotriene B4 is produced from leukotriene A4 by LTA4 hydrolase.  Leukotriene B4 binds with 
high affinity to BLT1R and with low affinity to BLT2R. 5-HETE and other arachidonic acid metabolites 
generated by cyclooxygenases can also bind BLT2R.  Lipoxin A4, binds FRP2 or LXA4R, inhibiting 
neutrophil chemotaxis.  
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furthermore, the chemotactic potency varies between peptide fractions generated by different 
bacterial species (Ye et al. 2009). The 440 Da tripeptide formyl-Met-Leu-Phe has been shown 
to be the most potent (Marasco et al. 1984).  Formyl-peptides can also be endogenous to 
cells, originating from damaged mitochondria, specifically NADPH dehydrogenase subunit I 
(Shawar et al. 1995).  During infection necrotic cells release DAMPs, including those produced 
by mitochondria, enhancing chemotaxis towards to tissue trauma (Shawar et al. 1995). 
 
Studying formyl peptide receptors has highlighted a range of ligands from formyl to non-formyl 
peptides. Le et al have reviewed these extensively (Le et al. 2002).  Three pertussis sensitive 
G-protein coupled receptors for formyl-peptides have been identified; formyl peptide receptor 
(FPR), FPR2 and FPR3 (Ye et al. 2009). FPR and FPR2 are highly expressed on monocytes 
and neutrophils whereas FPR3 mRNA has solely been detected in monocytes and mature 
dendritic cells (Durstin et al. 1994; Yang et al. 2002).  Furthermore, FPR3 is restricted to 
binding non-formylated proteins such as host acute phase proteins and amyloid-β (Le et al. 
2002).  FPR2 and FPR3 share 69% and 56% identity to FPR respectively; sequence 
divergence is most common in the receptor carboxyl tails required for signalling, whereas 
amino acid sequence is most conserved in the cytoplasmic loops (Ye et al. 2009).  FPR2 has 
a low affinity to fMLP but high affinity to the lipid mediator lipoxin A4, therefore FPR2 is also 
known as LXA4R (Fiore et al. 1994).  None the less both FPR and FPR2 are “promiscuous” 
receptors and bind a growing list pathogen and host derived peptides (Rabiet et al. 2007). 
 
 
 
Interestingly, several groups have compared neutrophil chemotaxis when stimulated 
simultaneously by opposing gradients of different chemotactic molecules (Lin et al. 2005; Kim 
and Haynes 2012).  Here, microfluidic platforms were used to precisely compare the potency 
of chemotactic molecules (Lin et al. 2005; Kim and Haynes 2012).  Initial reports by Lin et al. 
examining CXCL8 and LTB4 showed that CXCL8 is 4 to 5-fold more potent when used to 
induce chemotaxis at the same molar ratio (Lin et al. 2005).  Additionally, Lin et al. show that 
at high LTB4 concentrations CXCL8 promoted LTB4-meditated stimulation (Lin et al. 2005). 
 
Chemoattractants also have different roles within the different stages of chemotaxis.  It has 
been demonstrated that CXCL8 and LTB4 draw neutrophils from circulation to the affected 
tissue; whereas, fMLP and C5a are important for end-stage chemotaxis, directing neutrophil 
to the infection or trauma locus (Heit et al. 2002).  Heit et al. found that the p38 MAPK signalling 
pathway used by fMLP and C5a receptors could inhibit PI3K/Akt signalling by induced CXCL8 
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and LTB4 (Heit et al. 2002).  Therefore, C5a and fMLP can override other chemoattractants.      
Kim and Haynes later investigated the potency of host-derived and pathogen-derived 
stimulants by comparing fMLP, CXCL8, CXCL2 and LTB4 in a series of pairwise tug of wars.  
They established a hierarchy of chemotaxis showing that fMLP > CXCL8 > CXCL2 > LTB4 
confirming the initial reports by Heit et al.Kim and Hayes also noted that the above molecules 
had functions in addition to chemotaxis as determined by signalling pathways, such as 
priming, stimulating degranulation, cytokine release and upregulation of opsonic receptors.  In 
their summary Kim and Haynes reflected on the complex local environment in disease which 
is difficult in vitro (Kim and Haynes 2012). 
 
1.4.5. Phagocytosis 
 
Following transmigration to the affected tissues, neutrophils recognise pathogens using PPRs.  
These simulate the release of chemoattractants and pro-inflammatory cytokines as well as 
facilitating phagocytosis.  Neutrophils are phagocytic and possess opsonic receptors (CR1, 
CR3, CR4) that bind complement proteins (C3b, C4b, C1q, mannan-binding protein, iC3b), 
they also express Fc receptors for phagocytosis of pathogens opsonised with 
immunoglobulins  (Futosi et al. 2013).   The process of phagocytosis requires mobility of 
phagocytic/opsonic receptors (figure 1-16). 
 
Figure 1-16 Diagram of the process of phagocytosis 
 
 
                                                                                   , extracted from Freeman and Grinstein 
(Freeman and Grinstein 2014) a) Phagocytes probe the environment by projecting phagocytic and 
opsonic receptors on pseudopods. b) Mobility of receptors is increased by debranching and severing 
actin. c) Actin polymerisation projects pseudopods around pathogen. d)  Membrane merges and seals 
the phagosome.   
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Upon binding pathogens, actin is debranched by coronins and severed by cofilin and gelsolin 
so that further receptors can localise and enable the pathogen to be engulfed (Freeman and 
Grinstein 2014).  Activation of pro-inflammatory FcγRs and C-type lectins induces signalling 
via ITAM and the syk-pathway, this recruits WASP and Arp2/3 complexes that promote actin 
polymerisation and myosin mobilisation of actin to extend the membranes into pseudopods 
(Freeman and Grinstein 2014).  The final step is termination of actin polymerisation and fusing 
of the membrane to envelope the pathogen into the phagosome (Freeman and Grinstein 
2014). 
 
1.4.6. ROS production  
 
Endosomal compartments containing pathogens fuse with granules containing anti-microbial 
agents and proteases such as lactoferrin, mediators of ROS production (such as MPO and 
flavocytochrome) as well as NSPs (Cowland and Borregaard 2016).  ROS are generated by 
NADPH oxidase that reduce NADPH, donating the electron to oxygen, the by-product, H2O2, 
is subsequently converted to hypochlorous acid by MPO (El-Benna et al. 2016).  In 
combination O2-, H2O2 and hypochlorous acid are antimicrobial agents that destabilise and 
rupture cell membranes of phagocytosed pathogens within cytosolic compartments.  The 
dependence on ROS for combating pathogens is highlighted in chronic granulomatous 
disease, whereby patients can have one of five mutations in the gene for NADPH oxidase; 
these lead to reduced ROS production (Roos and de Boer 2014). Consequently, people with 
chronic granulomatous disease have recurrent infections caused by pathogens such as 
Burkholderia cepacia, Staphylococcus aureus and A. fumigatus (Roos and de Boer 2014). 
 
1.4.7. Degranulation 
 
Activation of neutrophils by factors such as fMLP and C5a, through their respective G-protein 
coupled receptors, induces a process called degranulation, whereby neutrophil granules fuse 
with the cell membrane and their contents (enzymes, anti-microbial peptides and ROS) are 
released into the extracellular environment.  Degranulation is not just important for clearance 
of pathogens but enables migration of neutrophils through the ECM, by degradation of the 
dense network of collagen fibres that support tissue structure.  Here, degranulation is induced 
by the interaction between ß-integrins and ICAMs (Mocsai et al. 1999; Mocsai et al. 2000; 
Fumagalli et al. 2007).   
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It has been found that neutrophils degranulate sequentially in response to different cues.  For 
example, during extravasation, or prolonged stimulation by cytokines.  However, 
overstimulation and inefficient phagocytosis of apoptotic neutrophils can result in an 
uncontrolled release of proteases (Cowland and Borregaard 2016). 
 
Three granule types have been described: Primary, secondary and tertiary granules and in 
addition secretory vesicles (table 1-5). 
 
Granule Component  Function 
Primary 
 
Neutrophil 
serine 
proteases 
Neutrophil Elastase 
Antimicrobial, immune activation, zymogen 
and cytokine activation, NET localisation 
Cathepsin G 
Proteinase 3 
Azurocidin 
Epithelial tissue permeability (family 
member but not protease) 
Acid 
hydrolases 
β-glucuronidase 
α-fucosidase 
α-mannosidase 
ECM breakdown 
Cationic 
Proteins 
Defensins Pattern recognition molecule 
MPO ROS production 
Lysozyme Bacterial cell wall breakdown 
Secondary 
Lactoferrin Iron-sequestering, biofilm breakdown 
Collagenase (MMPs) ECM breakdown 
Lysozyme See above 
Flavocytochrome NADPH oxidase component 
Tertiary 
(Gelatinase) 
Gelatinase 
Collagenase 
ECM breakdown 
Secretory vesicles 
fMLP receptor PRR, chemotaxis, degranulation 
CR3 C3b (opsonin) receptor 
CR1 C4b (opsonin) receptor 
Flavocytochrome See above 
Table 1-5: Neutrophil granules, the function of their contents. 
 
The three types of neutrophil granules contain proteases that are relevant to function.  A fourth 
type, secretory vesicles, enable quick mobilisation of PRRs and FcγR receptors to the cell 
surface (Cowland and Borregaard 2016).  Upon diapedesis from the circulation, tertiary 
granules release gelatinase and collagenase that break down ECM allowing access to 
infection site (Cowland and Borregaard 2016).  Whereas primary and secondary granules 
contain anti-microbial molecules and proteases (Cowland and Borregaard 2016).  
                                                                                               , adapted from Cowland and 
Borregaard 2016 (Cowland and Borregaard 2016). 
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Proteases are kept physically separate to prevent protease-protease degradation.  For 
example, neutrophil gelatinase-associated lipocalin, can be degraded by neutrophil elastase 
(NE) (Le Cabec et al. 1997).  For the same reason, NSPs such as NE and cathepsin G (CG), 
are stored as precursors and require proteolytic activation by cathepsin C (Lindmark et al. 
1994). 
 
 
 
NSPs are instrumental in the lysosomal degradation of phagocytosed pathogens and local 
breakdown of ECM.  The three proteases with highest granular expression are NE, CG, and 
proteinase 3 (PR3) (Cowland and Borregaard 2016).  NSPs are homologous and belong to 
the chymotrypsin super family. NE and PR3 share 53% sequence homology and their genes 
are located proximally on chromosome 19.  Coding for CG is found on chromosome 14 
alongside genes for chymase and granzyme H (Zimmer et al. 1992).  NSPs contain a serine 
residue within the active site that acts upon carbonyl bonds within substrate peptides.   
Substrate specificity is determined by amino acid sequence of the active site and the 
surrounding surface loops.  The active sites of NE and PR3 are similar due to shared 
homology; they are hemispherical and hydrophobic.  The active site of CG is larger than either 
NE or PR3.  It is separated into two compartments, with the lowest section carrying a negative 
charge.  All three NSPs preferentially cleave hydrophobic residues.  In particular, CG is 
characterised by chymotrypsin-like and trypsin-like activity, cleaving larger hydrophobic 
sequences (Korkmaz et al. 2010). 
 
NSPs are readily ensnared in NETs (section 1.4.8) due their positive charge, and the negative 
charge of the released DNA.  Using a panel of random fluorescently tagged peptides 
O’Donoghue et al. determined the proteolytic profile for the trapped proteases.  NE was shown 
to be the most active and have the most diverse substrate specificity, followed by CG and PR3 
respectively.  However, the majority of substrates were cleaved by all three NSPs 
(O'Donoghue et al. 2013).  It is therefore not surprising that NSPs have a wider role, not only 
as antimicrobial agents, but more widely in immune modulation. 
 
NSPs can also degrade ECM substrates such as elastin, fibronectin and collagen (Kelly et al. 
2008).  However, if there is unregulated release of NSPs then tissue is susceptible to 
remodelling causing a loss of organ function, a particular issue in airway diseases such as 
asthma, COPD and CF (Kelly et al. 2008). 
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NSPs have been reported to cleave bacterial cell components such as protein A on Gram 
negative bacteria and flagellin on P aeruginosa (Belaaouaj et al. 2000; Lopez-Boado et al. 
2004).  By generating NE deficient mice, Belaaouaj et al. showed a dependence on NE to 
eradicate bacterial infection during peritoneal infection.  More specifically, Gram-negative 
bacteria such as Klebsellia pnemoniae and Escherichia coli, but not Gram-positive pathogens 
such as Staphylococcus aureus (Belaaouaj et al. 1998).  With greater relevance to CF 
pathogens, Vethanayagam et al. determined the contribution of NE, CG and ROS to fighting 
bacterial pathogen Burkholderia cenocepacia and fungal pathogen, A. fumigatus.  
Interestingly, mice deficient in NADPH oxidase subunit p47phox were unable to clear A. 
fumigatus inoculated via the airway. Yet, those deficient in NE and CG but not p47phox 
recovered quickly. The authors concluded that the host requires multiple antimicrobial agents 
in addition to NSPs, for clearance of bacterial and fungal pathogens (Vethanayagam et al. 
2011). 
 
NSPs also have immunomodulatory roles such as activating inflammatory molecules from 
their pro- forms.  For example, IL-1β is an important stimulant for pro-inflammatory cytokines 
release (Joosten et al. 2009).  It is classically activated via inflammasome protease caspase-
1; however, PR3 has also been shown to cleave pro-IL-1β into the active form in capase-1 
deficient mice (Joosten et al. 2009).  This additional mechanism of activation has cast doubt 
on the efficacy of caspase-1 inhibitors to treat elevated IL-1ß in rheumatoid arthritis, an 
autoimmune disease that is characterised by neutrophilic inflammation of joints (Joosten et al. 
2009). 
 
As well as activation of pro-inflammatory cytokines, NSPs have been reported to promote 
inflammation via modulation of immune receptors.  Reports investigating NE function suggest 
that NE can upregulate expression of CXCL8 through induction of TLR4 signalling pathways 
(Devaney et al. 2003).  As a consequence, cells become more sensitive to LPS and release 
CXCL8.  Using PI-phospholipase, David et al. have demonstrated that PR3 binds GPI-
anchored FcγRIIIb (CD16) and NADPH oxidase located on neutrophil cell membranes, these 
interactions were shown to mediate induction of respiratory bursts (David et al. 2005). 
 
NSPs are also able to activate protease activated receptors (PAR).  PARs are G-protein 
coupled receptors that are activated upon binding of the ligand that, until cleaved, is fixed and 
distal from the signalling domain (Mercer et al. 2014).  They are expressed on myocytes, 
neurons, platelets and endothelial cells; they are well-documented for activation by thrombin 
(Mercer et al. 2014).  NSP modulation of PARs has been investigated.  It has been found that 
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NE cleavage sites on PAR-1 inactivates the receptor (Mercer et al. 2014).  Conversely, PR3 
cleaves PAR-2 stimulating CXCL8 release and an increase in endothelial permeability 
(Kuckleburg and Newman 2013).  In addition, NE has been shown to induce PAR-2 mediated 
release of MU5AC using goblet-like Calu-3 cells (Zhou et al. 2013a).  Therefore, because 
there is neutrophilic inflammation in the CF airway, NSPs could be important for elevated 
mucus production in this disease (Zhou et al. 2013a). 
 
 
 
Host-derived protease inhibitors regulate protease function to prevent tissue damage.  Several 
inhibitors control NSP activity in the lung, these are:   α1-anti-trypsin (AAT), Serpin B (including 
proteinase inhibitor 6 and proteinase inhibitor 9), secretory leukocyte protease inhibitor (SLPI) 
and elafin (Korkmaz et al. 2010).  I will discuss AAT, SLPI and elafin in more detail as these 
have been shown to be the most significant inhibitors of NSPs in the CF airway (Korkmaz et 
al. 2010). 
 
AAT is an inhibitor of NE, CG, MMP-12, trypsin and plasmin (Korkmaz et al. 2010).  AAT is 
from a family of proteinase inhibitors called serpins.  AAT is produced by the liver (acute 
phase), but it has also been shown to be produced by neutrophils (stored in granules), 
macrophages as well as epithelial cells (du Bois et al. 1991; Twigg et al. 2015).  AAT is a 52 
kDa glycoprotein, and therefore, because of its size, cannot easily diffuse from the circulation.  
This means that isolated tissues rely upon local production to maintain regulation of NE (and 
CG) activity (du Bois et al. 1991).  AAT binds irreversibly to NE and CG (and other proteases) 
at a ratio of 1:1.  During the interaction between NSP and AAT the peptide bond Met358-
Ser359 on AAT is cleaved by the protease causing a conformational change (Korkmaz et al. 
2010). 
 
An interesting secondary function of AAT is that it has been shown to bind the lipid 
chemoattractant LTB4 via protein-lipid hydrophobic interactions.  This prevents LTB4 from 
interacting with the chemotactic receptor BLT1R (O'Dwyer et al. 2015).  Furthermore, the 
interaction with LTB4 does not affect the inhibitory function of AAT towards NE (O'Dwyer et al. 
2015).   
 
To highlight the importance of AAT and NSP regulation, genetic mutations in the serpina1 
gene can lead to airway diseases that manifest as symptomless to severe pulmonary disease 
such as COPD (Janciauskiene et al. 2018).  Moreover, mutant “Z” variants of AAT (Glu to Lys 
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at position 342) can form polymers that have been shown to be chemotactic for neutrophils, 
driving pulmonary disease further (Janciauskiene et al. 2018). 
 
SLPI, is smaller than AAT (11.7 kDa), but like AAT SLPI is also produced by neutrophils and 
macrophages.  Additionally, in the lungs it can be generated by mucosal glands, alveolar 
macrophages and epithelial cells through stimulation by cytokines and LPS (Saitoh et al. 2001; 
Twigg et al. 2015).  SLPI is inhibitory towards NE, CG, trypsin and chymotrypsin (Saitoh et al. 
2001).  Despite homology with NE, the active site of PR3 has an isoleucine residue at position 
190 (compared to valine in NE), this one amino acid difference means that the PR3 active site 
is slightly smaller and therefore, cannot bind SLPI (Fujinaga et al. 1996). Unlike AAT, the 
interaction between SLPI and target proteases is reversible, this is because binding is 
mediated via 6 hydrogen bonds rather than conformational changes, as shown for AAT 
(Koizumi et al. 2008). 
 
An important structural property of SLPI is that it is small and, therefore, can diffuse more 
efficiently through tissue, protecting the ECM from excessive degradation (Korkmaz et al. 
2010).  As well as NSP inhibition, SLPI has also been demonstrated to have anti-inflammatory 
functions by dampening the response of monocytic cells to CXCL8, TNFα and to bacterial 
components such as LPS and lipoteichoic acid (Taggart et al. 2005).  The mechanism behind 
these anti-inflammatory functions are intracellular.  SLPI can enter the nucleus of monocytic 
cells and bind NF-kB, preventing pro-inflammatory cytokine transcription (Taggart et al. 2005). 
 
Elafin is also small (6 kDa) and shares 40% homology with SLPI; however, a significant 
structural difference is that elafin can be released as a pre-cursor molecule (pre-elafin or 
trappin-2) that possesses a transglutaminase substrate in the N-terminal (Schalkwijk et al. 
1999).  The importance of this N-terminal tail is that it facilitates incorporation of elafin into the 
lung ECM by a process called interstitial transglutamination (Schalkwijk et al. 1999).  Like 
SLPI, a small molecular weight and immobilisation in the ECM are crucial for protecting tissue 
remodelling by proteases (Korkmaz et al. 2010).  Interestingly, chimeric inhibitors combining 
the inhibitory specificity of SLPI and elafin have been recombinantly produced as a potential 
therapeutic for targeting all three major NSPs (NE, CG and PR3) (Zani et al. 2009). 
 
Similar to SLPI, elafin too has anti-inflammatory properties that work in the same way.  It has 
been shown that elafin inhibits NF-kB activation in monocytes reducing production of TNFα 
and macrophage inhibitory protein-2 (Butler et al. 2006).  Additionally, due to its cationic 
charge, elafin also has anti-microbial activity, binding several bacterial pathogens such as 
Staphylococcus aureus, P. aeruginosa and the fungal pathogen C. albicans (Bellemare et al. 
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2010).  Furthermore, elafin has been shown to accumulate in the cytosol of P. aeruginosa, 
bind DNA and interfere with the expression of virulence factors, such as biofilm production 
(Bellemare et al. 2010). This is of particular interest to CF because the above pathogens are 
prevalent in the CF airway. 
 
1.4.8. NET formation 
 
A final arm of the neutrophil arsenal against pathogens in the release of DNA to form NETs, a 
process that can be likened to a self-destruct mechanisms (Brinkmann 2018).  NETs form 
three-dimensional structures that ensnare Gram-positive, Gram-negative bacteria as well as 
yeast and hyphal forms of fungi (Branzk et al. 2014; Brinkmann 2018).  The negative charge 
of DNA within NETs captures anti-microbials, proteases and ROS that are released 
simultaneously with NETs (Brinkmann 2018).  NETs and their captured components, 
breakdown and kill the ensnared pathogens preventing them from spreading infection 
throughout tissue (Urban et al. 2009).  Complement proteins have also been detected in NETs. 
It has been shown that both the classical and alternative pathways can be activated using 
complement components ensnared in NETs (Wang et al. 2015a).  Despite this, it is unclear 
how significant the relationship between complement and NETs is for clearing infection or 
promoting pathogenesis during inflammation (Wang et al. 2015a). 
 
The process of generating NETs (NETosis) has been described as a death pathway that is 
not necrosis or apoptosis.  Furthermore, there is an element of control that dictates how much 
DNA is released meaning NETosis is not necessarily suicide (Brinkmann 2018).  NETosis has 
been shown to be induced by a list of mediators, such as: pathogen components (bacterial, 
fungal and viral), CXCL8, activated platelets, complement and ROS (Brinkmann 2018).  The 
pathways that lead to NETosis have been studied in most detail using phorbol 12-myristate 
13-acetate (PMA), a compound that is used throughout cell-biology to stimulate signal 
transduction via protein kinase 3 (PK3) (Fuchs et al. 2007). The subsequent generation of 
cytosolic ROS disintegrates mitochondria and the nucleus and increases intracellular calcium 
(Fuchs et al. 2007).   Rising calcium concentration activates peptidyl-arginine 4, facilitating the 
unravelling of chromatin, this is in tandem with NE degradation of histones (Neeli et al. 2009; 
Papayannopoulos et al. 2010). Together, nuclear membrane break-down and expansion of 
chromatin changes the appearance of neutrophil nucleus from lobular to a round mass, prior 
to cell rupture (Fuchs et al. 2007). 
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There are also reports that neutrophils can undergo non-suicidal apoptosis, whereby 
mitochondrial, but not nuclear DNA, was released from vesicles (Yipp et al. 2012).  Yipp et al. 
showed using knockout mice that C3 and TLR2 were essential for this process with preliminary 
analysis suggesting that C3a, and to a lesser extent C5a, were “vital NETosis” mediators.  The 
authors go on to conclude that it makes sense that neutrophils should be able release NETs 
but still maintain other antimicrobial mechanisms such as phagocytosis and ROS (Yipp et al. 
2012). 
 
I have briefly discussed the key effector mechanisms of neutrophils for the clearance of 
pathogens; however, neutrophils have also been reported to contribute to resolution by 
releasing annexins and pro-resolving lipid mediators such as lipoxin A4 (Jones et al. 2016b).   
Annexin-1 binds phospholipase A2, inhibiting neutrophil and macrophage responses to pro-
inflammatory cytokines and enzymes associated with nitric oxide synthesis (nitric oxide 
synthase) (Minghetti et al. 1999).  Lipoxin A4 reduces neutrophil chemotaxis by working as an 
antagonist against other pro-inflammatory lipids (leukotrienes), preventing upregulation of 
adhesion molecules and therefore slowing neutrophil migration to the site of inflammation 
(Papayianni et al. 1996; Scannell and Maderna 2006). 
 
In summary, neutrophils are essential for the clearance of pathogens and a key component of 
inflammation; however, if inflammation becomes chronic due to persistent infection or over-
stimulation, neutrophils can become pathological.  ROS and protease release can collaterally 
damage host tissue causing tissue remodelling, fibrosis and loss of function.   Diseases where 
neutrophils contribute chronic inflammation and tissue damage are: rheumatoid arthritis, 
cardiovascular disease, nephritis (Kruger et al. 2015).  Furthermore, neutrophils contribute to 
the pathology of several lung diseases such as pneumonia, COPD, asthma and CF (Kruger 
et al. 2015).  In the next section, I will discuss the role of neutrophil pathogenesis in the CF 
airway, particularly how neutrophils become dysfunctional and contribute to remodelling of the 
airway
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 Neutrophilic inflammation in CF airway 
 
The CF airway is characterised by chronic neutrophilic inflammation yet, despite their 
numbers, neutrophils are ineffective at clearing infection and are therefore considered 
dysfunctional.  Consequently, it has been well established that neutrophil count correlates with 
a decline in lung function, measured by FEV1 (Hartl et al. 2012). The phenomenon of neutrophil 
dysfunction is not unique to CF and has also been described in sepsis or systemic infection 
(Delano and Ward 2016).  Here, neutrophils are overwhelmed by pro-inflammatory signals 
and chemotactic molecules sending them into a state of “shock” (Delano and Ward 2016).  In 
that condition, over-activation of neutrophils together with recruitment of immature neutrophils 
from the bone marrow leads to ineffective pathogen clearance and consequently, mortality 
(Delano and Ward 2016).  The mechanisms behind neutrophil dysfunction in CF are poorly 
understood.  To understand neutrophil dysfunction in CF we need to answer:  1) Why does 
the CF airway become dominated by neutrophils? 2) Despite their number, why are they so 
ineffective at clearing pathogens?  I will address these questions by going through the key 
aspects of neutrophil dysfunction and how this has been shown to contribute to CF airway 
pathogenesis. 
 
1.5.1. Neutrophil PPR expression in the CF airway 
 
TLR2, TLR4 and TLR5 have been studied in depth with respect to expression in the CF airway 
(Hartl et al. 2012).  Neutrophils in the CF airway highly express TLR5, which recognises 
bacterial flagellin.  Using confocal microscopy and flow cytometry Koller et al. analyse 
neutrophils isolated from CF BAL fluid, there was significantly increased TLR5 expression 
compared to other TLRs and, there was significantly elevated expression on neutrophils in CF 
BAL fluid compared to healthy blood donors and non-CF bronchiectasis patients (Koller et al. 
2008).  Koller et al., also showed that TLR5 correlated with the detection of flagellated bacteria 
in these patients demonstrating that TLR5 is important for response to pathogens. 
Furthermore, high levels of circulating oestrogen have been shown to impede NF-κβ 
activation, a transcription factor important in TLR signalling (Chotirmall et al. 2010). This 
consequently leads to reduced cytokine expression in female CF patients, shedding light onto 
the gender gap with regards to reduced lung function in CF (Chotirmall et al. 2010). 
 
Neutrophils also store and degranulate pentraxin 3, an opsonic soluble PRR that recognises 
A. fumigatus and P. aeruginosa (Doni et al. 2016).  Pentraxin 3 has high affinity to complement 
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C1q, enhancing complement activation and opsonisation of pathogen surfaces (Gaziano et al. 
2004; Moalli et al. 2011; Doni et al. 2016).  Expression of pentraxin 3 is elevated in COPD, 
correlating with neutrophilic inflammation and decline in lung function. However, this 
correlation does not necessarily imply a causal relationship (Van Pottelberge et al. 2012).  
Pentraxin 3 expression has also been studied in the CF airway; Hamon et al. reported that 
pentraxin 3 concentration in CF sputum is lower than that of COPD and healthy controls 
(Hamon et al. 2013).  In explanation, the same authors demonstrate that proteases in the CF 
airway degrade pentraxin 3, particularly proteases released by A. fumigatus and therefore, 
degradation of pentraxin 3 may be a defence mechanism for this pathogen (Hamon et al. 
2013).  In conclusion, degradation of pentraxins by pathogen-derived and host-derived 
protease could be a contributing factor to poor pathogen clearance in the CF airway (Hamon 
et al. 2013). 
 
1.5.2. NSPs in the CF airway 
 
There have been numerous investigations into the dysfunction of neutrophil effector functions; 
however, there is not one single aspect of neutrophil dysfunction that is responsible for CF 
pathogenesis (Hartl et al. 2012).  None the less, NSPs have been identified as a major 
contributor to neutrophil dysfunction through the cleavage of cell surface receptors and 
cytokines (Twigg et al. 2015).  Furthermore, they have also been shown to promote non-
canonical activation of cytokines (such as CXCL8, see section 1.4.7a) and other proteases 
(Twigg et al. 2015).  In this section I will briefly discuss some of the substrates for NSPs that 
have been associated with neutrophil dysfunction in the CF airway. 
 
NSPs, as well as ROS, are critical for killing pathogens following phagosome-lysosome fusion 
(Cowland and Borregaard 2016).  NSPs and MMPs are also important for degradation of ECM, 
facilitating transmigration of leukocytes (Cowland and Borregaard 2016).  In the CF airway, 
excessive neutrophil activation and reduced clearance of late apoptotic and necrotic 
neutrophils causes the unregulated release of neutrophil proteases into the airway (Hartl et al. 
2012).  Neutrophils generate different classes of proteases during granulopoiesis (table 1-5) , 
but NSPs contribute widely to degradation of the ECM and, with relevance to neutrophil 
dysfunction, immune molecules and receptors (Hartl et al. 2012; Twigg et al. 2015; Cowland 
and Borregaard 2016). 
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In section 1.4.3 I discussed the array of phagocytic receptors on neutrophil cell surface.  It has 
been shown that several of these phagocytic receptors are susceptible to cleavage by NSPs 
(Hartl et al. 2012). Tosi et al. have shown that FcγRIIIB but not FcγRIIB is susceptible to 
cleavage by NE, reducing, but not completely abrogating, P. aeruginosa phagocytosis (Tosi 
and Berger 1988).  The same group also has shown that CR1, but not CR3, was susceptible 
to degradation; however, exposure to NE continued to prevent P. aeruginosa phagocytosis 
(Tosi et al. 1990).  Tosi et al. went on to demonstrate that P. aeruginosa-bound iC3b could be 
also cleaved by both NE and pseudomonas proteases, inhibiting pathogen uptake (Tosi et al. 
1990).  More recently, our group has shown that Dectin-1 is also susceptible to degradation 
by NE and proteases expressed by A. fumigatus, reducing macrophage uptake of zymosan 
particles (Griffiths et al. 2018).  In these experiments Dectin-1 cleavage was observed when 
exposed to CF BAL fluid with detectable NE activity, suggesting a role for impaired pathogen 
uptake in CF (Griffiths et al. 2018). 
 
 
 
C5aR1 is a G-protein coupled receptor that binds to the chemotactic complement fragment 
C5a (will be discuss in detail in section 1.7.3).  It has been shown by our group that NSPs, 
present in the CF airway, can cleave and inactivate C5aR1 (van den Berg et al. 2014).  This 
does not mean that C5a is not an important chemoattractant and inflammatory mediator in the 
CF airway.  It was hypothesised that the C5a/C5aR1 axis contributes to the influx of 
neutrophils to the CF lumen; however, upon infiltration to the chronically inflamed airway NSPs 
cleave C5aR1 rendering it unresponsive to stimulation (van den Berg et al. 2014).  As will be 
discussed later, C5a is not just a potent chemoattractant but critical for upregulation of PRRs 
and therefore, recognition and killing of pathogens (Hunniger et al. 2015). 
 
 
 
PR3 has been shown to cleave and activate PAR-2 stimulating CXCL8 release and an 
increase in endothelial permeability (Kuckleburg and Newman 2013).  In addition, NE has 
been shown to induce PAR-2 mediated release of MU5AC using goblet-like Calu-3 cells (Zhou 
et al. 2013a).  MUC5AC is a mucin that is elevated during chronic airway inflammation in 
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COPD and CF.  Increased expression of mucins leads to airway obstruction causing infection 
and reducing lung function (Kreda et al. 2012). 
 
NSP-mediated damage to cilia has also been investigated.  Amitani et al. have shown using 
human tissue that NSP cause epithelial disruption by detachment from the basal membrane 
however, there was no evidence that NE (or Pseudomonas elastase from P. aeruginosa) were 
able to degrade cilia (Amitani et al. 1991). 
 
Airway surfactants are important in reducing airway surface tension to facilitate gas exchange 
and prevent air collapse.  Surfactant protein-A and surfactant protein-D are collectins 
(collagenous lectins); they are like C-type lectins but are soluble PRRs that opsonise 
pathogens for phagocytosis by neutrophils.  It has been shown that both surfactant protein A 
and D concentrations are decreased in the CF airway compared to healthy controls (Postle et 
al. 1999).  In explanation, it has been shown that both surfactant protein-A and D are 
susceptible to degradation by NSPs, preventing the role of opsonising pathogens (Rubio et al. 
2004; Duvoix et al. 2011). 
 
1.5.3. Dysfunction in ROS in the CF airway 
 
ROS production is critical for pathogen killing, but it can also be detrimental towards host cells 
and can cause significant collateral damage when released in an unregulated manner, as 
observed in the CF airway (McGrath et al. 1999).  It was demonstrated by Starosta et al. that 
oxidation of pulmonary proteins by ROS may promote pathogenesis (Starosta et al. 2006).  
Specifically, the authors found that protein carbonyls were elevated in CF patients with 
predicted lung function (FEV1) less than <80%. Carbonyl groups (CO, aldehydes and ketones) 
are generated on protein side chains, especially during oxidation of amino acids such as 
proline, arginine and threonine (Dalle-Donne et al. 2003; Starosta et al. 2006).  Furthermore, 
it has been proposed that malabsorption of anti-oxidants by individuals with CF hinders the 
ability to counteract excessive ROS release (Skov et al. 2015).  To restore redox balance, two 
anti-oxidant derivatives, N-acetylcysteine and ascorbic acid, have been administered to CF 
patients in a trial (Skov et al. 2015).  Skov et al. measured efficacy by monitoring lung function 
and urine oxidation markers over a three-month period.  Despite observing encouraging 
trends, the authors concluded that the study was underpowered and could not confidently 
suggest routinely administering anti-oxidants (Skov et al. 2015).
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1.5.4. NSP inhibitors in the CF airway 
 
NSP inhibitors such as AAT, SLPI and elafin are essential for regulating NSP-mediated 
degradation; however, during excessive neutrophilic inflammation these inhibitors can be 
overwhelmed by the excessive release of NSPs themselves (figure 1-17).  Proteolysis of ECM 
components such as, elastin, collagen and fibronectin remodels the airway, reducing lung 
function.  Furthermore, the broad range and specificity of NSPs means that they can also 
activate PARs, cleave cytokines from pro-forms and inactivate phagocytic receptors and 
receptors that orchestrate neutrophilic inflammation, such as C5aR1 (Twigg et al. 2015). 
 
 
Figure 1-17: Protease and anti-protease balance in the normal and chronically inflamed airway. 
 
 
 
During a normal inflammatory response protease activity is regulated by protease inhibitors that are 
released by neutrophils, macrophages and resident lung cells.  B) During chronic neutrophilic 
inflammation inefficient clearance of apoptotic neutrophils and stimulation of neutrophils causes the 
excessive release of NSPs in to airway that overwhelm protease inhibitors.  The fine balance 
protease/anti-proteas balance is tipped and there is ECM degradation, tissue remodeling and 
consequently loss of lung function.   
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As well as there being an excess of proteases to inhibitors, it has also been shown that the 
inhibitors too are susceptible to degradation, reducing their activity towards proteases.  It has 
been observed that SLPI is inversely proportional to pseudomonas elastase and NE in BAL 
fluid from CF patients (Weldon et al. 2009).  Further investigation showed that NE could 
inactivate SLPI, cleaving at two different sites however, NE-degraded SLPI retained some 
inhibitory activity towards NE (Weldon et al. 2009).  Degradation of SLPI has also been 
demonstrated using cathepsins S, L and B cysteines released by macrophages and lung 
epithelial cells (Taggart et al. 2001).  As demonstrated for SLPI, Elafin can also be 
proteolytically inactivated by NE, as well as pseudomonas elastase (Guyot et al. 2008; Guyot 
et al. 2010).  Cleavage of the elafin protease-binding loop by NE did not reduce the anti-
microbial activity (Guyot et al. 2008). In contrast, AAT is resistant to proteolytic degradation 
by NE (and the other NSPs); however, inactivation by MMP-8 released by neutrophils has 
been demonstrated (Michaelis et al. 1990). 
 
1.5.5. NETs 
 
NETs entrap proteases and pattern recognition molecules such as collectins, ficolins and 
pentraxins; in turn these degrade or tag pathogens for phagocytosis (Brinkmann 2018).  Due 
to their size fungal pathogens such a C. albicans and A. fumigatus are readily trapped in NETs 
(Parks et al. 2009).  Conversely to the bactericidal function of NETs, P. aeruginosa can utilise 
DNA scaffolding in NETs to form biofilms, preventing recognition by the immune system (Parks 
et al. 2009).   In CF, extracellular DNA inversely correlates with pulmonary function suggesting 
that neutrophil necrosis and NET assembly contributes to pathogenesis.  However, bacterial 
lysis will also contribute to extracellular DNA (Lethem et al. 1990).  To counteract the 
detrimental effects of NETs, a trial of DNase was administered to children with CF (Ratjen et 
al. 2005).  Decreased DNA concentration was observed over 18 months, whilst neutrophil 
numbers were not significantly different to the placebo group (Ratjen et al. 2005).  The authors 
state that DNase is not directly anti-inflammatory; however, reviews of the long-term impact of 
this treatment on lung function suggest it is more beneficial for the most unwell patients 
(Konstan and Ratjen 2012). 
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1.5.6. Resolution of inflammation 
 
Efferocytosis of apoptotic neutrophils is an important initiator of inflammatory resolution.  
Neutrophils have a short life span in circulation (8 to 20 hours) and longer life span in tissue 
(1 to 4 days) (Greenlee-Wacker 2016).  Neutrophils are highly adaptive to their local 
environment allowing them to rapidly respond to infection or damage but also respond to pro-
resolution cues that prevent them causing collateral damage of tissue (Prince et al. 2017).  In 
a recent report investigating important pathways in neutrophil survival, Prince et al. stimulated 
neutrophils in vitro with several pro-survival cues (cAMP (protein kinase A agonist), GM-CSF, 
LPS, conditioned (LPS-treated) monocyte media, hypoxia (Prince et al. 2017).  Messenger 
RNA transcripts were quantified.  Interestingly, a combination of two PKA agonists (N6/8-AHA) 
upregulated an intriguing apoptosis pathway that involved transcription of nuclear receptors, 
NR4A2 and NR4A3 (Prince et al. 2017).  Further experimentation in murine cells knocking 
down expression of NR4A2 and NR4A3 using siRNA, revealed that NR4A2 but not NR4A3 
was important for neutrophil survival. 
 
Apoptosis of neutrophils can be triggered intrinsically or extrinsically with respect to the cell 
(Moriceau et al. 2010).  For example, ROS-induced disruption to mitochondrial membrane 
potential or ER can induce apoptosis intrinsically (Moriceau et al. 2010).   Neutrophil apoptosis 
can be triggered extrinsically by Fas via Fas receptors and tumour necrosis factor alpha 
(TNFα) via TNF-R1.  Moriceau et al. have demonstrated delayed neutrophil apoptosis in 
ΔF508 cftr heterozygotes and homozygotes in comparison to healthy controls (Moriceau et al. 
2010).  It was hypothesised that reduced glutathione, an important cellular anti-oxidant, may 
delay Fas-mediated apoptosis in CF patients due to deficiencies in the CFTR, but they 
recognised that other unknown factors could be responsible (Moriceau et al. 2010). 
 
Macrophages are essential for the efferocytosis of apoptotic neutrophils.  It has been shown 
that the phosphatidylserine receptor expressed on monocyte-derived macrophages is 
susceptible to NE and CG cleavage reducing uptake of apoptotic Jurkat cells (T-cell line) 
(Vandivier et al. 2002b).  In the same report it was shown that surfactant protein-D, found 
reduced in the CF airway and airway disease, is critical for clearance of apoptotic neutrophils 
through binding to MPO.  Later insight into surfactant protein D deficiency in the CF airway 
has revealed susceptibility to cleavage mediated by NE and CG (Duvoix et al. 2011).  
Investigation into the role of surfactant protein D in the CF airway by our group also revealed, 
that the level of surfactant protein D oligomerisation is important for function.  Particularly, 
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lower levels of surfactant protein D oligomerisation, as found in the CF airway, were less 
capable of binding zymosan (Kotecha et al. 2013). 
 
1.5.7. GAGs in the CF airway 
 
GAGs are linear repeats of heterogenous polysaccharides that are expressed on the cell 
surface and are important constituents of the ECM, particularly in the alveolar epithelium and 
subepithelial tissue of the airways (Reeves et al. 2011a).  GAGs have multiple homeostatic 
functions in cell migration, differentiation, adhesion, wound healing and inflammation (Reeves 
et al. 2011a).  The structural properties and function of GAGs in the airway will be discussed 
in greater detail in chapter 6 as part of the background to the study.  However, I will briefly 
cover some of the major aspects of GAGs and their role in pathogenesis of the CF airway. 
 
As well as protease inhibitors, GAGs, such as HS, play an important role in regulating NE 
activity (Reeves et al. 2011a). The mechanism here is that HS is generated in large arrays 
with a protein core (such as syndecan). During an inflammatory response NE can cleave 
syndecan releasing soluble HS (Spencer et al. 2006).  In turn, soluble HS inhibits NE activity, 
regulating activity and preventing extensive damage to the ECM or affecting the inflammatory 
process (Spencer et al. 2006).  However, during chronic neutrophilic inflammation of the 
airway, such as in CF, NE degrades HS proteoglycans, but the high NE activity overwhelms 
the above feedback mechanism, leading to tissue degradation (Spencer et al. 2006; Reeves 
et al. 2011a). 
  
Soluble GAGs, released by degradation of the ECM, have been shown to bind with multiple 
chemokines and anti-microbial peptides modifying their functions both positively and 
negatively (Reeves et al. 2011a). For example, LL-37 (also known as cathelicidin) is an anti-
microbial protein that binds LPS, it is also chemotactic for neutrophils and induces 
degranulation and ROS production via stimulation of FPR2 (Zanetti 2004; Bergsson et al. 
2009).  Binding of LL-37 to GAGs reduces antimicrobial activity furthermore, GAGs prevent 
degradation  of LL-37 allowing it to accumulate in the CF airway (Bergsson et al. 2009). 
 
CXCL8 is another important example of the immunomodulatory effects of soluble GAG binding 
in the CF airway (Reeves et al. 2011b).  It has been shown that several different GAGs bind 
to CXCL8.  Furthermore, it has been hypothesised that these interactions are important for 
establishing chemotactic gradients within tissue, such as the lungs (Pichert et al. 2012b).  
CXCL8, is elevated in the CF airway, despite susceptibility to degradation by NSPs (Dean et 
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al. 1993; Leavell et al. 1997).  It has been shown that when in complex with GAGs CXCL8 is 
resistant to degradation by NSPs (Reeves et al. 2011b). Unlike LL-37, GAG interaction with 
CXCL8 does not alter function however, in both the case of LL-37 and CXCL8, hypertonic 
saline, a mucolytic therapy in CF, disrupts GAG interactions increasing susceptibility to 
degradation (Bergsson et al. 2009; Reeves et al. 2011b; Schlorke et al. 2012). 
 
 
Figure 1-18: Overview of the reported mechanisms of neutrophil dysfunction in the CF airway 
 
In this section I have discussed several aspects of neutrophil dysfunction that drive 
pathogenesis in the CF airway (summarised in figure 1-18).  Impaired neutrophil function 
during chronic neutrophilic inflammation sheds light on why they might be ineffective at 
clearing pathogens; however, understanding the factors underpinning excessive PMN 
recruitment to the CF airway is crucial.  Investigating the conundrum of excessive neutrophil 
recruitment to the CF airway has been approached in two ways 1) characterising neutrophil 
chemoattractants that are elevated in the CF airway 2) Assessing defects in neutrophil 
efferocytosis.  Investigation of how neutrophilic inflammation is initiated and resolved in the 
CF airway has revealed that there is dysregulation in both (Hartl et al. 2012).  I have briefly 
discussed dysfunction in the clearance of apoptotic neutrophils in the CF airway in the 
previous section.  In the next section I will focus on the chemoattractants that have been found 
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elevated in the CF airway and how they individually contribute to pathogenesis in the CF 
airway. 
 
1.5.8. Neutrophil recruitment in the CF airway 
 
Neutrophil chemoattractants have been found elevated in the CF airway and are thought to 
be a major contributing factor to disease progression through neutrophil recruitment (Sagel et 
al. 2007; Mackerness et al. 2008).  The most intensively investigated chemoattractant is 
CXCL8; however LTB4, fMLP, platelet activation factor (PAF) and C5a have also been 
reported to be elevated (Mackerness et al. 2008).  Mackerness et al. used CF sputum to 
stimulate neutrophil migration and assessed the significance of each of the above chemotactic 
molecules using inhibitory antibodies or receptor antagonists (Mackerness et al. 2008).  They 
showed that inhibition of CXCL8 significantly reduced neutrophil chemotaxis towards sputum 
from 13 CF patients.  Additionally, only by including inhibitors of LTB4, fMLP, PAF and C5a or 
receptor antagonists could chemotaxis be fully arrested.  Furthermore, using flow cytometry 
they show that neutrophil shape change, an indicator of chemotaxis, following incubation with 
CF sputum could be partially arrested by pre-incubating sputum with inhibitors for CXCL8, 
LTB4, and fMLP.  C5a and PAF receptor inhibitors were additionally required to completely 
prevent any shape change (Mackerness et al. 2008). 
 
This important study highlights the fact that, despite CXCL8 being highly cited as the most 
significant factor contributing to neutrophil recruitment and activation, there are additional 
potent mediators that may also play a critical role in CF pathogenesis (Mackerness et al. 
2008).  We need to understand the function of each molecule and their role in CF pathogenesis 
before confidently pursuing them as therapeutic targets. I will discuss the significance of 
CXCL8, LTB4 and fMLP in the CF airway (as well as other airway diseases) and, where 
appropriate, therapeutics that have been developed to reduce their pathogenesis. 
 
 
 
CXCL8 is a member of the chemokine family and is a potent chemoattractant (Griffith et al. 
2014).  Several groups have measured CXCL8 in CF airway samples such as BAL fluid or 
sputum and reported that it is significantly elevated compared to healthy or non-diseased 
controls.  Furthermore, it is well established that CXCL8 correlates with neutrophilic count and 
markers of neutrophilic inflammation, such as NE activity (Dean et al. 1993; Richman-
Eisenstat et al. 1993; Sagel et al. 2001).  Due to the strong correlations reported between 
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CXCL8 and neutrophil count, CXCL8 is routinely used a marker of neutrophilic inflammation 
when investigating factors that promote neutrophilic inflammation or assessing the influence 
of therapeutics on CF airway inflammation (Ratjen et al. 2016; Barnaby et al. 2018). 
 
As mentioned in section 1.5.7, CXCL8 (and other chemokines) have been shown to bind to 
GAGs and this is an interesting field within CF pathology.  CXCL8, in complex with soluble 
GAGs, is protected from proteolysis by NSPs thereby, increasing its half-life within the CF 
airway.  In CF clinics, nebulised hypertonic saline is administered to patients followed by a 
vigorous physiotherapy routine.  Nebulised saline reduces mucus viscosity and alongside 
physiotherapy helps to free obstruction of the small airways.  Reeves et al. demonstrated that 
hypertonic saline could be used to disrupt ionic bonds between CXCL8 and GAGs, facilitating 
the proteolytic cleavage of free CXCL8 by proteases present in the airway (Reeves et al. 
2011b).  McElvaneny et al. have more recently engineered a compound, PA401, that could 
compete with CXCL8 for GAG-binding, therefore leaving CXCL8 susceptible to proteolysis by 
proteases (McElvaney et al. 2015).   It was shown using CF BAL fluid, that increasing the 
concentration of PA401 could prevent CXCL8-GAG binding leaving the free CXCL8 
susceptible to degradation by the constituent proteases however, the authors noted that 
PA401 was also susceptible to degradation by proteases (McElvaney et al. 2015).  This 
mechanisms of promoting degradation CXCL8 by NSPs could help reduce CXCL8 levels in 
the CF airway and reduce the recruitment of neutrophils (McElvaney et al. 2015). 
 
 
LTB4 is lipid neutrophil chemoattractant derived from arachidonic acid (Brink et al. 2003).  LTB4 
is elevated in CF patient sputum and correlates with increased expression of TNFα, an 
important pro-inflammatory cytokine that upregulates the LTB4-generating enzyme, 5-LOX 
(Greally et al. 1993).  Characterisation of LTB4 in CF BAL fluid revealed a 30-fold increase 
compared to healthy controls. Increased concentrations of less potent eicosanoids such as 
prostaglandins and thromboxane were also noted; these have functions including 
bronchoconstriction (Konstan et al. 1993).  Despite high concentrations of LTB4, chemotaxis 
of neutrophils was shown to be reduced in sputum from CF patients that were positive for P. 
aeruginosa, and in the presence of other chemotactic stimuli (fMLP), raising questions about 
cross-receptor inactivation or desensitisation (Lawrence and Sorrelli 1992). 
 
In light of the elevated levels of LTB4 in the CF airway, a double-blind clinical trial was carried 
out on a cohort of CF patients using a LTB4 antagonist, BIIL-284 BS, a BLT1R antagonist 
(Birke et al. 2001).  Children and adults with CF were treated orally with a placebo or the 
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antagonist over a 24-week period. The trial was terminated prematurely following a significant 
increase in serious adverse events, such as pulmonary exacerbation resulting in admission to 
hospital (Konstan et al. 2014).  In a separate study, the same group investigated the 
mechanism behind the adverse events in the BIIL-284 BS trial and found that inhibiting LTB4-
mediated neutrophil chemotaxis induced P. aeruginosa bacteraemia in mice (Doring et al. 
2014).   The BIIL-284 BS trial is further reason why we need to better understand the complex 
roles of the range of chemotactic and pro-inflammatory molecules in the CF airway before 
undergoing intervention. 
 
 
 
Formyl-Met-Leu-Pro is a by-product of bacterial protein synthesis. Recognition by surface 
receptors induces a potent chemotactic response and also stimulates degranulation and ROS 
production (Ye et al. 2009).  In COPD, like CF, neutrophil inflammation promotes disease 
progression (Hoenderdos and Condliffe 2013).  CXCL8 correlates with neutrophil recruitment 
during pulmonary exacerbation in COPD; however, fMLP-mediated ROS production plays an 
important role in pathogenesis, reducing lung function (Jones et al. 2016a).  Quantification of 
formyl peptides and small host derived peptides such as DAMPs in the CF literature is not 
well-documented.  Mackerness et al. identified formyl peptides in CF sputum using, ion-
exchange chromatography.  Furthermore, they used a FPR receptor antagonist, Boc-Met-Leu-
Phe, to inhibit fMLP-mediated chemotaxis in CF BALF, demonstrating that fMLP contributes 
to neutrophil stimulation in the CF airway   (Mackerness et al. 2008). 
 
Complement C5a has also been identified as an important mediator of neutrophilic 
inflammation in the CF airway (Fick et al. 1986; Sass et al. 2015; Hair et al. 2017). In the next 
chapter I will discuss the complement system with particular focus on the complement 
anaphylatoxins, C3a and C5a, and their potential role in CF disease pathogenesis. 
  
 The Complement system 
 
Complement is an evolutionary ancient arm of the immune system and crucial for the 
clearance of pathogens, necrotic cells and other foreign bodies (Ricklin and Lambris 2013).  
Throughout its evolution in humans complement has bridged adaptive and innate immune 
responses allowing specific targeting of pathogens via antibody complexes (Ricklin and 
Lambris 2013).  Complement is essentially a cascade of proteases that cleave fluid phase 
mediators, the products of which assemble to produce other proteases with alternative 
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substrate specificity (Ricklin and Lambris 2013).  There are three effector products of the 
complement system: the membrane attack complex (MAC), opsonins and the complement 
anaphylatoxins (figure 1-19).  The main source of complement proteins is the liver; however, 
local generation of complement components is widely reported as a source of complement in 
tissue (Li et al. 2007). 
 
1.6.1. Initiation and activation. 
 
There are two activation pathways, classical and lectin, with a third pathway, or amplification 
loop, that rapidly upregulates complement activation (also known as the alternative 
pathway)(Ricklin and Lambris 2013).  The classical pathway is predominantly initiated through 
C1q binding to immunoglobulins (IgG and IgM) on pathogen surfaces, or host cells in the case 
of auto-immune diseases such as systemic lupus erythematosus (Ricklin and Lambris 2013; 
Leffler et al. 2014). 
 
Upon binding immunoglobulins (and pentraxin 3), C1q forms complexes with proteases C1r 
and C1s that cleave C4 and C2 into C4a and C4b or C2a and C2b respectively (Ricklin and 
Lambris 2013).  C4b binds to cell surfaces and forms (with C2b) the C3 convertase (C4bC2b), 
a proteolytic complex central to the complement system (Ricklin and Lambris 2013). 
 
The lectin pathway is initiated by mannose-binding lectin (MBL), ficolins and collectins that 
bind to mannose and other carbohydrates on the surfaces of pathogens and host cells (Ricklin 
and Lambris 2013; Farrar et al. 2016).  Mannose-binding lectin associated proteases (MASPs) 
form complexes with MBL, ficolins and collectins and, like the C1 complex, cleave C2 and C4 
to help assemble the C4bC2b C3 convertases (Ricklin and Lambris 2013)  
 
The amplification loop is based around the principle that C3 can be spontaneously hydrolysed 
(C3(H2O)) in blood by surfaces of particles, lipids, platelets and gas bubbles (Nilsson and 
Nilsson Ekdahl 2012).  Factor D cleaves factor B into Bb, this binds with C3(H2O) on cell 
surfaces to form a C3(H2O)Bb C3 convertase (Nilsson and Nilsson Ekdahl 2012).  C3 
convertases (both C4bC2b and C3(H2O)Bb) cleave C3 into C3a and C3b, C3b drives 
generation of more C3 complexes (C3bBb) (Nilsson and Nilsson Ekdahl 2012). 
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Figure 1-19 Diagram of the complement system and its functions and regulation. 
  
 
 
 
 
 
                                                                                                                                           
The complement system is activated by two initiation pathways, classical(blue) and mannose binding 
lectin (orange).  Activation can also be regulated via the amplification loop (green) also known as the 
alternative pathway.  Complement activation converges on the assembly of C3 convertase (purple), 
cleavage of C3 produces C3b and C3a.  C3b opsonises pathogen and host surfaces and those of foreign 
bodies such as debris or cholesterol crystals.  The majority of C3b is inactivated or hydrolysed (iC3b) 
but this is still a functional opsonin.  C3b can further drive complement activation via the amplification 
loop or bind to C3 convertase forming C5 convertase (red).  C5 is cleaved by C5 convertase producing 
C5b and C5a.  C5b inserts into cell surfaces and with the terminal components forms the membrane 
attack complex (pink).  C3a and C5a are also produced by their respective convertases and have 
multiple pro-inflammatory functions.  Complement is tightly regulated by complement regulators 
(black/yellow) that inhibit activation (C1 inhibitor), destabilise convertases (CR1, CD46, CD55, factor H 
and factor I) and prevent MAC formation (CD59, clusterin, vitronectin).  The complement anaphylatoxins 
are inactivated by carboxypeptidases N and B. 
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1.6.2. Complement effector functions 
 
The cleavage of C3 by C3 convertases produces C3a and C3b. As well as forming new C3 
convertases, C3b can bind with C3 convertases to assemble C5 convertases (C4bC2bC3b 
and C3bBbC3b) (Ricklin and Lambris 2013).  C5 convertases cleave C5 into C5a and C5b, 
with C5b interacting with C6 to form C5bC6.  C5bC6 binds to cell surfaces and forms a larger 
assembly with C7 that inserts into the cell membrane (Ricklin and Lambris 2013).  The final 
step is the binding of C8 and >20 C9 components to C5b6-9 to form a pore in the cell 
membrane called MAC, through which there is free movement of water and ions across the 
membrane (Serna et al. 2016).  A threshold of multiple MACs on a cell surface are required to 
lyse pathogen and host cell membranes, below this threshold cell integrity is maintained, a 
phenomenon known as sub-lytic MAC formation (Triantafilou et al. 2013).  The diffusion of 
ions into the cell through MAC still occurs and, in particular, the flow of calcium ions into host 
cells like monocytes and neutrophils has been reported to induce intracellular calcium 
signalling pathways, triggering inflammasome activation and IL-1ß production (Triantafilou et 
al. 2013). 
 
C3b covalently binds hydroxyl groups on cell surfaces. These are mainly carbohydrates but 
can include protein amine groups (Ricklin and Lambris 2013). C3b on cell surfaces not only 
facilitates the assembly of C5 convertases and MAC formation but is also an opsonin for 
phagocytes through recognition by CR1 (Ricklin and Lambris 2013).   C3b is predominantly 
found in an inactivated form (iC3b) following inactivation by Factor I and co-factors (Ricklin 
and Lambris 2013).  Inactivated C3b cannot form C5 convertase but, along with other 
complement break-down products (such as C3d), can be recognised by complement 
receptors (CR1, CR2, CR3 (main iC3b receptor) and CR4) and therefore, iC3b is also opsonic 
(Ricklin and Lambris 2013).  Opsonic recognition by complement is essential for clearance of 
pathogens and necrotic cells during infection (Freeman and Grinstein 2014). 
 
The complement cascade also generates three anaphylatoxins, C3a, C4a and C5a (Ricklin 
and Lambris 2013).  C5a and C3a are important orchestrators of inflammation that induce 
chemotaxis, degranulation and ROS production in monocytes and neutrophils; they will be 
discussed in greater depth in sections 1.7 and 1.8 respectively. The role of C4a in inflammation 
is not clear.  A receptor for C4a has only recently been described, before then no function had 
been assigned.  Wang et al. investigated C4a signalling using a screen of cells transfected 
with individual G-protein coupled receptors (Wang et al. 2017).  The authors observed that 
C4a induced intracellular calcium flux via PAR 1 and 4 on endothelial cells, increasing 
72 
 
permeability.  Despite intriguing results, these preliminary data require further investigation as 
the authors could only speculate on a role in disease (Wang et al. 2017). 
 
1.6.3. Regulation of complement 
 
Complement is important for clearance of pathogens as well as immune complexes, apoptotic 
and necrotic host cells; however, tight regulation is required to maintain homeostasis and 
prevent pathogenesis (Ricklin and Lambris 2013).  The human complement system has 
several regulators that control activation and prevent MAC-mediated lysis of self-cells (Ricklin 
and Lambris 2013).  C1 esterase inhibitor is a serine protease inhibitor that prevents activation 
of complement by binding to C1r and C1s, it can also inhibit proteases in the coagulation 
pathway and MASPs (Riedl 2015).  Genetic deficiency in C1 esterase inhibitor causes 
hereditary angioedema, activation of complement and generation of complement 
anaphylatoxins (C3a and C5a) that consequently induce inflammation in the skin leading to 
swelling (Riedl 2015). 
 
Complement regulation is also maintained by several cell surface molecules that either 
prevent MAC formation (CD59), prevent the formation of convertases (CD35/CR1) or act as 
co-factors for factor I-mediated inactivation of C3b (CD35/CR1, CD46, CD55) (Ricklin and 
Lambris 2013).  CD59 is a glycophosphatidylinositol cell-surface anchored protein that 
prevents MAC formation by blocking C9 polymerisation on the C5b6-8 terminal pathway 
complex (Hillmen et al. 2006).  The significance of CD59 in restricting MAC deposition is 
highlighted in paroxysmal nocturnal haemoglobinuria (PNH), a complement-mediated disease 
that is caused by mutation in GPI, required for CD59 (and CD55) presentation on cell surfaces 
(Hillmen et al. 2006).  Erythrocytes only possess GPI-anchored cell surface complement 
regulators (CD59 and CD55) and therefore, are susceptible to lysis by MAC (Hillmen et al. 
2006).  As well as surface-bound MAC regulators, soluble MAC formation inhibitors, clusterin 
and vitronectin, bind to C7-C9 preventing MAC assembly and cell lysis (Ricklin et al. 2010). 
 
CD55 (or decay accelerating factor, DAF) is a membrane bound regulator that dissociates C3-
convertase (both C4b2b and C3bBb) and thereby prevents C5 convertase formation (Ricklin 
et al. 2010).  CR1 also has decay accelerating function as well as being a phagocytic receptor 
for C3b (Ricklin et al. 2010).  CR1 binds C3b and C4b acting as a cofactor for factor I-mediated 
inactivation to iC3b and iC4b; these inactivated fragments are unable to form convertases.  
Other regulators that act as cofactors for factor I are CD46 (membrane bound) and soluble 
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regulators such as factor H and factor H-like proteins, that interact with factor I and aid factor 
I mediated cleavage and inactivation of C3b, generating iC3b. 
 
Finally, C3a and C5a are potent mediators of inflammation and therefore require tight 
regulation. C3a and C5a are rapidly inactivated by carboxypeptidase N (CPB) and B (CPB) 
through cleavage of the arginine C-terminal residue (Campbell et al. 2002).  The products, 
C3adesArg and C5adesArg have substantially reduced activity (Campbell et al. 2002). 
 
1.6.4. Non-canonical activation of complement by endogenous and exogenous 
proteases 
 
An area of complement biology that has growing appreciation is the activation and regulation 
of complement by non-complement enzymes. These include, proteases from the coagulation 
system, NSPs released by neutrophils and also exogenous sources such as bacteria, fungi 
and protease from parasites such as dust mites (Brozna et al. 1977; Wetsel and Kolb 1983; 
Robbins et al. 1991; Giles et al. 2015).  In particular, the generation of the complement 
anaphylatoxins C3a and C5a from their parent molecules (C3 and C5) during infection and 
inflammation (Huber-Lang et al. 2012; Yuan et al. 2015; Hooshmand et al. 2017).  However, 
despite our knowledge of non-canonical C3a and C5a generation, our understanding of how 
much they contribute to disease pathology is unclear and will be discussed in much greater 
depth as part of the background to chapter 4. 
 
1.6.5. Complement in disease 
 
The complement system has important roles in homeostasis, development and immunity. 
Consequently, genetic deficiency in some complement components can lead to specific 
pathologies or susceptibility to infection (figure 1-20) (Ricklin and Lambris 2013).  As 
mentioned above, mutations in GPI and cell membrane anchors can lead to PNH through lack 
of CD59 and CD55 expressions on erythrocytes (Hillmen et al. 2006).  
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Figure 1-20: Diseases where complement has been reported to contribute to pathogenesis. 
 
Another well-characterised disease where complement plays a major pathogenic role is 
atypical haemolytic uremic syndrome (aHUS), an auto-immune disease caused by auto-
antibodies targeting factor H or mutation in genes coding for factor H (Wong et al. 2013).  
aHUS predominantly manifests in the kidneys whereby, over-activation of platelets or 
endothelial cell damage causes a loss of kidney function and leads to mortality through end-
stage renal disease (Wong et al. 2013).  To further highlight the importance of complement in 
host defence, there are rare cases of human genetic (homozygous) C3 deficiency (Botto et al. 
2009).  These patients have recurrent bacterial infections at a young age suggesting that 
complement plays an important role in host defence prior to establishing adaptive antibody 
repertoire (Botto et al. 2009).  These patients also shed light on to the role of C3 in adaptive 
immune response and development of B cell memory (Botto et al. 2009; Ricklin et al. 2010). 
 
A characteristic of many complement disorders is inflammation, a consequence of 
complement activation and generation of pro-inflammatory anaphylatoxins C3a and C5a, 
which recruit and stimulate migrating immune cells (Ricklin et al. 2010). 
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1.6.6. Complement and inflammation 
 
Inflammation is a pathogenic factor in many complement-meditated diseases.  Age-related 
macular degeneration (AMD) is a disease that causes a loss of vision in elderly people (Ricklin 
et al. 2010).  The causes of AMD are currently still under investigation; however, mutation in 
complement components such as C3, factor B and factor H are reported to be risk factors 
(Kauppinen et al. 2016).  AMD is a slow-acting disease driven and perpetuated by an 
imbalance in complement activation that promotes inflammation and damage of subretinal 
tissue (Kauppinen et al. 2016).  This damage is thought to be mediated by activation of 
monocytes, macrophages and neutrophils through the release of ROS (Kauppinen et al. 
2016). 
 
Dementia has become increasingly accepted as an inflammatory disease, with complement 
playing a role in promoting pathogenesis (Morgan and Harris 2015).  C1q has been shown to 
be elevated in brain tissue from Alzheimer’s patients and is thought to be important in synaptic 
pruning (selective killing of synapses) and neurodegeneration (Morgan and Harris 2015).  The 
role of C1q in synaptic pruning has been further elucidated in mice whereby C1q deficient 
mice were unable to efficiently clear inactive synapses (Morgan and Harris 2015; Hong et al. 
2016).  Alzheimer’s disease is characterised by the formation of amyloid-ß plaques and 
cytosolic Tau tangles (Pimplikar 2014).  It is hypothesised that amyloid-ß plaques can activate 
the classical pathway leading to the generation of C3a and C5a, these consequently stimulate 
microglia (macrophages in the brain) to release pro-inflammatory cytokines that can promote 
tissue damage (Morgan and Harris 2015).  
 
Complement activity has also been implicated in inflammatory airway diseases such as acute 
respiratory distress syndrome, asthma, COPD and CF (Pandya and Wilkes 2014).  The 
complement system is critical for eradication of airway pathogens.  C3-deficiency increases 
susceptibility to Streptococcus pneumonia and P. aeruginosa, pathogens associated with 
pneumonia (Pandya and Wilkes 2014).  Exposing the lungs of mice and rats to LPS (simulating 
bacterial infection) has demonstrated that complement is important for opsonisation of 
pathogens (Bolger et al. 2007).  Furthermore, LPS-induced lung injury elevated the expression 
of complement components (C1q, C1r, C1s, C2, C4, C3, C5, C6, factor B, and factor H)  in 
the airways of these animals (Bolger et al. 2007).  Despite reliance on complement for clearing 
pathogens associated with pulmonary infection, complement activation has also been 
reported to be a contributing factor to airway inflammation through the generation of C3a and 
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C5a (Fick et al. 1986; Marc et al. 2010).  In the next sections, I will discuss in depth the 
structure, function and pathogenic roles of C5a and C3a, focussing on the CF airway. 
  
 C5a 
1.7.1. C5a structure 
 
C5 convertase cleaves the C5 alpha-chain subunit to produce C5b, that through assembly 
with C6-9, form MAC on opsonised cell surfaces (Ricklin et al. 2010).  The by-product, C5a, 
is a 10.4 kDa glycoprotein comprised of 74 amino acids (Cook et al. 2010).  Nuclear magnetic 
resonance spectroscopy (NMR) reveals that the tertiary structure of C5a comprises a core of 
four α-helices, held in tight formation by three disulphide bridges, a disordered fifth helix on 
the C-terminus contains a pentapeptide receptor activation domain (figure 1-21) (Cook et al. 
2010).  The C5a structure has been determined using crystals of C5a dimers; however, it is 
not clear whether C5a functions as a dimer in vivo, or if this phenomenon is due to the 
methodology used to crystallise the proteins (Cook et al. 2010).  Interestingly, dimer formation 
has been shown to be important for CXCL8 function, which like C5a, is a low molecular weight 
potent chemoattractant (Das et al. 2010). 
 
1.7.2. Regulation of C5a activity  
 
C5a is a potent chemoattractant, but its activity in vivo is difficult to measure because it is 
rapidly inactivated by carboxypeptidases through cleavage of the C-terminal arginine to form 
C5a-desArg (Campbell et al. 2002).  Furthermore, no commercially available antibodies can 
differentiate between C5a and C5a-desArg and therefore, it is assumed that the majority of 
C5a quantified in serum is in the C5adesArg form (Campbell et al. 2002). Throughout this 
thesis C5a in vivo or ex vivo will be called C5a, despite knowledge that the majority of the C5a 
is presumably C5adesArg   Two carboxypeptidases have been reported to inactivate C5a:  
Zinc metalloprotease CPN and thrombin-activated pro-enzyme carboxypeptidase B2 (also 
known as CPB)  (Campbell et al. 2002).  Expression of CPN is constitutive whereas, CPB 
requires activation meaning its function can be regulated and therefore, in turn, controls the 
activity of C5a (Morser et al. 2018). 
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Figure 1-21: Amino acid sequence and secondary structure of C5a/C5adesArg. 
 
 
 
Morser et al. used cpb2-/- and cpn-/- mice to investigate C5a regulation in a model of aHUS.  
They showed that cpb2-/-, but not cpn-/-, mice were more susceptible to aHUS compared to 
wild type mice (Morser et al. 2018).  Interestingly, when injected with cobra venom factor, a 
protease able to cleave C5 into functional C5b and C5a, cpn-/- mice had a reduced renal 
function compared to cpb2-/-(Morser et al. 2018).  These experiments demonstrate that in mice 
CPN is constitutively expressed and required for acute challenges whereas, CPB is protective 
in more long-term conditions such as aHUS (Morser et al. 2018).  It should be noted that C5a 
is not the only substrate for CPN and CPB, they also facilitate clot regulation via the cleavage 
of terminal lysine on fibrin that prevent clot formation by plasmin (Kovacs et al. 2014).  
Exogenous enzymes expressed by invading pathogens have also been reported to cleave 
C5a C-terminal arginine (Klos et al. 2013).  For example, metallocarboxypeptidases, such as 
those released by parasitic nematodes, C5a peptidases released by Streptococcus pyogenes 
and Scp A peptidases secreted by enterobacterium Serratia marcenscens (Klos et al. 2013). 
 
C5a-desArg binds C5aR1, with 100-fold less affinity than C5a; furthermore, the binding 
orientation is altered when C-terminal Arg74 is removed (Nikiforovich et al. 2008).  In particular 
removing C-terminal arginine form C5a has been shown to reduce interaction between C5aR1 
residues Arg206 and Arg200 with the C5a residue Asp69 (Nikiforovich et al. 2008).  When the 
                                                                                                                                  Helices I-V are 
marked out by black arrows, constituent amino acids are in green, connecting loop amino acids are 
in black.  Cysteine residues and their sequence position are in red, dashed red lines are disulphide 
bonds.  Documented C5aR1 binding residues are in blue, terminal arginine is in orange within a 
dashed box.  N-glycosylation at asparagine-64 is highlighted in purple. 
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C-terminal arginine of C5a is cleaved by CPN/B, the C5a C-terminal alpha helix becomes 
flexible, extruding or merging with the second alpha helix, reducing functional activity via 
C5aR1 (Schatz-Jakobsen et al. 2014). 
 
Figure 1-22: N-glycosylation of C5a/C5adesArg. 
  
 
Another structural feature of C5a is an N-glycosylation site at Asn64 (figure 1-22).  The 
glycosylation of C5a increases the molecular weight by 25% and influences function (Gerard 
and Hugli 1981).  Glycosylation of C5a has been shown to significantly inhibit activity of 
C5ades-Arg form, this has been demonstrated by comparing to porcine C5a-desArg which, 
lacks N-glycosylation (Gerard and Hugli 1981). 
 
1.7.3. Receptors for C5a / C5adesArg 
 
There are two known C5a receptors, C5aR1 and C5aR2 (Klos et al. 2013); both receptors 
belong to the G-protein coupled receptor superfamily however, C5aR2 does not bind G-
proteins (Klos et al. 2013).   
 
 
 
C5aR1 is expressed in most tissues throughout the body, The highest expression is observed 
on monocytes, macrophages and PMNs such as eosinophils, basophils and neutrophils 
(Karsten et al. 2015).  However, expression of C5aR1 on cells of lymphoid origin is 
controversial (Klos et al. 2013).  Migration of B and T cells towards C5a has been 
demonstrated and there has also been extensive research investigating reduced apoptosis of 
T cells in response to C5a (Strainic et al. 2008). Yet, another study report that C5aR1 is 
expressed in a small population of T cells (CD3+) and can induce chemotaxis (Nataf et al. 
                                                                              , C5a based on data from Fernandez et al. 
(Fernandez and Hugli 1976). N-glycosylation accounts for up to 25% of the total C5a molecular 
weight.  C5a is glycosylated at Asn-64, the N-glycosylation is biantennary structure comprised of N-
acetylglucosamine (blue), mannose (purple), galactose (orange) and N-acetylneuraminic acid (red).        
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1999).  Non-immune cells have also been shown to express C5aR, such as neurons, 
astrocytes and cells from major organs (lungs, liver and heart) (Zwirner et al. 1999; Karsten et 
al. 2015). 
  
C5aR1 signal activation is induced via the C-terminal pentapeptide of C5a, inducing signal via 
acidic residues on the C5aR1 extracellular N-terminus (figure 1-23) (Nikiforovich et al. 2008). 
Interestingly, flexibility in the C5aR1 N-terminus may indicate different binding configurations 
for C5a and C5adesArg and may explain the difference in affinity for the two forms 
(Nikiforovich et al. 2008).  
 
 
 
Figure 1-23: Amino acid sequences and structures of C5aR1 and C5aR2. 
 
 
A study using site-directed mutagenesis or chimeric C5aR1 and fMLP receptors (FPR1 and 
FPR2) report that there are multiple C5a binding sites located within the connecting loops of 
C5aR1 transmembrane domains (loops) (Pease et al. 1994).  Furthermore, recombinant C5a 
(rhC5a), that has been genetically engineered to lack the C-terminal signalling domain, can 
bind but not activate C5aR1 (Nikiforovich et al. 2008).  More recent studies have demonstrated 
that C5a binds C5aR1 in a step-wise manner with the receptor undergoing a series of 
conformational changes, whereby receptor binding and activation occurring separately (Sahoo 
et al. 2018). 
                                                                                                                  , extracted from Monk 
et al. (Monk et al. 2007).  There is 35% amino acid conservation between C5aR1 and C5aR2; 
conserved residues in C5aR2 are shaded (dark grey on C5aR2).  Site-directed mutagenesis has 
revealed many C5aR1 residues that are important for ligand binding and signal transduction (blue).  
The amino acids essential for G-protein signalling in C5aR1 but are missing in C5aR2(red).  
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Investigation into receptor binding sites has also revealed that there are at least three 
additional naturally occurring agonists for the C5aR1: outer-membrane protein H ,a porin from 
Salmonella spp, Escherichia spp and Yersinia spp (Jia et al. 2010), a homodimer of ribosome 
S19 from apoptotic cells (Yamamoto 2000) and chemotaxis inhibitory protein expressed by 
Staphylococcus aureus (CHIPS) (Wright et al. 2007). Interestingly, Wright et al. have shown 
that CHIPS is an agonist of FRP1 but an antagonist of C5aR1; however, CHIPS is also highly 
immunogenic and induces the production of specific antibodies (Wright et al. 2007). 
 
C5aR1 is coupled to pertussis-toxin sensitive G proteins αi2; however, unlike most G-protein 
receptors the G-proteins are pre-coupled allowing rapid signal activation that override other 
G-protein coupled receptors such as CXCR1 (Klos et al. 2013).  Signal activation of C5aR1 
induces intracellular calcium release, MAPK, and PI3Kγ activation (Klos et al. 2013). The type 
of response depends on the cell type expressing C5aR1.  For instance, neutrophils release 
calcium from intracellular stores whereas monocytes rely upon extracellular calcium (Monk and 
Partridge 1993; Ibrahim et al. 2004).  In neutrophils, C5a-C5aR1 binding induces chemotaxis, 
degranulation, ROS production and NET release. C5a, acting via C5aR1, is also important for 
upregulation of phagocytic receptors such as CR3 and FcγR receptors (Hunniger et al. 2015). 
Priming by C5a is also important for inflammasome activation and the release of IL-1ß and IL-
18 (An et al. 2014; Grailer et al. 2014). 
 
 
 
The function of C5aR2 (previously known as C5L2) is the subject of debate: the most popular 
hypothesis is that C5aR2 is a decoy receptor that removes fluid phase C5a or C5a des-Arg 
(Klos et al. 2013).  This hypothesis is supported by evidence that C5a/C5adesArg binds 
C5aR2 with equal affinity whereas, C5a binds C5aR1 with higher affinity than C5adesArg 
(Scola et al. 2009).  C5aR2 is a seven-transmembrane receptor that lacks the ability to couple 
G-proteins, a characteristic also observed with other decoy receptors such as IL1RII (Futosi 
et al. 2013).  C5aR2 is highly expressed on cells of myeloid origin; however, studying PMNs 
suggests that basal expression is low and requires activation (Cain and Monk 2002).  C5aR2 
does not undergo ligand-induced internalisation but does cycle between the cell surface and 
intracellular compartments allowing sequestering and lysosomal degradation of C5a or 
C5adesArg (Cain and Monk 2002).  This recycling function of C5aR2 has been shown to be 
more efficient for C5a-desArg than C5a (Scola et al. 2009). 
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C5aR1 can form homodimers, as well as heterodimers with CCR5, enabling co-internalisation 
when under at  equivocal states of phosphorylation (Huttenrauch et al. 2005).  It is not fully 
understood whether hetero-dimerisation occurs between other G-protein coupled receptors 
and C5aR2; however, it has been speculated that dimerisation may enable differential 
signalling between G-protein dependent and β-arrestin-mediated pathways and could reveal 
additional functions of C5aR2 (Defea 2008; Rabiet et al. 2008). Further cross-communication 
between receptors may occur between C5aR2 and non-G protein-coupled receptor such as 
TLRs and therefore, C5aR2 could have regulatory function towards C5aR1 and TLRs (Raby 
et al. 2011). 
 
1.7.4. C5a Function 
 
C5a has multiple functions; these are dependent on cell type and expression of C5aR1.  C5a 
activation of C5aR1 on PMNs and monocytes in the airway can trigger three functions 
(Hunniger et al. 2015); 
 
1) Increased expression of ß-integrins allowing adherence to the vascular endothelium and 
transmigration to affected tissue.  
 
2) Activation of granulocytes inducing degranulation, ROS production and pro-inflammatory 
cytokine release.  
 
3) Priming by upregulation of pathogen recognition receptors allowing efficient targeting and 
phagocytosis of pathogens. 
 
These functions are critical for an inflammatory response to infection or trauma.  For example, 
Hunniger et al. used neutrophils isolated from healthy blood to demonstrate the dependence 
on C5a to orchestrate response to C. albicans infection (Hunniger et al. 2015).  By inhibiting 
either C5aR1 or C5a Hunniger et al. showed that C5a was required for a rapid response, 
occurring within 10 minutes; however, other factors, such as CXCL8, were necessary for a 
sustained response (Hunniger et al. 2015).  Additionally, the authors showed that C5a primed 
neutrophils by upregulating CR3 (CD11b), Fc receptors (CD16) and L-selectin (CD62L) 
(Hunniger et al. 2015).  Supporting this, other groups have observed that C5a is required for 
efficient clearance of bacterial pathogens such as Staphylococcus aureus and Escherichia 
coli (Mollnes et al. 2002; Skjeflo et al. 2014). 
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In particular, Skjeflo et al. used a micro-sphere array to detect cytokine expression during a 
blood infection induced using lipoteichoic acid (bacterial cell wall component).  They 
demonstrated that blockade of C5a generation or activity using eculizumab, compstatin, or a 
C5aR1 antagonist significantly reduced the expression of IL-1ß, TNFα, IL-6, and CXCL8.  With 
greater relevance to the CF airway, Höpken et al. intratracheally infected C5ar1-/- mice with P. 
aeruginosa (Hopken et al. 1996).  The authors observed that 10 out of 11 C5aR1 deficient 
mice died within two days of the challenge, whereas all wild type mice survived over a six-day 
period.  Interestingly, they also show elevated neutrophil numbers in the lungs of C5ar1 
knockout mice, meaning that C5a may not be crucial for recruitment to the lung but, it is 
essential for clearance of P. aeruginosa from the airway (Hopken et al. 1996).  However, P. 
aeruginosa is an opportunistic pathogen in diseases such as COPD and CF wherein, the role 
of C5a is more complex and can promote pathogenesis.  This will be discussed in the next 
section. 
 
The upregulation of FcγRs is critical for phagocytic cells to fight infection however, the 
relationship between the C5a/C5aR1 axis and FcγRs is not simple (Karsten et al. 2012).  
Cross-talk between C5aR1 and FcγRs enables heightened response to pathogens but also 
regulation.  This function is mediated through the differential expression of activating FcγRs 
and inhibitory FcγRIIB (Karsten et al. 2012).  Karsten et al. used FcγRI knockout mice to 
demonstrate the inhibitory effect of FcγRIIB on C5aR1-mediated chemotaxis of neutrophils 
and macrophages.  Following injection of C5a into mouse peritonea, they observed that there 
was significantly reduced chemotaxis of neutrophils in activating-FcγR knockout mice (Karsten 
et al. 2012).  In explanation, Karsten et al. show that immune complexes inhibited chemotaxis 
of wild type neutrophils.  This effect was reversed by administering an inhibitory antibody 
towards FcγRIIB in mice.  The result of these experiments was that FcγRIIB blocks C5aR1 
mediated ERK1/2 phosphorylation and intracellular calcium release.  Further investigation by 
the authors using Forster resonance energy transfer (FRET) demonstrated that FcγRIIB 
associates with dectin-1; an interaction that was dictated by the glycosylation state of the IgG.  
For example, highly glycosylated IgGs promoted FcγRIIB-dectin-1 association, although 
interaction was not through direct binding of glycosylated IgG with dectin-1.  In conclusion, 
Karsten et al., reported strong evidence demonstrating that glycosylation of IgG can regulate 
cellular responses to C5a during inflammation and that this may play an important 
inflammatory role during autoimmune disease where self-antibodies are not glycosylated 
(Karsten et al. 2012). 
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1.7.5. Pathogenic roles of C5a 
 
The potency of C5a to induce inflammatory response in multiple cell types also means that it 
is a contributing factor to inflammatory disorders whereby dysregulation of C5a activity 
contributes to pathogenesis (Klos et al. 2013).   Elevated C5a is a contributing pathogenic 
factor in many inflammatory diseases, listed in table 1-6. 
 
Disease Role of C5a in disease Reference 
Sepsis Systemic infection leading to organ failure, high mortality rate 
associated with exaggerated inflammatory response.  C5aR1 
and C5aR2 inversely proportional to disease severity 
reflecting neutrophil activation by C5a.   
(Xu et al. 
2016) 
ischemia-reperfusion 
injury 
Inflammation following prolonged tissue hypoxia caused by 
myocardial infarction, stroke or organ transplant.  
Complement activation leading to MAC deposition and 
generation of C5a.  C5a associated with chemotaxis of 
monocytes and PMNs to hypoxic tissue leading to further 
tissue damage.  C5a induction of cytokine release by 
epithelial and endothelial cells.  
(Peng et al. 
2012) 
Glomerulonephritis  Assembly of autoimmune complexes in the glomerulus 
following chronic serum sickness.  Complement activation 
generates C5a leading to macrophage inflammation of 
endocapillaries. 
(Alexander et 
al. 2015) 
Rheumatoid Arthritis Assembly of autoimmune complexes within the synovium 
causes complement activation and inflammation.  Activation 
and degranulation of granulocytes leads to joint degradation. 
(Jose et al. 
1990) 
Neuromyelitis Optica Assembly of autoimmune complexes against aquaporin-4, a 
water pore within astrocytes of the CNS. Complement 
activation promoting lysis and targeting of astrocytes within 
the optic never and spinal cord. 
(Kuroda et al. 
2013) 
Airway Disorders 
Acute lung injury/ 
respiratory distress 
syndrome (ARDS) 
Inflammation of the airway in response to airborne particles 
or microorganisms.  Complement activation generates C5a 
promoting influx of PMNs and monocytes.  Poorly regulated 
inflammation leads to tissue damage.  C5a plays pivotal role 
in lung damage during ARDS, growing evidence supporting 
the role of C5a in pathogenesis of influenza A viruses 
(Wang et al. 
2015b) 
Chronic Obstructive 
Pulmonary Disease 
(COPD)  
Long term exposure to air pollution such as smoking.  
Shortness of breath caused by emphysema, inflammation 
induced bronchoconstriction.  Inflammation and activation of 
granulocytes driven by C5a.  
(Marc et al. 
2010) 
Asthma In allergic asthma the airway is hyper-responsive to 
environmental stimulants.  C5a induces the release of pro-
inflammatory cytokines (IL-4, IL-5 and IL-13) by Th2 cells. 
(Khan et al. 
2015) 
Table 1-6 Role of C5a in disease 
 
In blood, C5a is responsible for an exaggerated inflammatory response during sepsis and 
ischemia-reperfusion injury (Scola et al. 2007; Xu et al. 2016).  As a result, C5b (MAC 
formation) and C5a generation are therapeutic targets and have led to the development of 
numerous agonists, antagonists and monoclonal antibodies (Morgan and Harris 2015).  
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Eculizumab is a humanised mouse anti-C5 monoclonal antibody primarily designed to prevent 
C5 cleavage by C5 convertase, inhibiting MAC formation and C5a generation.  It was designed 
as a therapeutic for patients with aHUS or PNH.  Administration of eculizumab has been 
successful in treating these diseases over the last 15 years (Hillmen et al. 2006; Zuber et al. 
2012).  Neutrophil activation by C5a causes the release of MPO and PR3 during necrotizing 
and crescentic glomerulonephritis; CCX168 is a C5aR antagonist that is currently in phase II 
clinical trials to reduce disease severity (Bekker et al. 2016).  Specifically targeting C5a, a pre-
clinical trial of IFX-1 has been shown to be effective against influenza A induced acute lung 
injury in African green monkeys (Sun et al. 2015). 
 
There are few reports of C5a quantification in airway disorders including CF; therefore, the 
role of C5a in promoting pathogenesis in these diseases is unclear.  C5a correlates with a 
decline in clinical scoring particularly in asthma, acute lung injury, COPD and CF (see table 1-
7).   
 
 
Disease Sample type C5a 
Median 
(ng/mL) 
C5a 
Range 
(ng/mL) 
Sample 
size 
Immunoass
ay 
Reference 
Cystic 
Fibrosis 
sputum 1.0 0 – 3.0 15 ELISA R&D 
systems 
OR 
ELISA BD 
biosciences 
(Sass et al. 
2015) 
Cystic 
Fibrosis 
BAL fluid 258 0 – 590 9 RIA Upjohn 
diagnostics 
(Fick et al. 
1986) 
Asthma BALF 
Fluid 
(allergen 
challenge) 
16.4 1.0 – 
54.0 
14 Affinity 
Chromatography  
(Krug et al. 
2001) 
Asthma sputum 1.2 0.2 – 5.8 10 Cytometric Bead 
array  
BD sciences 
(Marc et al. 
2004) 
COPD sputum 1.6 0.2 – 6.5 7 Cytometric Bead 
array 
BD sciences 
(Marc et al. 
2004) 
COPD sputum 1.2 0.4 – 1.9 13 Cytometric Bead 
array 
BD sciences 
(Marc et al. 
2010) 
COPD Sputum  
(during 
exacerbation) 
1.19 0.5 – 
50.7 
24 ELISA BD 
biosciences 
(Westwood et 
al. 2016) 
Normal 
plasma 
 8.0 7.0 – 9.0 53 Cytometric Bead 
array 
BD sciences 
(Strey et al. 
2009) 
Table 1-7 Quantification of C5a/C5adesArg in airway diseases 
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In the asthmatic airway, C5a stimulates mast cells to release histamine causing smooth 
muscle contraction along the vasculature and increases permeability to migrating cells by 
inducing the relaxation tight junctions between cells (Khan et al. 2015).  C5ar1 knock-out mice 
have also been used to demonstrate the role of C5a in orchestrating dendritic cell modulation 
of T-helper cells in asthma (Khan et al. 2015).  C5a activation of conventional pulmonary 
dendritic cells induces the expression of IL-17 and IL-22, promoting Th2 adaptive immunity in 
the asthmatic airway (Khan et al. 2015).  Furthermore, inducing allergenic asthma symptoms 
in patients using ovalbumin elevated C5a and neutrophil influx, suggesting that it is an 
important contributor to inflammation (Khan et al. 2015). 
 
The role of C5a/C5aR1 in driving disease progression has added complexity in that it has 
been shown to be dependent on the stage of disease(Staab et al. 2014).  C5aR1 knock-out 
mice and a C5aR1 antagonist, PMX205, have been used to show that C5aR1 has a protective 
role during the sensitising stage of asthma; here there is initial contact between the allergen 
and dendritic cells and the subsequent interaction with Th-2 cells..  It was found that C5aR1 
expression on both cell types was important for controlling the response (Kohl et al. 2006).  In 
contrast once an allergic response has been established (following allergen exposure) C5a 
signalling accentuates hyper-responsiveness by driving eosinophilic inflammation (Kohl et al. 
2006; Staab et al. 2014). 
 
In COPD, BAL fluid C5a levels correlated negatively with lung function and were associated 
with disease progression (Marc et al. 2010).  There was no significant difference in plasma 
C5a between patients and the controls group, supporting evidence that complement activation 
occurs locally in the airway (Marc et al. 2010). 
 
1.7.6. C5a in the CF airway 
 
C5a has also been reported to contribute to disease progression in the CF airway (Fick et al. 
1986; Sass et al. 2015; Hair et al. 2017). Fick et al. report elevated C5a in CF BAL fluid 
compared to healthy volunteers, the authors also showed that elevated C5a correlated 
positively with PMNs in these patients.  It was hypothesised by Fick et al. that, C5a was 
generated through C5 proteolysis by proteases expressed in the lung, rather than complement 
activation and production of C5a by C5 convertase (Fick et al. 1986).  As mentioned in section 
1.6.4, several endogenous and exogenous non-complement proteases have been shown to 
generate functional C3a and C5a-like anaphylatoxins.  Fick et al. showed that inhibition of 
serine proteases and P. aeruginosa metalloproteases in BAL fluid ex vivo reduced C5a 
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production from purified C5, suggesting that these proteases contribute to elevated C5a in the 
CF airway (Fick et al. 1986). 
 
More recently, Sass et al. measured C5a in CF sputum during an investigation comparing 
generation of C5a by protease from Staphylococcus aureus and complement activation (Sass 
et al. 2015).  They reported that proteases released by dead and living pathogens were able 
to generate C5a; however, they concluded that complement activation, rather than non-
canonical generation, was responsible for elevated C5a in the CF airway (Sass et al. 2015). 
The same group also published a longitudinal study measuring elevation of C5a in sputum 
during pulmonary exacerbation (Hair et al. 2017).  They observed that C5a concentrations 
spiked during exacerbation, hypothesising that C5a is a driving factor behind neutrophilic 
inflammation in the airway (Hair et al. 2017). 
 
Our group has shown that C5aR1 is susceptible to proteolysis and subsequent inactivation by 
serine proteases expressed in CF BAL fluid (van den Berg et al. 2014).  This was  replicated 
by exposing C5aR1 to supernatant from primary neutrophils following stimulation with C5a 
(van den Berg et al. 2014).  Inactivation of C5aR1 was confirmed by exposing U937 
monocytes transfected with C5aR1 to purified NSPs.  The conclusion to this work was that, 
loss of C5aR1 during chronic neutrophilic inflammation of the CF airway disorientates 
neutrophils, preventing communication between innate immune cells and neighbouring 
epithelial cells.  Consequently, clearance of pathogens is inefficient, prolonging infection and 
inflammation leading to the loss of lung function (van den Berg et al. 2014).
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 Extracted from Cook et al. 2010.  Superimposition of C5a NMR structure (blue), C5a X-ray structure 
(green) and C3a NMR structure (yellow).  Terminal ammino acids have been annotated. 
 
 C3a 
 
C3a is produced by cleavage of the C3 alpha chain by C3 convertases (C4bC2b and C3bBb) 
also generating C3b, an important opsonin and component for the assembly of further 
convertases for the assembly of MAC (Ricklin and Lambris 2013). C3a shares structural and 
sequence (35%) homology with C5a however, there are subtle differences as well as 
differential receptor expression that means their roles in inflammation are quite distinctive 
(Klos et al. 2013). 
 
1.8.1. Structure and regulation 
 
C3a is a 77 amino acid protein and, like C5a, the structure forms a four-helix core with signal 
activity residing in the C-terminus (figure 1-24 and 1-25) (Caporale et al. 1980; Muto et al. 
1987).  The NMR structure of C3a has been compared with C5a (Cook et al. 2010). Cook et 
al. showed that the alpha helices of C3a are on average shorter than C5a; however, they do 
not comment on how this relates to function (Cook et al. 2010).  Furthermore, C3a and C5a 
NMR structures were performed on dimerised proteins, but C3a was dimerised via the C-
terminus whereas C5a was dimerised through core arginine residue at position 40 and 46 
(Cook et al. 2010).  Cook et al., speculated that the significance of different dimerisation sites 
is that C5a could function as a dimer as the C-terminal signalling domains remain exposed, 
unlike C3a where dimers form via the C-terminal (Cook et al. 2010). 
 
 
Figure 1-24 Comparing tertiary structures of C5a and C3a 
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Another structural dissimilarity between C3a and C5a is that C3a is not glycosylated (Caporale 
et al. 1980).  Cleavage of C-terminal arginine by CPB or CPN prevents receptor binding 
suggesting that both binding and signalling activity is located within the C-terminus (Caporale 
et al. 1980). C3a / C3aR binding and activation has been shown using a pentapeptide 
construct of the signalling domain, Leu-Gly-Leu-Ala-Arg.  Caporle et al. showed that this 
construct retained 0.2% molar activity in stimulating smooth muscle contraction compared to 
full-length C3a, but when inducing mast cell degranulation of histamine this construct had 10% 
activity (Caporale et al. 1980).  Additionally, longer C-terminal constructs possess greater 
activity: 21 amino acid C3a constructs (C3a c-terminal residues 57-77) retain 100% function, 
meaning that the majority of the C3a N-terminal is redundant for function  (Huey et al. 1984).   
 
Figure 1-25: Amino acid sequence and secondary structure of C3a. 
 
 
 
1.8.2. Receptors for C3a / C3adesArg 
 
C3a binds C3aR, a seven transmembrane G-protein coupled receptor (Klos et al. 2013). 
Expression of C3aR has been detected in most human tissues including on epithelial and 
endothelial cells as well as astrocytes and smooth muscle cells (Klos et al. 2013). Unlike 
C5aR1, C3aR expression on leukocytes, such as neutrophils, is low and there is no basal 
expression on lymphocytes, unless stimulated with interferon-γ (Werfel et al. 2000).  None the 
                                                                                                                Helices I-V are marked 
out by black arrows, constituent amino acids are in green, connecting loop amino acids are in black.  
Cysteine residues and their sequence position are in red, dashed red lines are represent disulphide 
bonds.  Signalling domain is in blue, terminal arginine is in orange within a dashed box.  
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less, C3aR has been detected on monocytes, macrophages, microglia and, mast cells (Klos 
et al. 2013). 
 
Expression of C3aR on neutrophils is controversial (Klos et al. 2013).  Those that have shown 
C3aR expression suggest that it stimulates calcium flux, as observed for other granulocytes 
(figure 1-26) (Norgauer et al. 1993; Vibhuti et al. 2011). 
 
Figure 1-26: Functions of C3a are dependent on cell type. 
 
 
 
 
Those who doubt C3aR expression in neutrophils suggest that the cells used for the above 
experiments were contaminated with other granulocytes (Klos et al. 2013).  Despite this, Wu 
et al. used C3ar -/- mice to propose a role for C3a suppression of neutrophil migration from 
bone marrow into circulation during their maturation (Wu et al. 2013).  The authors observed 
that mice lacking C3aR had elevated neutrophil influx during ischemic reperfusion injury of the 
                                                                                                 , extracted from Coulthard et al. 
(Coulthard and Woodruff 2015).  C3a has pro and anti-inflammatory affects upon binding C3aR but 
function depends on cell type. C3a induces eosinophil degranulation and histamine release from 
mast cells.  In monocyte/macrophage C3aR-meditated inflammasome causes the release of IL-1ß. 
T-cell expression of C3aR is controversial however, it has been reported that C3a suppresses T-
regulatory cell production and prevents polarisation of Th1 cells to Th2 phenotypes. C3aR 
expression on neutrophils is also controversial but it has been proposed that C3a inhibits neutrophil 
release from the bone marrow.  C3a itself also has microbial properties. 
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intestines compared to wild type mice. Wu et al. used a C3a “super agonist” 
(WWGKKYRASKLGLAR), previously reported to have 2 to 15-fold higher activity over native 
C3a, to reduce neutrophil migration to circulation (Ember et al. 1991; Wu et al. 2013). In 
conclusion, the authors suggested that C3a may have a therapeutic role to prevent neutrophil 
migration from bone marrow in ischemic reperfusion. 
 
Activation of C3aR induces calcium response although, in comparison to C5a, such activation 
is weaker than that triggered by C5aR1 activation (Norgauer et al. 1993).  Degranulation of 
mast cells is induced via ERK 1/2 pathway activation. ß-arrestins may also have an important 
role in C3aR signalling beyond desensitisation and internalisation (Vibhuti et al. 2011).  For 
example, silencing ß-arrestin 1 prevented degranulation of mast cells in response to C3a 
(Vibhuti et al. 2011).  As well as degranulation in mast cells, C3a has been shown to induce 
IL-1ß from monocytes and macrophages by priming the NLRP3 inflammasome (Asgari et al. 
2013).  Therefore, binding of C3a to C3aR has been shown to have both anti-inflammatory 
(neutrophils, anti-microbial) and pro-inflammatory (mast cells, eosinophils, 
monocytes/macrophages) functions depending on cell type (Coulthard and Woodruff 2015). 
 
Interestingly, C3adesArg has been shown to be identical to acylation-stimulating protein 
(ACP), a mediator of triglyceride synthesis that may be important for metabolic and immune 
function (Cianflone 2003).  It has been suggested that C5aR2 on adipocytes binds ACP 
however, despite several publications, this topic remains highly controversial (Cianflone 2003; 
Klos et al. 2013).  Yet, C5aR2 knock-out mice have been shown to have macrophage 
inflammation in adipose tissue, and the same mice were more susceptible to developing 
insulin resistance when fed a diabetes-inducing diet (Fisette et al. 2013).  However, these 
experiments do not prove that ACP is a ligand for C5aR2 and these could be explained by 
possible hetero-dimerisation between C5aR2 and C5aR1 or C3aR (Zhang et al. 2017). 
 
1.8.3. The pathogenic roles of C3a 
 
C3adesArg has very little or no affinity for C3aR which means that C3adesArg is not cleared 
from the circulation/tissue (Klos et al. 2013).  Consequently, C3adesArg can accumulate to 
greater concentrations than C5a/C5adesArg during complement activation because 
C5a/C5adesArg can be removed by internalisation of C5aR1 and C5aR2 (Klos et al. 2013).  
Additionally, C3 concentrations are 10-fold higher than C5 in blood and therefore, there is 
greater capacity to generate C3a.  Consequently C3a/C3adesArg concentration in plasma is 
approximately 50 ng/mL compare to 5 ng/mL for C5a/C5adesArg (Barnum and Schein 2018).  
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Accumulation of C3adesArg in disease as a result of reduced clearance means that it can be 
a good candidate biomarker of complement activation and has been used to indicate infection, 
inflammation and tumour growth; an extensive list of these diseases can be found in Klos et 
al. 2013 (Klos et al. 2013). 
 
C3a, like C5a, is thought to contribute to pathogenesis in inflammatory airway diseases such 
as asthma, COPD and CF (table 1-8) (Krug et al. 2001; Marc et al. 2004; Sass et al. 2015).  
C3a has been shown to be elevated during hyper-allergenic response in asthma; furthermore, 
the role of C3a in the asthmatic lung may be multi-factorial (Engelke et al. 2014).  C3a is 
known to induce mast cell and eosinophil degranulation; both these cells types are found 
elevated in the asthmatic airway during an allergenic challenge (Engelke et al. 2014).  
Furthermore, C3a has been shown to induce smooth muscle contraction, a symptom of 
asthma (Humbles et al. 2000).  Increased mucus production has also been reported. In 
explanation, Dillard et al. hypothesise that C3a stimulates Clara cell MUC5A production, an 
important constituent of mucus (Dillard et al. 2007).  Wild type and C3 knock-out mice were 
compared and it was demonstrated that wild type mice had increased mucus production and 
airway obstruction during hyper-allergenic challenge (Dillard et al. 2007). However, 
neutrophils have not been shown to contribute to any of these C3a-mediated pathogenic 
factors in asthma, which is likely to be due to low or absent of C3aR expression on the 
neutrophil cell surface (Dillard et al. 2007; Klos et al. 2013). 
 
Disease Sample 
type 
Median 
(ng/mL) 
Range 
(ng/mL) 
Sample 
size 
Immunoassay Reference 
Cystic 
Fibrosis 
sputum 15.0 
(approx.) 
0 – 170 
(approx.) 
14 ELISA R&D 
systems 
OR 
ELISA BD 
biosciences 
(Sass et al. 
2015) 
Asthma BALF 
Fluid 
(allergen 
challenge) 
29.0 3.9 - 854 14 Affinity 
Chromatography  
(Krug et al. 
2001) 
Asthma sputum 2.12 0.14 – 
50.1 
10 Cytometric Bead 
array  
BD sciences 
(Marc et al. 
2004) 
COPD sputum 0.67 0.5 – 8.7 7 Cytometric Bead 
array 
BD sciences 
(Marc et al. 
2004) 
COPD Sputum 
(during 
exacerbation) 
15.4 1.5 - 
30.8 
24 ELISA BD 
biosciences 
(Westwood et 
al. 2016) 
Normal 
plasma 
 33.0 28.5 – 
37.5 
53 Cytometric Bead 
array 
BD sciences 
(Strey et al. 
2009) 
Table 1-8: Quantification of C3a/C3adesArg in airway diseases. 
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A recent short abstract by Westwood et al. describe elevated C3a and C5a in sputum from a 
cohort of 24 COPD patients (Westwood et al. 2016).  Both complement factors correlated with 
increased recovery time following exacerbation however, the authors could not attribute 
pathogenesis to either C5a or C3a (Westwood et al. 2016).  Marc et al. have also measured 
C3 in COPD (and asthma) and performed correlations with disease progression; however, 
despite elevated C3a in the airway, there were no significant correlations (Marc et al. 2010). 
The authors concluded that C5a has a more significant role in disease progression in COPD 
and the asthmatic airway. 
 
1.8.4. C3a in the CF airway 
 
In CF, Sass et al., observed elevated C3a compared to healthy controls (and C5a, as 
described above) and, unlike C5a, C3a correlated with reduced inflammation and improved 
lung function (Sass et al. 2015).  Furthermore, C3a inversely correlated with neutrophil count 
supporting evidence that C3a may be an important regulator of neutrophil migration from the 
bone marrow (Wu et al. 2013; Sass et al. 2015); however, because there is controversy over 
the expression of C3aR on neutrophils, further investigation is required to confirm a role of 
C3a in regulation of neutrophilic inflammation in the CF airway.
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 Summary and background to the project 
 
In this literature review I have described the current understanding of neutrophil biology and 
how their dysfunction promotes pathogenesis in the CF airway.  C5a and C3a are important 
mediators of lung inflammation and have been associated with disease progression including 
airway disorders such as asthma, COPD and CF.  Despite recent publications, the precise 
mechanisms by which they promote CF pathogenesis are not well understood.  Our group has 
recently shown that C5aR1 is susceptible to cleavage by NSPs during chronic neutrophilic 
inflammation disarming neutrophils.  Despite this, there may be functional modifications of 
C5a and C3a mediated by the CF airway environment that also contribute to pathogenesis in 
this disease; this will be the focus of investigation in this thesis. 
 
It has been shown in three reports (Fick et al. 1986; Sass et al. 2015; Hair et al. 2017) that 
C3a and C5a is elevated in the CF airway and that C5a (and C3a) correlates with neutrophilic 
inflammation and loss of lung function.  Despite higher levels of C5a and C3a in the CF airway, 
there is inefficient pathogen clearance and consequently chronic neutrophilic inflammation 
that contributes to loss of lung function and mortality.  There is growing evidence suggesting 
that non-complement proteases can generate functional forms of C3a and C5a.  Yet, it is not 
known whether there are functional differences between the de novo C3a and C5a forms 
compared to their native convertase generated counterparts.  The functional differences in 
C3a and C5a generated by NSPs will be investigated as part of this project. 
 
There is also evidence that the abundance of soluble GAG released through degradation of 
the airway ECM can modify inflammation in the CF airway, specifically through interaction with 
CXCL8.  There is evidence suggesting that C5a can bind to GAGs; however, it is not fully 
understood if these interactions modify C5a activity and promote CF pathogenesis as a 
consequence.  As well as characterising the generation of C5a in the CF airway I will also 
investigate the influence of GAGs on C5a function. 
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 Hypothesis 
 
I hypothesise that during chronic neutrophilic inflammation of the CF airway, alternative forms 
of C3a and C5a are generated by NE, CG and PR3 which have modified function over their 
convertase-produced counterparts. In addition, I hypothesise that current complement 
therapeutics that inhibit C5a conversion by C5 convertase are ineffective at preventing C5a 
generation by NSPs.  I also hypothesis that C5a (and C3a) interact with GAGs in the local 
lung environment also modifying their function. Together, C3a and C5a interaction with the 
local lung environment modifies their activity and promotes pathogenesis in the CF airway. 
  
 Aims 
 
1. Characterise C3a and C5a in BAL fluid from a cohort of 33 paediatric CF patients and 
correlate with markers of neutrophilic inflammation (CXCL8, NE activity neutrophil 
count) and disease progression (lung function; FEV1). 
 
2. Investigate non-canonical ex vivo generation of C5a (and C3a) by proteases present 
in CF BAL fluid.  Further, functionally characterise C5a-like and C3a-like fragments 
generated by NSPs using C5aR1 and C3aR transfected cell lines. 
 
3. Assess the effectiveness of complement therapeutic C5 convertase-inhibiting 
monoclonal antibodies at preventing non-canonical C5a generation by NSPs.  Quantify 
generation and measure activity of C5a-like fragments generated by NSPs whilst in 
the presence of therapeutic C5 cleavage inhibitor. 
 
4. Investigate interaction between C5a and soluble GAGs that have been shown to be 
elevated in during neutrophilic inflammation of the CF airway.  Assess the functional 
significance of C5a-GAG complexes by measuring activity using RBL-C5aR1 cell line 
following exposure to either CPN/B and NSPs. 
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2. Materials and methods 
 
 Buffers and solutions 
2.1.1. Phosphate buffered saline (PBS), pH 7.4 
 
Fresh PBS was prepared before each experiment. PBS was prepared by diluting 10X stock 
solution (Fisher Scientific, Loughborough, UK) 1 in 10 in de-ionised H2O to produce a 1X PBS 
solution.  For cell work, a sterile 10X PBS (for cell culture) stock solution (Fisher Scientific, 
Loughborough, UK) was used and diluted in sterile H2O in a tissue culture hood. 
 
2.1.2. PBS-tween (PBS-T), pH 7.5 
 
Fresh sterile PBS-T was prepared before each experiment however, for ELISAs PBS-T was 
not sterile and prepared in a 1 L bottle and was prepared when required.  PBS-T was prepared 
by adding 0.05% (v/v) tween-20 (Fisher Scientific, Loughborough, UK) to 1X PBS. 
 
2.1.3. Bovine serum albumin (BSA) 
 
Fresh BSA was prepared for each experiment. 1% (w/v) BSA solution (typical concentration, 
unless stated otherwise) was prepared by weighing out 10 mg protease-free BSA (Sigma 
Aldrich, Dorset, UK) and dissolving in a 30 mL universal container with 1 mL PBS and mixing 
by vortex. These amounts were scaled up for larger quantities. 
 
2.1.4. 1 M trisamino(hydroxy)methane (TRIS), pH 7.5 
 
60.57 g TRIS (Fisher Scientific, Loughborough, UK) was weighed out in a 250 mL capacity 
weigh-boat and added to a 0.5 L glass bottle.  De-ionised H20 was added to approximately 
450 mL and mixed by magnetic follower. 0.5 M HCl was added by Pasteur pipette and pH 
measured by bench pH meter with TRIS compatible probe, until pH reached 7.5.  Solution was 
transferred to a 0.5 L measuring cylinder and de-ionised H2O was added until the solution 
reached the 0.5 L mark. 1 M TRIS stock solution was stored in a glass bottle at 4°C.   For ß-
hexosaminidase assays, 1 M TRIS was prepared but at pH 9.0. 
96 
 
2.1.5. 1 M NaCl 
 
58.44 g NaCl (Fisher Scientific, Loughborough, UK) was weighed out in a 250 mL capacity 
weigh-boat and added to a 1 L glass bottle.  De-ionised H2O was added to approximately 950 
mL and mixed by magnetic follower, solution was transferred to a 1 L measuring cylinder and 
de-ionised H2O was added until the solution reached the 1 L mark. 1 M NaCl stock solution 
was stored in a glass bottle at 4°C. 
 
2.1.6. NE activity buffer  
 
Activity buffer was prepared fresh for each experiment, 4 mL de-ionised H2O, 5 mL 1 M NaCl, 
1 mL 1 M TRIS (pH 7.5), 50 µL Triton X-100 (Fisher Scientific, Loughborough, UK) were added 
to 30 mL universal container and vortexed for 5 seconds until Triton had diluted.  Activity buffer 
was stored at room temperature until used. 
 
2.1.7. Carbonate buffer (2%) – ELISA capture antibody diluent 
 
Sodium bicarbonate (2g) was weighed and dissolved in approximately 90 mL de-ionised H2O 
in a glass bottle on a stirrer with magnetic follower.  Once dissolved solution was transferred 
to a 100 mL measuring cylinder and H2O added to make 100 mL, solution was returned to the 
glass bottle and stored at room temperature. Required volume of carbonate buffer was filtered 
through 0.2 µm filter before each use. 
 
2.1.8. 0.1 M Citrate buffer for ß-hexosaminidase release experiments 
 
0.2 M citric acid solution was prepared by dissolving 1.92 g citric acid in 50 mL de-ionised 
H2O.  0.24 M tri-sodium citrate solution was prepared by dissolved 1.58 g tri-sodium citrate in 
40 mL de-ionised H2O.  The 50 mL 0.2M citric acid and 0.24 M tri-sodium citrate were 
combined and 0.5 M NaOH was added by Pasteur pipette slowly, pH was monitored by bench 
top pH meter.  0.5 M NaOH was added until pH reached pH 4.5.  Solution was transferred to 
100 mL measuring cylinder and made up to 100 mL with de-ionised H2O. 0.1 M citrate buffer 
was aliquoted into volumes of 20 mL in universal containers and stored at -20°C until use. 
 
97 
 
2.1.9. Solid phase binding assay buffer  
50 mM Sodium acetate, 100 mM NaCl, 0.1% tween-20, pH 6.0. NaCl (2.92 g) was weighted 
out and added to 0.5 mL bottle with 8.33 mL 3 M sodium acetate (Fisher Scientific, 
Loughborough, UK).  Approximately 400 mL de-ionised H2O was added and solution was 
stirrer by magnetic follower until NaCl had dissolved. 0.5 mL tween-20 was added and stirred 
until dissolved.  Using a pH meter, pH was corrected to 6.0 using a Pasteur pipette to slowly 
add 0.5 M NaOH.  Solution was transferred to a 0.5 L measuring cylinder and H2O added to 
a volume of 0.5 L. Solution was returned to the glass bottle and stored at 4°C until use. 
 
2.1.10. Complement haemolysis assay buffer 
 
One complement fixation test tablet (Oxoid, Hampshire, UK) was added to 100 mL de-ionised 
H2O in a 0.25 L glass bottle and stirred by magnetic follower until dissolved.  Solution was 
stored at room temperature. The final solution is 3 mM barbitone, 154 mM NaCl, 1.8 mM 
MgCl2, 2.5 mM CaCl2 at pH 7.2. 
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 Complement proteins, Proteases, Protease inhibitors, glycosaminoglycans 
Reagent Manufacturer Typical Stock 
Concentration 
Storage 
Complement Proteins  
C3 Complement 
technology, Texas, 
US 
1 mg/mL -80°C 
C5 Complement 
technology, Texas, 
US 
1 mg/mL -80°C 
C3a Complement 
technology, Texas, 
US 
100 µg/mL -80°C 
C5a (native, purified from 
human blood) 
Complement 
technology, Texas, 
US 
100 µg/mL -80°C 
Recombinant C5a (produced 
in E. coli) 
Hycult Technology, 
Uden, Netherlands 
100 µg/mL -80°C 
Proteases/peptidases  
Neutrophil Elastase Athens research, 
Georgia, US 
500 µg/mL (16.9 µM) -20°C 
Cathepsin G Athens research, 
Georgia, US 
500 µg/mL (16.9 µM) -20°C 
Proteinase 3 Athens research, 
Georgia, US 
1000 µg/mL (34 µM) -20°C 
Porcine Carboxypeptidase B  Sigma Aldrich, Dorset, 
UK 
1 mg/mL -20°C 
Protease Inhibitors  
Phenylmethylsulfonyl fluoride 
(PMSF) 
Sigma Aldrich, Dorset, 
UK 
100 mM solution 4°C 
4-(2-
Aminoethyl)benzenesulfonyl 
fluoride hydrochloride 
(AEBSF) 
Sigma Aldrich, Dorset, 
UK 
10 µg/mL -20°C 
Alpha-1-antitrypsin (AAT) Sigma Aldrich, Dorset, 
UK 
2 mg/mL -20°C 
Glycosaminoglycans 
Heparan sulphate sodium salt 
from bovine kidney 
Sigma Aldrich, Dorset, 
UK 
1 mg/mL -20°C 
Chondroitin sulphate from 
shark cartilage 
Sigma Aldrich, Dorset, 
UK 
3 mg/mL -20°C 
Hyaluronic acid from Rooster 
comb 
Sigma Aldrich, Dorset, 
UK 
3 mg/mL -20°C 
Complement Inhibitors  
SKY59 (monoclonal antibody) Roche, Basel, 
Switzerland 
10 mg/mL -80°C 
Eculizumab (monoclonal 
antibody) 
Gift from Santiago 
Rodrigues de 
Cordoba, Madrid, 
Spain 
10 mg/mL -80°C 
OmCI Gift from Paul 
Morgan, Cardiff, UK 
8.4 mg/mL -80°C 
RaCI Gift from Matthijs 
Jore, Oxford, UK 
0.8 mg/mL -80°C 
Table 2-1: Other reagents used in this study, where they came from, stock concentrations and 
storage conditions 
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                                                                                  Antibodies used throughout this project, their target, the species they were produced in, the 
class of the antibody, clone if applicable, manufacturer and the concentration they were diluted to for each application: E – ELISA, WB – western 
blot, IH – in-house. HRP-horseradish peroxidase (HRP). 
  Antibodies 
 
Target  Host species Type (Isotype) Clone Manufacturer Dilution used 
Human C5a/C5a des-
Arg 
Mouse Monoclonal (IgG1) 2952  Hycult Biotechnology 
2 µg/mL [C5a-IH E] 
Human C5/C5a 
(C5 alpha chain)   Mouse Monoclonal (IgG2a) 557 Hycult Biotechnology 
0.2 µg/mL [WB] 
1 µg/mL [C5 E] 
2 µg/mL [C5a-IH E] 
Human C5 Mouse 
(humanised) 
Monoclonal (IgG4) SKY59 Roche 
1 µg/mL [C5 E] 
Human C5 
(C5 Beta chain) 
Mouse Monoclonal (IgG1) 2D5 In-house 
1 µg/mL [C5 E] 
Human C3/C3a Mouse Monoclonal (IgG1) 2898 Hycult Biotechnology 0.2 µg/mL [WB] 
Human C3a/C3a-
desArg Rabbit Polyclonal N/A Complement Technology 
40 µg/mL (total protein) 
[WB] 
Mouse IgG 
Goat HRP-conjugate N/A Stratech Scientific Ltd 
37.5 ng/mL [WB] 
60 ng/mL [C5 E] 
 
Mouse IgG2a 
Goat HRP-conjugate N/A Stratech Scientific Ltd 
50 ng/mL [WB] 
160 ng/mL [C5a-IH E] 
Rabbit IgG Donkey HRP-conjugate N/A Stratech Scientific Ltd 100 ng/mL [WB} 
Table 2-2: Antibodies used throughout project.
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 BAL fluid sample processing 
 
BAL fluid samples were collected by Dr. Julian Forton as part of a separate study investigating 
airway microbiome in the CF airway (Ronchetti et al. 2018).  Ethical approval was obtained 
from the Research Ethics Committee, Cardiff & Vale University Health Board, Cardiff, UK.  
Written informed consent was obtained by parents or legal guardians.  The cohort in this study 
had 32 CF patients however, there were 41 sampling events in total because repeated 
measures were taken for 7 patients; 5 patients had 2 recorded events and 2 patients had 3 
recorded events.  Following my analysis (section 3.4), I determined that repeated measures 
would be included in the population and therefore, there were 41 events in total.  BAL was 
performed by clinicians in accordance with guidelines published in the ERS (European 
Respiratory Society) Task Force on BAL in children (de Blic et al. 2000).  A flexible 
bronchoscope is inserted into the right middle lobe and 0.9% sterile saline is instilled at a 
volume of 3 mL/Kg to a maximum volume of 20 mL.  Following collection, BAL fluid was 
immediately placed on ice until collection for processing. 
 
BAL fluid was processed within 1 hour of collection.  The volume of each sample was 
determined by weight, using the assumption that 1 g = 1 mL BAL fluid.  Cells were removed 
from suspension by centrifugation at 500 x g for 5 minutes at 4°C, the supernatant was 
aliquoted and immediately stored at -80°C.  Cell pellets were resuspended in 1-3 mL 10 mM 
EDTA/PBS, depending on pellet size, and cells counted using a haemocytometer, cells were 
further diluted in trypan blue at a 1:1 ratio so that dead cells (positively stained) could be 
omitted from the count, an approximation of percentage dead cells was recorded.  Cells were 
diluted to 1 x 106 cells/mL in 10 mM EDTA/PBS and 50 µL (50,000 cells) were fixed to 
polylysine slides by cytofuge (centrifuge for slides) at 500 x g for 5 minutes, room temperature.  
Slides were dried in air for 24 hours then stored at -20°C in slide cassettes wrapped in foil.  All 
BAL fluid aliquots and cytospin slides numbers were recorded as part of the human tissue act 
(HTA) 2004 (https://www.legislation.gov.uk/ukpga/2004). 
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 CF cohort characterisation 
2.5.1. Differential cell counts 
 
 
Cytospins were removed from -20°C and thawed at room temperature.  Slides were stained 
with Hemacolor® (Merck Millipore, UK) as recommended by the manufacturer.  In brief, each 
slide was submerged in a fix stain containing methanol for 1 minute then blotted dry.  Stain 
and drying was repeated for an eosinophilic stain (granular stain) followed by the azure nuclear 
stain.  Slides were dried for at least one hour at room temperature.  A coverslip was fixed 
using DPX mounting medium (Fisher Scientific, Loughborough, UK) and left to solidify for at 
least one hour.  Slides were stored in a locked cupboard, as directed by HTA guidelines, at 
room temperature prior to microscopy. 
 
 
 
Microscopy was performed on a Leica microscope at 20X magnification, at least four spatially 
separate fields were captured for each slide, ensuring not to capture the same cells in multiple 
fields.  For some samples, cell counts were low and therefore up to eight fields were captured.  
Using Microsoft Paint, cell types were counted and marked.  At least 300 cells were counted 
for each sample; however, for six samples between <300 cells were counted because of low 
cell numbers in the BAL fluid, analysis was performed on all data. 
 
 
 
Cells were identified as polymorphonuclear leukocytes (PMNs), “mononuclear”, or, “cellular” 
but not enough evidence to determine cell type.  For mononuclear cells, cell types were further 
differentiated into monocytes (including macrophages and lipid laden macrophages), 
squamous epithelial cells and monocyte other (lymphocytes) (figure 2-1).  Due to subjective 
nature of differential cell counting a selection of five slides from five different BAL fluids that 
were considered difficult to count were also counted by my supervisor, Dr. Eamon McGreal, 
to compare and validate counting technique.  Where cell counts differed by more than 10% (2 
samples), a mean between our two counts was used, for differences <10% I used my counts 
in the analysis.  An example of the cells counted and three typical CF cytospins from my study 
can be found (table 2-3 and figure 2-1).  Neutrophil count was calculated assuming that PMNs 
were predominantly neutrophils.  The percentage of each cell type was calculated for each 
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slide, by dividing the number of that type of cells (in all the fields for that sample) by the total 
amount cells included in the count (in all fields for that sample) and multiplying by 100.  The 
neutrophil count for each sample was calculated by multiplying the cell count 
(haemocytometer) by the percentage of neutrophils (PMNs) for that sample. 
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                                                                                                               Polymorphonuclear leukocytes 
are round, smaller than monocyte/macrophages, and had multilobular nuclei.  Basophils were rare (2 
counted in over 180 slides), they were similar to PMNs, but positively stained red. 
Monocyte/macrophages were typically large and had a “fried-egg” appearance. Lipid-laden macrophage 
were similar to monocyte/macrophages but contained light patches.  Epithelial cells were distinctive with 
a rectangular shape and a “fuzzy” patch of cilia at the apical membrane.  Suspected lymphocytes were 
smaller than PMNs and a nucleus that occupied most of the cell.  
 
  
Table 2-3: Typical examples of cells identified in CF BAL fluid.
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                                                                                                                    Top) unannotated field B) 
Annotated to show which cells were included in the differential count.  Monocyte/macrophages were 
circled in red, PMNs were circled in green, lung epithelial cells are in yellow rectangles and other non-
identified cells (but would have been included in the haemocytometer count) were circled in blue.  
 
Figure 2-1: A typical example of a captured field from a cytospins.
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2.5.2. NE activity assay 
 
CF BAL fluid (50 µL) was removed from -80°C and thawed on ice, prior to use BAL fluid was 
centrifuged 10,000 RPM for 1 min at room temperature in a microfuge. Initially, BAL fluid was 
diluted 1:3 using activity buffer (100 mM TRIS, 500 mM NaCl, 0.05% (v/v) Triton X-100, 
pH7.5), further dilutions were made depending on activity of the sample.  For example; 
samples that had low activity a dilution of no less than 1:1 was used, or if samples had activity 
higher than the standard curve then BAL fluid was diluted further.  For standards, purified 
human NE was diluted serially in activity buffer to give a range of 80nM to 1.125nM.  Activity 
buffer without NE was used as a negative control. 
 
For the assay, 50 µL diluted BAL fluid or standard was added to a 96-well plate in duplicate.  
50 µl protease-specific chromogenic substrate (2 mM Suc-Ala-Ala-Pro-Val-pNA in activity 
buffer, Bachem, Cambridge, UK) was added to each well to start the assay.  Absorbance from 
each well was read at 405nm using a spectrophotometer, a protocol was programmed to take 
a reading every minute for 20 minutes.  Protease activity was quantified by calculating the 
mean change in absorbance over time (20 minutes).  NE activity in CF BAL fluid was 
interpolated from a quadratic curve generated from change in absorbances of the purified NE 
standards, these was calculated in Graphpad Prism 7.  The interpolated NE activity was 
multiplied by the dilution factor for each respective BAL fluid sample.  The limit of detection for 
this assay was between 80 and 1.125 nM NE however, 16 out of 41 samples had no detectable 
NE activity; however, these data still provide valuable information about inflammation.  I 
consulted our group statistician (Dr. Samuel Touchard), he advised that rather than omitting 
them from the data set, these samples were given the value half-way (mean) between the limit 
of detection (1.125 nM) and zero, so 0.563 nM.   
 
2.5.3. CXCL8 
 
Duo-set CXCL8 ELISA (R&D systems, Abingdon, UK) was performed as recommended by 
the manufacturer.  A 96-well Maxisorb plate (NUNC (Fisher Scientific, Loughborough, UK)) 
was coated with 100 µL 4 µg/mL capture antibody in PBS and incubated overnight at room 
temperature.  Coated wells were washed three times with 250 µL PBS-tween20 (0.05% (v/v)) 
and blotted dry on paper towel.  Wells were blocked with 200 µL reagent diluent (1% BSA/PBS 
(w/v), prepared in-house) and incubated for 60 minutes at room temperature.  Wells were 
washed, and 100 µL standard or sample loaded in duplicate.  For standards, CXCL8 
(provided) was diluted serially in 2-fold increments from 2000 pg/mL to 31.123 pg/mL in 
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reagent diluent.  CF BAL fluid was removed from -80°C, thawed and kept on ice, prior to use 
BAL fluid was centrifuged 10,000 RPM for 1 min at room temperature in a microfuge.  BAL 
fluid was diluted 1 in 3 with reagent diluent.  BAL fluid with high NE activity, indicative of 
neutrophilic inflammation, were diluted 1 in 10.  The plate was incubated for 2 hours at room 
temperature.  Wells were washed and 100 µL 1.2 µg/mL detection antibody in reagent diluent 
was added. The plate was incubated for 2 hours at room temperature.  Wells were washed 
and 100 µL streptavidin-HRP conjugate (diluted 1 in 40, as specified by the manufacturer) was 
added.  The plate was incubated for 20 minutes at room temperature.  Wells were washed 
and 100 µL 3,3',5,5'-Tetramethylbenzidine (TMB) substrate was added.  Colour (blue) was 
allowed to develop for 2-3 minutes until standards were visible.  Reaction was stopped 
immediately by adding 50 µL 2 N sulphuric acid to each well.  Optical absorbance was 
measured for each well at 450 nm with 570 nm reference filter using a spectrophotometer 
(Dynex, Worthing, UK).  CXCL8 concentration in BAL fluid was interpolated from a sigmoidal 
curve using log10 standard concentrations, calculations were performed by Graphpad Prism® 
7.  The interpolated value for each BAL fluid sample was multiplied by the dilution factor for 
that sample.  The limits of detection for this assay were between 2000 to 31.125 pg/mL.  As 
for NE activity, any samples that had no detectable CXCL8 were given the value 15.56 pg/mL, 
the mean of the lower limit of detection and zero. 
 
2.5.4. Complement Meso Scale Discovery (MSD) multiplex platforms 
 
Antibody pairings for the MSD platform were optimised in-house by Dr. Rowan Orme as part 
of several studies measuring complement in disease (Kopczynska et al. 2017; Kopczynska et 
al. 2018).  The majority of the antibodies used for the detection of analytes using this platform 
were developed in-house under the supervision of Prof. B. Paul Morgan.  Plates were coated 
and prepared by MSD using a combination of commercial and in-house antibody pairings.  
Complement components were organised onto two plates depending on the dilution factor 
required for detection and quantification from the standard curve.  The activation plates 
measured C3, C5, factor H, factor B, factor I, and iC3b.  Due to issues with detection, C5 data 
were excluded from these plates and were measured by ELISA (see C5 ELISA). The second 
plate measured C5b-9 (terminal complement complex) factor Bb, C5a, C3a, and factor D. Due 
to technical issues with C5a standards, C5a data were excluded from these plates and were 
measured by commercial C5a ELISA. 
   
For MSD assay, wells were blocked with 150 µL 3% BSA in PBS (w/v) and incubated at room 
temperature for 2 hours on an orbital shaker (600 RPM).  Blocking solution was removed by 
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blotting on paper towel. In duplicate, 25 µL standards or sample was added to the plate and 
incubated for 1 hour at room temperature on shaker.  For standards, a pre-made master mix 
prepared for each plate type was diluted 1 in 10 or 1 in 20 for activation and regulator plates 
respectively.  Both standard sets were serially diluted 5-fold in 1% BSA (w/v)/10mM 
EDTA/PBS to give a 7-point standard curves for each analyte.  CF BAL fluid was removed 
from -80°C, thawed and kept on ice, prior to use BAL fluid was centrifuged 10,000 RPM for 1 
min at room temperature in a microfuge.  BAL fluid was diluted in 1% BSA (w/v)/10mM 
EDTA/PBS, 1:1 for activation plates or 1/2000 for regulator plate.  Wells were washed four 
times with 200 µL tween-20/PBS (0.05%, v/v) and blotted dry on paper towel.  For detection, 
a SULFO-tag conjugated antibody mix specific to each plate was diluted to 1 µg/mL in 1% 
BSA/10mM EDTA/PBS and 25 µL added to each well. The plate was incubated for 1 hour at 
room temperature on shaker.  Plate was washed and blotted dry, then 150 µL read buffer 
(provided by MSD) was diluted 1:1 with H2O and added to each well.  Plate was immediately 
read using MSD plate reader.  Data was analysed using MSD workbench® v4.0 and a 
template protocol that was programmed to interpolate values from each standard curve.  Each 
analyte was multiplied by the dilution factor for that BAL fluid sample; a factor of 2 for the 
activators plate and a factor of 2000 for the regulators plate.  Any analytes below the lower 
limits of detection were not included in the analysis. 
 
 C5 ELISA 
 
A C5 ELISA was developed and optimised in-house, (section 3.7.1) Maxisorb 96-well plates 
were coated with 50 µL/well 1 µg/mL SKY59 (Roche Pharmaceuticals, Basel, Switzerland) 
humanised mouse anti-human C5 monoclonal antibody in 2% carbonate buffer (w/v) and 
incubated 60 minutes at 37°C.  Wells were washed three times with 200 µL PBS-Tween20 
(0.05%, v/v) and blotted dry on paper towel.  Wells were blocked with 250 µL 1% BSA/PBS 
(w/v) and incubated for 60 minutes at 37°C.  Plate was washed, 50 µL standards or sample 
was added in duplicate and incubated for 60 minutes at 37°C.  For standards, purified C5 from 
human serum (Complement Technology, Texas, US) was diluted 5-fold serially in 1% 
BSA/PBS from 1000 to 0.064 µg/mL (v/v).  For cohort characterisation CF BAL fluid was 
removed from -80°C, thawed and kept on ice, prior to use BAL fluid was centrifuged 10,000 
RPM for 1 min at room temperature in a microfuge, samples were then diluted 1 in 2 with 1% 
(w/v) BSA/PBS.  For quantification of C5 in C5a generation experiments (section 4.7.3), 
samples were diluted 1 in 5000 in 1% BSA/PBS. After incubation with standards or samples, 
plates were washed then, 50 µL mouse anti-human C5/C5a antibody clone 557 (Hycult 
Biotech, Uden, Netherlands) in 1% BSA/PBS was added to each well and incubated for 60 
minutes at 37°C.  Plate was washed, 50 µL 60 ng/mL goat anti-mouse IgG-HRP conjugate 
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antibody (Stratech Scientific Ltd, Suffolk, UK) was added and incubated for 60 minutes at 
37°C.  Plate was washed and 50 µL TMB substrate was added to each well and colour was 
allowed to develop (up to 5 minutes) until standards were visible. To stop reaction, 25 µL 1 N 
(4%) hydrochloric acid was added to each well.  Optical absorbance at 450nm with 570 nm 
reference filter, was measured on a spectrophotometer.  C5 concentration in samples was 
interpolated from a sigmoidal curve using Graphpad Prism® 7. Interpolated C5 concentration 
was multiplied by the dilution factor for that sample. The detection range for this assay was 
1000 to 0.064 ng/mL. For a single CF BAL fluid sample, the C5 concentration was detectable 
but >3 standard deviations below the mean and therefore, regarded as an outlier and omitted 
from the data set. 
 
Two versions of the C5 ELISA were used for detection of C5 during C5a generation 
experiments.  These versions either used different detection antibodies: Hycult anti-C5/C5a 
antibody, as described above, or an in-house monoclonal antibody, 2D5 (Giles et al. 2015).  
Both antibodies were used at the same concentration and all other conditions remained the 
same. 
 
2.6.1. C3a ELISA 
 
C3a Microvue™ ELISA (Quidel®, San Diego, US) was performed as recommended by the 
manufacturer, all reagents were provided by the manufacturer.  Briefly, 100 µL standard or 
sample was added in duplicate to pre-coated 96-well plates and incubated at room 
temperature for 60 minutes.  For standards, ready-to-use dilutions were used, these had been 
made from dilutions of human serum.  CF BAL fluid was removed from -80°C, thawed and 
kept on ice, prior to use BAL fluid was centrifuged 10,000 RPM for 1 min at room temperature 
in a microfuge.  For sample dilution, BAL fluid was diluted 1 in 20 with sample diluent (“buffered 
protein base” in 0.035%  (w/v) ProClin®) however, BAL fluid that had high C5a concentrations 
(C5a was quantified in samples before C3a), indicative of anaphylatoxin generation, were 
diluted 1 in 30.  After incubation with standards or samples, wells were washed twice with 
wash 300 µL 1X wash solution (PBS, 1% tween-20, and 0.035% (w/v) ProClin® 300, made 
fresh by diluted 20X stock solution 1 in 20 in de-ionised H2O) using a wash bottle and blotted 
dry on paper towel.  For detection, 100 µL conjugate antibody was added and incubated for 
60 minutes at room temperature.  Wells were washed four times and 100 µL substrate solution 
added to each well and incubated at room temperature. Colour was allowed to develop until 
the standard curve was visible (up to 15 minutes).  Reaction was stopped with 100 µL stop 
solution (1 N HCl) and optical absorbance was measured at 450 nm using a 
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spectrophotometer.  C3a concentration in CF BAL fluid was interpolated from a sigmoidal 
curve using Graphpad Prism® 7.  Interpolated values were multiplied by the dilution factor for 
that sample.  The detection range for this assay was 4810 to 50 pg/mL.  3 samples out of 41 
had no detectable C3a, like NE and CXCL8, these were given an arbitrary value halfway 
between the lower detection limit and zero, 25 pg/mL. 
 
2.6.2. C5a ELISAs 
 
Two different C5a ELISAs were used as part of this study; a commercial C5a ELISA and one 
that was developed in-house.  The commercial ELISA was used for quantification of C5a 
where C5 might also be present such as CF BAL fluid and C5a generation experiments (using 
purified C5).  The in-house ELISA was used for quantification of C5a when no C5 was used 
in the experiment, such as quantifying C5a in gel chromatography experiments. 
 
 
 
C5a Microvue™ ELISA (Quidel®, San Diego, US) was performed as recommended by the 
manufacturer, all reagents were provided by the manufacturer.  Pre-coated 96-well plates 
were hydrated with 300 µL 1X wash solution (PBS, 1% tween-20, and 0.035% ProClin® 300, 
made fresh by diluted 20X stock solution 1 in 20 in de-ionised H2O) and incubated at room 
temperature for 2 minutes.  Wells were washed twice with wash solution using a wash bottle 
and blotted dry on paper towel.  100 µL standard or sample was added to the plate and 
incubated at room temperature for 60 minutes for standards, ready-to-use dilutions were 
added, these were provided by the manufacturer and made from dilutions of human serum. 
For CF samples, CF BAL fluid was removed from -80°C, thawed and kept on ice, prior to use 
BAL fluid was centrifuged 10,000 RPM for 1 min at room temperature in a microfuge.  BAL 
fluid was diluted 1 in 3 with sample diluent (PBS, 0.05% tween-20, 2.5% “protein stabilisers”, 
and 0.035% ProClin) however, CF BAL fluid with high CXCL8 concentrations, indicative of 
inflammation, were diluted 1 in 4.  For C5a generation experiments in section 4.7.1, samples 
were diluted 1 in 5000.  After incubation with standards or samples, wells were washed five 
times and then 100 µL conjugate antibody was added and incubated for 60 minutes at room 
temperature.  Wells were washed five times and 100 µL substrate solution added to each well 
and incubated at room temperature. Colour was allowed to develop until the standard curve 
was visible (up to 15 minutes).  Reaction were arrested with 100 µL stop solution (1 N 
Hydrochloric acid) and optical absorbance was measured at 450 nm using a 
spectrophotometer.  C5a concentration in samples was interpolated from a linear curve using 
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Graphpad Prism® 7.  The C5a value was multiplied by the dilution factor for that sample to 
calculate C5a concentration. The detection range for this assay was 953 to 10 pg/ml.  There 
was no detectable C5a in 8 out of 41 CF samples.  As mentioned above for another analytes, 
these samples were given values between the lower detection limit and zero, in this case 5 
pg/mL. There are no commercially available ELISAs that can distinguish between C5a and 
C5adesArg.  Therefore measurement of C5a/C5adesArg in BAL fluid in this study is referred 
to as C5a; however, it is assumed that the majority of this C5a is actually C5adesArg.  
 
 
 
Maxisorb 96-well plates were coated with 50 µL 2 µg/mL mouse anti-human C5a neo epitope 
monoclonal antibody clone 2952 (Hycult Biotechnology, Uden, Netherlands) diluted in 2% 
(w/v) carbonate buffer and incubated overnight at room temperature.  Wells were washed 
three times with 200 µL PBS-tween20 (0.05%, v/v) and blotted dry on paper towel.  Plates 
were blocked with 150 µL 1% semi-skimmed milk (Sigma, Dorset, UK)/ PBS and incubated 
for 60 minutes at room temperature.  Wells were washed, and 50 µL standard or sample were 
added in duplicate and incubated for 90 minutes at room temperature.  For standards, purified 
native C5a was diluted serially 2-fold from 16 ng/mL to 0.5 ng/mL in 1% milk / PBS.  For C5a 
quantification in column chromatography fractions, samples were diluted 1/2.5 in 1% milk / 
PBS.  Wells were washed, and 50 µL 2 µg/mL mouse anti-human C5/C5a in 1% milk / PBS 
(Hycult Biotechnology, Uden, Netherlands) was added and incubated for 60 minutes at room 
temperature.  Plates were washed, and 50 µL 160 ng/mL goat anti-mouse Ig2a HRP-
conjugated antibody (Stratech Scientific Ltd, Suffolk, UK) in 1% milk /PBS and incubated 60 
minutes at room temperature.  Wells were washed, and 50 µL TMB substrate was added and 
the plate was incubated for 20-30 minutes at room temperature in the dark.  Reaction was 
stopped with 50 µL 5% HCl (v/v).  Optical absorbance was measured at 450 nm with 570 nm 
reference filter using a spectrophotometer.  C5a concentration in samples was interpolated 
from a linear curve using GraphPad Prism® 7, interpolated values were multiplied by the 
dilution factor (2.5).  The detection range for this assay was 16 ng/mL to 0.5 ng/mL. 
 
2.6.3. Total protein 
 
Bicinchoninic acid (BCA) assay (Fisher Scientific, Loughborough, UK) was used to measure 
total protein in CF BAL fluid.  BSA protein standard (Fisher Scientific, Loughborough, UK) was 
diluted 2-fold serially in PBS from 200 to 1.25 µg/mL.  CF BAL fluid was removed from -80°C, 
thawed and kept on ice, prior to use BAL fluid was centrifuged 10,000 RPM at room 
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temperature in a microfuge. For quantification of total protein CF BAL fluid was diluted 1 in 3 
in PBS.  For the assay, 75 µL of standard or sample was added in duplicate to a sterilin™ 96-
well plate.  To each well 75 µL a BCA solution containing 25 parts reagent A, 24 parts reagent 
B and 1 part reagent C was added.  The plate was incubated for 3 hours at 37°C. Optical 
absorbance was measured at 570 nm using a spectrophotometer.  Total protein concentration 
in CF BAL fluid was interpolated from a sigmoidal curve using Graphpad Prism® 7, the 
interpolated values were multiplied by the dilution factor for that CF sample to give the total 
protein concentration. The detection range for this assay was 200 to 1.25 µg/mL.  For 2 out of 
41 samples total protein was not quantified because only a small volume of BAL fluid was 
recovered from these patients and characterisation of total protein was considered not to be 
a priority. 
 
2.6.4. CPB and CPN activity assay 
 
Protocol for the quantification of CPB and CPN activity was adapted from Mueller-Ortiz et al. 
(Mueller-Ortiz et al. 2009).  CPB/N activity was quantified using a specific chromogenic 
substrate, furylacryloyl-Ala-Lys (Bachem, Cambridgeshire, UK). For standards, porcine CPB 
was diluted 2-fold serially in PBS from 15 µg/mL to 0.94 µg/mL.  For CF samples, CF BAL 
fluid was removed from -80°C, thawed and kept on ice, prior to use BAL fluid was centrifuged 
10,000 RPM for 1 min at room temperature in a microfuge, BAL fluid was diluted 1 in 4 in PBS.  
For experiments investigating the influence of factors on porcine CPB activity, 15 µg/mL 
porcine CPB was incubated 1:1 with the experimental sample ( section 6.9.3).   For the assay, 
100 µL standard or sample (in duplicate) was pipetted into a sterilin™ 96-well plate, followed 
by 150 µL 833 µM substrate (solubilised in activity buffer (0.1 M HEPES, 0.5 M NaCl at pH 
7.8)).  The plate was loaded onto FluorSTAR® Omega plate reader (BMG labtech, Aylesbury, 
UK).  Change in optical absorbance at 336 nm was measured over time for no more than 25 
minutes.  Activity in samples was interpolated from the change in absorbance of the standards, 
calculated using a linear curve in GraphPad Prism® 7. Interpolated values were multiplied by 
the dilution factor for those samples.  The detection range for this assay was 15 to 0.94 µg/mL. 
 
2.6.5. Dimethyl methylene blue staining – GAG quantification 
 
Dimethyl-methylene blue (Sigma, Dorset, UK) was used to quantify soluble sulphated GAGs 
in CF BAL fluid, the protocol was adapted from Stone et al. (Stone et al. 1994). Stain was 
prepared be dissolving 8 mg/mL dimethyl-methylene blue in a stain solution of 40.5 mM 
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glycine and 625 mM NaCl, pH 4.0.  The stain was filtered through 0.2 µm filter and stored at 
4°C.  For standards, HS was diluted 2-fold serially from 200 to 6.25 µg/mL in PBS.  For 
samples, CF BAL fluid was removed from -80°C, thawed and kept on ice, prior to use BAL 
fluid was centrifuged at 10,000 RPM for 1 min at room temperature in a microfuge.  BAL fluid 
was diluted 1:1 in PBS.  For the assay, 20 µL of standard or sample was loaded onto a sterilin® 
96-well plate, in duplicate.  To each well 200 µL dimethyl methylene blue stain was added, 
optical absorbance was measure at 570 nm on a spectrophotometer.  GAG concentration was 
interpolated from a sigmoidal curve using Graphpad Prism® 7, the interpolated values were 
multiplied by the dilution factor for those samples. The detection range for this assay was 200 
to 6.25 ng/ml.  Dimethyl methylene blue stains sulphated GAGs and therefore, although a HS 
standard curve was used in this assay, other GAGs may have been detected as several 
different GAGs have been shown to be present in the CF airway (table 6-1).  Therefore, GAG 
concentration is relative to HS. 
 
Dimethyl methylene blue was also used to quantify purified GAG concentration in elute from 
chromatography columns.  Quantification of GAGs in fractions was performed on samples that 
had been diluted for the in-house C5a ELISA therefore, the dilution factor was 1 in 2.5.  Assay 
was performed as for quantification of GAGs in CF BAL fluid. 
 
 Protease cleavage experiments 
2.7.1. Proteolysis of C3a or C5a by proteases present in CF BAL fluid 
 
Aliquots were removed from -80°C and thawed on ice.  Prior to use BAL fluid was centrifuged 
10,000 RPM for 1 min at room temperature in a microfuge.  Supernatant was carefully 
removed and diluted 1:1 in cold PBS-T.  Purified C3a or C5a were removed from -80°C and 
diluted to 10 µg/mL in cold PBS-T.  In 0.5 mL Eppendorf tubes, the above complement 
components were exposed to an equal volume of CF BAL fluid and incubated at 37°C (water 
bath) for 60 minutes.  Following exposure, tubes were centrifuged at 10,000 RPM for 15 
seconds to reduce sample loss in condensate.  Proteolytic activity from serine proteases was 
inhibited using 5 mM PMSF or 20 µg/mL AAT (inhibitor use is specified in respective figure 
legends). 5X Laemmli buffer (10% sodium dodecyl sulphate (w/v), 50% glycerol (v/v), 0.001% 
(w/v))  bromophenol blue was added to each sample at a ratio of 1:4, and samples were stored 
at -20°C prior to SDS-PAGE. 
 
 
 
113 
 
2.7.2. Generation of C3a and C5a by proteases present in CF BAL fluid 
 
CF BAL fluid aliquots were removed from -80°C and thawed on ice.  Prior to use BAL fluid 
was centrifuged 10,000 RPM at room temperature in a microfuge.  Supernatant was carefully 
removed and diluted 1:1 in cold PBS-T.  Purified C5 and C3 were removed from -80°C and 
diluted to 300 µg/mL in cold PBS-T.  In 0.5 mL Eppendorf tubes, the above complement 
components were exposed to an equal volume of CF BAL fluid and incubated at 37°C (water 
bath) for 60 minutes.  Following exposure, tubes were centrifuged at 10,000 RPM for 15 
seconds to reduce sample loss in condensate.  Proteolytic activity from serine proteases was 
inhibited using 5 mM PMSF or 20 µg/mL AAT (inhibitor use is specified in respective figure 
legends). 5X Laemmli buffer was added to each sample at a ratio of 1:4, and samples were 
stored at -20°C prior to SDS-PAGE. 
 
2.7.3. Generation of C3a and C5a by purified NSPs. 
 
Purified C5 and C3 were removed from -80°C and diluted to 300 µg/mL in cold PBS-T.  Purified 
NSPs were removed from -20°C and diluted from stock solutions of 17 µM (NE, CG) or 34 µM 
(PR3) using PBS-T, unless specified NSPs were diluted to a final concentration of 420 nM.  In 
0.5 mL Eppendorf tubes, C5 or C3 were exposed to an equal volume of individual protease 
and incubated at 37°C for the time limits described in the figure legends.  Following exposure, 
tubes were centrifuged at 10,000 RPM for 15 seconds to reduce sample loss in condensate.  
Proteolytic activity from serine proteases was inhibited using 5 mM PMSF or 20 µg/mL AAT 
(inhibitor use is specified in respective figure legends). For SDS-PAGE (section 2.8.1), 5X 
Laemmli buffer was added to each sample at a ratio of 1:4, and samples were stored at -20°C. 
For quantification of C5 or C5a, 1 µL of sample was removed at diluted 1 in 5000 in the dilution 
buffers required for the respective ELISAs.  For C3a or C5a activity assays (section 2.9.2), 
samples were diluted 1 in 10 in phenol red-free DMEM. For complement haemolysis assays, 
samples were diluted 1 in 47 in complement fixation buffer (section 2.1.10). 
 
 
2.7.4. Inactivation of C3a and C5a by porcine CPB 
Purified C3a (1.5 µg/mL) or C5a (2.5 µg/mL) or the C3a-like or C5a-like fragments generated 
by NSPs (section 2.7.3) were incubated with an equal volume of 30 µg/mL (final concentration 
15 µg/mL) porcine CPB at 37°C for 60 minutes. Following exposure, tubes were centrifuged 
114 
 
at 10,000 RPM for 15 seconds to reduce sample loss in condensate.  For activity assays, 
samples were diluted 1 in 10 in phenol red-free medium. 
 
 Polyacrylamide gel electrophoresis (PAGE) 
2.8.1. SDS-PAGE 
 
Different gel types were used for resolution of the different proteins investigated in this study, 
these have been specified in the figure legends.  Bis-Tris (37:5:1) gels were cast using Mini-
Protean® hand-cast system (Bio-Rad, Hertfordshire, UK).  Running gel contained 94 mM 
TRIS, 1% SDS (w/v), acrylamide (concentrations as stated in legends), 0.1% ammonium 
persulphate (w/v), and 0.1% Tetramethylethylenediamine (TEMED, v/v) at pH 8.8.  Stacking 
gels consisted of 120mM Tris, 1% SDS, 4% acrylamide, 0.1% APS, and 0.1% TEMED at pH 
6.8.  For western blots analysis 1.5 mm gels were cast, 1 mm gels were cast for silver staining. 
 
Pre-cast 0.75mm gradient gels, 4-20% Tris-glycine (SDS-free) (ThermoFisher, 
Loughborough, UK), were used to resolve C3 and C5 cleavage fragments and were used in 
native-PAGE and blue native-PAGE experiments. 
 
Electrophoresis of both gel types were carried out in 25 mM Tris, 0.1% SDS, and 192 mM 
glycine.  Fixed concentration gels were run at 40 mA(constant) per gel for approximately 45 
minutes at room temperature.  Gradient gels were run at 80 V (constant) for 2 h at room 
temperature.  Samples were loaded using a pipette and loading tips, volume loaded was 10 
µl for 1 mm gels and 15 µl for 1.5 mm gels.  For reference 2.5 µl of either 2 – 40 kDa ladder 
(Fisher Scientific, Loughborough, UK) or EZ-Run 11 - 170 kDa (Fisher Scientific, 
Loughborough, UK) protein ladder was loaded.  Blank wells were loaded with the dilution 
buffer of the samples that had been diluted in 5X Laemmli buffer. 
 
2.8.2. Native PAGE 
 
For native PAGE (SDS-free), pre-cast 4-20% gradient gels were used.  Samples were diluted 
in 5X SDS-free loading buffer that contained 500 mM TRIS, 50% glycerol (v/v), 1% 
bromophenol blue (w/v) at pH 8.6.  For resolution, 10 µL sample was loaded per well, gels 
were submerged in native running buffer containing 25 mM TRIS and 192 mM glycine at pH 
8.3.  Electrophoresis was performed at 100V for 2 h, tank was cooled by placing in ice on a 
magnetic stirrer. 
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2.8.3. Blue native-PAGE (BN-PAGE) 
 
BN-PAGE protocol was developed from Fiala et al. (Fiala et al. 2011). For native BN-PAGE 
(SDS-free), pre-cast 4-20% gradient gels were used.  Coomassie blue G-250 was used as a 
protein charge carrier instead of SDS or the native charge of the proteins.  Samples were 
diluted in a SDS-free loading buffer similar to that used for native-PAGE (section 2.8.2) 
however, in addition, 0.1% (v/v) Coomassie blue R-250 (Fisher Scientific, Loughborough, UK) 
was added.  For resolution, 10 µL sample was loaded per well, gels were submerged in native 
running buffer containing 25 mM TRIS, 192 mM glycine and 0.02% (v/v) coomasie blue R-250 
(pH 8.3). Electrophoresis was performed at 100V for 2 h, tank was cooled by placing in ice on 
a magnetic stirrer. 
 
2.8.4. Silver staining 
 
Protocol for silver staining was adapted from Shevchenko et al. 1996 (Shevchenko et al. 
1996).  All washes and stains were performed using sterile H2O in 250 mL capacity weigh 
boats.  Following electrophoresis gels were immediately fixed in 50% methanol (v/v) / 5% 
acetic acid (v/v) in sterile water for 20 minutes on a rocker at room temperature.  Gels were 
washed twice in 50% methanol for 10 minutes followed by two 60 second rinses in H2O. Gels 
were sensitised in 0.02% sodium thiosulphate (w/v) for 60 seconds and rinsed twice in H2O.  
Gels were stained with cold 0.1% silver nitrate (w/v) for 45 minutes at 4°C.  Stain was 
discarded, and gels were rinsed twice in H2O.  To develop, gels were washed in cold 0.04% 
formalin (v/v) / 2% sodium carbonate (w/v) until protein bands were visible (~30 minutes).  
Developing was stopped by discarding formalin solution and washing in 5% acetic acid (v/v) 
for at least 5 minutes, at room temperature.  For imaging gels were soaked in 20% glycerol 
(v/v) overnight and dried between dialysis membranes. Dried gels were scanned and 
annotated using Corel Graphics Suite X5 v15.2.0.661. 
 
2.8.5. Western blotting 
 
 
Proteins resolved by electrophoresis on polyacrylamide gels were transferred to nitrocellulose 
membranes (Pall Life Sciences, Hampshire, UK) in 25 mM TRIS, 192 mM glycine, 20% 
methanol (v/v) at 100 V (fixed) for 60 minutes, cooled by ice block on a magnetic stirrer.  For 
visualisation of fragments generated by the proteolysis of C3 or C5, membranes were cut in-
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two along the line of the 56 kDa protein reference ladder.  All membranes were treated the 
same during the following steps.   Membranes were blocked in 5% semi-skimmed milk (Sigma, 
Dorset, UK) (w/v) / PBS for at least 30 minutes at room temperature.  For staining blots were 
incubated in 2.5 mL antibody / 5% milk (See antibody table 2-2 for antibody dilutions) in 60 
mL falcon tubes overnight on rollers at room temperature.  Blots were washed three times with 
15 mL PBS-T and once with 15 mL PBS for at least 15 minutes each, at room temperature on 
rollers.  Membranes were stained with respective HRP-conjugate antibody in 2.5 mL / 5% milk 
for 60 minutes at room temperature on rollers.  Blots were washed three times in both PBS-T 
then PBS as above. 
 
 
 
For developing, membranes were incubated with 250 µL enhanced chemo-luminescent 
substrate (ECL) for 2 minutes, three levels of ECL sensitivity were available high, medium or, 
low (ECL select (GE Lifesciences, Buckinghamshire, UK), ECL prime (GE Lifesciences, 
Buckinghamshire, UK) or Pierce ECL (Fisher Scientific, Loughborough, UK)). In a dark room, 
Super RX Fuji X-ray film (VWR, Leicestershire, UK) was exposed to membranes for 2 minutes 
(typical length of time) and subsequently developed by submerging in developer for 1 minute 
(or as long as it takes to visualise bands), washing in tap water and finally in fixer for at least 
30 seconds.  The ECL sensitivity or exposure time were varied for each blot so that different 
aspects of the gel could be visualised. For example, for C5 and C3 cleavage experiments blots 
were cut in two and incubated with different ECLs, as described in figure legends.  This was 
because the large amounts of C3 or C5 that had been resolved on the gels meant that blots 
became over-exposed when they were developed.   Exposed films were scanned and 
annotated using Corel Graphics Suite X5 v15.2.0.661.  Figures showing western blots 
represented all the bands that could visualised, unless stated otherwise. 
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 Cell reporter assays 
2.9.1. Cell culture 
 
 
U937-C5aR1 monocytes (A gift from Prof. Eric Prossnitz, New Mexico, USA) were cultured in 
10% (v/v) FCS (Fisher Scientific, Loughborough, UK), 5000 U/mL penicillin-streptomycin 
(Fisher Scientific, Loughborough, UK), 2 mM L-glutamine in RPMI1640 (Fisher Scientific, 
Loughborough, UK).  Cells were cultured at 37°C 5% CO2 in 50 mL flasks and passaged 
every 3-4 days when confluent. 
 
 
 
Rat basophil leukaemia (RBL-2H3) cells transfected with C5aR1 (RBL-C5aR1) and RBL-
C3aR (both cell lines were gifts from Dr. Peter Monk, Sheffield University, UK) adherent cell 
lines were cultured in 10% (v/v) FCS, 5000 U/mL penicillin-streptomycin, 4 mM L-glutamine in 
DMEM (Fisher Scientific, Loughborough, UK).  Cells were cultured at 37°C 5% CO2 in 50 mL 
flasks and passaged by trypsinisation every 3-4 days when confluent. 
 
2.9.2. Intracellular calcium signalling assay 
 
 
U937-C5aR1 were cultured until exponential growth phase. When confluent, cells were 
poured into a 30 mL universal container and centrifuged at 500 x g for 3 minutes at room 
temperature.  Supernatant was discarded, and cell pellet resuspended in sterile 0.9% saline 
and then centrifuged a second time.  Cell pellet was resuspended in 2-3 mL saline, a 20 µL 
sample was removed and added to an equal volume of trypan blue, to check for dead cells.  
Cells were counted using a haemocytometer under 20X magnification.  Following counting, 
cell suspension was topped up to 20 mL with saline and centrifuged.  Supernatant was 
discarded, and pellet was resuspended at 1 x 107 cells/mL in culture medium.  Cells were 
incubated with 2 µM Fura-2-AM in culture medium for 30 minutes at room temperature.  
Following incubation, cells were washed in saline, centrifuged and resuspended at 5 x 106 
cells/mL in Krebs / HEPES buffer (120mM NaCl, 25mM HEPES, 4.8 mM KCl, 1.2 mM KH2PO4 
and, 1.2 mM MgSO4, 1.3mM CaCl2, pH 7.4). 
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U937-C5aR1 Cells (5x106) were seeded in a 96-well plate and placed in a FLUOstar Omega 
microplate reader set at 37°C and acclimatised for 5 minutes.  Cells were stimulated with 10 
µL sample, this was either purified C5a or cleavage fragments diluted 1 in 10 in Krebs-HEPES.  
Intracellular calcium release was quantified by measuring emission from Fura-2 at 510 nm 
when excited at 340 nm and 380nm.  The ratio of fluorescent intensity was calculated for 
maximum and minimum calcium release by adding 0.5% (v/v) triton X-100 or 0.08 M ethylene 
glycol tetraacetic acid (EGTA) respectively.  Calcium release upon stimulation was quantified 
by the following equation:  Ca2+ = K(R – Rmin)/ (Rmax – R) where K = 0.2865 µM and R is the 
ratio of fluorescence (340/380) as described by Al-Mohanna and Hallet (Al-Mohanna and 
Hallett 1988). 
 
For C5aR1 inhibition, U937-C5aR1 cells were pre-incubated with 80 µM AS-65121 C5aR1 
antagonist (Cambridge Bioscience Ltd, Cambridge, UK) for 10 minutes at 37°C.  Cells were 
seeded, and assay performed as above. 
 
 
 
RBL-C3aR and RBL-C5aR1 were cultured until in exponential growth phase.  When confluent, 
supernatant was discarded and cells trypsinised in 5mL 0.11 mM Trypsin, 0.91 mM EDTA for 
10 minutes at 37°C 5% CO2.  Trypsin was neutralised by adding an equal volume of culture 
media.  Cells were centrifuged 500 x g for 3 minutes at room temperature, supernatant was 
discarded, and cells were resuspended in 2-3 mL media.  A 20 µL sample was removed and 
added to an equal volume of trypan blue.  Cells were counted using a haemocytometer under 
20X magnification.  Cells were diluted to 5 x 105 cells/mL in medium and 50,000 cells were 
seeded into a sterile 96-well plate and allowed to adhere overnight at 37°C 5% CO2.  
Supernatant was discarded using a pipette and cells were washed with 150 µL sterile PBS.  
Saline was immediately removed, and cells were stimulated with 50 µL sample for 30 minutes 
at 37°C 5% CO2. For reference in assays using RBL-C5aR1, purified native C5a was diluted 
5-fold in series using phenol red free medium from 250 to 0.4 ng/mL C5a. For reference in 
assays using RBL-C3aR, purified native C3a was diluted 2-fold in series using phenol red free 
medium from 250 to 15.63 ng/mL.  Experimental samples were diluted at least 1/10 in DMEM 
prior to stimulation (see figure legends).  After stimulation, supernatant was immediately 
removed and added to 50 µL ß-hexosaminidase substrate (1 mM 4-Nitrophenyl N-acetyl-β-D-
glucosaminide in 0.1 M citrate buffer (pH4.5)) and incubated for 3 hours at 37°C.  Colour 
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change was induced by addition of 150 µl 1M TRIS (pH 9), absorbance was measured at 
405nm on a spectrophotometer.  C5a or C3a activity in samples was interpolated from a 
sigmoidal curve generated using reference standards (purified C3a and C5a), curve was 
calculated using Graphpad Prism® 7.  Cell stimulation could also be quantified as a 
percentage of maximum ß-hexosaminidase, released by inducing lysis by incubating the cells 
with 50 µL 0.1% (v/v) triton X-100. 
 
 Classical pathway complement haemolysis assay 
2.10.1. Sheep erythrocyte sensitisation  
 
One millilitre sheep erythrocytes (TCS Bio-science, Botolph Claydon, UK) were washed three 
times in 20 mL PBS by centrifugation at 872 x g for 5 minutes at 4°C, supernatant was removed 
using a 20 mL syringe and kwill.  After the final wash step the pellet was unsettled by gentle 
tapping against the hand and 200 µL erythrocytes from the residual volume were sensitised 
in 10 mL 1 in 4000 sheep anti-sera (Siemens Healthcare, Marburg, Germany) in complement 
fixation at room temperature for 30 minutes on rollers.  Sensitised sheep erythrocytes were 
washed three times in PBS, as above, and resuspended in 10 mL complement fixation buffer 
. 
2.10.2. Haemolysis assay 
 
In a U-bottomed 96-well plate 50 µL sensitised sheep erythrocytes were added to 90 µl 1% 
C5-depleted normal human serum (in-house).  10 µL 1.81 µg/ml C5 (following cleavage 
experiments in detailed in section 4.7.3) was added and incubated for 45 minutes at 37°C.  
The plate was centrifuged at 500 x g for 5 minutes at room temperature.  50 µL erythrocyte 
supernatant was transferred to 100 µL H2O in a flat-bottomed plate and optical absorbance 
was measured at 405nm using a spectrophotometer.  Sheep erythrocytes lysis was calculated 
as a percentage of the positive control (erythrocytes lysed with 100 µL H2O) minus negative 
control (erythrocytes incubated with complement fixation buffer only) for example: % lysis = 
((sample absorbance – negative control absorbance) / (positive control absorbance – negative 
control absorbance)) x 100. 
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 Fluid-phase column chromatography 
2.11.1. Size exclusion chromatography 
 
Superdex 75 (SD75) or Superose 6 columns (GE Lifesciences, Buckinghamshire, UK) were 
attached to AKTA prime FPLC (GE Lifesciences, Buckinghamshire, UK), washed with two 
column volumes of H2O and, equilibrated in PBS.  All washes and gel filtration were performed 
at 4°C, 0.3 mL / min flowrate and back pressure did not exceed 0.8 MPa. All buffers were 
filtered through 0.2 µm filters prior to use.  Volume, flowrate, conductivity and ultra violet (UV) 
were continually recorded throughout all experiments. 
 
Purified native C5a (10 µg/mL) was incubated for 2 h at 37°C with 500 µg/mL HS sodium salt 
from bovine kidney or chondroitin sulphate (CS) sodium salt from shark cartilage (Sigma 
Aldrich, Dorset, UK) diluted in H2O.   Two hundred microliters sample was loaded onto 
columns via a 200 µL induction loop.  For each run the induction loop was washed with 5 mL 
PBS, the loop was then was bypassed for the remainder of the run; in total, during each run, 
the columns had a one column volume of PBS flowed through.  Fractions were collected in 
12mm polystyrene tubes from 5 mL onwards, 0.5 mL fractions were collected into an equal 
volume of 2% semi-skimmed milk powder (w/v) / 0.1% tween-20 (v/v) / PBS at 4°C.  Fractions 
were stored at 4°C until C5a quantification.  Due to the limit of sensitivity in the UV 
spectrometer, C5a concentration was measured by in-house C5a ELISA (section 2.6.2b). 
 
2.11.2. Affinity chromatography 
 
A heparin 1 mL HiTrap affinity column (GE Lifesciences, Buckinghamshire, UK) was attached 
to AKTA prime and washed with 15 mL (15 column volumes) H2O, followed by 1 M NaCl in 
PBS until conductivity plateaued.  Column was re-equilibrated in PBS (154 mM NaCl). All 
washes and gel filtration were performed at 4°C, 0.5 mL / min flowrate and back pressure did 
not exceed 0.3 MPa. 
 
Purified native C5a was incubated with GAGs as described for experiments using size 
exclusion chromatography. Two hundred microliters sample was loaded via a 200 µl induction 
loop.  For each run the induction loop was washed with 2 mL PBS, the loop was bypassed 
and a further 5 mL PBS run through the column.  The material on the column was eluted with 
a gradient of NaCl / PBS from 154 mM to 1000 mM that increased at a rate of 10% / min, real-
time conductivity was recorded as a measure of increasing NaCl concentration.  Fractions 
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were collected in 1.5 mL Eppendorf tubes throughout entire run, until buffer reached 100% 
1000 mM NaCl / PBS.  Fraction volumes of 0.5 mL were collected into an equal volume of 2% 
semi-skimmed milk powder (w/v) / 0.1% tween-20 (v/v) / PBS.  C5a concentration in fractions 
was measured by in-house C5a ELISA. 
 
 Solid phase binding assay: C5a – GAG interaction 
2.12.1. Biotinylation of HS 
 
Method for biotinylation of HS was adapted from Clark et al. (Clark et al. 2006). One milligram 
lyophilised HS sodium salt from bovine kidney was reconstituted in 126 µL 0.1 M (2-(N-
morpholino) ethanesulfonic acid, MES).  Biotinylation was carried out by adding 3.6 µL 18.55 
mg/mL biotin / DMSO (ThermoFisher) and 1.6 µL 0.522 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride in 0.1 M MES.  Reagents were incubated at room temperature 
overnight.  Biotinylated-HS was concentrated on Vivaspin protein concentrator spin column 
(GE life sciences, Buckinghamshire, UK) with a molecular weight cut off of 10 kDa.  Spin-
columns were centrifuged at 13,000 RPM for 10 minutes in a microfuge cooled to 4°C.  Run-
through was discarded, and columns were washed twice with 500 µL sterile PBS with 
centrifugation at 13,000 RPM for 10 minutes, 4°C.  Biotinylated-HS retained on the column 
was reconstituted with 1 mL PBS and stored at 4°C. For long-term storage, biotinylated HS 
was added to 50% glycerol and stored at -20°C. 
 
 Solid phase binding assay 
 
Protocol for solid phase binding assay was adapted from Clark et al. (Clark et al. 2006). 
Maxisorb 96-well plates were coated with 150 µL purified C5a, C3a, C3 or C5 in sterile PBS 
or PBS only (negative control) at concentrations stated in figure legends for respective 
experiments.  Coated plates were sealed and incubated at 37°C, overnight.  Plates were 
washed with 300 µL assay buffer (50 mM sodium acetate, 100mM NaCl, 0.1 % tween-20 (v/v) 
pH 6.0) three times, blotting dry on paper towel between washes. Plates were blocked with 
200 µL 1% (w/v) BSA / assay buffer and incubated for at least 90 minutes at 37°C.  After 
blocking plates were washed a further three times in 300 µL assay buffer.  To each well, 150 
µL 1 µg/mL biotinylated HS in assay buffer was added and incubated for 3 h at 37°C.  For 
competition experiments, varying concentrations of non-biotinylated HS, CS or HA were 
added to biotinylated HS maintaining a final concentration of 1 µg/mL biotinylate-HS.  After 
incubation with biotinylated-HS plates were washes three times and blotted dry, 150 µL 25 
ng/mL streptavidin-HRP was added to each well and incubated for 30 minutes at 37°C. Plates 
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were washed three times, blotted dry, and 150 µL TMB substrate was added to each well. 
Colour was allowed to develop for up to 15 minutes, reaction was arrested using 4% HCl.  
Absorbance of each well was read by spectrophotometer at 450 nm.  For figures, data is either 
plotted as absorbance values however, for competition experiments data was calculated as 
percentage absorbance of positive controls (biotinylated-HS). 
 
 Statistics 
 
All statistical analyses were performed by Graphpad Prism 7, apart from the correlation matrix 
in figure 3.7 whereby analyses were performed in GraphPad prism, but matrix was drawn by 
Dr. Samuel Touchard using the statistic software R (https://www.r-project.org/). 
 
All statistical tests were performed on data with n ≥ 3, significance was reported when p<0.05. 
All statistical analyses were reported in figure legends.  Reporting of statistical outcomes in 
figures uses the following annotation ns – non-significant, * p < 0.05, ** p < 0.01, *** p < 0.001 
and P < 0.0001. 
  
When tested, there was not enough evidence to suggest that all data from the CF cohort had 
a Gaussian distribution and therefore, non-parametric tests were performed to analyse 
correlations between variables (Spearman rank correlation) and difference in medians 
(Wilcoxon paired t-test).  The data population from the CF cohort contained seven patients 
that had repeated measures.  After analysis (section 3.4), I determined that it was not 
appropriate to correct for repeated measures.  For the correlation matrix in figure 3.7, testing 
for multiple comparisons was performed using the Holm-Bonferroni test for multiple 
comparisons (Holm 1979). Correlation analysis and presentation of Cohort data was 
performed on data transformed by log 10.  
 
For dose-response and time-course experiments means were compared by two-way ANOVA 
with correction for multiple comparisons by Tukey’s multiple comparisons test.  Data in figures 
for experimental data was plotted as means with standard deviation.  For preliminary data 
where n<3 data was presented as the mean. 
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3. Characterising C3a and C5a in bronchoalveolar lavage fluid from a 
cohort of CF patients 
 
 Background to the study 
 
The CF airway is a complex environment containing host-cells, pathogens and a multitude of 
endogenous and exogenous factors that continuously stimulate and regulate the immune 
system (Sagel et al. 2007; Sly et al. 2013).  For example: DNA, cytokines, chemotactic 
molecules, endotoxins (PAMPs) and DAMPs have been investigated in the CF airway 
(Mackerness et al. 2008; Hartl et al. 2012; Kruger et al. 2015).   Despite identification and 
quantification of these factors, the full picture of their roles in disease pathogenesis is very 
much incomplete. 
 
Reflecting on our lack of understanding of the complex inflammatory environment in the CF 
airway, many anti-inflammatory therapeutics targeting single molecules in the CF airway have 
been mostly ineffective, or any modest benefits could not be measured over short trial periods 
(Cantin et al. 2015).  Examples of pro-inflammatory molecules that have either been trialed or 
identified as therapeutic targets in the CF airway are: CXCL8, LTB4, CXCR2 and IL-17/IL-17R 
(McAllister et al. 2005; Moss et al. 2013; Konstan et al. 2014; McElvaney et al. 2015).  
Furthermore, ibuprofen is the only anti-inflammatory drug that slows decline in lung function 
and is prescribed for long-term management (Konstan et al. 2007).  Yet, only 10% patients 
are prescribed ibuprofen for long-term use (Konstan et al. 2007).  This is due to concern over 
adverse effects in the GI tract, owing to high doses combined, with dehydration of the CF GI 
tract (Konstan et al. 2007; Mogayzel et al. 2013).  Instead, over 50% of CF patients (including 
children) are given long-term courses of inhaled corticosteroids, despite reports that they only 
deliver modest improvements in lung function and concern that they may cause adverse 
developmental effects in paediatric patients (Lai et al. 2000; Mogayzel et al. 2013; Balfour-
Lynn and Welch 2016).  The mechanism of corticosteroid function is not well-defined but, it is 
reported that they prevent the release of pro-inflammatory cytokines through inhibition of NF-
kB transcription factors (de Benedictis and Bush 2012). The effects of corticosteroids are not 
limited to inhibiting pro-inflammatory cytokine release, other reported effects of corticosteroids 
are decreased mucus production, accelerated eosinophil apoptosis but the promoting of 
neutrophil survival (Saffar et al. 2011; de Benedictis and Bush 2012). 
 
To improve understanding of inflammation in the CF airway there needs to more 
comprehensive characterisation of the different factors involved in promoting disease.  This 
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can be an issue because laboratories have access to different types of airway fluid samples.  
These may only represent a small section of the airway or make assumptions that 
inflammation is spread throughout the airway.  More recently, there is growing appreciation of 
the fact that infection and inflammation maybe localised throughout the airway (McNally et al. 
2017; McElvaney et al. 2018).  In this background section I will discuss the types of samples 
used to characterise inflammatory mediators and what has previously been reported on C3a 
and C5a using clinical samples. 
 
3.1.1. Fluid sampling in airway disease and CF 
 
One of the primary reasons for sampling the CF airway is because a patient has symptoms of 
pulmonary exacerbation such as difficulty breathing, chronic cough or wheezing (de Blic et al. 
2000). Airway fluid is sampled to identify pathogens and enable the administration of the most 
effective antibiotics.  A follow-up examination is performed after a course of antibiotics to 
confirm eradication of the infection (Brennan et al. 2008).  Airway fluid samples are also 
essential for research, such as monitoring the efficacy of a therapeutic during a trial or, like 
myself, characterising pro-inflammatory mediators in the CF airway.  There are three types of 
sampling techniques that can be used for lower airway sampling these are: BAL, induced 
sputum or cough swab.  There is an ongoing debate about which of these is most appropriate 
for identifying pathogens and pathogenic factors. The advantages and disadvantages of each 
technique will be discussed below and are summarised in table 3-2. 
 
 
 
The ERS has published several guidelines on pathogen surveillance in CF; they state that 
BAL is “gold standard” for identification of pathogens in the CF airway (de Blic et al. 2000; 
Brennan et al. 2008).  BAL is an invasive procedure that involves inserting a flexible fiberoptic 
bronchoscope into the airway whilst the patient is sedated.  Due to the fact that patients have 
to be sedated, BAL may also be performed on CF patients whilst undergoing other surgery 
that also requires anesthetic; this allows further opportunity for surveillance of the airway. An 
example of such surgery is the insertion of a portacath; these to allow antibiotics to be directed 
straight into the circulation (Ronchetti et al. 2018).  
 
When performing BAL, the bronchoscope is primarily positioned in the right middle lobe (figure 
3-1); this is because this site is most straight forward to access.  The left lung is more difficult 
to access due to a more acute angle in the left primary bronchus; this is skewed because of 
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the location of the heart.  The “gold-standard” for performing BAL on CF patients for the 
detection of pathogens is to sample from the right middle lobe followed by the left lower lobe 
or infection site depending on imaging availability (figure 3-1) (Brennan et al. 2008).  Moreover, 
a recent study suggests that a six-site sampling technique is most effective for comprehensive 
detection of pathogens (Ronchetti et al. 2018).  The six-sites in the study by Ronchetti et al. 
were sampled in the same order for each patient: right middle lobe, left lingular, right lower 
lobe, right upper lobe, left lower lobe, and left upper lobe. 
 
 
Figure 3-1: Diagram of the lobes in the human lungs. 
 
 
Once the bronchoscope is situated at the correct sample site, saline is instilled at a volume 
proportional to the patient weight (recommended: 3 mL/Kg to a maximum of 20 mL)(de Blic et 
al. 2000).   A syringe attached to the end of the tubing is used to aspirate fluid, along with 
cells, pathogens and debris, back out so that they can be analysed in the laboratory.  It should 
be noted that, due to mucus obstruction in the airway not all the volume of saline instilled is 
recovered.  The ERS guidelines for performing BAL on the CF airways state that recovery of 
greater than 40% of the instilled volume is acceptable (de Blic et al. 2000). 
 
The identification of pathogens in BAL (and from sputum or cough swabs) is performed using 
positive selection culture media for known pathogenic strains in CF (de Blic et al. 2000; Bakare 
et al. 2003; de Vrankrijker et al. 2010).   A disadvantage of using growth cultures is the time it 
                                                                                      The human airway is separated into two lungs 
(left and right), these are further divided into upper, middle and lower however, the left middle lobe (lingula 
or tongue) is small and has a notch to accommodate the heart. Standard procedure for 2-lobe 
bronchoalveolar lavage is to sample from the right middle lobe followed by the left lower lobe. 
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takes for pathogens to grow (48 hours), particularly if laboratories are sub-culturing strains 
and testing antibiotic susceptibility as this can take a further 48 hours (Burns and Rolain 2014).  
Culture media are specific for the detection of Haemophilus influenzae, Staphylococcus 
aureus, methicillin-resistant Staphylococcus aureus (MRSA), P. aeruginosa, Burkholderia 
cepacia complex species, non-tuberculous Mycobacterium species, Achromobacter 
xylosoxidans, Stenotrophomonas maltophilia, and Klebsiella pneumoniae (Ronchetti et al. 
2018).  Polymerase chain reaction (PCR) based assays that sequence 16S rRNA are 
becoming more routine; PCR is quicker than culture growth, but despite several reports, it is 
not clear whether PCR is more advantageous than growth cultures for pathogen identification 
(Miles 2010).  A further method of identifying pathogens is to use mass spectrometry, this is 
quick and has shown to be 98% successful at identifying pathogens at the genus level using 
growth cultures as a reference (Desai et al. 2012). 
 
As well as the identification of pathogens there are also guidelines for processing BAL fluid for 
analysis of cells and supernatant (de Blic et al. 2000).    The ERS recommends that BAL fluid 
should be stored on ice until processed and, that samples should be processed within 30 
minutes and stored at -70°C or below.  The report also states that, further “processing” is not 
standardised and, that BAL fluid “should be optimised for the particular questions being asked” 
(de Blic et al. 2000). 
 
A controversial issue with BAL (and other airway fluid sampling techniques) is that when 
reporting on CF fluid constituents (cells, cytokines and other factors), concentration should be 
reported as concentration per millilitre (de Blic et al. 2000; Brennan et al. 2008).  Reporting 
concentration in this way is in contrast to other tissue fluid samples whereby concentrations 
are standardised to total protein or albumin.  Correcting for total protein cannot be performed 
on airway samples due to capillary leakage in the airway during inflammation (de Blic et al. 
2000).   Other methods of standardising BAL fluid have been investigated, such as using 
secreted components of IgA and Urea. Secreted components of IgA are complexes of 
polymeric immunoglobulin receptors and IgA that protect IgA from degradation (Kaetzel et al. 
1991). They are released by epithelial tissue and have not been reported to be influenced by 
lung injury or lung permeability (Watts and Bruce 1995).  Urea is a product of mammalian 
metabolism and is ubiquitous throughout the cardiovascular system. Urea has been used to 
standardise the measurement of airway surface hydration and mucin concentration (Esther et 
al. 2017).  The problem with standardising using urea, is that with each successive aliquot of 
BAL fluid removed from the airway the urea concentration increases, a consequence of urea 
leakage from circulation (Marcy et al. 1987).  For the same reason, the ERS recommend that 
pathogen identification is performed on the first aliquot removed during each BAL procedure 
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(Brennan et al. 2008).  Despite the above attempts to standardise the reporting of airway fluid 
constituents, the ERS recommends that analytes should be stated as grams per millilitre (de 
Blic et al. 2000; Brennan et al. 2008). 
 
A disadvantage of BAL sampling is that it is an invasive procedure that requires sedation of 
the patient.  None the less, the ethical issues of using of BAL to sample the CF airway are out-
weighed by the necessity to identify pathogens.  Despite this, the invasiveness of BAL is a 
problem for clinical trials requiring longitudinal monitoring of a patient.  Moreover, it is ethically 
inappropriate to perform an invasive technique such as BAL on healthy patients therefore, 
control populations for reporting in CF BAL use other non-CF patient populations that also 
undergo BAL, these are summarised in table 3-1.  Despite identification of control populations 
that can be used as “healthy” controls for studies investigating CF, many non-CF conditions 
that require BAL are caused by infection (Brennan et al. 2008).  Therefore, it cannot be 
guaranteed that healthy controls are free from pathogens. Consequently if studying 
inflammatory markers in the airway, concentrations of analytes may not represent the normal 
airway  (Ringholz et al. 2014). 
 
In summary, performing BAL in the CF airway is an invasive but effective and well-established 
technique for the identification of pathogens; however, there can be a lack of standardisation 
in processing and concentration reporting across different laboratories that makes it difficult to 
make comparisons of the constituent components. 
Disease Cause Limitations in use as a 
control population for CF 
Reference of use in 
CF study 
Tonsillectomy Recurrent infections of the 
tonsils – surgical removal of 
tonsils  
No guarantee that the patient is 
healthy or free of airway 
infection 
 
Tonsillectomy is being phased 
out as a treatment for tonsillitis 
(McGreal et al. 2010; 
Kotecha et al. 2013) 
Primary ciliary 
dyskinesia 
Genetic defect that reduces 
motility of flagella 
Recurrent infections 
 
Pulmonary obstruction 
(Ringholz et al. 2014) 
Structural airway 
abnormalities  
 
(Stridor – 
blockage of the 
larynx) 
Infection, blockage (foreign 
bodies), tumour or 
laryngospasm 
Recurrent infection 
 
Inflammation 
(Armstrong et al. 2005; 
Brennan et al. 2008) 
Severe recurrent 
wheezy bronchitis 
Neutrophil mediated 
inflammation 
Controls for defects in cellular 
function through loss of CFTR  
 
Not necessarily “healthy” control 
and some patients may have 
some degree of neutrophilic 
inflammation 
(Le Bourgeois et al. 
2002) 
Table 3-1 Control population used in studies reporting on BAL fluid. 
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One important advantage of BAL over induced sputum and cough swabs is that it can be 
performed on young paediatric CF patients; this is because it does not require any degree of 
cooperation between patient and clinician due to the anaesthesia  (de Blic et al. 2000).  This 
is an important advantage because it allows the identification of airway risk factors from an 
early age giving insight into the initial stages of lung inflammation (Sly et al. 2013).  This is 
integral for developing therapeutics to prevent decline in lung function in CF patients from 
birth.   I will now discuss other methods of airway fluid sampling in CF such as induced sputum 
and cough swabs. 
 
 
 
Older CF patients can often produce sputum spontaneously; however, with paediatric patients 
it can be difficult to get a patient to cooperate or understand instruction. Furthermore, disease 
severity is less advanced in paediatric CF patients and therefore, there is less mucus to 
expectorate (Forton 2015).  In order to obtain airway samples from paediatric patients more 
consistently, sputum can also be induced.  The induced sputum procedure involves inhaling 
nebulised saline (as with spontaneous sputum sampling) but in addition patients are given 
vigorous physiotherapy to help produce a sample.  Physiotherapy is routinely given to CF 
patients to help free up obstruction and mucus in the airway; it involves percussion (tapping 
on the back), vibration and active breathing cycles to help produce sputum (Ronchetti et al. 
2018). 
 
In comparison to BAL, induced sputum is relatively inexpensive and easy to perform, it does 
not require sedation or invasive insertion of a bronchoscope.  A disadvantage of sputum 
sampling is that, unlike BAL there is no guarantee or standardisation over where in the airway 
the sample originates.  In BAL, the bronchoscope is directed to the same locations in the 
airway; however, in sputum the sample could be a pool of material from several locations 
(Forton 2015).  The use of induced sputum to detect pathogens in the CF airway has been 
compared with BAL fluid; Jung et al. compared P. aeruginosa isolates in cough swabs, sputum 
and BAL fluid from 38 stable CF patients (Jung et al. 2002).  The authors found that sputum 
was as effective as BAL fluid at detecting P. aeruginosa in the CF airway, but there was a 
greater diversity in strains detected in sputum than BAL fluid; this is further evidence that 
sputum is heterogenous.  In a more comprehensive study comparing CF airway fluid sampling 
techniques, Ronchetti et al. report that 6-lobe BAL and 2-lobe BAL (ERS recommended) 
detects a greater bacterial diversity than sputum and cough swabs (Ronchetti et al. 2018). 
Despite this, the authors found that there were some pathogen isolates detected in sputum 
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that were not found in BAL fluid.  In conclusion, Ronchetti et al. state that even though sputum 
was not as sensitive as BAL they recommend sputum sampling becomes common practice 
for frequent surveillance of pathogens in the lower airway.  If a patient presents with chronic 
cough and wheezing, an indication of pulmonary exacerbation, then BAL is performed for more 
sensitive identification of pathogens (Ronchetti et al. 2018). 
 
As well as pathogen surveillance, and with greater relevance to my own study, quantification 
of inflammatory markers such as NE activity and CXCL8 have been compared in sputum and 
BAL fluid from CF patient.  It was shown by McElvaney et al. that although there are 
correlations between inflammatory markers and lung function in sputum and BAL fluid from 
the CF airway, these associations are stronger in BAL fluid (McElvaney et al. 2018).  A reason 
for this is that the reducing agent dithiothreitol is routinely added to the sputum during 
processing of the samples to release cells from mucus to facilitate differential cell counts 
(McElvaney et al. 2018).  It has been shown that dithiothreitol reduces sensitivity for the 
detection of IL-6, macrophage migration inhibitory factor and MPO in sputum compared to 
addition of BSA (Pignatti et al. 2002).  Recently, McElvaney et al. have modified sputum 
collection, so that it no longer requires dithiothreitol and show that the new method improves 
detection of inflammatory markers in the CF airway to comparable levels as BAL fluid 
(McElvaney et al. 2018).  The authors promote cell release from mucus plugs through washes 
with PBS and centrifugations rather than adding dithiothreitol; this relatively simple 
modification improved detection of NE activity and IL-1ß quantification to the same level as 
BAL fluid. In light of the Ronchetti et al. study comparing pathogen isolates in sputum and in 
BAL fluid, the detection of pathogens was not compared using the modified sputum processing  
(Ronchetti et al. 2018).  This new method of processing sputum studied by McElvaney et al. 
is an important step forward that enables non-invasive sampling of the CF airway for assessing 
inflammation in the laboratory (McElvaney et al. 2018). 
 
 
 
Cough swabs are also used to identify pathogens in the CF airway.  Swabbing can be 
performed on young paediatric patients that cannot expectorate sputum.  The cough swab 
procedure involves placing a cotton-tipped swab into the posterior pharynx.  It is critical that 
the swab does not touch the posterior pharynx as it will become contaminated by bacterial 
species on the surface and would therefore not represent the lower airways (Maiya et al. 
2004).  As for sputum and BAL fluid, pathogens isolated from cough swabs are identified using 
growth cultures, and more recently PCR and 16S RNA (Ronchetti et al. 2018). 
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An initial report comparing cough swabs and sputum in non-CF and CF patients with 
symptoms indicating airway infection found that for 92% of CF patients cough swabs led to 
the same choice of antibiotics as would have been made with sputum (Equi et al. 2001).  
Despite this, the authors raised the issue that cough swabs only had 34% sensitivity compared 
to sputum and therefore, there was a high chance of not detecting pathogens in symptomatic 
patients (false negatives).  As discussed above, Ronchetti et al. compared the presence of CF 
pathogens in cough swabs, sputum and BAL fluid; their study supported data from Equi et al. 
showing that sputum detected more pathogen isolates than cough swabs (Equi et al. 2001; 
Ronchetti et al. 2018).  None the less, as already mentioned, Ronchetti et al. found that BAL 
was the most sensitive procedure for identifying exacerbation-causing pathogens (Ronchetti 
et al. 2018). 
 
 
Procedure Advantages Disadvantages 
Bronchoalveolar 
lavage 
- Samples specific sites 
- Best procedure for 
identifying pathogens 
- Can be performed on 
paediatric patients 
- Invasive 
- Requires sedation 
- Unethical to perform on 
healthy volunteers 
- expensive 
Induced sputum 
- Non-invasive 
- Inexpensive 
- Does not require 
specialist equipment 
- Good detection rates of 
pathogens 
- Can be performed 
frequently 
- Difficult to acquire samples 
from paediatric patients 
- No guarantee of origin of 
sample and therefore there is 
a risk of error (false 
negatives) 
- Addition of dithiothreitol may 
affect characterisation of 
airway fluid components 
Cough swab 
- Non-invasive 
- Inexpensive 
- Does not require 
specialist equipment 
- Can be performed 
frequently  
- Easily contaminated 
- Pathogen detection not as 
good as other sampling 
methods  
Table 3-2: Advantages and disadvantages of the different techniques used to sample the CF 
airway 
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3.1.2. Using airway fluid to investigate neutrophilic inflammation in the CF airway 
 
I have summarised the use of three sampling techniques that are commonly used for detection 
of pathogens in the lower airway of CF patients with symptoms of pulmonary exacerbation.  
Airway fluid sampling is critical for monitoring the lower airway for pathogens but can also 
provide valuable information about inflammation and other biological processes. Several 
inflammatory markers have been reported to be risk factors for pulmonary exacerbation; Sly 
et al. used BAL fluid, CT and, clinical scores to identify predictors of bronchiectasis (airway 
remodelling) in paediatric (3 months to 3 years) CF patients (Sly et al. 2013).   The authors 
found that NE activity was highly predictive of airway disease. Others have also shown that 
the presence of neutrophils and NE activity correlates with loss of lung function (Konstan et 
al. 1994; McElvaney et al. 2018).   A comprehensive longitudinal study of inflammatory 
biomarkers in CF sputum by Sagel et al. found that as well neutrophil count and NE activity, 
other factors were associated with decline in lung function; these were CXCL8, IL-6, IL-1ß and 
MMP-9 (Sagel et al. 2012). 
 
It is important to establish markers of neutrophilic inflammation in the CF airway so that 
pathogenic factors can be investigated and targeted therapeutically.  Furthermore, markers 
such as neutrophil count, NE activity and CXCL8 are also important for monitoring the effect 
of therapeutics on inflammation during trials and treatment courses (Ratjen et al. 2016; 
Barnaby et al. 2018; Sagel et al. 2018).  For example, Lumacaftor is a CF therapeutic that 
facilitates CFTR transport to the apical membrane of airway epithelial cells (Elborn et al. 2016).  
Lumacaftor is administered to CF patients with a cftr phenotype that is characterised by CFTR 
mis-folding or reduced transport to the apical membrane of the epithelial cells, such as 
ΔF508Del (see table 1-1) (Elborn et al. 2016).   Several trials have shown that Lumacaftor 
slows the decline in lung function and reduces rates of pulmonary exacerbations in CF 
patients; however, only more recently have groups investigated the effects on inflammatory 
markers (Barnaby et al. 2018).  Lumacaftor has been trialled in combination with a similar 
therapeutic that facilitates CFTR function, ivacaftor, that is given to patients with CFTR 
mutations such as G551D (Wainwright et al. 2015).  A significant finding by Barnaby et al. was 
that ivacaftor, when used in combination with lumacaftor, reduced phagocytosis of P. 
aeruginosa by monocyte-derived macrophages by reducing cytokine release. Therefore, the 
authors suggested that patients that are prescribed this drug combination might be more at 
risk of infection by P. aeruginosa.   The study by Barnaby et al. highlights the importance of 
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measuring inflammation during drug trials in CF patients in order to better understand the 
effects on the immune system. 
 
3.1.3. Investigating the role of complement in promoting neutrophilic inflammation in the 
CF airway 
 
Establishing markers of neutrophilic inflammation in the CF airway is also important for 
investigating other mechanisms of neutrophil dysfunction and contributors to pathogenesis.  
The complement anaphylatoxins have been shown to contribute to airway diseases such as 
asthma and COPD (Marc et al. 2004; Khan et al. 2015), as discussed in sections 1.7 and 1.8.  
A mass-spectrometry proteomic analysis of CF BAL fluid showed that several complement 
components were less abundant in the airway CF patients (n=8) compared to non-CF controls 
(asthma, n=4), these include; C1q, C2, C4b, C5 and C6 (Gharib et al. 2009).  Interestingly, 
computational analysis by Gharib et al. found that the comparative levels of these complement 
components were associated with proteases such as MMP8 and MMP9 as well as adhesion 
molecules.  A similar analysis by Pattisons et al. investigated the proteomic profile in sputum 
from CF patients (n=12) infected with P. aeruginosa (Pattison et al. 2017).  Using two-
dimensional liquid chromatography and mass-spectrometry, the authors found a relative 
decrease in complement component C3 compared to non-smoking healthy controls (n=12).  
The relationships between complement, particularly C3a and C5a, and pathways associated 
with neutrophilic inflammation were not reported on in the study by Pattison et al. as they were 
by Gharib et al.  Despite this, leukocyte extravasion and Fcᵧ-mediated phagocytosis pathways 
(protein pathway configured set by Ingenuity Pathway Analysis) were significantly 
upregulated; these are both pathways that complement anaphylatoxins, such as C5a, have 
critical roles in promoting (Hunniger et al. 2015; Pattison et al. 2017).  The above proteomic 
analyses give insight into the most significant pathways that are upregulated in the samples 
tested but they do not provide specific information on mechanism and therefore, the extent to 
which C3a and C5a contribute to CF disease pathology is not fully understood. 
 
Elevated levels of C3a and C5a have been reported in the CF airway (Fick et al. 1986; Sass 
et al. 2015; Hair et al. 2017).  Together with the mass spectrometry studies above (that show 
decreased C3 and C5), increased C3a and C5a suggest that there is increased complement 
activation in the CF airway. It has been shown that C5a correlates negatively with lung function 
(FEV1) (Fick et al. 1986; Sass et al. 2015; Hair et al. 2017).  Furthermore, Hair et al. have 
reported that C5a levels in CF sputum spike during pulmonary exacerbation; however, is not 
clear whether elevated C5a is a consequence or cause of exacerbation (Hair et al. 2017).  As 
133 
 
well as association with clinical makers, the importance of C5a in promoting neutrophilic 
inflammation has been investigated in relation to other chemotactic molecules (Mackerness 
et al. 2008). 
 
For my project, I am interested in the mechanisms by which C5a (and C3a) contribute to 
pathogenesis in CF.  In particular, I am interested in the non-canonical generation of C5a and 
C3a in the CF airway by NSPs.  In addition, I am also interested in how interaction with the 
local lung environment modifies C5a function.  As part of this study, I have processed BAL 
fluid from a cohort of CF patients and used it to both characterise C3a and C5a as mechanisms 
of neutrophil inflammation in the CF airway, in addition to exploring mechanisms of C3a and 
C5a generation.  In this first chapter, I will characterise neutrophilic inflammation in CF BAL 
fluid and explore the relationships between inflammation and complement components, 
particularly the complement anaphylatoxins C3a and C5a.  This is primarily to assess whether 
there is any evidence in the CF cohort to suggest that C3a and C5a contribute to chronic 
neutrophilic inflammation in the CF airway (table 3-3).
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Table 3-3:   Uses of CF BAL fluid in this study.                                                                      CF BAL fluid was used to characterise (blue) neutrophilic inflammation, complement 
components and soluble GAG concentration.  CF BAL fluid was also used to study mechanisms (green) in which the local lung environment 
modifies the activity of C3a and C5a. Techniques performed are linked by dashed lines to each corresponding component.  
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 Hypothesis 
 
I hypothesise that complement C3a and C5a correlate with markers of neutrophilic 
inflammation in CF BAL fluid and clinical markers of disease progression. 
 
 Aims 
The aim of this section is to investigate the relationships between complement and neutrophilic 
inflammation in the CF airway, with particular focus on the complement anaphylatoxins, C3a 
and C5a. 
 
1. Assess the clinical characteristics of the CF cohort, including lung function, BMI and 
age. 
 
2. Measure well-established markers of neutrophilic inflammation in CF such as 
neutrophil count, NE activity and CXCL8 concentration in BAL fluid from the CF cohort. 
 
3. Investigate the role of complement in promoting neutrophilic inflammation by 
measuring complement components in CF BAL fluid using multiplex and singleplex 
ELISA-style platforms.  Perform correlation analyses between complement 
components and markers of neutrophilic inflammation in the CF airway. 
 
4. Further characterise the role of C3a and C5a in driving neutrophilic inflammation in the 
CF airway by performing correlation analyses against markers of neutrophilic 
inflammation and clinical makers of disease progression (lung function and BMI)
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 Airway sampling and correcting for repeated measures 
 
As part of a separate study, Dr. Julian Forton performed BAL on CF patients attending the 
Children’s Hospital for Wales (Cardiff, UK). The procedure was carried out on patients that 
were admitted for chest exacerbation, attending an annual review or those under general 
anaesthetic for routine surgery.  BAL fluid from the right middle lobe (figure 3-1) was sampled 
with a total of 41 sampling events; however, from 32 individual CF patients over the study 
period. Therefore, for seven patients repeated measures were taken; five patients had two 
recorded events and two patients had three recorded events.  As discussed in the background 
to the study, there are a number of reasons for performing BAL on a CF patient and therefore, 
repeated measures could have been recorded for a number of reasons.   I did not categorise 
patients into “reasons for lavage” because this will reduce population size and consequently 
lower power of statistical analyses.  The issue that arises from using repeated measures is 
that data from the same patients are not independent and therefore, could skew the population 
data set.  Therefore, I assessed whether data from repeated measures could be included as 
part of my population.    The effect of repeated measures was investigated by testing two 
variables; NE activity and CXCL8 concentration, these are well-established markers of 
neutrophil inflammation in the CF airway (McElvaney et al. 2018).  The overall aim of this 
analysis was to determine whether the data required standardisation as a consequence of the 
repeated measures (figure 3-2). 
 
Initially I reviewed the time interval between recorded events for each patient that had 
repeated measures taken (figure 3-2A).  This was to assess whether events were measured 
within quick succession; a factor that might reduce variation between events and therefore 
skew the data.  For example, if the time interval is short between recording events, it could 
indicate that airway surveillance is being performed to monitor worsening condition and 
therefore, inflammatory markers could be elevated in these samples.  The mean time between 
sampling from the same patients was 1.69 years, the greatest time between samples was 3.39 
years and the least time between samples was 0.12 years. Considering that all but one of the 
time intervals between sampling were greater than one year, I did not have any evidence to 
suggest that time interval between repeated measures had any influence on these data. 
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Figure 3-2: Effect of repeated measures on sample population levels of CXCL8. 
 
 
 
To further support the inclusion of repeated measures in the cohort data set, CXCL8 
concentration recorded in each event for each patient (with repeated measures) was plotted 
(figure 3-2B). The mean change in CXCL8 between recording events for each patient 
(regardless of increase or decrease) was 1566 pg/mL CXCL8.  This demonstrates that there 
is variation between repeated measures and therefore, provides more evidence to support 
that each event is independent of the one before it. 
 
Finally, the mean CXCL8 concentration or median NE activity was compared between a 
population including all data, a population without any patients with repeated measures or the 
repeated measures only (figure 3-2C and 3-2D).  There were no statistical differences between 
the medians in these populations for either variable when compared by one-way ANOVA 
(Kruskal-Wallis).  From these analyses I determined that there was no conclusive evidence to 
suggest that I could not include these data as separate events in my population.  Therefore, 
any further analysis will describe a population of 41 events, unless stated otherwise. 
                                                                                                                               A) Interval 
between repeated measures for each patient where two or three events were recorded. Dotted line 
represents the mean interval between repeated measures. B) CXCL8 concentration in BAL fluid for 
each patient between sampling. C) CXCL8 concentration and D) NE activity in BAL fluid from all 
events (n=41, black circles) or without repeated measures (n=26, half-filled circles (filled left), or 
repeated measures only (n=15, half-filled circles (filled right) medians are plotted for each (solid black 
line). Comparison of medians by Non-parametric t-tests (Mann-Whitney).  
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 Clinical description of the CF cohort 
 
To begin characterising the CF cohort I have collated clinical data about the patients, table 3-
4 is a clinical description of the population in this study.  Importantly, this population is young; 
it has a median age of 8.3 years enabling me to investigate early stages of neutrophilic 
inflammation in the CF airway. The proportion of this population that has at least one 
ΔF508Del allele is 90.2% which, is similar to the UK average 90.9% (UK CF registry 2016).  
Three of the four patients that did not possess at least one ΔF508Del (class II) mutation had 
at least one R709X (class I) allele: class I and II mutations have severe disease phenotypes 
(see table 1-1 for description of classes, R709X not listed due to low prevalence in UK 
population) (Elborn 2016).  BMI is used as a measure of malnutrition, a symptom of poor 
nutrient uptake due to reduced pancreatic secretion and bile duct blockade. The median body 
mass index was 17.7 Kg/m2, this is below the “normal” classification (18.5 to 25 Kg/m2) 
moreover, 70% (26/37 patients with recorded BMI) had a BMI that was sub-normal. 
 
 
FEV1 and FVC are measures of lung function and capacity respectively, these require co-
operation with the clinician and therefore are difficult to perform on paediatric patients (below 
5 years old).  In my cohort FEV1 and FVC were recorded for 29 out of 41 events, 12 of the 
events that did not have these variables recorded were because the patient was five years old 
Table 3-4: Clinical description of the CF cohort 
Number of events (patients) 41 (33) 
Repeated measures 
26 patients with 1 measure 
5 patients with 2 measures 
2 patients with 3 measures  
Gender % Male / Female 53.7 / 46.7 
Median Age, (range) 8.3 (1.0 – 17.7) decimal years 
Cftr genotype 
 ΔF508Del  
 
% homozygous 43.9 
% heterozygous 46.3 
% non - ΔF508Del 9.8 
Median Body Mass Index (range) n=37 17.7 (10.6 – 21.4) Kg/cm2 
Median FEV1 (range) % predicted n=29 80 (41 – 110.0) 
Median FEC (range) % predicted n=29 83.5 (52 – 121.0) 
Percentage P. aeruginosa colonisation  
within the last 3 years  
46.2  
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or younger.  The percent predicted FEV1 for the population had a range of 40 – 110%, 
demonstrating that my population represents a spectrum of well and unwell patients. 
 
Neutrophilic inflammation is a pathogenic factor for reducing lung function in the CF airway, 
therefore correlation analyses were performed between age, lung function (FEV1) and BAL 
fluid neutrophil count (figure 3-3).   
 
   
Figure 3-3: Analysis of clinical parameters and neutrophilic inflammation in the CF cohort. 
 
 
 
 
 
These data support a consensus on CF pathology in that as a patient ages there is a decline 
in lung function (figure 3-3A) (UK CF registry 2016).  A negative trend was observed between 
neutrophil counts, from differential stains of cytospins and lung function however, this trend 
was not statistically significant (figure 3-3B).  These analyses were performed to investigate 
the associations between neutrophilic inflammation and the collateral loss of lung function in 
the CF cohort; however, Spearman rank correlation analyses do not prove a causal 
relationship. 
 
Clinical data, as well as variables in BAL fluid such as neutrophil count, show that the CF 
cohort in this study reflects general trends that have been observed in the UK CF population 
(UK CF registry 2016). Therefore, data from my cohort is a suitable platform for analysis of 
neutrophil inflammation and the role of complement anaphylatoxins in promoting 
pathogenesis. 
 
                                                                                                                                                     
A) Percentage predicted FEV1 (y-axis) was correlated with Age (x-axis), a linear regression was fitted 
(solid line) and Spearman rank statistical outcomes (r and p values) in black box.  Vertical dashed 
lines marks where FEV1 data is unlikely to be obtained due to the age of the patient. B) Percentage 
predicted FEV1 (y-axis) was correlated with polymorphonuclear leukocyte (PMN) count in BAL fluid 
from CF cohort (PMN, x-axis). A linear regression was fitted (solid line) and Spearman rank statistical 
outcomes (r and p values) in black box. 
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 Characterising neutrophilic inflammation in CF BAL fluid 
 
CF is characterised by neutrophilic inflammation of the airway.  To investigate inflammation, 
neutrophil count, NE activity and CXCL8 are routinely used by researchers as markers of 
neutrophilic inflammation (McElvaney et al. 2018).  Furthermore, they are also used in clinical 
trials to assess changes in neutrophilic inflammation in response to therapy (Dittrich et al. 
2018).  To investigate neutrophilic inflammation in the CF cohort, I performed correlations 
between the above variables. 
 
Neutrophil counts were performed on differentially stained cytospins produced using CF BAL 
fluid.  NE activity in CF BAL fluid was measured using a chromogenic substrate that is specific 
to NE, quantifying against a standard curve of NE purified from primary human neutrophils.  
CXCL8 was measured by commercial ELISA. 
  
It has been reported that CXCL8 and IgGs can be degraded by serine proteases present in 
CF airway fluid (Prince et al. 1979; Leavell et al. 1997); therefore, I investigated whether the 
addition of a serine protease inhibitor (AEBSF) improved quantification of CXCL8.  To each 
sample (n=13), I added either 10 mM AEBSF in assay diluent (1% BSA) or the equivalent 
volume of diluent without the inhibitors, the ELISA was performed as recommended by the 
manufacturer. 
 
Figure 3-4: Influence of a serine protease inhibitor on CXCL8 levels measured by ELISA. 
 
 
                                                                                                                                             
CF BAL fluid samples were diluted 1 in 10 in 1% BSA (protease free)(blue) or serine protease inhibitor 
(AEBSF (10mM)) in 1% BSA (red) and incubated for 15 minutes at room temperature, CXCL8 ELISA 
was performed as instructed by the manufacturer.  Values were interpolated from a standard curve of 
purified CXCL8 (without inhibitor) and multiplied by the dilution factor (10). Median CXCL8 (y-axis) for 
both conditions was compared by Wilcoxon matched pairs t-test (p = 0.519)   
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There was no statistical in difference in the median CXCL8 concentration when CF BAL fluid 
was incubated with or without a serine protease inhibitor (figure 3-4).  I concluded from this 
experiment that even though it is reported that CXCL8 and IgG are susceptible to proteolysis 
by NSPs, this phenomenon is not significant enough to influence quantification of CXCL8 by 
ELISA (Prince et al. 1979; Leavell et al. 1997).  I continued to compare markers of neutrophilic 
inflammation in the CF airway (figure 3-5). 
 
 
Figure 3-5: Correlations between markers of neutrophilic inflammation measured in CF BAL 
fluid. 
 
 
 
 
Neutrophil count had a statistically significant, positive correlation with NE activity and 
supports neutrophils as a major source of NE in the CF airway (figure 3-5A)(Hartl et al. 2012).  
NE activity is quantified in CF airway fluid rather than NE concentration, this is because NE 
activity is a better indicator of potential airway remodeling (Sagel et al. 2012). 
 
         Variables were analysed using Spearman rank correlation analysis, statistical outcomes (r and 
p values) for each test are in boxes on the respective plots. Correlations were performed between A) 
Neutrophil count and neutrophil elastase activity, B) neutrophil count and CXCL8, and C) between 
neutrophil elastase activity and CXCL8. In “C” the asterisk highlights six overlapping data points where 
data were assigned a value halfway between zero and the limit of detection for both parameters (see 
methods).  N=41. 
142 
 
Neutrophil count also positively correlated with CXCL8 concentration, a well-characterised 
neutrophil chemoattractant that is found elevated in the CF airway (Dean et al. 1993) (figure 
3-5B).  Finally, NE activity positively correlated with CXCL8 (figure 3-5C).  The statistical 
outcomes from these three plots support the use of neutrophil count, NE activity and CXCL8 
to measure neutrophilic inflammation in the CF airway. 
 
So far, I have shown that the CF cohort used in this study reflects the clinical nature of CF by 
demonstrating that lung function is negatively correlated with neutrophil count (Sagel et al. 
2012).  I have also demonstrated that markers of neutrophilic inflammation in the CF airway 
strongly correlate with each other.  From these data I can be confident that observations made 
from my study also reflect what is happening in the CF population as a whole, and not just an 
isolated cohort.  I continued to investigate the relationship between neutrophilic inflammation 
and complement in CF BAL fluid.  
 
 Complement in the CF airway 
 
The role of complement in promoting pathogenesis in the CF airway is not clear.  Proteomic 
analysis by Gharib et al. has previously identified that several complement components (C1q, 
C2, C4b, C5, C6, C2) are significantly reduced in CF BAL fluid compared to non-CF controls 
(Gharib et al. 2009).  Two multiplex platforms were developed by our group. These platforms 
used a combination of commercial and in-house antibodies. The MSD platforms were 
optimised for measuring complement components in serum but were sensitive enough to 
quantify analytes in other tissues as well as BAL fluid.  Complement components were 
separated onto two plates: one that measured factor Bb, factor D, C5b-9 complex, C3a, C5a 
and iC3b and the other plate measured C3, C4, C5, factor I, factor B and factor H. 
 
A technical problem with the standards meant that C5 and C5a could not be measured using 
the MSD platform; therefore, C5a and C5 were measured using single-plex ELISAs. This 
problem did not affect quantification of the other components.  C3a was detectable by the 
MSD platform; however, I also quantified C3a by ELISA.   C3a and C5a were measured by 
separate commercial ELISAs (Quidel), this manufacturer was carefully selected as some 
commercial C5a ELISAs reported cross-reactivity to C5.  In serum, the molar concentration of 
C5 is between 200-1000-fold that of C5a therefore, any cross-reactivity with C5 in an ELISA 
would skew C5a quantification (Barnum and Schein 2018). 
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Comparison of three mouse anti-C5 antibodies, using each in different combinations as either capture or 
detection.  Antibodies were compared using a titration of C5 from 1000 to 250 ng/mL (x-axis) in 1% 
BSA/PBS.  Different tertiary antibodies were required for quantification, these were either: goat anti-
mouse IgG HRPO, goat anti-mouse IgG2a HRPO or donkey anti-human FAB fragment HRPO. B) 
Sensitivity of SKY59:Hycult (red) (capture: detection) and SKY59:2D5 (green) pairings using a titration of 
C5 from 0.24 to 1000 ng/mL (x-axis). n=1. 
 
3.7.1. Developing an in-house ELISA for the detection of C5 
 
Commercial C5 ELISAs are available; however, the group I was working with specialised in 
developing antibodies for measuring complement components. Therefore, an in-house C5 
ELISA was developed for sensitive quantification of C5.  Three monoclonal anti-C5 antibodies 
were compared to assess which ELISA pairing combination was most sensitive for 
quantification of C5. The three antibodies were:  An in-house mouse monoclonal anti-C5 
antibody (2D5), a commercial monoclonal mouse anti-C5/C5a antibody (Hycult-577) and a 
commercial humanized antibody from Roche that is not available on the market (SKY59).  
Antibody pairings compared the use of different antibodies for capture and detection.  Not all 
pairings were tested because the appropriate HRP-conjugated tertiary antibodies were not 
available.  Appropriate HRP-conjugated tertiary antibodies were commercially available but 
were not required because preliminary experiments showed that the pairings used were 
suitable for C5 quantification (see below).    The monoclonal antibodies and HRPO-conjugated 
antibodies pairings were compared using a dilution series of C5 ranging from 250 to 1000 
ng/mL (figure 3-6). 
 
Figure 3-6: Developing a sensitive ELISA for the quantification of C5 in CF BAL fluid.
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Each of the antibody combinations used produced an absorbance curve for the concentrations 
of C5 tested (figure 3-6A). The best sensitivity for the detection of C5 was obtained using 
SKY59 as the capture antibody, therefore further comparisons were made between C5 ELISA 
antibody combinations using SKY59 as a capture antibody and either 2D5 or the Hycult 
antibody for detection.  It has previously been shown that C5 is almost depleted in CF BAL 
fluid compared to asthmatic controls (Gharib et al. 2009).  For this reason, I assessed the limit 
of detection for SKY59:2D5 and SKY59:Hycult ELISA pairings.  Sensitivity was compared for 
the above two pairings by titrating C5 from 1000 ng/mL to 0.24 ng/mL in a 4-fold dilution series 
(figure 3-6B). 
 
The SKY59:Hycult pairing was more sensitive at measuring low concentrations of C5 than the 
SKY59:2D5 pairing.  For instance, there was a discernable difference in signal at 0.98 ng/mL 
C5 between the two antibody pairings with SKY59:hycult having a higher absorbance value, 
this was not tested statisitically because it was an optimisation experiment.  In the same 
experiment, cross-reactivity with C5a, C3a and C3 was assessed, none of the above 
components had any detecable signal when tested at equimolar concentrations to 1000 ng/mL 
C5 (5.26 nM) (not shown).  Despite only performing a single experiment, from these data I 
decided that the SKY59:Hycult C5 ELISA pairing would be most suitable for measuring C5 
concentrations in CF BAL fluid.  The use of the different pairing to those I tested 
(SKY59:polyclonal anti-C5) has recently been reported by our lab (Zelek et al. 2018).  Having 
optimised and developed a sensitive ELISA for the detection of C5, I went on to measure C5 
and the other complement components (that I had platforms for) in CF BAL fluid. 
 
3.7.2. Correlating complement with markers of neutrophilic inflammation 
 
Complement components were quantified in CF BAL fluid.  Values for these components were 
correlated against neutrophil counts, NE activity and CXCL8 using Spearman rank analyses 
and the outcomes combined in a matrix (figure 3-7).  This was to give an overview of the 
relationship between complement and neutrophilic inflammation of the CF airway.  Not all CF 
BAL fluid samples measured on the MSD platform were used in the analysis due to variation 
within the duplicates. This was because of technical error handling small sample volumes and 
sensitivity of the plates to user error.  Due to availability of the plates these samples could not 
be re-tested.  This meant that for Bb, factor D, C5b-9 complex, C3a (MSD), C5a (MSD) and 
iC3b the sample size was reduced to 28 from a total of 41.  As mentioned above, C5a and 
C3a were also quantified by commercial ELISA and therefore these analytes were not 
affected.  Analytes measured on the second complement component plate (C3, C4, C5, factor 
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I, factor B and factor H) were not affected and therefore sample number on this plate was 
n=41. 
 
 
 
Figure 3-7: Correlations between markers of neutrophilic inflammation and complement 
component measured in CF BAL fluid. 
 
 
 
 
 
 
 
 
                                                                  C3a, C5a and C5 were quantified by individual 
ELISAs; all other complement components were measured by MSD platforms. C5b-9 “TCC".  
CXCL8 “IL.8”, neutrophil elastase activity, and neutrophil count used the data from figure 3-5.  
All variables were analysed using Spearman rank correlations, the strength of the correlations 
(r values) are signified by circle shade (using the scale to the right of the chart) and circle size. 
For example, a strong positive correlation will have a large deep blue circle.  Analyses that were 
not statistically significant were labelled with a black cross. Red dashed box indicates 
correlations between complement and markers of neutrophilic inflammation.  Post-hoc Holm-
Bonferroni analysis for multiple comparisons (Holm 1979) was performed on ranked p-values, 
correlations that remained statistically significant after corrections for multiple comparisons are 
annotated with a green tick (see key).  
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Spearman rank correlation analysis was performed to test the relationships between the 14 
analytes tested.  Further post-hoc analysis was performed by Holm-Bonferroni test for multiple 
comparisons (Holm 1979).  Holm-Bonferroni analysis is less conservative than traditional 
Bonferroni post-hoc analysis.  This is because for significance at p = 0.05, the Bonferroni test 
for multiple comparison requires the p values of each corresponding correlation to be less than 
0.05 (significance level) divided by the number of comparisons made (105).  In the case of my 
analysis this would mean that there would be statistical significance at p < 0.05 / 105 = 
0.00047.  The Holm-Bonferroni test is similar; however, the correlations are ranked by their p 
values from lowest to highest.  Therefore, the most significant p value (lowest) would be 
ranked 1 and least significant p value (highest) would be 105.  Each respective correlation is 
significant if the p value for that test is less than 0.05 (significance level) divided by number of 
tests (105) minus the rank of the p value (1 to 105).  This is means that correlations with less 
statistically significant p values are less likely to be discarded.  In comparison, without 
correcting for multiple comparisons there were 68/105 statistically significant correlations at 
p=0.05.  Correcting using the Bonferroni method there would have been 8/105 significant 
correlation; however, with the method I performed (Holm-Bonferroni), there were 36/105 
significant correlations.  Therefore, I have corrected using a less conservative method that 
reduces the number of false-negatives. 
 
My first observation was that analytes from the complement component plate measuring Bb, 
factor D, C5b-9 complex, and iC3b, had more non-significant outcomes than the other 
analytes.  This could reflect lower sample sizes, a consequence of technical error.  Before 
correction for multiple comparisons, there are a striking number of statistically significant 
positive relationships between complement components and three markers of neutrophilic 
inflammation (neutrophil count, NE activity and CXCL8 concentration).  After correction for 
multiple comparisons Holm-Bonferroni, the strongest correlations were between the three 
markers of neutrophilic inflammation.  There were also positive relationships between C3, 
C3a, C4 and, factor I with either neutrophil count and CXCL8.  A significant positive correlation 
was also observed between C5a and CXCL8. 
 
3.7.3. Assessing the relative levels of complement in CF BAL fluid 
 
As well as investigating the relationship between complement and neutrophilic inflammation, 
I also compared complement in BAL fluid from the CF airway to the levels that have been 
reported in the plasma from healthy normal control (Barnum and Schein 2018).  As mentioned 
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above, Gharib et al. have reported that the relative levels of several complement components 
are reduced in the CF airway compared to healthy controls (Gharib et al. 2009).  Despite 
proteomic analysis of BAL fluid, comprehensive quantification of complement in CF or normal 
BAL fluid has not previously been performed.  In my study, I did not have a healthy control 
population and therefore, I cannot make the same comparisons as Gharib et al.  As a method 
of investigating the levels of complement components in BAL fluid from CF airway without a 
control population, I standardised the mean of each component in CF BAL fluid against C3, a 
component that is abundant in plasma and central to complement activity.  For comparison 
with normal plasma, I performed the same standardisation on the mean concentrations of 
complement components in plasma from healthy donors that have been reported in the 
“Complement facts book”, a collaborative review of complement dogma that includes reported 
concentrations in normal plasma (Barnum and Schein 2018).  The values for the complement 
components from BAL fluid or plasmaplasma were divided by the respective C3 measured in 
those samples. 
 
 
 
 
Table 3-5: Comparing complement levels in CF BAL fluid with plasma from normal plasma.  
 
 
 
In table 3-5 I have collated the mean complement components measured in CF BAL fluid and 
the mean of those that have been reported in normal plasma (Barnum and Schein 2018).  
Before I assessed complement to C3 ratios, I made a visual comparison of complement 
The mean complement concentrations from CF BAL fluid were calculated from measurements made 
by MSD platforms and ELISAs. The mean concentrations of components in plasma were collated 
from the Complement Facts Book (Barnum and Schein 2018).  Complement components were 
standardised against mean C3 concentration for CF BAL fluid (grey) and plasma (white) respectively. 
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component concentrations between CF BAL fluid and normal plasma.  The concentration of 
complement components in CF BAL fluid is less than what has been reported in normal 
plasma (Barnum and Schein 2018).   The main source of complement components in plasma 
is the liver however, cells from various tissues have been also shown to produce complement 
components locally (Li et al. 2007).  Furthermore, local generation of complement may be an 
important source of complement in the airway (Hetland et al. 1986).  Although complement 
component levels in CF BAL fluid are lower than in normal plasma this does not necessarily 
mean that complement is not functioning and therefore, a pathogenic factor in the CF airway. 
In addition to comparing the levels, complement components were also standardised with C3 
as a method of comparing the relative levels of complement between the CF airway and 
plasma. 
 
As mentioned above, I standardised the complement component concentrations by calculating 
the C3 to complement component ratio. Then, I used normal plasma as a reference of 
functional complement to investigate whether there was any evidence that complement is 
dysfunctional in the CF airway.  Interestingly, the C3 to other component ratios between 
components such as Factor Bb, Factor D and C3a are not too dissimilar when comparing 
normal plasma and CF BAL fluid; however, other components generally had a higher C3 to 
complement component ratio in CF BAL fluid than compared to normal plasma (table 3-5).  
This could either imply that complement components in CF BALF fluid are less abundant in 
relation to C3 than those in normal plasma or C3 is elevated in the CF airway compared to 
other components.  With particular interest to this project, the C3 to C5 ratio in CF BAL fluid 
was over 100-fold of that in normal plasma.  C5 is essential for activation of the terminal 
complement cascade and in turn important for the elimination of pathogens.  Unlike the 
majority of the other components, the terminal complement complex (C5b-9) had a lower ratio 
to C3 in BAL fluid than in normal plasma.  This means that there is more C5b-9 in CF BAL 
fluid compared to normal plasma, relative to C3, and therefore, suggests that there is more 
terminal complement activation.  Furthermore, markers of complement activation, such as C3a 
and C5a, did not correspond with each other when comparing the ratio with C3 between CF 
BAL fluid and normal plasma.  Specifically, there is a 10-fold reduction in the ratio of C3 to 
C5a in the CF BAL fluid compared to normal plasma but, there was a 1.5-fold increase in the 
C3 to C3a ratio. 
 
The above analysis has been performed with the assumption that plasma concentrations are 
correct.  In summary, there appears to be more terminal complement activation in the CF 
airway than normal plasma, reflecting that complement is more active.  In addition, C5 is very 
low, almost depleted, suggesting that it is being consumed.  This hypothesis is supported by 
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the increase in terminal complement pathway activation (C5b-9).  C5a is also very low, 
particularly when comparing the C3 to C5a and C3 to C3a ratios. 
 
From my analysis of complement in CF BAL fluid, I have found that concentrations of several 
complement components measured positively correlate with markers of neutrophilic 
inflammation.  Furthermore, in comparison, levels of complement components in CF BAL fluid 
are lower than normal plasma and, when standardised against C3, there are clear differences 
in the relative abundance of some components, particularly C5.  These data are descriptive 
and have not been statistically analysed.  This because data was compared to the literature 
and not to data from my own study or measured by the same platforms.  Therefore, any 
conclusions from these data are speculative.  Nevertheless, it does indicate that there are 
perturbations in complement and relative levels in the CF airway. 
 
The main aim of this chapter was to use CF BAL fluid to investigate whether C3a and C5a 
contribute to CF pathogenesis by driving neutrophilic inflammation.  In the next sections I will 
analyse the relationships between the complement anaphylatoxins, C3a and C5a, and 
neutrophilic inflammation individually.  
 
 Correlating C3a with markers of neutrophilic inflammation in the CF airway 
 
The analysis in figure 3-7 indicated that C3a positively correlated with markers of neutrophilic 
inflammation in CF BAL fluid.  C3a is elevated in CF sputum (Sass et al. 2015).  Furthermore, 
it has been shown by Sass et al. that C3a concentration in CF sputum positively correlated 
with lung function.  This led the authors to suggest that there is a protective role for C3a in the 
CF airway (Sass et al. 2015).   Furthermore the same group later reported that C3a in CF 
sputum positively correlated with markers of neutrophilic inflammation in the CF airway such 
as NE activity, MPO and DNA (Hair et al. 2017).  To further examine the relationship between 
C3a and CF pathology, Spearman rank correlation analyses were performed between C3a 
and either lung function (FEV1), age, neutrophil count, or CXCL8 concentration (figure 3-8). 
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Figure 3-8: The relationship between C3a and neutrophilic inflammation in CF BAL fluid. 
 
 
 
                                                                                                                                               
Spearman rank correlations were performed between C3a concentration and either A) FEV1 (n=29), 
B) Age (n=40), C) neutrophil count (n=41), D) Mononuclear cell count (n=41), E) neutrophil elastase 
activity (n=41) or, F) CXCL8 concentration (n=41).  An asterisk (*) marks overlapping data points for 
n=2 (E) and n=2 (F). Statistical outcomes (r and p values) are annotated in black boxes.  
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A sensitive commercial C3a ELISA was used to determine the concentration of C3a in CF 
BAL fluid.  The median concentration was 1670 pg/mL with a range between 25 and 52110 
pg/mL.  There was a statistically significant negative correlation between C3a and lung 
function (FEV1) in CF BAL fluid, r = -0.153 and p = 0.023 (figure 3-8A).  Additionally, despite 
a negative trend, the correlation between C3a concentration and age was not statistically 
significant (figure 3-8B). 
 
Neutrophil-mediated damage to the CF airway can irreversibly remodel the CF lung reducing 
pulmonary function.  Therefore, additional correlations between C3a and neutrophil count, NE 
activity or CXCL8 were performed to investigate whether C3a is associated with neutrophilic 
inflammation (figure 3-8C, E and F).  There were statistically significant positive correlations 
between C3a and either neutrophil count (r = 0.473, p = 0.002), NE activity (r = 0.390, p = 
0.012) or CXCL8 (r = 0.659, p < 0.0001).  The expression of C3aR on neutrophils is 
controversial but expression has been shown on monocytes, macrophages and T cells (Klos 
et al. 2013).  C3a is chemotactic for monocytes and therefore, the correlation between C3a 
and mononucleated cells in CF BAL fluid was analysed (figure 3-8D).  From my data there 
was no statistically significant correlation between C3a and mononuclear cells. 
 
As mentioned above, C3a concentrations in CF BAL fluid were measured in a commercial  
ELISA and the in-house MSD platform; this provides an opportunity to compare the values 
that were measured by each platform.  It has been reported that singleplex and multiplex 
platforms from the same manufacturers can give different results and as a consequence skew 
relationships between analytes (de Koning et al. 2012).  Therefore, C3a concentration, 
measured by MSD and ELISA, were compared to investigate whether alternative methods of 
measuring C3a gave different medians and influenced the relationship with other analytes.  As 
mentioned above, the MSD used to measure C3a plate did not give values for all samples and 
therefore, the comparison of C3a measured by these platforms compared 28 paired samples 
(figure 3-9). 
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Figure 3-9: Comparing quantification of C3a measured by singleplex (ELISA) and multiplex 
(MSD) platforms. 
 
 
 
The median C3a concentrations measured by each platorm were compared by paired t-test 
(figure 3-9A). C3a measured by the MSD platform was significantly higher (p < 0.0001) than 
when measured by the ELISA (means: 4867 ng/mL and 1186 ng/mL respectively). 
 
Even though the medians are statisically different this does necessarily infer that correlations 
with other analytes are different, this is because the correlations are ranked.  Therefore, as 
long as the C3a values for each sample are ranked the same, then correlations with other 
markers shouldn’t be affected; this hypotheis was tested by correlating C3a form each platform 
with neutrophil count, a correlation that I previously found to be statisitcally significant (figure 
3-8). 
  
When correlating with neutrophil count, C3a measured by ELISA and MSD platforms had 
statistically significant positive correlations (figure 3-9B).  Furthermore, the strength of these 
correlations (r value) was similar for C3a when measured by both platforms (ELISA: r = 0.412, 
MSD r = 0.391).  A comparion of the two regressions, plotted for each correlation, was 
compared to assess whether there was any statistical difference.  There was a statistical 
difference in the intercept (p = 0.0002) but not the slope (p = 0.860), this analysis supports the 
fact that there are differences in the C3a values measured by the two platforms, but there is 
no statistical difference in their correlation with neutrophil count.  Therefore, I conlclude that 
either C3a data set could be used for analysis of C3a in CF BAL fluid in my study; however, 
because the Quidel ELISA quantified levels of C3a in more samples, there would be more 
power in analyses using this data set. 
                              A) C3a concentration in CF BAL fluid samples (n=28) measured by C3a ELISA 
(red) or MSD platform (blue), medians are indicated by black bars.  Statistical comparison of medians 
was performed using Wilcoxon paired t-test (p < 0.0001). B) Correlation between neutrophil count 
(PMN, y-axis) and C3a (x-axis) measured by ELISA (red) and MSD platform (blue), best-fit linear 
regressions were fitted for both plots. Outcomes (r and p values) of Spearman rank analysis are 
provided in boxes coloured respectively.  Comparison of regressions was also performed comparing 
slope or intercept of both regressions, p values are given for each comparison.  
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 Correlating C5a with markers of neutrophilic inflammation in the CF airway 
 
Like C3a, elevated C5a has also been reported in the CF airway.  Moreover, C5a has been 
reported to correlate with markers of neutrophilic inflammation (NE, MPO and DNA) and spike 
dramatically during pulmonary exacerbation (Fick et al. 1986; Sass et al. 2015; Hair et al. 
2017).  A sensitive commercial C5a ELISA was used to determine the concentration of C5a 
in CF BAL fluid.  The median concentration was 57.8 pg/mL with a range between 5 and 807.4 
pg/mL. 
 
In the correlation matrix analysis in figure 3-7, C5a positively correlated with neutrophil count 
and CXCL8 concentration; therefore, the role of C5a in CF disease progression was further 
investigated.   Correlations were performed with either lung function (FEV1) or age to 
investigate whether C5a was associated with disease progression (figure 3-10).  There was 
no correlation between C5a and lung function; however, there was a statistically significant 
negative correlation between C5a and age, r = -0.337 and p = 0.034.  The relationship between 
C5a and markers of neutrophilic inflammation such as neutrophil count, NE activity and, 
CXCL8 concentration were also investigated.  There were statistically significant positive 
correlations between C5a and both neutrophil count (r = 0.353 and p = 0.024) and CXCL8 (r 
= 0.465, p = 0.002).  Despite a positive trend the correlation between C5a and NE activity was 
not statistically significant (r = 0.286, p = 0.070).  C5a is also chemotactic for monocytes and 
macrophages and therefore, the correlation between C5a and mononuclear cells was also 
analysed. There was a statistically significant positive correlation between C5a and 
mononuclear cells in CF BAL fluid. 
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Figure 3-10: The relationship between C5a and neutrophilic inflammation in CF BAL fluid
Spearman rank correlations were performed between C5a concentration and either A) FEV1 (n=29), 
B) Age (n=40), C) neutrophil count (n=41), D) mononuclear cells (n=41), E) neutrophil elastase activity 
(n=41) or, F) CXCL8 concentration (n=41) An asterisk (*) marks overlapping data points for n=6 (E) 
and n=5 (F).  Statistical outcomes (r and p values) are annotated in black boxes. 
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 Stratification of the CF cohort for further analysis of C3a and C5a as pathogenic factors 
 
I have found that there were statistically positive correlations between markers of inflammation 
and both C3a and C5a.  Despite previous studies reporting a negative correlation between 
C5a and lung function, in my study there was a weak negative correlation between C3a with 
lung function but no correlation with C5a (Sass et al. 2015).  An explanation for this could be 
the variation in patients and inflammation at the time when the BAL fluid was taken.  As 
mentioned in the background to this study there are several reasons that the BAL procedure 
might be performed, such as: portacath insertion (for direct administration of antibiotics to the 
lungs), surveillance after a course of antibiotics or the patient may have a chronic cough and 
clinicians may want to identify the pathogen before administering antibiotics.  Therefore, 
despite ongoing disease, CF patients will go through periods of stability where they are 
relatively well. 
 
I hypothesised that, if I could stratify the cohort using the clinical justification for the BAL 
procedure, I could test whether C3a or C5a were associated with disease progression.  The 
cohort was stratified into two groups using the notes provided by clinicians at the time the BAL 
was performed, these groups were: “well” or “unwell”.   An example of a “well” sample: one 
CF patient underwent circumcision and therefore, BAL was performed in parallel, whilst the 
patient was under general anesthetic.  An example of an “unwell” patient would be admission 
to hospital with pulmonary exacerbation.  A tally of the reasons for BAL for each patient has 
been provided in table 3-6.  
 
Reason for bronchoalveolar lavage Number of patients 
Well (no active infection) 
Portacath 3 
Incidental surgery 1 
Surveillance but otherwise well 10 
Total 14 
 
Unwell (suspected infection) 
Suspected Burkholderia cepacia infection  1 
Pulmonary exacerbation 6 
Chronic cough / Symptoms of airway infection 5 
Identification of Pseudomonas aeruginosa strain 1 
Total 13 
Table 3-6: Justification for stratification of well and unwell CF patients 
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Information facilitating “well” and “unwell” stratification was only available for 27 patients 
furthermore, only 17 of these patients also have data for lung function.  This was because this 
type of information was recorded by the clinician for medical records but not consistently 
recorded as part of this study. 
 
Different parameters were investigated using the stratified cohort, these were: age, lung 
function (FEV1), neutrophil count, CXCL8, C3a and C5a (figure 3-11).  Before comparing 
markers of lung function, neutrophilic inflammation and complement anaphylatoxins, I 
compared the ages of the two groups (figure 3-11A).  The reason for this was that if the two 
stratification groups differed in age then this might skew the data sets because lung function 
and neutrophilic inflammation worsens with age.  There was no significant difference in age 
between the “well” and “unwell” patients and therefore, I was confident that age was not 
skewing the variables in the following analyses. 
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Figure 3-11: Comparing neutrophilic inflammation and complement following stratification of 
the CF cohort. 
 
 
 
 
 
                 .    .     Non-parametric t-tests (Mann-Whitney) were performed on the medians of “well” 
(blue) and “unwell” (red) CF patients for A) Age (n = 26), B) Lung function (FEV1, n=17), C) Neutrophil 
count (n=27), D) CXCL8 (n=27), E) C3a (n=27) and F) C5a (n=27).  Medians are plotted for each 
variable and condition. 
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I first tested lung function, neutrophil count and CXCL8 concentration in CF BAL fluid to verify 
that the stratification I performed reflected disease pathology.  I hypothesised that “unwell” 
patients would have worse lung function and greater neutrophilic inflammation than “well” 
patients.  There was no signficant difference in the median lung function between “well” and 
“unwell” patients however, percentage of predicted FEV1 data was not available for all the 
patients stratifed (figure 3-11B).  The median percentage predeicted FEV1 for “unwell” patients 
was 72%, compared to 86% for “well” patients. Therefore, there is a trend suggesting that lung 
function of “unwell” patients is less than “well” patients; however, there may not have been 
sufficient statistical power in this analysis due to missing data points.  It may also be possible 
that there is no statistical difference. 
 
Despite there being no statistically signifcant trends in lung function between “well” and 
“unwell” patients, there was a significant difference between “well” and “unwell” patients when 
comparing the medians of neutrophil counts, and particularly CXCL8 (p = 0.0497 and p < 
0.0001 respectively)(figure 3-11C and figure 3-11D).  Neutrophilic inflammation of the CF 
airway can permenantly reduce lung function. Therefore, neutrophil count and CXCL8 data 
are in support of lung function data and suggest that, when analysed, “unwell” patients are 
pathologically unwell.   Having performed these analsyes I was confident that my stratification 
reflected that CF disease progession is episodic in that patients go through periods where 
they are, relatively speaking, “well” or “unwell”. 
 
Having analysed the CF cohort sub-groups for lung function and markers of inflammation, I 
next investigated whether CF patients had different levels of C3a or C5a during “unwell” 
periods.  Hair et al have previously shown that there was a spike in C5a concentration during 
pulmonary exacerbation in CF patients (Hair et al. 2017).  The median C3a and C5a levels 
were compared in “well” and “unwell” patients. The median C3a concentration was significantly 
higher in CF patients that were “unwell” compared those that were “well” (figure 3-11E, p = 
0.030).  The median C5a concentration was also higher in “unwell” patients compared to “well” 
patients however, the difference was not statistically significant (figure 3-11F) (69.2 pg/mL 
compared to 55.0 pg/mL respectively).
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 Discussion  
 
In this section I have used BAL fluid from a cohort of CF patients to characterise complement 
components and the complement anaphylatoxins, C3a and C5a, in the CF airway.  I have 
performed analyses with markers of disease progression and neutrophilic inflammation to 
investigate whether there is evidence that either C3a or C5a promote CF pathogenesis.  I 
have found that both C3a and C5a correlate with neutrophilic inflammation; however, there 
was a significant negative correlation between lung function and C3a, but not C5a.  To further 
investigate whether C3a and C5a are linked to worsening disease I stratified the cohort into 
“well” and “unwell” patients.  There were statistically higher levels of C3a in “unwell” CF patient 
BAL fluid compared to “well” BAL fluid.  The median C5a concentration in BAL fluid from 
“unwell” patients was higher than “well” patients but the difference was not statistically 
significant 
 
I initially performed analyses to determine whether the CF cohort I was using for my study 
reflected the national (UK) CF population and therefore, any pathologically relevant outcomes 
may also be applicable to the wider CF population (UK CF registry 2016).  First, I described 
the clinical characteristics of my cohort such as age, sex, cftr genotype, BMI and percentage 
predicted lung function (FEV1).  The median age of the patients used in my study, at the time 
the sample was taken (with respect to repeated measures), was 8.3 years, this is less than 
the UK median (20 years)(UK CF registry 2016).  Furthermore, the oldest patient in my study 
was 17.7 years, reflecting that the population I am characterising is paediatric and therefore, 
importantly, highlights that the cohort in this study is appropriate for investigating the initial 
stages of chronic neutrophilic inflammation. 
 
The cftr genotype of the patients in the cohort used in this study was also similar to the national 
trend; 90.2% had at least one F508del allele compared to 90.9% across the UK.  It is important 
that the cftr genotype in my cohort reflects the UK population because each mutation has a 
different phenotype that influences the severity of disease; these have been classed from 1-6 
(figure 1-1) (Elborn 2016).  Therefore, 90.9% of the UK CF population have at least one allele 
for a severe disease phenotype.  If my cohort significantly differed from this then the outcomes 
from my study may not be applicable to the more severe disease forms. 
 
I also assessed the correlation between lung function and age in my CF cohort; neutrophilic 
inflammation of the CF airways causes remodeling, bronchiectasis and loss of lung function 
(Schafer et al. 2018).  Therefore, there is a negative trend in percentage predicted FEV1 over 
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time, this has been well illustrated by the UK CF registry who have collated all lung function 
data for UK patients (figure 3-12)(UK CF registry 2016).  
 
 
Figure 3-12: Median percentage predicted FEV1 in CF patients over 6 years. 
 
 
In support of the national trend, analysis of clinical information available from 29 CF patients 
in this study, at the time that BAL was performed, showed a statistically significant negative 
trend between percentage predicted FEV1 and age.  I initially investigated whether the cohort 
clinical data used in this study reflected the UK CF population.  In conclusion, I found that my 
data reproduced trends that have been reported nationally and therefore my cohort was 
representative of the UK CF population, as shown in figure 3-12 (UK CF registry 2016). 
 
As well as assessing clinical data from my CF cohort, I also investigated markers of 
neutrophilic inflammation; this would allow me to investigate whether complement or 
complement anaphylatoxins, C3a and C5a, are associated with neutrophilic inflammation. I 
first assessed whether my cohort supported what has previously been reported.  Neutrophil 
counts, NE activity and, CXCL8 are well established markers of neutrophilic inflammation in 
the CF BAL fluid and sputum (Sagel et al. 2007; McElvaney et al. 2018).  In table 3-7, I have 
reviewed the literature for reported measurements of the above markers in CF BAL fluid. 
                                                                                                                                Data from the UK 
CF registry, FEV1 of patients, excluding those who are younger than 6 years and who have had lung 
transplants, n=7830. Red dashed line is the target FEV1 that would be in the near-normal lung function 
range (UK CF registry 2016). 
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Data was collated from studies investigating markers of inflammation in CF BAL fluid and efficacy of 
therapeutics.  Data from another study from the same centre as my study that used the same BAL fluid 
processing and analyte quantification methods (grey highlight). Data from some studies was collated from 
selected populations that might be skewed, such as: unwell (positive for pathogens) or newborn screening 
(*).  In most studies NE activity is only reported for samples where there are detectable levels, these are 
given as percentage positive (%) for NE activity. For studies that did not report numerical values, levels 
were estimated from graphs (~). 
 
 
 
 
 
 
Reviewing the reported levels of the markers of neutrophilic inflammation used in my study, I 
found that the neutrophil counts and levels of CXCL8 I recorded are similar to those reported 
by others (table 3-7).  Despite this, the mean NE activity in my study was generally less than 
what has been reported by others.  Importantly, a study from the same centre as my cohort, 
that was characterised using the same protocols, reported similar NE activity (McGreal et al. 
2010).   Low NE activity in my study compared to other reports could be accounted for by the 
fact that some groups only report samples that are positive for NE activity (Sly et al. 2009; 
McNally et al. 2017).  Another difference and advantage to my study is the age of my cohort 
(8.3 decimal years); this is lower than other reports and is significant because CF disease get 
progressively worse with age. Therefore, in a more paediatric cohort, markers of neutrophilic 
inflammation could be lower; however, a more paediatric cohort allows the initial stages of 
neutrophilic inflammation in the CF airway to be studied. 
 
In my study, I confirmed that there are strong positive correlations between neutrophil count, 
NE activity and CXCL8 verifying their use as markers of neutrophilic inflammation in this is 
Neutrophil 
count 
(106/mL) 
Neutrophil 
elastase 
activity (nM) 
CXCL8 
(pg/mL) 
Median age 
(decimal years) Reference 
1.93 114 1948 8.3 Current study 
0.62 81 (56.3%) 1122 6.4 (McGreal et al. 2010) 
- 1100 - 28.2 (McElvaney et al. 2018) 
- 8200 - 28.0 (McElvaney et al. 1991) 
- 10600 243 27.0 (McElvaney et al. 1992) 
7.14 - - 25.1 (Roum et al. 1999) 
0.0039* - ~3000 6.0 (Wojtczak et al. 2001) 
0.0041* 
4000 
(29.7%) 
320 
0.25 
(Sly et al. 2009) 
2.33 - - 3.2 (Sly et al. 2013) 
0.8 1040 1198 3.2 (Ringholz et al. 2014) 
- 
~2000 
(37.7%) 
878 
4.9 
(McNally et al. 2017) 
1.15 - 1614 22.1 (Gutierrez et al. 2001) 
2.81 - 1153 19.1 (Armstrong et al. 2005) 
Table 3-7: Reported means of neutrophil count, NE activity and CXCL8 in CF BAL fluid.  
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study. This was important because in order to investigate the role of C3a and C5a in promoting 
neutrophilic inflammation I required good reference markers to compare with.  Despite my 
choice (and others) to compare analytes with these markers (see references in table 3-7), 
neutrophil count, NE activity and CXCL8 are not the only biomarkers of inflammation and 
disease progression in CF.  Sagel et al. performed a multivariate analysis of cytokines, 
proteases and protease inhibitors in sputum (Sagel et al. 2012).  The authors found that as 
well as NE activity and CXCL8 other markers such as IL-6 and IL-1ß improved the overall 
predictive value when monitoring the decline in lung function (Sagel et al. 2012).  Considering 
the other candidate markers of inflammation and disease progression that have been reported 
in the CF airway, I am confident that the three markers of neutrophilic inflammation used in 
my study were the most appropriate for investigating the role of complement anaphylatoxins 
in promoting neutrophilic inflammation (Sagel et al. 2007; Sagel et al. 2012; McElvaney et al. 
2018). 
 
In the next part of my study, I measured an array of complement components using a multiplex 
platform that has previously been used to report on complement involvement in various 
diseases such as epilepsy, psychosis, multiple sclerosis and neuromyelitis optica (Hakobyan 
et al. 2017; Kopczynska et al. 2017; Kopczynska et al. 2018).  C3a and C5a were measured 
by commercial ELISAs and C5 was measured using an in-house ELISA that utilised a sensitive 
commercial mouse anti-C5 antibody (SKY59), not currently available on the market.  I recently 
contributed to a publication on diagnostic uses of this antibody (Zelek et al. 2018). 
 
Two groups have previously published proteomic analysis of complement components in CF 
airway fluid, one of these groups reported that several complement components were less 
abundant in CF compared the airways of asthmatic patients, these were: C1q, C2, C4b, C5 
and C6 (Gharib et al. 2009).  A more recent study performed proteomic analysis on sputum 
from CF patients chronically infected with P. aeruginosa (Pattison et al. 2017).  Despite gaining 
further insight into complement in the CF airway, neither of the two proteomic analyses 
specifically studied the analytes that were measured by multiplex platform in my experiments.  
Therefore, my analysis is the first to comprehensively report on complement in the CF airway 
and its association with neutrophilic inflammation. 
 
Interestingly, in my analysis, many of the complement components measured as part of this 
study positively correlated with neutrophil count and CXCL8.  Despite this, relationships with 
NE activity were weak and not statistically significant.  An explanation of weaker associations 
between complement and NE activity maybe be that these components are susceptible to 
degradation by NE and therefore their relationships maybe be more complex.  Proteolysis of 
163 
 
C3, C5, C3a and C5a by NE has been reported and will be discussed in depth in the next 
chapter (Huber-Lang et al. 2006).  A literature search using the terms “neutrophil elastase” 
and “complement”, “factor B”, “factor H” or “factor D” did not provide any information about NE 
degradation of the other complement components measured in this study and could be an 
interesting research topic. 
 
Of interest to the other components that positively correlated with neutrophil counts, factor B 
has been shown to be elevated during sepsis, a condition where neutrophil dysfunction also 
contributes to pathogenesis (Zou et al. 2013).  Factor B, along with factor D (figure 1-19), are 
important mediators of the amplification loop (alternative pathway) and complement activation, 
leading to the generation of C3a and C5a, and consequently neutrophil recruitment 
(Hajishengallis et al. 2017).  Zou et al. have shown that factor B is released by macrophages 
upon stimulation of TLR-4 in response to infection and suggest that factor B is a pathogenic 
factor in sepsis (Zou et al. 2013).  This therefore, could also be an interesting mediator of 
neutrophilic inflammation in the CF airway during infection. 
 
Factor H did not correlate with either neutrophil count or NE activity but did positively correlate 
with CXCL8.   Factor H is a complement inhibitor that binds to the alternative pathway C3 and 
C5 convertases (C3b,Bb and C3b,Bb,C3b) causing the release of the catalyst, Bb preventing 
activation (de Cordoba and de Jorge 2008).  Factor H is also a co-factor for factor I, a serine 
protease that cleaves C3b into iC3b, a form which retains opsonic activity but cannot form 
convertases (figure 1-19).  Factor H has been shown to bind complement receptor 3 (CR3) on 
neutrophils.  Furthermore, fungal pathogens such as A. fumigatus and C. albicans 
(opportunistic pathogens in the CF airway), have also been shown to bind factor H, a 
mechanism that reduces complement activation (Losse et al. 2010).  Furthermore, it has been 
shown by Losse et al. that interaction between CR3, factor H and pathogen surfaces enhances 
neutrophil response to these pathogens causing increased release of ROS and CXCL8. 
 
The focus of this study was on the role of C3a and C5a in promoting neutrophilic inflammation.  
The concentration of C5a, but not C3a, has previously been reported in CF BAL fluid.  Both 
C3a and C5a concentrations have been reported in CF sputum; the median C5a levels in 
these reports were 258 ng/mL and approximately 1.0 ng/mL (from graph) respectively (Fick et 
al. 1986; Sass et al. 2015).  In my study I found that the median concentration was 57.8 pg/mL, 
almost 2000-fold less than Fick et al. reported in CF BAL fluid and approximately 20-fold less 
than what has been reported in sputum by Sass et al.  There are three reasons that may 
account for these differences: 
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1. Age. CF disease progresses with age and therefore, chronic neutrophilic inflammation 
will be less severe in a more paediatric cohort.  The median age of the cohort used in 
this study was 8.3 whereas Fick et al. and Sass et al. report on C5a and C3a levels in 
populations with a median age of 19 years in smaller cohorts (9 and 15 CF patients 
respectively). 
2. Quantification method. Fick et al. use a radioimmunoassay (Upjohn Diagnostics, now 
Thermo through several mergers) to measure C5a in CF BAL fluid however, this kit is 
no longer available. Radioimmunoassays use radio-labelled antibodies to bind targets, 
complexes are then precipitated and the radioactivity in the pellet is measured.  Using 
an appropriate antibody is critical here because any cross-reactivity with C5 will skew 
the data, this could also be an issue for the kit used by Sass et al. for quantification of 
C5a in sputum.  It is unclear from the manuscript by Sass et al. whether the kit they 
use is from BD bioscience or R&D systems however, both manufacturers report cross-
reactivity for C5 in their C5a kits (0.89% (mole/mole) and 25% (mole/mole) 
respectively, http://www.bdbiosciences.com/ and https://www.rndsystems.com/).  In 
my study, CF BAL fluid had a maximum C5 concentration of 250 ng/mL therefore, in a 
worse-case scenario, using the above kits for C5a quantification in BAL fluid from my 
study would skew C5a levels by 62.5 ng/mL (R&D systems) and 2.2 ng/mL (BD 
bioscience). 
3. Sample processing.  In my analysis I processed BAL fluid by removing the cellular 
component through centrifugation at 500 x g for 5 minutes at 4°C, the supernatant was 
aliquoted and stored at -80°C within 60 minutes.  In contrast, Fick et al. concentrated 
BAL fluid 10-fold using positive pressure ultrafiltration and stored fluid at -78°C (Fick 
et al. 1986).  Due to difficulty in standardising airway fluid samples (as mentioned in 
section 3.1.1a), I think it would be difficult to measure fluid concentration accurately 
and therefore, concentrating BAL fluid would introduce error when reporting C5a 
concentration by weight per millilitre.  A different method for sample processing was 
also used by Sass et al., they report that sputum was centrifugated at 14,000 x g for 
60 minutes at 4°C (Sass et al. 2015).  A reason for this vigorous centrifugation step is 
that the authors were using a similar method to a previous report investigating mucins 
in CF sputum, which may require a more mechanical extraction method (Davies et al. 
1999).  My concern here is that C5a may bind to soluble GAGs present in the sputum, 
ultracentrifugation may separate larger C5a-GAG complexes and therefore, 
complexed C5a may not be included in the quantification but may be relevant to 
pathogenesis, this will be explored in more depth in chapter 6. 
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The above reasons may explain the discrepancies observed between our studies.  In summary 
of quantification of C5a in my study, I have carefully selected an appropriate commercial C5a 
ELISA that has no reported cross-reactivity for C5 (https://www.quidel.com/).  I have also used 
a gentle method of sample processing that maintains a more native state then compared to 
the processing methods described by Fick et al. and Sass et al.(Fick et al. 1986; Sass et al. 
2015) 
 
C3a in sputum was also quantified by Sass et al.; they report a median concentration of 
approximately 40 ng/mL (from graph) whereas, in CF BAL fluid I measured a median of 1.67 
ng/mL by commercial ELISA and 4.1 ng/mL in-house MSD multiplex platform.   Like C5a, there 
are also issues with C3 cross-reacting with C3a ELISA kits; BD bioscience, but not R&D 
systems, manufacture C3a ELISAs.  The manual from the manufacturer’s website 
(http://www.bdbiosciences.com/) states that weight for weight there is <0.0384% cross-
reactivity with C3 in their kit.  C3 is almost 20-fold heavier than C3a; therefore, on a mole for 
mole basis this cross-reactivity could be 0.77% (0.0384% multiplied by 20).  Furthermore, C3 
is vastly more abundant than C3a when measured in plasma (20,000 fold) (Barnum and 
Schein 2018), and CF BAL fluid (>36,000 fold) as quantified by my own study.  Crucially, even 
a small degree of cross-reactivity in this assay would significantly skew C3a quantification. 
 
I found that there were positive correlations between either C3a or C5a and neutrophil count, 
NE activity (C5a non-significant) or CXCL8 concentration.  This is the first study to correlate 
C3a and C5a in CF BAL fluid with neutrophil counts and CXCL8 however, it has previously 
been shown in CF sputum that both C3a and C5a significantly correlate with NE concentration, 
MPO activity and DNA concentration (Hair et al. 2017).  In my study, the correlation between 
C5a and NE activity in CF BAL fluid was not significant compared to Hair et al. where a strong 
positive correlation was demonstrated.  However, Hair et al. quantified total NE not NE activity; 
the difference here is that serine protease inhibitors such as AAT and SLPI are also present 
in the airway and therefore, NE concentration alone does not indicate enzyme activity.  AAT 
and SLPI have been measured in CF sputum as measures of neutrophilic inflammation and 
neutrophilic mediated damage (Sagel et al. 2012).  Hair et al. go further than testing 
correlations between C3a or C5a and markers of neutrophilic inflammation; they also perform 
linear models with confidence intervals for each of the analytes tested. The analysis in my 
study fitted best-fit lines but did not establish direct relationships between analytes. This 
because Spearman rank analysis does not demonstrate causal relationships. 
 
In my analysis I performed correlations between measures of disease progression (lung 
function (FEV1) and age) and C3a or C5a.  In contrast to my data, the same group has twice 
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reported positive correlations between C3a (sputum) and lung function (Sass et al. 2015; Hair 
et al. 2017). This group suggested that C3a has a protective role in the CF airway, this follows 
reports that C3a has an inhibitory role in preventing neutrophil migration from the bone marrow 
during ischemia-reperfusion injury (Wu et al. 2013).   An explanation for this discrepancy is 
that the cohort used in my study is paediatric whereas, in the Sass et al and Hair et al. studies 
the cohort age is older (19 and 24 years respectively).   It has been reported that C3a is a 
biomarker of inflammation and disease progression in several pathologies such as: kidney 
disease, cardiovascular disease and arthritis as well as airway conditions such as asthma and 
pneumonia (P. aeruginosa); Klos et al. has reviewed an extensive list for reference (Mueller-
Ortiz et al. 2006; Dillard et al. 2007; Klos et al. 2013).  Therefore, it is not clear whether the 
presence of C3a (and C3a desArg) in the CF airway has a causal relationship with lung 
function, or whether it is a marker of inflammation and complement activation. 
 
Despite there being no evidence of a correlation between C5a and lung function in my data, 
others have reported negative correlations.  In CF BAL fluid, Fick et al. demonstrated that C5a 
correlated with a worse clinical score and poorer lung function; however, the population size 
for that study was nine and therefore small (Fick et al. 1986).  Sass et al. and Hair et al. both 
describe negative correlations with between C5a and lung function (Sass et al. 2015; Hair et 
al. 2017). Interestingly, Hair et al. also perform a longitudinal study on C5a (and C3a) and 
demonstrate for 3 CF patients that C5a spikes simultaneously with decline in lung function 
(Hair et al. 2017).  Furthermore, for 3 different CF patients Hair et al. show that an increase in 
sputum C5a also precedes a decline in lung function.  They conclude that C5a in sputum is 
not only a marker of disease progression but could also be used as a predictor for pulmonary 
exacerbation (Hair et al. 2017). 
 
I also performed correlations between C3a or C5a with age and found negative relationships 
for both anaphylatoxins however, this association was not statically significant for C3a.  Hair 
et al. also describe negative correlations between C3a in CF sputum with age, in contrast to 
my study, the same group demonstrate a positive relationship between C5a and age in an 
earlier report on 9 patients (Sass et al. 2015; Hair et al. 2017).  Unfortunately, they do not 
report the correlation between C5a and age in the more recent manuscript describing 34 
patients (Hair et al. 2017). 
 
The CF airway is a dynamic and complex environment and, sampling of airway is not always 
performed during pulmonary exacerbation.  Therefore, the population in my study reflects a 
number of scenarios within the disease in addition to exacerbation, such as periods of relative 
stability or inflammatory resolution following a course of antibiotics.  Consequently, this 
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episodic nature of infection in the CF airway is reflected in my data, particularly by the markers 
of neutrophilic inflammation that showed both extremes of high and low levels of inflammation. 
 
A disadvantage of this study was that I did not have a control population.  These are difficult 
to access because the BAL procedure is invasive and requires sedation therefore, making it 
unethical to perform BAL on healthy individuals.  Other control populations can be used such 
as patients undergoing tonsillectomy however, it is not always clear, despite being “healthy”, 
how well their airways reflect normality (Brennan et al. 2008).  Instead of comparing against a 
control population I stratified my data into two groups “well” and “unwell”; this stratification 
revealed statistically significant differences between neutrophil count, CXCL8 and C3a. 
 
An advantage to this study was that the population size was greater (n=41) than previous 
reports investigating C3a and C5a in the CF airway (n= 9, 15 and 34 respectively)(Fick et al. 
1986; Sass et al. 2015; Hair et al. 2017).  Furthermore, because airway fluid was sampled by 
BAL, I was able to assess a more paediatric CF cohort; this is essential for investigating the 
early stages of neutrophilic inflammation in the CF airway.  An additional critical advantage 
was the use of a sensitive commercial C5a (and C3a) ELISA that had no reported cross-
reactivity to C5.  It is important that we understand initial mechanisms that promote chronic 
neutrophilic inflammation, so we can more effectively target causative molecules or pathways. 
 
 Conclusion to the chapter 
 
In this chapter I have analysed complement components (C3, C5, C3a and C5a) and revealed 
that the level of many components is low and, relative to C3 there are significant differences 
compared to normal plasma.  Focusing on the complement anaphylatoxins, I have shown that 
C3a and C5a are associated with neutrophilic inflammation, supporting findings that have 
previously been reported (Fick et al. 1986; Sass et al. 2015; Hair et al. 2017).   Despite showing 
positive correlations between C3a or C5a with neutrophilic inflammation the relationship with 
lung function and disease progression was not clear.  The mechanisms by which these two 
molecules promote chronic airway disease, particularly CF, is not fully understood.  In the next 
sections I will explore the mechanisms by which C3a and C5a could promote CF 
pathogenesis; I will investigate how C3a and C5a interact with the CF lung environment and, 
as a consequence, whether their activity is modified.  Specifically, I will investigate the 
generation and proteolysis of C3a and C5a by NSPs that are present in the CF airway. I will 
also investigate whether C5a interacts with soluble GAGs and, if so, whether these 
interactions modify function. 
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4. Generation of C5a and C3a by neutrophil serine proteases in the CF 
airway 
 
 Background to the study 
 
The complement cascade is not a closed system, it can be regulated by other pathways such 
as metabolic pathways (Barbu et al. 2015), pathogen virulence factors (Hovingh et al. 2016), 
and crosstalk with the coagulation system (Foley 2016). 
 
In particular, the coagulation system has co-evolved with the complement cascade to enable 
quick response to wounds and systemic infection.  Consequently, several coagulation system 
proteases are able to generate functional C5a from C5, independently of C5-convertase; these 
are thrombin, Factor IX, Factor Xa, Factor XI, plasmin and kallikrein (Huber-Lang et al. 2006; 
Foley 2016).  It has been proposed that generation (in addition to complement activation) of 
functional C5a by these enzymes facilitates leukocyte recruitment to the wound or infection 
site, accumulating and facilitating coagulation.  Furthermore, plasmin and factor Xa can also 
cleave C5 into functional C5b, enabling terminal complement activation and the formation of 
MAC (Huber-Lang et al. 2006).  Therefore, the crosstalk between the coagulation and 
complement cascades can be beneficial for wound responses; however, without tight 
regulation this may also lead to thrombosis (Foley et al. 2016). 
 
4.1.1. Atypical generation of C3a and C5a by non-complement proteases 
 
Atypical cleavage of C3 and C5 into functional C3a-like and C5a-like fragments is not unique 
to the coagulation pathway and has been demonstrated for a growing list of non-complement 
proteases (see table 4-1).  Endogenous C3a and C5a-generating proteases have been 
identified as pathogenic factors in several inflammatory diseases such as rheumatoid arthritis 
and asthma, these will be discussed later (Giles et al. 2015; Yuan et al. 2015).   Exogenous 
non-complement proteases expressed by bacteria, fungi, parasites and venomous animals 
such as snakes and insects have evolved to deplete or evade the complement system; 
facilitating colonisation, parasitic living or death of the host (Reed et al. 1995; Luo et al. 2018).  
Also, proteases expressed in peanuts have been shown to generate C3a and C5a-like formsl 
these anaphylatoxins could  
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Protease Anaphylatoxins 
Generated 
Associated pathology Reference 
Endogenous 
Neutrophil proteases: 
Neutrophil serine proteases – (neutrophil elastase 
and cathepsin G) 
 
Matrix metalloproteinase 12 
C3a CNS pathology 
COPD 
(Huber-Lang et al. 2012; Yuan et 
al. 2015; Hooshmand et al. 2017) 
C5a COPD  
Rheumatoid Arthritis 
 
(Brozna et al. 1977; Wetsel and 
Kolb 1983; Robbins et al. 1991; 
Giles et al. 2015) 
Neutrophil MPO-generated hypochlorite C5a Inflammation (Vogt 1996) 
Coagulation Proteases (thrombin, plasmin, Factors 
IX, X, XI and kallikrein) 
C5a Thrombus formation 
Asbestos 
(Wetsel and Kolb 1983; Governa et 
al. 2000; Huber-Lang et al. 2006) 
C3a C. albicans invasion (Irmscher et al. 2018) 
Apoptosis pathways 
(Granzyme B, cathepsin D) 
C5a Trauma (Huber-Lang et al. 2012; Perl et al. 
2012) 
Trypsin C3a and C5a Acute pancreatitis  (Wetsel and Kolb 1983) 
Beta-tryptase C3a, C4a and C5a Asthma (Fukuoka et al. 2008) 
Bacterial 
Pseudomonas aeruginosa 
Pseudomonas elastase 
C5a Cystic fibrosis (Fick et al. 1986) 
Porphyromonas gingivalis 
gingipain-1 
C3a (inactive) and C5a Periodontal disease (Wingrove et al. 1992) 
Streptococcal spp. 
ScpA 
C3a and C5a Bacterial invasion (Lynskey et al. 2017) 
Parasite 
Entamoeba histolytica 
cysteine proteinase 
 
C3a and C5a Parasite colonisation (Reed et al. 1995) 
Dust mite (Dermataphagoides farina) 
Derp1 
C3a and C5a Asthma (Maruo et al. 1997) 
Fungal 
Aspergillus fumigatus 
Alp1 
C3a and C5a generation Fungal colonisation (Behnsen et al. 2010; Shende et al. 
2018) 
Candida albicans 
Pra1 
C3a (inactive) Fungal colonisation (Luo et al. 2018) 
Animal toxins 
 (Bothrops pirajal) 
Batroxase 
C3a, C4a, and C5a Complement depletion (Menaldo et al. 2016) 
Inc. Cobra venom factor  
(Naja naja) 
C3a and C5a Complement depletion (Tambourgi and van den Berg 
2014) 
Plants 
Peanut proteases C3a and C5a Peanut allergy (Javaux et al. 2016) 
Table 4-1: List of exogenous and endogenous proteases that have been reported to generate C3a-like and C5a-like fragments. 
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contribute to pathology during peanut allergenic response; this phenomenon is probably a 
result of proteases broad substrate specificity rather than co-evolution (Javaux et al. 2016).   
 
4.1.2. Generation of functional forms of C3a and C5a by NSPs 
 
The generation of C3a and C5a by NSPs was initially investigated in the 1970s and 1980s; it 
was demonstrated that NE and CG were both able to cleave C3 and C5, producing fragments 
with chemotactic activity (Venge and Olsson 1975; Brozna et al. 1977; Wetsel and Kolb 1983).  
After a review of the literature, C5a generation by NSPs proteases has generally been more 
widely explored than C3a.  This likely reflects the potency of the C5a/C5aR1 axis as a driver 
of inflammatory disease.  Despite building on knowledge of non-canonical generation of C3a 
and C5a for the past four decades, the significance of atypically generated C5a and C3a in 
pathogenesis is still not fully understood. 
 
The pathogenic roles of NSP-generated C3a and C5a in rheumatoid arthritis and COPD will 
be discussed in-turn below.  These are both diseases where neutrophils have been shown to 
contribute to pathology and therefore, could be relevant for studying atypical generation of 
C3a and C5a in the CF airway. 
 
The role of C5a generation by NE has been investigated with respect to rheumatoid arthritis 
(Giles et al. 2015).  A single nucleotide polymorphism coding a mutation (V802I) in C5 has 
been previously identified as a risk factor for the disease, as well as other inflammatory 
diseases such as periodontitis and poor outcome in pneumococcal meningitis, cardiovascular 
diseases and stroke (Kurreeman et al. 2007; Giles et al. 2015).  Giles et al. demonstrate using 
V802I mutant C5 constructs, that the substitution of valine for isoleucine at position 802 
increases C5 turnover by NE leading to increased C5a production.  The authors suggested 
that this phenomenon could contribute to disease pathology by increasing neutrophil 
recruitment to joints, a hallmark of disease pathology (Wright et al. 2014).  Giles et al. also 
observed that NE-generated C5a-like fragments from both C5 constructs were 1 KDa larger 
than C5 convertase-generated C5a (Giles et al. 2015).  The authors concluded by speculating 
that NE cleaved C5 at an alternative site compared to C5-convertase. Valine at position 760 
was speculated as this alternative site, based on cleavage preferences of NE. 
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4.1.3. Generation of C3a and C5a by proteases present during airway disease 
 
C3a and C5a generation by NE has also been reported in a study investigating cigarette 
smoke-mediated emphysema in COPD (Robbins et al. 1991; Yuan et al. 2015).  Exposing 
normal serum to cigarette smoke, Robbins et al. observed an increase in chemotactic activity 
towards monocytes and neutrophils (Robbins et al. 1991).  Furthermore, inhibition of canonical 
complement activation, by addition of EDTA (a metal chelator that sequesters calcium 
preventing calcium dependant assembly of the C1 complex), did not completely arrest the 
generation of chemotactic activity in the serum (Robbins et al. 1991).  MMPs are also sensitive 
to EDTA, as they require co-factors such as zinc (or similarly charged ions like cobalt).  Further 
characterisation by the authors demonstrated that C5a generation could be inhibited by 
addition of EDTA therefore, suggesting that C3a generation by non-complement protease 
(other than MMPs) may be responsible for chemotactic activity (Robbins et al. 1991). 
 
Yuan et al. investigated C3a generation by NE in smoke-mediated lung disease (Yuan et al. 
2015).  In particular, they demonstrated that C3 deficient mice were less susceptible to lung 
disease induced by cigarette smoke inhalation.  Moreover, Yuan et al.  demonstrated that 
purified NE, CG and MMP12 but not PR3 was able to generate a C3a-like fragment from 
purified C3.   The authors also showed that the C3a fragment produced by NE but not MMP12 
was active and induced chemotaxis of bone marrow-derived dendritic cells and myeloid-
derived dendritic cells; dendritic cell-induced differentiation of Th1 and Th17 cells has been 
shown to be a feature of smoke induced emphysema in mice (Kurimoto et al. 2013).  Yuan et 
al. linked C3a generation and C3 proteolysis to the human disease by demonstrating that C3 
cleavage fragments could be visualised on ex vivo lung tissue from smokers with emphysema 
(Yuan et al. 2015). Yuan et al. suggested that atypical C3a generation by the above proteases 
creates a feedback loop of C3aR upregulation, immune activation and recruitment that leads 
to collateral lung tissue damage. 
 
4.1.4. Generation of C5a by proteases present in the CF airway 
 
With relevance to the CF airway, non-canonical generation of C5a by pseudomonas elastase 
(from the bacterium P. aeruginosa) and proteases released by S. aureus have been reported 
(Fick et al. 1986; Sass et al. 2015).  As discussed in the previous chapter Fick et al. reported 
elevated C5a in the CF airway, they further demonstrate that complement-mediated 
chemotactic activity, induced by adding C5 to zymosan activated CF BAL fluid, could not be 
completely arrested by EDTA.  EDTA is an inhibitor of complement activity and 
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metalloprotease activity such as MMPs and pseudomonas elastase, a metalloprotease, 
released by opportunistic CF pathogen P. aeruginosa.  (Fick et al. 1986).  Additionally, a serine 
protease inhibitor, PMSF, also did not fully arrest C5a generation (Fick et al. 1986).  From 
here, Fick et al. investigated C5a-generating components of CF BAL fluid such as 
pseudomonas elastase by resolving proteolytic fragments of C5 by SDS-PAGE.  In addition, 
they demonstrate using a radioimmunoassay, that pseudomonas elastase can generate C5a 
from purified C5.  Furthermore, in a scenario more relevant to the CF airway, they show that 
C5a is generated when alveolar macrophages from normal lungs (a source of C5 in the lung) 
are incubated with pseudomonas elastase (Fick et al. 1986). 
 
Almost 30 years later, Sass et al. investigated C5a generation by proteolytic factors released 
by S. aureus and P. aeruginosa.  They demonstrated that C5a was generated when dead and 
live forms of both bacteria species were incubated with CF sputum (Sass et al. 2015).  
Furthermore, they also show that generation of C5a could be inhibited by a classical/lectin 
pathway inhibitor developed by their group (Mauriello et al. 2013).  Therefore, Sass et al. 
suggest that complement activation by canonical proteases, rather than pathogen-proteases, 
are responsible for C5a generation in these experiments (Sass et al. 2015).  
 
In summary, it is well-established that non-complement proteases can generate functional 
C3a-like and C5a-like fragments. Furthermore, noncanonical production of complement 
anaphylatoxins has been associated with inflammatory disease progression including airway 
disorders such as asthma, COPD and CF.  NSPs have been reported to generate active C3a 
and C5a in the airway (Fick et al. 1986; Robbins et al. 1991; Yuan et al. 2015); however, the 
significance of NSP-mediated anaphylatoxin generation in the CF airway is not fully 
understood. 
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 Hypothesis 
 
I hypothesise that, NSPs generate alternative forms of C3a and C5a that are functionally 
different to their native counterparts and that these de novo forms promote pathogenesis in 
the CF airway.  
 
 Chapter aims 
 
1. Assess evidence for non-canonical C3a and C5a generation in BAL fluid from CF 
patients.  
 
2. Investigate and confirm C5a and C3a generation by proteases present in CF BAL 
fluid. 
 
3. Use purified NSPs to comprehensively characterise the generation of C3a-like and 
C5a-like fragments. 
 
4. Investigate functional differences between NSP-generated C3a and C5a and their 
native, convertase-generated counterparts. 
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  Evidence of C3a and C5a generation by NSPs in the CF airway. 
 
Before investigating the mechanisms of non-canonical C3a and C5a generation in the CF 
airway, evidence for C3a and C5a generation was assessed in CF BAL fluid.  Data from the 
chapter 3 suggested that C3 expression in the CF lung was over 2000-fold that of C5, whereas 
in blood a 10-fold difference is expected (Barnum and Schein 2018).  I also investigated in the 
previous section how these different ratios impacted on complement activity in terms of levels 
of terminal pathway components and the relative abundance of C3a and C5a.  Visual analysis 
revealed that the C3 to C3a or C5a ratios were different in the CF airway compared to normal 
plasma and therefore, could suggest an abnormality in the generation of these anaphylatoxins 
in the CF airway. 
 
4.4.1. Evidence of complement activation and generation of C3a and C5a 
 
Initially, I analysed the data from the CF BAL fluid for evidence of C3a and C5a generation in 
the CF airway, this was investigated by correlating C3a and C5a levels with their respective 
parent molecules, C3 and C5 (figure 4-1).   C3a strongly correlated with C3 (figure 4-1A), 
Spearman rank analysis gave r and p values of 0.853 and <0.0001 respectively.  A significant 
but weaker positive correlation was also observed between C5 and C5a (r = 0.389, p = 
0.014)(Figure 4-1B). 
 
 
Figure 4-1: Evidence of C3a and C5a generation in BAL fluid from the CF airway.  
 
 
 
Data from chapter 3.  Spearman rank analysis of correlations between A) C3 (MSD) and C3a (ELISA) 
n = 41 B) C5 (ELISA) and C5a (ELISA), n=40.  Best-fit linear regressions were fitted to the data (solid 
black lines).  Statistical outcomes r and p values and in black boxes.  
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A stronger correlation between C3/C3a than C5/C5a suggested that there are differences in 
the generation of C3a compared to C5a in the CF airway.  If complement activation was 
“normal” in the CF airway strong positive correlations might be expected between terminal 
complement components (C5b-9) and C3a or C5a.  The correlations between C3a or C5a with 
terminal complement components (C5b-9) were investigated as an indication of canonical 
complement activation (figure 4-2). 
 
 
Figure 4-2: Evidence of normal complement activity in BAL fluid from the CF cohort 
 
 
As mentioned in section 3.7.2, there were technical difficulties when performing one of the 
MSD plates therefore, there was C5b-9 data for 28 out of 40 CF BAL fluid samples.  C3a 
positively correlated with C5b-9 (figure 4-2A) (r = 0.494, p = 0.008); however, a correlation 
between C5a and C5b-9 was not significant (figure 4-2B).  Data from figure 4-1 and figure 4-
2 suggested that there are differences between C3a and C5a generation in the CF airway.   
An explanation for the difference between C3a and C5a generation could be the differential 
influence of NSPs within the CF airway.  Therefore, the CF cohort was analysed for evidence 
of NE-mediated generation of C3a and C5a. 
  
Correlations between C5b-9 and A) C3a or B) C5a. Spearman rank analysis was performed on data from 
CF BAL fluid with best-fit linear regressions (solid black lines).  Statistical outcomes r and p values and 
in black boxes. n=28. 
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4.4.2. Evidence for the generation of C3a and C5a by NE in the CF airway 
 
It has been shown that NSPs are able to generate C3a-like and C5a-like fragments from the 
respective parent molecules (Wetsel and Kolb 1983; Yuan et al. 2015).  I analysed the data 
from the CF cohort for evidence of C3 or C5 proteolysis; for instance lower C3/C5 
concentrations in samples with higher NE activity.  Cohort data was analysed to explore 
whether any correlation existed between NE activity and levels of C3 or C5 (figure 4-3). 
 
Figure 4-3: Correlation of C3 and C5 proteolysis by NE in BAL fluid from CF patients.  
 
 
Correlations between NE and either C3 or C5 were not significant, suggesting either that NE 
does not degrade C3 or C5 or, a more likely explanation, given the literature on C3 and C5 
proteolysis and C3a/C5a generation, is that, CF is a complex disease and that relationships 
between NE and either C3 or C5 are not directly related (Huber-Lang et al. 2012).  NSP-
mediated generation of C3a and C5a has previously been reported (Wetsel and Kolb 1983; 
Yuan et al. 2015) and therefore, evidence supporting C3a and C5a generation by NE in the 
CF airway was investigated. 
 
There was a weak but significant positive relationship between NE and C3a (figure 4-4A) (r = 
0.390, p = 0.012) however, despite a positive trend, the correlation between NE and C5a was 
not significant (figure 4-4B) (r = 0.286, p = 0.070).  As I mentioned above in explanation of 
data in figure 4-3, although there was not any strong evidence from analysis of the cohort to 
support C3a and C5a generation by NE, the relationships between these components may 
not be simple and further investigation is required to elucidate the mechanism involved. 
 
                                                                                                                                                 
Correlations between NE activity and A) C3 or B) C5. Spearman rank correlation analysis performed 
on data from CF BAL fluid with best-fit linear regressions (solid black lines).  Statistical outcomes r 
and p values and in black boxes. n=40.  
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Figure 4-4: Evidence of C3a and C5a generation by NE in BAL fluid from CF patients. 
 
 
Data from CF BAL fluid showed that C3a and C5a were present in the CF airway and that NE 
correlated with elevated expression of these complement anaphylatoxins.  As well as C5a 
generation, it has been reported that C5a can be degraded by NSPs, reducing activity in vitro 
(Brozna et al. 1977).  Furthermore, it has been shown that CXCL8, a potent neutrophil 
chemoattractant in the CF airway is also susceptible to degradation by NSPs (Leavell et al. 
1997).  Like CXCL8, C3a and C5a may also be susceptible to degradation by NSPs which, 
may explain the weak correlations observed above (figure 4-4). Therefore, although the main 
aims of this chapter were to characterise generation of C3a and C5a in CF airway I also 
investigated further proteolysis of C3a and C5a by NSPs. 
 
  Degradation of C5a and C3a by proteases present in the in the CF airway 
 
Recombinant C5a (rhC5a) has been used by others in previous investigations of C5a function 
(Miyabe et al. 2017).  There are structural differences between “native”, C5 convertase-
generated C5a (nC5a) compared to rhC5a, such differences might affect proteolysis.  In 
particular, rhC5a is expressed in E. coli, therefore rhC5a could be alternatively folded 
compared to nC5a; X-ray diffraction of the two forms have not been compared.  Due to 
expression in a prokaryotic system, rhC5a is not N-glycosylated at asparagine residue at 
position 64 (see figure 1-21).  In addition, a “His-tag” containing sequence (amino acid 
sequence: MRGSHHHHHHGSDYDIPTTENLYFQGGS (see page 286)) is incorporated into 
the N-terminal of rhC5a to facilitate purification.  For these reasons, nC5a and rhC5a were 
compared to investigate whether structural differences affected susceptibly to proteolysis. 
 
                                                                                                                                                   
Correlations between NE activity and A) C3a or B) C5a. Spearman rank correlations performed on 
data from CF BAL fluid with linear regressions (solid black lines). Asterisks (*) mark overlapping data 
(A*) n = 2 and (B*) n = 6.  Statistical outcomes r and p values and in black boxes. n=41.  
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                         Recombinant C5a and native C5a (5 µg/mL) diluted in PBS or PBS-tween-20 (0.05%, 
v/v) were incubated at 37°C for 30 minutes “30’ ” or 60 minutes “60’ ” or stored on ice “0’ ”.  Both C5a 
forms were resolved under non-reducing conditions on 15% bis-tris polyacrylamide gels by 
electrophoresis, then transferred to nitrocellulose. C5a was visualised by mouse anti-C5/C5a 
monoclonal antibody and goat anti-mouse HRP conjugate antibody. Annotation of possible dimers or 
higher oligomeric structures are marked by arrows. The above blot is from a single gel with a reference 
ladder resolved between the left and right sides. Representative of n=3. 
 
4.5.1. Optimising the visualisation of C5a on SDS-PAGE. 
 
SDS-PAGE and western blotting was chosen as a method of detecting C3a and C5a 
proteolysis because it enables visualisation of cleavage fragments.  Before performing 
degradation experiments, separation and detection of rhC5a and nC5a by SDS-PAGE and 
Western blot was optimised (figure 4-5). 
 
 
Figure 4-5: Recombinant C5a and native C5a separation and detection by SDS-PAGE and 
Western blot.
 
 
 
Recombinant C5a and nC5a forms were incubated at 37°C following dilution in PBS or 
PBS/Tween-20.  C5a and C3a have been reported to be sticky molecules and therefore a 
detergent, tween-20, was used to reduce aggregation (Klos et al. 2013).   For western blots, 
C5a was separated under non-reducing conditions detected using a mouse anti-C5/C5a 
monoclonal antibody that binds to the c-terminal signaling domain of C5a (see figure 1-21) 
(Klos et al. 1988).   The first observation from western botting was that nC5a had a molecular 
weight approximately 1 kDa greater than rhC5a, 14 and 13 kDa respectively (figure 4-5).  Yet, 
when the combined mass of each of the constituent amino acids is calculated, the rhC5a 
sequence has a molecular weight of 11.3 kDa and nC5a has a molecular weight of 8.2 kDa.  
An explanation could be that nC5a may differ depending of N-glycosylation composition which 
increases the molecular mass by up to 25%, depending on the variable composition of the N-
glycosylation (Fernandez and Hugli 1976).  It was also observed that both C5a forms 
assembled in higher oligomeric structures when diluted in PBS and incubated at 37°C; this 
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was evident from the molecular weight of the oligomeric bands.  For example, rhC5a bands 
were visualised at ~13 kDa (monomeric), ~25 kDa (dimer), ~36 kDa (trimer), and ~50 kDa 
(tetramer).  The addition of a detergent, tween-20, reduced oligomer formation, increasing 
band intensity of the monomeric C5a band; however, dimeric rhC5a was still evident at 60 
minutes even in the presence of tween-20.  The NMR structure of nC5a has been determined; 
interestingly, the structure was solved using dimeric nC5a, but the relevance of dimeric C5a 
in vivo is not fully understood (Cook et al. 2010). For this reason, I modified my experimental 
procedures to reduce oligomerisation by adding tween-20 to my dilution buffers, this was so 
that experimentation on C5a was performed when in a monomeric state. 
  
4.5.2. Proteolysis of C5a by purified NSPs 
 
Having optimised C5a resolution by SDS-PAGE, proteolysis of C5a by NSPs was investigated 
by exposing purified C5a to NE, CG and PR3 and visualising cleavage by western blot (figure 
4-6).  Degradation of nC5a by NE was observed over a 6 h period, this was evident from a 
reduction in band intensity, suggesting the loss of the epitope for the mouse anti-C5a c-
terminal monoclonal antibody (figure 4-6A). However, some bands did not completely transfer 
from the gel to the blot given the appearance of reduced signal.  Native C5a appeared more 
resistant to proteolysis by CG and PR3 than NE over 24 h.  It is also possible that nC5a was 
not degraded and nC5a signal was reduced due to sticking of C5a to plastic tubing.  
Proteolysis of nC5a and rhC5a was compared using a dilution series of NE, CG and PR3 over 
1h (figure 4-6B).  In support of data from figure 4-6A, there was no observable degradation of 
nC5a by any of the three proteases over the 1 h at 37°C.  Interestingly, rhC5a was more 
susceptible to degradation by each of the three NSPs than its native counterpart (figure 4-6B 
and figure 4-6C). 
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                                                                                    A) Native C5a (5 µg/mL) was exposed to 420 
nM of each protease at 37°C for up to 24 h, at 1, 2, 6 and 24 h a sample was removed, and protease 
activity was arrested by adding 5 mM PMSF.  Each protease was also incubated with PMSF “i” prior 
to incubation with nC5a to show that loss was due protease degradation.  Proteins were resolved on 
15% bis-tris poly-acrylamide gels and transferred to nitrocellulose for western blotting using mouse 
anti-C5/C5a monoclonal Ab and detection by goat anti-mouse HRP-conjugate.  B) Degradation of 
nC5a “native” was compared to rhC5a “recombinant” when exposed to NSPs over a 4-fold dilution 
series (420 to 26 nM) for 1 h at 37°C.  Proteins were resolved and visualised as for “A”. C) Comparing 
degradation of nC5a and rhC5a using silver staining.  C5a was exposed 420 nM of three NSPs for up 
to 2h, samples were taken at 30’, 60’ and 120’. As for “A” PMSF was pre-incubated to show 
degradation was specific to proteases. For “C” blots were cut to only show C5a bands, but NSPs were 
also visible and can be seen in figure 4-8B (with respect to C3a) n=3 for each figure. 
 
Figure 4-6: Proteolysis of C5a by purified NSPs.  
 
 
 
 
 
 
Furthermore, rhC5a exposed to each NSP generated a lower molecular weight fragment when 
detecting all resolved proteins by silver staining (figure 4-6C).  The same lower molecular 
weight fragments of rhC5a were detected by Western blot when rhC5a was incubated with 
CG (figure 4-6B).  The lower molecular weight fragments generated from rhC5a by NE or PR3 
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                                                                                                                                                Native 
C5a (A) or rhC5a (B) (5 µg/mL) was incubated with PBS-T or one of three BAL fluid (BAL1, 2, or 3) 
for 1 h at 37°C. After incubation 5 mM PMSF was added. BAL 3 was also incubated with PMSF “i” 
prior to incubation with C5a to show that serine proteases were responsible for degradation.  Proteins 
were resolved on 15% bis-tris poly-acrylamide gels and transferred to nitrocellulose for western 
blotting using mouse anti-C5/C5a monoclonal Ab and detection by goat anti-mouse HRP-conjugate, 
n=2. 
were not detected by Western blot and therefore, reflects that the rhC5a C-terminal epitope 
for the detection antibody is being cleaved by these proteases. Whereas, for CG the epitope 
is still present and therefore suggests that the N-terminal is cleaved. None the less, the main 
observation from these experiments is that nC5a is more resistant to proteolysis by NSPs 
compared to rhC5a and reveals that the structural differences have implications when 
investigating C5a exposure to NSPs. Quantification by ELISA would provide further 
information into the comparable rate of degradation of these two C5a forms.   
 
4.5.3. Degradation of C5a by proteases in CF BAL fluid 
 
The above experiments have shown that rhC5a and, to a lesser extent, nC5a were susceptible 
to proteolysis by purified NSPs.  To investigate the hypothesis that C5a in the CF airway is 
susceptible to degradation, both C5a forms were incubated with CF BAL fluid (figure 4-7).  
Three BAL fluid samples were chosen that had increasing NE activity.  Additionally, BAL 3, 
that had the highest NE activity, was pre-incubated with a serine protease inhibitor (PMSF) to 
investigate whether NSPs were responsible for degradation. 
 
Figure 4-7: Degradation of C5a by proteases present in BAL fluid from CF patients.  
 
 
 
 
From western blots in figure 4-6B it was observed that rhC5a was susceptible to proteolysis 
by proteases present in CF BAL fluid when exposed for 1 h at 37°C. In support of experiments 
performed with purified proteases, there was evidence of rhC5a degradation when exposed 
to BAL 2 and BAL 3, these BAL fluid samples had 178 nM and 554 nM NE activity respectively.   
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Inhibition of serine protease activty in BAL 3, the sample with highest NE activity, partially 
prevented degradation, suggesting that serine proteases are at least partly responsible for 
proteolysis of rhC5a.  There was no evidence of nC5a degradation following exposure to any 
of the CF BAL fluids tested (figure 4-7A); however, part of the “BAL3 + I” is missing due to 
inefficient transfer from the gel.  These data further supported data from experiments where 
nC5a was incubated with purified NSPs and showed that nC5a was resistant to degradation 
(figure 4-6A).  The above experiments show that the strucutral difference in rhC5a compared 
to nC5a has implications when exposing to purified NSPs and those present in CF BAL fluid.  
Furthermore, despite reports that C5a is suspectable to proteolysis by these proteases, in my 
experiments nC5a was resistant to degradation (Brozna et al. 1977). 
 
4.5.4.  C3a proteolysis by purified NSPs 
 
Proteolysis of native C3a by NSPs was also investigated.  Initial observations (not shown) 
suggested that native C3a did not aggregate as observed with C5a; however, C3a cleavage 
experiments were still performed in PBS-tween20 so that a comparison with C5a could still be 
made.  Replicating C5a experiments, C3a was exposed to purified NE, CG or PR3. 
 
Degradation of C3a was visualised by western blot using a mouse anti-C3/C3a monoclonal 
antibody that recognises the C3a C-terminal signaling region (figure 4-8).  C3a was readily 
degraded by NE and PR3 but not CG following 1 h exposure when detecting degradation by 
western blot.  Proteolysis of C3a by NE and PR3 was prevented by pre-incubating each NSP 
with PMSF.  To visualise break-down products that do not possess the epitope for the 
monoclonal antibody, gels were stained for protein using silver nitrate (figure 4-8B).  
Interestingly, the extent of C3a degradation observed in figure 4-8A was less pronounced 
when visualised by silver stain suggesting that the antibody epitope used for western blotting 
was susceptible to degradation.  Moreover, cleavage of C3a did not clearly reduce molecular 
weight suggesting that degradation may be minor and only cleave the C-terminal signaling 
domain.  Further analysis by mass spectrometry would help compare the molecule weights of 
C3a following exposure to NSPs.  C3a exposed to CG appeared more susceptible to 
degradation than when fragments were visualised by western blotting.  This phenomenon 
suggested that there was a subtle cleavage site for this protease within the epitope for the 
monoclonal antibody used in this stain. 
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                                                                                    C3a (5 µg/mL) was exposed to 420 nM of each 
NSP at 37°C for up to 24 h, at 1, 2 and 6 h a sample was removed, and protease activity was arrested 
by adding 5 mM PMSF.  NSPs were also pre-incubated with PMSF “i” prior to incubation with C3a, to 
show that loss was due serine protease degradation.  Proteins were resolved on 15% bis-tris poly-
acrylamide gels and visualised (A) proteins were transferred to nitrocellulose for western blotting using 
mouse anti-C5/C3a monoclonal Ab and detection by goat anti-mouse HRP-conjugate.  B) Gels were 
stained with silver nitrate for visualise total protein. n=3 for both sets of experiments. 
 
 
Figure 4-8: Proteolysis of C3a by purified NSPs.
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C3 (A) and C5 (B) were incubated at 37°C for 1 h with five CF BAL fluid samples (CF1 to 5) that had 
a range of NE activity.  CF BAL fluid was also pre-incubated with (+) or without (-) 5mM PMSF. 
Proteins were resolved by SDS-PAGE on 4-20% tris-glycine gradient polyacrylamide gels.  
Generation of C3a and C5a was visualised by western blot using mouse anti-C3/C3a or mouse anti-
C5/C5a monoclonal antibodies respectively with detection by goat anti-mouse HRP conjugate 
secondary antibody.  For staining, blots were cut at 56 kDa reference maker and stained identically. 
For developing top blots (containing C3 and C5) were incubated in low sensitivity ECL, bottom blots 
(containing C3a and C5a) were incubated with high sensitivity ECL. C3, C3a, C5, nC5a (red) without 
CF BAL fluid were also resolved for reference. Red boxes indicate suspected C3a-like and C5a-like 
fragments, red arrow indicates molecular weight of C3a or C5a respectively. Blots representative of 
n=2. 
 
In section 4.4.2 I reported weak correlations between NE and C3a or C5a.  I hypothesised that 
C3a and C5a could be susceptible to degradation by NSPs present in the CF airway.  In this 
section it was observed that C3a was more susceptible to degradation by NSPs than nC5a, 
when exposed to the same protease concentration over the same time period.  As well as 
hypothesising that C3a and C5a could be susceptible to proteolysis, I also hypothesised that 
NSPs generate C3a and C5a from parental C3 and C5.  In the next section, atypical generation 
of C3a and C5a by NSPs was investigated. 
 
 Generation of C3a and C5a by proteases present in CF BAL fluid. 
 
To investigate C3a and C5a generation in the CF airway, C3 or C5 was incubated with CF 
BAL fluid samples from five patients (figure 4-9).  BAL fluid was selected by level of NE activity 
so that there was a range from high (1.74 µM) to low (0.01 µM) activity.  Each BAL fluid sample 
was also pre-incubated with or without serine protease inhibitor, PMSF, to determine if serine 
proteases were responsible for any C3a or C5a generation observed. 
 
Figure 4-9: C3a and C5a generation by proteases expressed in BAL fluid from the CF cohort. 
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Interestingly, C3a-like or C5a-like fragments of similar molecular weight to their convertase-
generated counterparts were produced when C3 or C5 were incubated with CF BAL fluid that 
had the highest NE activity.  Unfortunately, a comparison of molecular weight between C5a-
like fragments and nC5a was difficult to make due to a “smile” in gel used to resolve C5.  
Generation of C3a-like fragments was observed even when C3 was incubated with CF5, that 
had low NE activity (figure 4-9A), suggesting that C3 is labile and that C3a is readily generated 
by protease in CF BAL fluid.  Unlike C3a, C5a-like forms were not detected when C5 was 
incubated with CF4 or CF5 (figure 4-9B). 
 
Pre-incubating CF1 with PMSF did not appear to prevent generation of C3a-like and C5a-like 
fragments.  Addition of PMSF to CF2 and CF3 had a more obvious effect on C3a and C5a 
generation.  Visually, band intensity for C5a-like fragments was greater when C5 was 
incubated with CF2 and CF3 compared to CF1, despite less NE activity in these samples.  
These data suggest that C3 may be more susceptible than C5 to degradation by proteases 
present in CF BAL fluid.  Moreover, it has been shown that both C3 and C5 are susceptible to 
proteolysis by non-serine proteases however, pre-incubation of BAL fluid with PMSF 
demonstrated that serine proteases are predominantly responsible for C3a-like and C5a-like 
generation.
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                                                                                                 A) C5 was incubated with either NE, CG 
or PR3 at 37°C for 2 or 6 h. In addition, each protease was pre-incubated with “+” or without “-” 5 mM 
PMSF.  Proteins were resolved by SDS-PAGE on 4-20% tris-glycine gradient polyacrylamide.  
Generation of C5a-like fragments was visualised by western blot using mouse anti-C5/C5a with 
detection by goat anti-mouse HRP-conjugate secondary antibody.  For staining, blots were cut at 56 
kDa and stained identically. For developing, top blots (containing C5) were incubated in low sensitivity 
ECL, bottom blots (containing C5a) were incubated with high sensitivity ECL. C5 and C5a (red) without 
protease were also resolved for reference. Red boxes indicate suspected C5a-like fragments, red 
arrow indicates molecular weight of C5a (n=4).  B)  C5 was exposed to 2-fold serial dilution of each 
NSP 420 to 105 nM for 1 h at 37°C and proteins resolved on 20% bis-tris polyacrylamide gels.  
Proteins were visualised as for “A”. For “B” C5a reference protein was included on the blot but required 
a different exposure time so not to interfere with other bands. The C5a reference is therefore in 
separate box but the band position on blot but has not been altered (n=1). 
 
  Generation of functional C5a-like fragments by purified NSPs 
 
The generation of functional C5a-like fragments by NE and CG (but not PR3) has been 
previously shown but they have not been well-characterised (Brozna et al. 1977; Kolb et al. 
1981; Giles et al. 2015).  In this section I sought to reproduce and expand on data showing 
the generation of C5a-like fragments by NSPs that has previously been published. 
 
4.7.1. Visualising NSP-generated C5a by SDS-PAGE and Western blot 
 
The generation of functional C5a-like fragments from C5 by NSPs was investigated using 
purified components.  C5 was incubated with NE, CG and PR3 for 2 and 6 hours at 37°C 
(figure 4-10). 
 
 
Figure 4-10: Generation of C5a-like fragments by NSPs.
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C5a-like fragments, with similar molecular weight to nC5a, were generated when C5 was 
exposed to each of the three NSPs (figure 4-10A).  Despite previous reports of C5a generation 
by NE and CG, this is the first time that PR3 has been shown to generate C5a-like fragments 
(Brozna et al. 1977; Kolb et al. 1981; Giles et al. 2015).  I observed that NE-generated C5a 
was subject to further degradation when incubated over 6 hours; this was visually evident by 
reduced band intensity of NE-generated fragments at 6 h compared to 2 h. 
 
Pre-incubating the separate NSPs with PMSF prevented C5 degradation, demonstrating that 
the NSPs were responsible for C5a generation.  Interestingly, the band pattern of C5 
breakdown products differed for each protease, highlighting the variation in cleavage site 
specificity and potential for the generation of alternative forms of C5a. 
 
Giles et al. reported a 1 kDa difference between nC5a and C5a-like fragments generated by 
NE (Giles et al. 2015).  It was not clear from my own 4-20% tris-glycine gels whether there 
were any minor differences in molecular weight between nC5a and the C5a-like fragments 
generated by NSPs (figure 4-10A).  To make a comparison of NSP-generated C5a-like forms 
easier, fragments were resolved on a 20% bis-tris polyacrylamide gel.  C5 was exposed to 
serially diluted NSPs from 420 to 105 nM for 1 h at 37°C (figure 4-10B).  The generation of 
C5a-like fragments (band intensity) was titratable with the concentration of each protease.  
Interestingly, higher molecular weight C5a-like bands were produced following exposure of C5 
to 105 nM CG compared to 420 nM.  On closer inspection, the band generated by 420 nM CG 
appeared to be of a lower molecular weight than nC5a.   Even when resolving C5a-like 
fragments with 20% acrylamide gels, I could not confirm data from Giles et al that showed that 
NE-generated C5a had a higher molecular weight than nC5a (Giles et al. 2015).  I also could 
not detect a difference in molecular weight between PR3-generated C5a and nC5a. 
 
In the above experiments I have shown that each NSP can generate C5a-like fragments that 
are of similar molecular weight to nC5a however these data did not indicate whether these 
fragments are functional.  The monoclonal antibody used for detection in the above experiment 
(figure 4-10) binds to an epitope on the C5a signaling domain in the C-terminal and therefore, 
suggests that the C5a-like fragments generated by NSPs possess the signaling domain and 
could be functional.  The activity of C5a-like fragments generated by NSPs was investigated 
using a U937 monocyte reporter cell line that had be stably transfected with C5aR1. 
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4.7.2. Assessing the functional activity of NSP-generated C5a-like fragments using a 
U937-C5aR1 reporter cell line 
 
Intracellular calcium signaling in U937-C5aR1 has previously been used to investigate the 
activity of C5a-like fragments generated by NE (Giles et al. 2015).  As discussed in section 
1.4.3a, calcium flux is important for G-protein coupled receptors, such as C5aR1, to signal 
and induce a cellular response like ROS production and chemotaxis.  Monitoring intracellular 
calcium flux enables real-time observation of receptor activation and cell stimulation.  In this 
assay, a fluorochrome (Fura-2-acetoxymethyl ester) is incubated with U937-C5aR1 cells 
whereby, it diffuses through the cell membrane.  Once inside the cells, acetoxymethyl ester is 
cleaved from Fura-2 by cytoplasmic esterases preventing Fura-2 from diffusing back out.  
Fura-2 binds to intracellular calcium, fluorescence of Fura-2 is measured at 340 and 380 nm 
and the ratio 340/380 is calculated to give an approximation of the intracellular calcium 
concentration.  Monocytes use extracellular calcium to initiate intracellular flux.  Therefore, in 
the calcium signaling assay the calcium concentration in assay buffers was known and 
enabled the calculation of intracellular calcium concentration during signaling events. 
 
 
 
Initially, a titration of nC5a was performed to assess the sensitivity of U937-C5aR1 cells 
(Figure 4-11A).  Native C5a induced a concentration dependent increase in intracellular 
calcium U937-C5aR1, and calcium release could still be detected at 25 ng/mL nC5a (figure 4-
11A).  A potent C5aR1 antagonist was titrated to determine the concentration required to 
prevent intracellular calcium release in U937-C5aR1 stimulated by 250 ng/mL of nC5a (Figure 
4-11B).  This preliminary experiment was to confirm that U937-C5aR1 activity in this and future 
experiments was a result of C5aR1 stimulation, rather than non-specific activation of another 
G-protein coupled receptor expressed on the surface leading to intracellular calcium release.  
These experiments indicated that 25 µM antagonist was sufficient to prevent U937-C5aR1 
activation by 250 ng/mL nC5a. Therefore, this concentration of antagonist was used in future 
experiments. 
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                                                                                                      A) U937-C5aR1 loaded with Fura-2 
were stimulated with 250, 50 and 25 ng/mL nC5a.  (B) U937-C5aR1 cells were also stimulated with 250 
ng/mL nC5a following pre-incubating cells with Krebs-HEPES buffer or a 10-fold dilution series from 25 
to 0.025 µM of C5aR1-specific antagonist NDT9513727 for 15 minutes at room temperature (green 
shades).  Fluorescence of calcium-bound Fura-2 was measured every five seconds until signaling event 
plateaued.  Data are from single experiments.  
 
Figure 4-11: Optimising a U937-C5aR1 C5a reporter assay.
 
 
 
 
 
To investigate the activity of C5a-like fragments, C5 cleavage experiments were performed as 
they were for the SDS-PAGE analysis (figure 4-10) and samples used to stimulate intracellular 
calcium release from U937-C5aR1 (figure 4-12).  Purified C5 was exposed to individual NSPs 
for 2 and 6 h at 37°C, protease activity was arrested using a native serine protease inhbitor, 
AAT.   C5 was also exposed to individual NSPs that had been pre-incubated with AAT to verify 
that U937-C5aR1 signalling was a consequence of C5a generation by NSPs. In addition, 
U937-C5aR1 cells were pre-incubated with the C5aR1 antagonist tested in the previous 
section (figure 4-11b), this was to verify that any calcium signaling events observed were a 
result of C5aR1 activiation. 
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                                                                                                                                              C5 was 
incubated with 420nM (A) NE (B) CG, or (C) PR3 for 2 h (black dashed line) or 6 h (black dotted line) 
at 37°C.  C5 was also exposed for 6 h with each protease pre-incubated with AAT (solid red line).  To 
show C5aR1-specific stimulation cells were pre-incubated with C5aR1 antagonist for 15’ at room 
temperature (solid) green line.    Samples were diluted 1/20 in Krebs-HEPES buffer prior to cell 
stimulation and kept on ice.  Fluorescence of calcium-bound Fura-2 (y-axis) was measured every five 
seconds (x-axis) until signaling event plateaued.  Data is representative of 2 experiments for each 
protease. 
C5 cleavage fragments generated following exposure to either NE, CG or PR3 induced 
intracellular calcium release within U937-C5aR1 (figure 4-12A – C).  Confirming data from 
western blots, prolonged incubation with each protease reduced the activity of C5a-like 
fragments, diminishing calcium response at the 6 h time point.  Furthermore, pre-incubating 
each protease with AAT, prevented signaling, confirming that calcium release is mediated by 
protease degradation of C5. 
 
Figure 4-12: Assessing the activity of NSP-generated C5a using U937-C5aR1 cells.  
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Cells were incubated with a potent C5aR1 antagonist to verify that the signal induced by NSP-
generated C5a-like fragments was a consequence of C5aR1 activation.  Pre-incubating cells 
with NDT9513727 prevented calcium release under all NSP conditions, confirming C5a-like 
signaling is mediated through C5aR1. C5a-like fragments, generated by each protease, 
induced comparable calcium response after 2 hours, ~160-170 nM.  Calcium response in 
U937-C5aR1 was variable over different days and therefore, graphs in figure 4-12 are 
representative of responses observed from two experiments. 
 
4.7.3. Comprehensive analysis of C5a-like fragments generated by NSPs 
 
In the previous sections I have investigated the generation of C5a by NSPs and shown that 
each NSP is able to generate a C5a-like fragment that is biologically active and induces 
calcium flux in U937-C5aR1 monocytes.  In the next section, I will further characterise NSP-
mediated C5a generation and C5 degradation by quantifying C5a and C5 concentrations after 
exposing C5 to individual NSPs for 15, 30, 60 and 120 minutes at 37°C.  In addition, samples 
from the same experiments were used to measure C5 activity in a complement hemolysis 
assay. This was to investigate the effects of NSPs on the function of C5.  Samples from each 
experiment were diluted for each assay type to allow accurate measurement on each platform, 
for example; 1/5000 for C5a ELISA, 1/5000 for C5 ELISA and 1/47 for haemolysis assays. 
The remaining sample was diluted in loading buffer and loaded on to 4-20% polyacrylamide 
gels. 
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                                                                                                                           C5 was exposed to 
each NSP for 15, 30, 60 and 120 minutes at 37°C (x-axis).  Cleavage fragments were diluted 1 in 
5000 in sample buffer provided by the manufacturer, C5a was quantified by C5a ELISA (commercial).  
C5a concentration in each sample was interpolated from a standard curve provided by the 
manufacturer.  Obtained values were multiplied by the dilution factor and plotted above (y-axis). At 
t=0, C5 was measured without NSP (untreated). Data plotted as mean ± SEM Statistical analysis by 
Two-way ANOVA with Tukey’s test for multiple comparisons, n=3. 
 
 
 
The rate of C5a generation by NSPs was measured by commercial C5a ELISA (Quidel) that 
has no reported cross-reactivity for C5 (figure 4-13). 
   
Figure 4-13: Quantification of C5a generation by NSP proteolysis of C5.  
 
 
 
Interestingly, detectable C5a was generated within 15 minutes of exposing C5 to each NSP.  
At the same time point, NE generated 4.7 ± 1.3 µg/mL C5a, statistically more, than PR3 (2.8 
± 0.3 µg/mL, p=0.0014) but not significantly more than CG (3.9 ± 0.8 µg/mL, p=0.463).  After 
the first 15 minutes there was no statistically significant change in C5a concentration, 
irrespective of the NSPs that C5 was exposed to.  After 2 h there was no statistical difference 
in C5a concentration when comparing each NSP. Visually, C5a concentration, when C5 was 
incubated with PR3, appeared to increase over 30 minutes then decrease after 120 minutes; 
however, there was not enough evidence to support this observation statistically.  In summary 
of figure 4-13, the majority of C5a is generated by each of the NSPs within 15 minutes with 
NE having the highest C5a-generating activity.  As well as characterising C5a generation, I 
also investigated C5 degradation by measuring C5 concentration in the same samples. 
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                                                                                 ,  adapted from Barnum et al. 2018. C5 comprises 
of two chains α and ß, these are joined by a single disulphide bond (MG6-MG6).  C5a (hashed box) 
is cleaved from C5α.  Hycult 557 antibody binds to the C-terminal pentapeptide. SKY59 binds to α-2-
macroglobulin 1 (MG1) on C5ß.  The suspected binding site of 2D5 (in-house) monoclonal is on C5α.  
 
 
C5 degradation by NSPs was also quantified by in-house C5 ELISA, as used for quantification 
of C5 in CF BAL fluid in section 3.7.1.  In section 3.7.1, I used a combination of antibodies 
(SKY59-Hycult) in the C5 ELISA to enable the quantification of intact C5.  In this ELISA SKY59 
binds the C5ß chain and the Hycult anti-C5 antibody binds the C5α chain (figure 4-14). 
Additionally, a second in-house C5 ELISA (SKY59-2D5) was also performed in section 3.7.1.  
This alternative C5 ELISA uses an in-house mouse anti-C5 antibody specific to the C5α chain 
for detection. Therefore, following exposure of C5 to NSPs, the two different C5 ELISAs could 
potentially detect different C5 fragments, with the SKY59:Hycult pairing detecting more intact 
C5 and the SKY59:2D5 pairing potentially detecting partially degraded C5. 
 
Figure 4-14: Simplified structural diagram of C5. 
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                                                                                                           C5 was exposed to each NSP for 
15, 30, 60 and 120 minutes at 37°C (x-axis).  Cleavage fragments were diluted 1 in 5000 in 1% BSA, 
C5 was quantified by in-house C5 ELISA using either A) SKY59-Hycult antibody pairing or B) SKY59-
2D5 pairing.  C5 concentration in each sample was interpolated from a standard curve (same for both 
antibody pairings).  Obtained values were multiplied by the dilution factor and plotted above (y-axis). 
At t=0, C5 was measured without NSP. Data plotted as mean ± SEM, statistical analysis by Two-way 
ANOVA with Tukey’s test for multiple comparisons, n=3. 
 
C5 was quantified in the same samples used for the quantification of C5a, from the 
experiments performed in the previous section (figure 4-15). 
 
Figure 4-15: Quantification of C5 following exposure to NSPs.
 
 
When C5 was measured using SKY59-Hycult C5 ELISA antibody pairing, there was a 
statistically significant difference in mean C5 concentration between C5 (129.5 ± 25.1 µg/mL) 
and C5 exposed to either NE (42.9 ± 15.2 µg/mL), CG (53.9 ± 13.3 µg/mL) or PR3 (47.3 ± 
13.1 µg/mL) after 15 minutes (p<0.0001 in each case, figure 4-15A).  From the same data, 
there was also a statistically significant difference in mean C5 concentration when C5 was 
exposed to NE (3.6 ± 1.9 µg/mL) over 120 minutes than when exposed to CG (38.9 ± 4.9 
µg/mL) or PR3 (44.1± 7.4 µg/mL) over the same time period; p=0.023 and p=0.008 
respectively. 
Interestingly, different trends were observed using the SKY-2D5 antibody pairing; a 
statistically significant difference in C5 concentration was demonstrated for NE and CG 
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                                                                                                                                               Data from 
figure 4-13 and figure 4-15 (SKY59:Hycult ELISA pairing data) were converted to molar 
concentrations for A) NE B) CG and, C) PR3. C5a (blue) was calculated as a percentage of C5 (red). 
Other non-C5a intermediates (green) were calculated by subtracting percentage C5a from 
percentage C5 (C5 – C5a = non-C5a intermediates) (y-axis). Data is plotted against time (x-axis) 
Data plotted as mean ± SEM, n =3. 
between 0 and 120 minutes; p=0.020 and p = 0.035 respectively (figure 4-15B).  The 
difference in C5 concentration when exposed to PR3 was not significant between 0 and 120 
minutes.  There was also no significant difference between each protease at each time point. 
These data further highlight difficulties in accurately measuring C5 in diseases characterised 
by neutrophilic inflammation.  This is because the C5 ELISA being used for quantification may 
detect partially degraded C5 that may not be functional (C5b-9 (MAC) formation), this will be 
investigated later in section 4.7.3e. 
 
 
 
Further analysis of C5a generation was performed by converting the concentration of C5a and 
C5 measured by ELISAs to molar concentrations.  This enabled the calculation of percentage 
conversion from C5 to C5a and other non-C5a intermediate breakdown products (figure 4-16).   
 
Figure 4-16: Percentage conversion of C5 to C5a and other non-C5a intermediates. 
 
 
 
NE converted approximately 60% of C5 to C5a over 120 minutes, whereas in comparison CG 
converted approximately 50% of C5 to C5a and PR3 converted approximately 30% (figure 4-
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16). Therefore, NE is the most potent at generating C5a-like fragments however, these data 
do not take into consideration subsequent simultaneous degradation of C5a-like fragments, 
as discussed earlier in this section.   
 
As well as characterising NSP-mediated C5a generation, the effects of C5 degradation on 
activity were also investigated.  In figure 4-15, it was observed that intact C5 concentration, 
measured by the C5 ELISA (SKY59-Hycult), decreased by almost 70% within 15 minutes 
exposure to NE. Further evidence of rapid C5 degradation was also visualised by western blot 
(section 4.7.1), yet it is not known what effect this has on the ability to contribute to terminal 
complement pathway activation and MAC formation.  To address this, C5 activity following 
exposure to NSPs was measured using a haemolysis assay. 
 
 
 
The haemolysis assay measures complement activity by lysing sheep erythrocytes that have 
been sensitised with rabbit anti-sheep erythrocyte antibodies.   Human serum is added to the 
erythrocytes as a source of complement components.  Complement activation is triggered by 
the anti-sheep antibodies, forming MAC on the erythrocytes causing lysis.  Consequently, 
haemoglobin from the erythrocytes is released into the supernatant, giving a red hue.  
Measuring absorbance of the supernatant at 405 nm enables calculation of percentage lysis 
compared to maximum lysis, induced by incubating the erythrocytes with water. 
 
The haemolysis assay was optimised to investigate the effects of NSP exposure on C5 
function.  C5-depleted serum was used as a complement source in haemolysis assays.   This 
allowed me to undertake experiments C5, which then could be added back to investigate the 
impact of C5 modification.  Furthermore, normal serum contains protease inhibitors, such as 
AAT, that would make performing these experiments on whole serum difficult.  This is because 
these inhibitors would prevent the generation of C5a-like fragments by the NSPs, as shown in 
the previous experiments. 
 
It has previously been shown that atypical cleavage of C5 by NE may be a mechanism for 
complement activation through the generation of functional C5b (Vogt 2000).  Testing the 
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               C5 was diluted 4-fold serially from 2660 ng/mL to 0.14 ng/mL (x-axis) and added to C5-
depleted serum.  Complement activity was compared by measuring lysis of sensitized sheep 
erythrocytes (y-axis). Non-linear does-response curve was fitted on triplicate values from a single 
experiment and final C5 concentration at 50% lysis calculated (dashed cross-hair).  
 
generation of functional C5b is complex and requires purifying individual complement 
components to “build-up” the terminal complement cascade and MAC formation.  In my project  
I am interested in alternative activation of complement by non-complement proteases but have 
focused on C5a (and C3a generation) by NSPs.  Despite this, I am aware that NSPs could 
generate functional C5b as well as C5a.  Therefore, a single preliminary experiment was 
performed whereby C5 was titrated to a concentration that could induce 50 % lysis when 
added back to C5-depleted serum. This was to enable the detection of reduced or potentially 
increased complement activity mediated via C5 cleavage by NSPs.  In these experiments 1% 
C5-depleted serum was used so that less C5 and serum was required, both precious 
resources.  In order to establish the concentration of C5 required for 50% lysis, C5 was serially 
diluted in 4-fold increments from 2660 ng/mL to 0.14 ng/mL (final concentration) and added to 
C5-depleted serum (figure 4-17). 
 
 
Figure 4-17: Determining the concentration of C5 required for 50% lysis in 1 % C5-depleted 
serum.
 
 
I observed that erythrocyte lysis, as a measure of complement activity, decreased as C5 was 
diluted.  A dose-response curve was fitted by GraphPad prism®, assuming maximum lysis at 
2.66 µg/mL C5.  It should be noted that 100% erythrocyte lysis, induced by incubation of sheep 
cells with water, was not achieved through complement activation using this protocol.  
Therefore, 50% on the dose-response curve was achieved at approximately 39.5% sheep 
erythrocyte lysis.  Interpolating 39.5% lysis value from the fitted curve gave a final C5 
concentration of 0.181 µg/mL.  This meant that samples from the C5 cleavage experiments 
were diluted by 1/47, a factor that equated to 0.181 µg/mL C5. 
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                                                                                                             A) Haemolysis assay was 
performed using samples from the above experiment series. C5 was exposed to NE (blue), CG (red), 
and PR3 (green) over 15, 30, 60, and 120 minutes at 37°C (x-axis). Samples were diluted (1 in 47) so 
that C5 was limited to give 50% sheep erythrocyte lysis (y-axis).  B) Data from “A” was standardised 
by calculating percentage C5 activity using t=0 as 100%. Statistical comparisons for both plots were 
by Two-way ANOVA with Tukey’s test for multiple comparisons. For “B” statistical outcomes are for NE 
only (blue) and compare activity between 15 mins and all other later time points, all other comparisons 
were not significant, Data plotted as mean ± SEM, n=3. 
 
 
Samples from the above C5 cleavage experiments, used to characterise C5a generation and 
C5 degradation by NSPs, were also used to measure C5 activity in the optimised haemolysis 
assay.  Based on the analysis in figure 4-17, C5 samples were diluted 1/47 so that untreated 
C5 led to approximately 50% sheep erythrocyte lysis (figure 4-18).  This was to allow the 
detection of increased or decreased C5 activity.  
 
Figure 4-18: Assessing C5 activity following exposure to NSP. 
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Despite diluting samples so that untreated C5 gave a theoretical value of 50% lysis, in the 
current experiment I observed values that gave a mean of 23.2%.  This is probably because 
the calculation of C5 required for 50 % was made from a single experiment.  None the less, 
an increase or decrease would still be able to be detected because this value was still on the 
exponential part of the curve from figure 4-17.  C5 exposed to NE rapidly lost activity, as shown 
by a reduction in sheep erythrocyte lysis. At t=120 minutes, there was a statistically significant 
difference in erythrocyte lysis when C5 had been exposed to NE compared to PR3 (p=0.032).  
Interestingly, despite C5 concentration (SKY59:Hycult) decreasing by over 60% when 
exposed to PR3 (figure 4-15A), C5 function was retained between t=0 and t=120 minutes.  
This contrast in ELISA and activity data reveals differences in cleavage site preference 
between the different PR3. Furthermore, C5 may retain function despite susceptibility to 
cleavage by PR3.  
 
To reduce variation in these data erythrocyte lysis was standardised; this was done by 
calculating percentage C5 activity based on C5 at t=0 (figure 4-18B); percentage activity = 
((percentage lysis due to sample) / (percentage lysis at t=0) x 100).  As for figure 4-18A, there 
was no significant difference in percentage activity between t=0 and t=120 when C5 was 
exposed to either CG or PR3. In contrast, there was a significant difference in percentage C5 
activity when C5 was exposed to NE between t=15 and t=60 or t=120 (p=0.011, and p<0.0001 
respectively). 
 
From these sets of experiments that measured C5a generation, C5 degradation and C5 
activity, I observed that there is evidence of differential cleavage of C5 by individual NSPs.  In 
particular, I found that exposure of C5 to NE has the most detrimental effect on C5 function 
and is also most potent in C5a generation (figure 4-16). 
 
Despite previous reports of C3a and C5a generation by NE and CG by other groups, it is not 
clear whether such NSP-generated C5a is functionally identical to nC5a produced by C5 
convertase.  The functional differences in NSP-generated C5a will be investigated in section 
4.9.4.  In this section I have investigated C5a-generation by three NSPs; however, C3a 
generation by NE and CG has also been previously reported (Yuan et al. 2015).  I also 
investigated the generation of C3a by NSPs, but because the expression of C3aR on 
neutrophils is a controversial topic the characterisation of C3a generated by NSPs was less 
comprehensive (Klos et al. 2013)
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                                                                                                              C3 was incubated with a 2-fold 
dilution series (420 to 105 nM) of either NE, CG or PR3 at 37°C for 1 h. In addition, each protease at 
420nM was pre-incubated with 5 mM PMSF “i”.  Proteins were resolved under non-reducing conditions 
by SDS-PAGE on 4-20% tris-glycine gradient polyacrylamide gels.  Generation of C3a was visualised 
by western blot using mouse anti-C3/C3a monoclonal (A) or goat anti-C3a polyclonal antibodies (B) 
with detection by goat anti-mouse or donkey anti-rabbit HRP-conjugate secondary antibodies 
respectively.  For staining blots were cut at 56 kDa reference maker and stained identically.  For 
developing, top blots (containing C3) were incubated in low sensitivity ECL, bottom blots (containing 
C3a) were incubated with high sensitivity ECL. For “A” the lower part (dashed black box) was developed 
over a longer exposure time for visualisation of band.  C3awas resolved for reference (green).  Red 
boxes indicate suspected C3a-like fragments, red arrow indicates molecular weight of C3a, n=3. 
 
 
 C3a generation by NSPs 
 
Atypical C3a generation by NE in the emphysematous airway has previously been reported 
(Robbins et al. 1991; Yuan et al. 2015).  In the previous chapter I found that C3a positively 
correlated with neutrophil count in CF; however, this does not necessarily imply a causative 
relationship.  In the current chapter I also found a statistically significant positive correlation 
between C3a and NE (figure 4-4A).  Furthermore, C3a-like fragments generated by proteases 
in CF BAL fluid were visualised by Western blot. To confirm data from previous reports and 
further characterise generation of C3a by NE (and other the NSPs) C3 was exposed to a 2-
fold dilution series of each protease for 30 minutes at 37°C.  C3 cleavage fragments were 
resolved by SDS-PAGE and visualised by western blotting using a mouse anti-C3/C3a 
monoclonal antibody that targets the C3a C-terminal signalling domain (figure 4-19). 
 
 
Figure 4-19: Generation of C3a-like fragments by purified NSPs.
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                                                                                                                                                  C3 was 
incubated with a 2-fold dilution series (420 to 52 nM) of either NE, CG or PR3 at 37°C for 1 h. Proteins 
were resolved under non-reducing conditions by SDS-PAGE on 20% bis-tris polyacrylamide gels.  
Generation of C3a was visualised by western blot using a rabbit anti-C3a polyclonal antibody with 
detection by donkey anti-rabbit HRP-conjugate secondary antibody. For staining blots were cut at 56 kDa 
reference maker and stained identically.  Due to separation using high-density gels, only low molecular 
weight bands could be identified.  Red dashed line indicates molecular weight of C3a based on the 
reference protein, n=1. 
 
C3a-like fragments generated by CG had a similar molecular weight to native C3a, produced 
by C3 convertase (figure 4-19A). Unfortunately, a smile in the gel made it difficult to compare 
the molecular weight of C3a-like fragments with native C3a.  In contrast to previous reports 
(Yuan et al. 2015), only faint C3a-like bands were visualised when C3 was exposed to NE in 
my experiments.  C3a-like bands could not be detected when C3 was exposed to PR3, yet it 
was apparent that C3 was degraded because other break-down products were present and 
the intact C3 band was less intense than the negative control (untreated C3). 
 
I hypothesised that the C3a-like fragments, generated by each of the NSPs, were subject to 
further degradation of the C-terminus, preventing detection by the monoclonal antibody.  I 
hypothesised that this could be because the epitope for anti-C3/C3a antibody is in the C-
terminal signaling domain of C3a.  Therefore, the same samples were resolved by SDS-PAGE 
but detected using anti-C3a polyclonal antibody, a commercial antibody made by immunising 
rabbits with the entire native C3a protein (figure 4-19B). Interestingly, C3a-like bands were 
observed in C3 break-down products produced by individual NSPs.  For CG and PR3 C3a-
like band intensity was dependent on protease concentration.  Unfortunately, as with figure 4-
19A, a smile in the gel made it difficult to compare molecular weights of C3a-like bands with 
convertase-generated C3a.  For this reason, greater resolution was sought by resolving C3 
degradation products using single-concentration 20% bis-tris polyacrylamide gels (figure 4-
20). 
 
Figure 4-20: Resolving NSP-generated C3a fragments on 20% polyacrylamide gels.
 
  
 
 
As visualised using gradient gels, C3a-like fragments, generated by each of the three NSPs, 
could be detected using the goat anti-C3a polyclonal antibody.  In addition to figure 4-19B, 
further dilution of each protease to 52 nM enabled a titratable effect to be observed for each 
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protease whereas before an effect was only found with CG exposure to PR3.  There was no 
apparent smiling in the gel and therefore, a comparison of molecular weights could be made; 
NE and CG generated a C3a-like band with a similar molecular weight to C3 convertase 
generated C3a.  Interestingly, C3a-like bands generated by PR3 had a lower molecular weight 
than C3a, this could reflect loss of the C-terminal signaling domain preventing detection by 
the monoclonal antibody used in figure 4-19A.  Due to technical difficulties repeating this 
experiment, there is only one blot comparing the molecular weights of NSP-generated C3a 
with native C3a and therefore, further confirmation by mass spectrometry is required to more 
accurately compare difference in molecular weight. 
 
In replication of previous reports, I have shown that NE and CG were able to generate C3a-
like fragments through cleavage of C3 (Yuan et al. 2015).  Furthermore, in contrast to the 
previous account by Yuan et al. I have also shown that PR3 can also generate a C3a-like 
fragment.  Despite this, only C3a-like fragments generated by CG, and to a lesser extent NE, 
could be visualised using a monoclonal antibody that binds to the C3a signaling domain.  
Therefore, I hypothesised that only C3a-like fragments that stained positively for the 
monoclonal antibody would be active.  To test the activity of NSP-generated C3a I used a 
reported cell line transfected with C3aR. 
 
4.8.1. Optimisation of a C3a activity assay for measuring the activity of C3-like 
fragments 
 
RBL-2H3 cells stably transfected with the C3aR were used to investigate the function of C3a-
like fragments.  In brief, stimulation of the RBL cells, via the C3aR, induces degranulation, 
releasing enzymes into the media.  The extent of degranulation, or stimulation, can be 
quantified by measuring the release of ß-hexosaminidase, an enzyme that, in a physiological 
setting, breaks down ganglioside through cleavage of N-acetyl galactosamine.  ß-
hexosaminidase activity is quantified by incubation with a specific chromogenic substrate (4-
Nitrophenyl N-acetyl-β-D-glucosaminide), that turns yellows when cleaved, allowing 
absorbance measurement at 405 nm.  Data can be calculated as a percentage of total ß-
hexosaminidase release, achieved by lysing cells with triton X-100.  C3a activity can also be 
calculated using a standard curve of known concentrations of C3a; an example is given in 
figure 4-21. 
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A 2-fold dilution series of C3a from 1000 ng/mL to 0.12 ng/mL (x-axis).  RBL-C3aR cells were stimulated 
for 30 minutes at 37°C 5% CO2, supernatant was transferred to a 96-well plate and substrate was added 
to each well and incubated for 3 h at 37°C.  Stimulation was measured as a percentage of total ß-
hexosaminidase release (y-axis).  Mean values from assay duplicates were plotted. N=1 
 
Figure 4-21: Example of a standard curve for RBL-C3aR ß-hexosaminidase reporter assay. 
 
 
 
 
4.8.2. Activity of C3a-like fragments generated by NSPs 
 
To investigate the activity of C3a-like fragments generated by NSPs, C3 cleavage experiments 
were performed as for the western blot analyses in figure 4-19; C3 was exposed to a 2-fold 
dilution series of individual NSPs for 1 h at 37°C (figure 4-22).   
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C3 was incubated with a 2-fold dilution series (420 to 52 nM) of either (A) NE (blue shades), (B) CG 
(green shades) (C) or PR3 (orange shades) at 37°C for 1 h.  C3a 62.5 ng/mL was used as a reference 
(red).  A native serine protease inhibitor, AAT, was also pre-incubated with the highest concentration 
of each protease (diagonal stripe).  Non-specific degradation of the ß-hexosaminidase substrate was 
assessed by adding protease only (black).  RBL-C3aR cells were stimulated for 30 minutes at 37°C 
5% CO2, supernatant was transferred to a 96-well plate and substrate was added to each well and 
incubated for 3 h at 37°C. Data was plotted as mean ± SEM, statistical analyses by Two-way ANOVA 
with Tukey’s test for multiple comparisons (n=3).   
 
Figure 4-22 Assessing the activity of C3a-like fragments generated by NSP. 
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A small modification to the protocol was that the proteolytic activity of NSPs was arrested 
using AAT rather than PMSF, this is due to the cytotoxic effects of PMSF on cells.  NSPs 
diluted in PBS-T to a concentration of 420 nM (but not added to C3) were included as a 
negative control and confirmed that each NSP was not able to cleave ß-hexosaminidase 
substrate and generate a false-positive (even though protease activity was arrested with AAT).  
Interestingly, CG, but not NE or PR3, generated functionally active C3a-like fragments that 
could stimulate degranulation of RBL-C3aR cells. The difference in the activity between these 
C3a-like fragments further demonstrate the alternative cleavage site preferences for these 
proteases.  For instance, cleavage of the C-terminal signaling domain that is required for C3aR 
activation.  Activity of C3a-like fragments generated by 420 nM CG had mean ß-
hexosaminidase release similar to that induced by 62.5 ng/mL C3a (p = 0.787) (figure 4-22B).  
It was shown in figure 4-19A, that NE-generated C3a-like fragments that were faint but visible 
by western blot.  There was also minor residual activity in NE-generated C3a-like fragments; 
however, activity was not statistically different to C3 incubated with PBS (p = 0.705) (figure 4-
22A).  Data from the C3a activity assay support my hypothesis that cleavage of the C-terminal 
epitope for the monoclonal antibody coincides with the loss of activity in these fragments. 
 
C3a standards in experiments performed with NE (figure 4-22A) had lower ß-hexosaminidase 
release compared to CG and PR3 experiments (figure 4-22B and figure 4-22C). This was 
particularly evident when comparing ß-hexosaminidase release following stimulation by 
purified C3a across each set of experiments.  This was probably due to fluctuation in the 
capacity of the cells to signal from week to week however, total ß-hexosaminidase release, 
measured from lysed cells, remained the same (not shown).  Therefore, this phenomenon 
may have reduced the ability to detect low levels of C3a activity. 
 
So far, I have shown that C5a and C3a can be generated by proteases present in CF BAL 
fluid.  I have confirmed and expanded on previous reports of functionally active C5a and C3a 
generation by purified NSPs; however, it is not known whether functional differences exist 
between NSP-generated anaphylatoxins and their convertase-generated counterparts; this 
will be explored in the next section. 
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                                                                                                             A) A standard curve of 
carboxypeptidase activity was established by diluting purified porcine CPB 2-fold serially from 1.5 to 0.023 
µg/mL (black line). CPB (1.5 µg/mL) was also pre-incubated with 5mM 1,10 phenanthroline (black star 
“*”). Activity was quantified using a chromogenic substrate, Furylacryloyl-Ala-Lys, by measuring change 
in absorbance (336nm) every minute for 20 minutes.  Mean change was calculated by line of best fit over 
20 minutes.  B) 13 CF BAL fluid were diluted 1 in 4 and added to substrate (median annotated by black 
bars). Normal human serum was diluted 1 in 15 for comparison.  Carboxypeptidase activity was calculated 
by interpolating values from the standard curve in “A” and multiplying by the corresponding dilution factors. 
n=13 for CF BAL fluid, n=5 of the same normal serum sample. 
 Functional differences in alternatively generated forms of C3a and C5a 
 
C3a and C5a are potent pro-inflammatory mediators and therefore require tight regulation. In 
blood, C3a and C5a are rapidly inactivated by CPB and CPN; these cleave the C-terminal 
arginine, producing C3a-desArg and C5a-desArg respectively.  Expression of CPB and CPN 
in the normal and CF airway has not been described.  Therefore, inactivation of NSP-
generated C3a-like and C5a-like fragments by CPB and CPN was investigated. 
 
4.9.1. Measuring CPB and CPN activity in CF BAL fluid. 
 
Before investigating CPB and CPN inactivation of C3a and C5a, expression of these inhibitors 
was measured in the CF airway as this has not previously been reported. Carboxypeptidase 
activity was measured using a chromogenic substrate specific for CPN and CPB, 
Furylacryloyl-Ala-Lys.  As for the NE activity assay, CF BAL fluid sample is added to the 
carboxypeptidase substrate and the mean change in absorbance (336nm) over time is 
calculated using a best-fit linear regression.  To quantify CPN and CPB expression, purified 
porcine CPB was used as a standard curve, an example is given in figure 4-23A.  
 
 
Figure 4-23: Quantifying CPB and CPN activity in CF BAL fluid.  
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Human sources of CPB are available but are significantly more expensive. Furthermore, it has 
been reported that there is no difference in function between porcine and human CPB 
(Marinkovic et al. 1977).  Porcine CPB was diluted serially 2-fold from 1.5 to 0.023 µg/mL and 
change in absorbance was measured upon exposure to the chromogenic substrate.  CPN 
requires zinc as a co-factor for activity, a chelator of metal ions, 1,10 phenanthroline was also 
pre-incubated with the highest standard (1.5 µg/mL) to show that substrate breakdown was 
specific to porcine CPB (figure 4-23B). 
 
The rate of chromogenic substrate breakdown was titratable with porcine CPB concentration 
between 1.5 and 0.023 µg/mL.  A metal chelator, 1,10 phenanthroline was effective at 
preventing substrate breakdown when pre-incubated with 1.5 µg/mL showing that activity is 
specific to the CPB in this experiment.  Similar porcine CPB standard curves as shown in 
figure 4-23A were used to interpolate CPB activity in 13 CF BAL fluid samples and serum from 
a single healthy donor (figure 4-23B). The mean CPB activity in CF BAL fluid was 174 ng/mL 
(range: 95 – 233 µg/mL) compared to 15.56 µg/mL in serum from a single healthy donor. Due 
to the sensitivity of this assay, CPN and CPB activity was measured using the lower part of 
the standard curve.  It should be noted that Furylacryloyl-Ala-Lys is not specific to CPB and 
will also be cleaved by CPN therefore, carboxypeptidase activity in the above figure is relative 
to porcine CPB. 
 
Analysing data from figure 4-23B, the carboxypeptidase activity in the CF airway is over 70-
fold less than in circulation; however, I did not yet know whether C5a (or C3a) could still be 
inactivated by this amount of activity. 
 
4.9.2. A RBL-C5aR1 reporter cell line for measuring C5a activity  
 
A RBL-C5aR1 reported cell line was used to investigate inactivation of C5a by CPB.  As for 
RBL-C3aR, ß-hexosaminidase release is used to measure receptor stimulation.  In section 
4.7.2 I assessed the activity of C5a-like fragments using an U937-C5aR1 reporter cell line.  
The RBL-C5aR1 reporter assay became available later on during my project and was chosen 
over the U937-C5aR1 calcium signalling because it enables simultaneous testing of different 
conditions.  The protocol for the U937-C5aR1 activity assay only allowed for one condition to 
be tested at a time.  By this I mean that U937-C5aR1 cells were loaded with Fura-2-AM and 
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                                                                                                          RBL-C5aR1 cells were stimulated for 
30 minutes at 37°C 5% CO2, supernatant was removed and added to an equal volume of chromogenic 
substrate, 4-Nitrophenyl N-acetyl-β-D-glucosaminide and incubated for 3 h at 37°C. Tris (1 M) was added 
and absorbance measured at 405 nm. Data were calculated as a percentage of total ß-hexosaminidase 
release induced by incubating cells with 0.1% triton X-100 (y-axis).  Background signal measured by 
stimulating cell with phenol-red free media only was subtracted from all data points. C5a was diluted 10-
fold from 250 to 0.0025 ng/mL (x-axis) in PBS-T (0.00125 % (final concentration)), data was plotted as 
mean values from assay duplicates. Data from a single experiment. 
then there was a two-hour window to perform cell stimulations.  Beyond this, leakage of Fura-
2 from the cells affects the data.  Each test would take 10-15 minutes and therefore, only a 
set amount of conditions could be tested in one sitting.  RBL cell reporter assays were 
performed in 96-well plates with all conditions tested simultaneously.  Before investigating the 
inactivation of NSP-generated C5a (and C3a), the sensitivity of RBL-C5aR1 reporter assay 
was tested. 
 
To quantify activity of C5a-like fragments generated by NSPs and measure inactivation of C5a 
by CPB, a standard curve was established using purified nC5a by performing a 10-fold serial 
dilution series from 250 to 0.0025 ng/mL in PBS-T.  A variable slope was fitted by GraphPad 
prism®, r = 0.984 (figure 4-24).  ß-hexosaminidase was detectable when nC5a was diluted to 
0.4 ng/mL therefore, for future experiments a standard curve would range from 250 to 0.4 
ng/mL in a 5-fold dilution series. 
 
Figure 4-24: Optimisation of RBL-C5aR1 C5a reporter assay.
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                                                                                                               A) C5a (1 µg/mL) or B) C3a (0.5 
µg/mL) was incubated with a 5-fold dilution series of porcine CPB from 15 µg/mL to 192 pg/mL (38.pg/mL) 
for C3a for 1 h at 37°C (x-axis). Samples were diluted 1 in 10 using phenol red-free media prior to cell 
stimulation.  RBL-C5aR1 or RBL-C3aR cells were stimulated for 30 minutes at 37°C 5% CO2, and ß-
hexosaminidase release was measured using chromogenic substrate). C5a and C3a activity were 
quantified by interpolating values from a standard curve produces using purified nC5a and C3a.  
Percentage inactivation was calculated by dividing the activity of each condition by the activity of untreated 
C5a or C3a and subtracting from 100. Data points are triplicates from a single experiment (mean and 
standard deviation).  A four-variable non-linear least squares regression was fitted on triplicate values 
from a single experiment by Graphpad prism® (red). Median carboxypeptidase activity in CF BAL fluid 
was annotated by a dotted line. 
4.9.3. Inactivation of native C3a and C5a by porcine CPB 
 
Having optimised the RBL-C5aR1 reporter assay, porcine CPB was used to briefly investigate 
whether levels of carboxypeptidases observed in CF BAL fluid, from figure 4-23B, were able 
to inactivate nC5a or C3a.  In preliminary experiments, nC5a and C3a were incubated with a 
series of porcine CPB dilutions from 15 µg/mL to 192 pg/mL for 1 h a 37°C and, the exposed 
anaphylatoxins were used to stimulate RBL-C5aR1 or RBL-C3aR respectively.  Complete 
inactivation of nC5a was not achieved at the highest porcine CPB concentration used (figure 
4-25A), this concentration was similar to the CPB activity observed in serum from a single 
healthy donor (15.56 µg/mL) (figure 4-23B).  C3a was more readily inactivated by porcine CPB 
than C5a furthermore, additional dilution of CPB (to 38.4 pg/mL) was required before 
inactivation of C3a was no longer detectable (figure 4-25B). 
 
Figure 4-25: Inactivation of native C5a and C3a by porcine CPB.
 
 
 
 
 
4.9.4. CPB inactivation of C3a and C5a forms generated by NSPs 
CPB/N activity was found in CF BAL fluid.  Furthermore, the equivalent concentration of 
porcine CPB could reduce C5a activity and completely inactivate C3a.  I have shown that 
NSPs can generate functionally active C5a-like and C3a-like fragments, but it is not known 
whether CPB/N can inactivate these alternative forms.  Active C3a-like and C5a-like fragments 
were generated by exposing C3 to 420nM CG and C5 to 420nM of each NSPs for 1 h at 37°C.  
NSP-generated C3a and C5a fragments were subsequently exposed to 15 µg/mL porcine 
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                                                                                                                                          A) C5 was 
exposed to NE or PR3 for 1 h at 37°C, AAT was added subsequently added to inhibit protease activity. 
Purified C5a (125 µg/mL) or C5 cleavage fragments were exposed to PBS (blue) or 15 µg/mL 
(uquivalent to activity in serum) porcine CPB (red) for 1 h at 37°C then used to stimulate RBL-C5aR1.  
C5a activity was interpolated from a standard curve of purified C5a (y-axis). Data was presented as 
mean ± SEM, Two-way ANOVA (Tukey’s multiple comparison) was performed to compare means, n=3. 
B) Data from “A” was calculated as percentage inactivation, by dividing the activity of each condition 
by the activity of their respective untreated control (no CPB), this value was multiplied by 100 then, 
subtracted from 100. Mean inactivation for each condition were compared by One-way ANOVA, n=3. 
CPB for 1 h at 37°C and activity was compared with the respective convertase-generated 
counterparts (C3a and C5a). 
 
 
 
I first investigated inactivation of NSP-generated C5a by CPB (figure 4-26).  Interestingly, there 
was no statistical difference in C5a activity when C5a-like fragments generated by NE and 
PR3 were exposed to porcine CPB, suggesting resistance to inactivation (p > 0.999 and p > 
0.999 respectively, figure 4-26A). 
 
Figure 4-26: Inactivation of NSP-generated C5a-like fragments by porcine CPB. 
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As shown in figure 4-25A, porcine CPB reduced nC5a activity significantly (p < 0.006) but did 
not completely abolish function; it was unclear from these experiments why nC5a retained 
function after exposure to CPB.  There was a significant difference in C5a activity between C5 
convertase-generated C5a and the C5a-like fragments generated by NE and PR, without 
exposure to porcine CPB (p = 0.008 and p = 0.020 respectively).  This difference in activity 
between nC5a and protease-generated C5a was due to the concentration of nC5a that I used 
for reference in these experiments.  Therefore, because the activity of nC5a and C5a-like 
forms was different, data from figure 4-26A was re-calculated as percentage inactivation in 
relation to the untreated control (figure 4-26B).  Analysing these standardised data, there was 
a significant difference in the percentage inactivation of nC5a compared to C5a generated by 
NE and PR3 (p < 0.01). 
 
Previous quantification of C5a activity was performed by measuring intracellular calcium flux 
in U937-C5aR1.  Despite demonstrating activity from CG-generated C5a-like fragments using 
U937-C5aR1, no detectable activity was detected from these fragments when measuring ß-
hexosaminidase release from RBL-C5aR1 (shown in figure 5-6 in a similar type of 
experiment). None-the-less, C5a activity was detected in C5a-like fragments generated by NE 
and PR3. 
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                                                                                                                                       A) C3 was 
exposed to CG for 1 h at 37°C, AAT was added subsequently added to inhibit protease activity. 
Purified C3a (75 ng/mL) or C3 cleavage fragments were exposed to PBS (blue) or 15 µg/mL porcine 
CPB (red) for 1 h at 37°C then used to stimulate RBL-C5aR1.  C3a activity was interpolated from a 
standard curve of purified C3a (y-axis). One-way ANOVA was performed to compare means, n=3. B) 
Data from “A” was calculated as percentage inactivation, by dividing the activity of each condition by 
the activity of their respective untreated control (no CPB), this value was multiplied by 100 then 
subtracted from 100. Mean inactivation for each condition were compared by One-way ANOVA with 
Dunnett’s test for multiple comparisons, n=3. 
 
 
 
A similar set of experiments was also performed comparing CPB inactivation of C3a-like 
fragments generated by CG (figure 4-27). 
  
Figure 4-27: Inactivation of CG-generated C3a-like fragments by porcine CPB. 
 
 
 
 
There was a statistically significant reduction in C3a activity when either purified C3a or CG-
generated C3a-like fragments were exposed to 15 µg/mL porcine CPB (p = 0.001 and p = 
0.009 respectively, figure 4-27A).  Furthermore, re-calculating data as percentage activation 
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confirmed that there was no statistical difference in inactivation of CG-generated C3a 
compared to native, C3 convertase-generated C3a (p = 0.500, figure 4-27B).  These data 
suggest that there is no difference in susceptibility to inactivation by porcine CPB between 
C3a and the C3a-like fragments generated by CG.  Data from CPB C3a and C5a inactivation 
experiments were the first to find that the C5a-like fragments generated by NE and PR3 are 
resistant to inactivation compared to native C5 convertase-generated C5a.  
 
 Discussion 
 
The complement anaphylatoxins, C3a and C5a, are elevated during chronic neutrophilic 
inflammation of the CF airway and there is evidence from my study (chapter 3) and other 
reports that they contribute to neutrophilic inflammation and pathogenesis (Fick et al. 1986; 
Sass et al. 2015; Hair et al. 2017).  Non-canonical generation of C3a and C5a by pathogen-
derived proteases has been reported in the CF airway and may contribute to elevated C5a 
expression during infection (Fick et al. 1986; Sass et al. 2015).  NSP-mediated C3a and C5a 
generation has previously been reported in inflammatory airway disease such as COPD 
however, this mechanism has not been fully explored in the CF airway (Kolb et al. 1981; Fick 
et al. 1986; Robbins et al. 1991; Yuan et al. 2015).  I hypothesised that NSPs in the CF airway 
generate alternative forms of C5a and C3a that are functionally different to their native 
counterparts. 
 
4.10.1. Evidence for C3a and C5a generation by NSPs in the CF airway  
Initially, I assessed data from CF BAL fluid in chapter 3 for evidence of non-canonical C3a and 
C5a generation.  Interestingly, C3a but not C5a correlated with terminal complement pathway 
activation (C5b-9).  A study of canonical complement activation using zymosan (a complement 
activating fungal glucan) has previously demonstrated that cleavage of one C3 molecule does 
not necessarily equate to one C5a (after assembly of C5-convertase) (Morad et al. 2015).  
Furthermore, the same group show that the C3a:C5a ratio is not linear and the C3a:C5a ratio 
increases as complement becomes more active, suggesting dynamic kinetics within the 
complement system (Morad et al. 2015).  Despite improving our understanding of complement 
activation and anaphylatoxin generation, the above study does not simulate complex 
environments such as the CF airway.  I think that there may be alternative fates for C5a 
compared to C3a in the CF airway that could account for the difference in their relationships 
with C5b-9.   A possible explanation is that there could be higher C5aR1 expression on cells 
present in the CF airway compared to C3aR and therefore C5a is more readily removed by 
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receptor internalisation.  During infection, the CF airway is dominated by neutrophils that have 
high expression of C5aR1 whereas there is ongoing controversy over whether neutrophils 
express C3aR (Ember et al. 1991; Norgauer et al. 1993).  Moreover, it has been shown that 
neutrophils from patients with sepsis had reduced C5aR1 expression as result of C5aR1 
stimulation and internalisation however, C5aR1 degradation by NSPs (reported by our group) 
may also reduce expression (Unnewehr et al. 2013; van den Berg et al. 2014). As well as 
differences in internalisation of C5a and C3a,  it has been shown that C5a is susceptible to 
degradation by NE and CG; this was further characterised in my study (Brozna et al. 1977).  I 
have shown that, under similar conditions, C3a was more susceptible to degradation than C5a 
which may be contrary to my argument for why C3a correlates with C5b-9 but not C5a.  
Despite this, I have observed that C3 is present at concentrations 1000-fold greater than C5, 
whereas in circulation this difference is more like 10-fold (Barnum and Schein 2018).  In 
summary the CF airway is a complex environment that cannot be fully understood by simple 
two-way relationships. 
 
4.10.2. Comparing NSP proteolysis of recombinant and native C5a forms 
 
In initial experiments, I compared functional differences between rhC5a and nC5a.  
Recombinant C5a has been used by other groups in substitute for nC5a however, there are 
structural differences, such as glycosylation of nC5a, that may be important when performing 
investigations on C5a (Miyabe et al. 2017).  In this study, I have shown that rhC5a is more 
susceptible to degradation by NSPs than nC5a; this has not previously been reported.  The 
N-glycosylation of asparagine-64 of C5a accounts for 25% of total C5a molecular weight 
therefore, a large glycosylation residue could sterically hinder NSPs access to cleavage sites 
(see figure 4-29)(Fernandez and Hugli 1976).  Sareneva et al. have reported that two N-
glycosylation sites on interferon-γ are important for protection against plasmin, NE and CG 
(Sareneva et al. 1995).  I attempted to de-glycosylate nC5a in order to investigate whether the 
n-glycosylation site did indeed protect nC5a from degradation; however, I was unable to 
confirm successful de-glycosylation (not shown). 
 
4.10.3. Generation of C3a-like and C5a-like fragments by proteases present in CF BAL 
fluid 
 
NSPs have been reported to generate functional C3a-like and C5a-like fragments (Wetsel and 
Kolb 1983; Robbins et al. 1991; Yuan et al. 2015). In my study, evidence of C3a and C5a 
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generation by NSPs in CF BAL fluid was initially investigated by correlating NE activity with 
either C3a or C5a.  C5a is a potent activator of neutrophils that induces the release of NE, 
further driving C5a generation; however, as mentioned above, NE can also in turn degrade 
C5a (Goldstein and Weissmann 1974; Brozna et al. 1977).  None the less, Fick et al. 
demonstrate a strong correlation (r = 0.97, p = 0.03) between C5a concentration and 
elastolytic activity in BAL fluid from 7 CF patients (Fick et al. 1986).  It should be noted that 
elastolytic activity in the above study may originate from pseudomonas elastase and other 
proteases as well as NE. This is because radiolabeled elastin was used as a substrate and 
elastin can be degraded by a range of proteases and not just pseudomonas elastase (Fick et 
al. 1986; Cowland and Borregaard 2016).    Without specific antibodies that can differentiate 
between different C5a forms such as native C5a, C5a-desArg and alternatively generated 
C5a-like fragments, I think it will be difficult to conclusively demonstrate C3a and C5a 
generation in complex samples such as CF BAL fluid. 
 
To further investigate C3a and C5a generation by NSPs in the CF airway, purified C3 and C5 
were incubated with CF BAL fluid. C3a and C5a-like molecules of similar molecular weight to 
nC5a were produced.  Furthermore, a serine protease inhibitor (PMSF) was sufficient to block 
the majority of C3a and C5a generating activity indicating that it was due to serine proteases.  
Fick et al. have also demonstrated C5a generation by CF BAL using SDS-PAGE however, 
I125-C5 was used to visualise cleavage fragments rather than western blotting (Fick et al. 
1986).  They observed different molecular weight C5a-like bands when CF BAL fluid was pre-
incubated with PMSF, suggesting alternative forms of C5a were generated by serine and non-
serine proteases. The addition of C5-convertase generated C5a was not resolved on their gels 
for comparison but would improve identification of C5a-like fragments.  Furthermore, the use 
of I125-C5 to visualise C5a generation means that non-C5a fragments of similar molecular 
weight to nC5a may produce false positives.  An advantage of my study was the use of a 
monoclonal antibody with an epitope in the c-terminal signaling domain to visualise C5a-like 
fragments. 
 
In support of my data, Fick et al. also demonstrated that serine proteases were predominantly 
responsible for C5a-generation in their experiments; they found that PMSF reduced C5a-
generation by 32-48% (Fick et al. 1986). Moreover, they also show that a different serine 
protease inhibitor, AAT, reduced C5a-generation by 49-66%. 
 
After a review of the literature, my study is the first to show and visualise non-canonical 
generation of C3a by proteases expressed in CF airway;however, some of these data were 
preliminary and therefore further characterisation is required.  In my study, C3a-generation 
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was not completely arrested when CF BAL fluid was pre-incubated with PMSF.  Others have 
observed that C3a-like fragments, whilst not active (as measured by monocyte chemotaxis 
assays), can be generated by MMP12 a protease also released during neutrophil 
degranulation (Yuan et al. 2015). 
 
4.10.4. Generation of functional C3a-like forms by purified NSPs 
 
I demonstrated that C3a could be generated by purified NSPs.  My results confirm generation 
of C3a-like fragments by NE and CG reported by Yuan et al. (Yuan et al. 2015).  In addition, I 
detected C3a-like generation by PR3, a fragment not found by Yuan et al. This is likely to be 
because they stained their C3a-like fragments using a different monoclonal antibody (R&D 
systems, clone 354113) against C3a.  It is not clear from the manufacturer’s website 
(https://resources.rndsystems.com/) where on C3a the epitope for this antibody is located.  An 
advantage to my study, was the use of two anti-C3a antibodies for the detection of C3a-like 
fragments; these were a monoclonal antibody for the C3a C-terminal signaling domain and, a 
polyclonal antibody against native C3a.  PR3-generated C3a was detected using the 
polyclonal antibody but not the monoclonal antibody.  PR3-generated C3a fragments had a 
lower molecular weight but these data were from a single experiment and require confirmation 
using mass spectrometry.  I also show that C3a-like fragments generated by CG, that stained 
positive for the C3a C-terminus, were active and stimulated the release of ß-hexosaminidase 
from RBL-C3aR.  The anti-C3a polyclonal antibody demonstrated generation of C3a-like 
peptides by all three proteases but only CG generated C3a had detectable activity.  By 
comparison, Yuan et al. showed that NE-generated C3a induced chemotaxis of bone-marrow 
derived and monocyte derived dendritic cells (Yuan et al. 2015). In explanation, the authors 
use 1:1000 ratio of NE to C3, whereas in my own experiments the greatest ratio of NE to C3 
was 1:150.  Therefore, there may be intermediate NE-derived C3a-like species during limited 
proteolysis that are active. Subsequent minor degradation, removing residues from the 
signaling domain could inactivate these fragments explaining why their activity was not 
detected in my experiements.  From my observations of the CF airway the median ratio of NE 
to C3 was 1:263 however, the smallest ratio, in samples with the greatest inflammation, was 
1:0.7.  Therefore, with a ratio of between 1:10 and 1:150 my experiments may be more 
representative of C3a generation by NSPs in the inflamed airway, or at least the CF airway. 
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4.10.5. Generation of functional C5a-like forms by purified NSPs 
C5a-generation by NE and CG has previously been shown  (Brozna et al. 1977; Wetsel and 
Kolb 1983; Huber-Lang et al. 2002; Giles et al. 2015) yet, to my knowledge, this is the first 
time C5a-like fragments cleaved from C5 by PR3 has been documented.  Despite, the above 
reports on C5a-generation, a more comprehensive characterisation was performed on each 
protease.  A time-course experiment of C5 proteolysis be each protease was carried out over 
2 h; C5a was quantified by ELISA, C5 was quantified by two in-house C5 ELISAs and C5 
activity was measured by haemolysis assay.  It was found that the majority of C5a-like 
fragments were generated within 15 minutes of exposure to each NSP. 
 
Giles et al. have also reported a time-course experiment by exposing C5 to NE; however, the 
rate of C5a generation that they demonstrate appears to be less than my experiments (Giles 
et al. 2015). This could be explained by the ratios of C5 to NE; in my experiments I used a 
ratio of 1:10 whereas Giles et al. report using 1:20, double my own cleavage assays. 
 
4.10.6. Assessing C5 function following exposure to purified NSPs 
 
I also quantified C5 degradation in cleavage experiments using two ELISAs that detected C5 
using alternative antibody pairings.  The two alternative C5 ELISAs enabled the measurement 
of theoretically intact (SKY59-Hycult pairing) and partially cleaved C5 (SKY59-2D5 pairing).  
Interestingly, intact C5 concentration decreased dramatically within the first 15 minutes, 
mirroring C5a-generation.  Only NE degraded C5 to near-zero concentrations over the 2 h 
period observed.  The SKY59-2D5 pairing demonstrated a less-severe loss of C5 when 
exposed to each NSP.  These data further support observations of low intact C5 
concentrations in CF BAL fluid reported in the cohort characterisation in the previous chapter.  
In addition, C5 activity was quantified by measuring sheep erythrocyte lysis in a classical 
pathway haemolysis assay. Interestingly, visually, C5 function mapped more closely to the C5 
concentration by the C5 ELISA that can detect partially cleaved C5. This observation suggests 
that complement activation can occur with C5 that has been partially cleaved by each NSP 
however, further experimentation would be required to test this theory. The most striking result 
was that the function of C5 exposed to PR3 did not significantly change over 2 hours despite 
the generation of C5a and evidence of degradation by western blots.  The generation of 
functional C5b-like fragments by NE but not CG or PR3 has been reported (Vogt 2000).  
Although my experiments have been designed to investigate C5b-like generation, there is 
evidence to suggest that PR3, more so than NE and CG, may also cleave functional C5b.  A 
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comprehensive experiment using C5-depeleted serum and purified complement components 
would be required to definitively demonstrate function C5b-like generation. 
 
4.10.7. Investigating CPB inactivation of C3a-like and C5a-like fragments  
 
The most interesting finding from this chapter was that NE and PR3-generated C5a was 
resistant to inactivation by porcine CPB.  CPN and CPB are crucial for regulating C3a and 
C5a in circulation (Skidgel and Erdos 2007).  It has recently been demonstrated using acute 
and subacute systemic disease models that, despite functional similarities, CPB and CPN 
have different roles.  CPN is constantly expressed in circulation; however, CPB is upregulated 
via thrombin during acute challenge (Morser et al. 2018).     With relevance to the CF airway, 
I measured carboxypeptidase activity in CF BAL fluid to assess whether carboxypeptidase 
inactivation of C3a and C5a was still an important mechanism for regulation of activity in the 
CF airway.  CPB and CPN activity was measured in 13 CF BAL fluid samples and a serum 
sample from a single healthy donor; serum CPB activity was over 70-fold higher than that 
found in CF BAL fluid.  A disadvantage to my study was that I did not differentiate CPB and 
CPN activity. Commercial ELISAs are available for CPN and CPB.  Alongside activity data, 
these would provide comprehensive insight into C3a and C5a regulation in the CF airway.  
Carboxypeptidases are expressed by hepatic cells, it is not clear whether non-liver cells, such 
as airway epithelial cells or alveolar macrophages, can produce carboxypeptidases locally 
(Skidgel and Erdos 2007).  CPB activity in sera has previously been measured in CF patients; 
this was to investigate whether pancreatic deficiency, caused by bile duct blockage, reduced 
carboxypeptidases in circulation (Koheil et al. 1979).  The authors did not observe any 
significant difference between CPB activity in CF sera compared to age and gender matched 
control subjects with ciliary dyskinesia. 
 
In my experiments, porcine CPB was used to inactivate C3a and C5a.  A comparison of 
porcine and human CPB by Erdos et al. showed that CPB from both species have identical 
substrate specificity (terminal lysine and arginine) (Marinkovic et al. 1977).  A dissimilarity was 
that human but not porcine CPB activity was fully arrested by EDTA (Marinkovic et al. 1977).  
Reviewing the literature, I did not find any reports that compared inactivation of C5a (or C3a) 
by human and porcine CPB. 
 
The role of carboxypeptidases and C5a inactivation has been reported in a mouse model of 
asthma (Fujiwara et al. 2012).  The authors observed that CPB knock-out mice were more 
sensitive to ovalbumin-induction of airway hyperresponsiveness. Furthermore, symptoms of 
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Activated and necrotic neutrophils release NSPs into the airway.  NSPs generate C5a-like 
fragments that are resistant to carboxypeptidase regulation.  NSP-generated C5a facilitates further 
neutrophil recruitment to the CF airway.  Upon infiltrating the airway, C5aR1 is cleaved by NSPs 
from the neutrophil surface preventing C5a-mediated function.  Without C5a communication 
neutrophils are less effective at clearing pathogens driving a vicious cycle. 
hyperresponsiveness were reduced when CPB knock-out mice were administered a C5aR 
antagonist.  The authors concluded that carboxypeptidases are important for regulating C5a 
activity in the asthmatic airway; however, they did not comment on the non-canonical 
generation of C5a by NSPs. 
 
 
 
For the first time, I have demonstrated that NE and PR3-generated C5a-like forms are 
resistant to inactivation by porcine CPB.  This means that NSPs are not only important for 
elevating levels of C5a in the CF airway but the C5a that NSPs produce is functionally different.  
I propose a model whereby NSP-generation of functionally different C5a promotes neutrophilic 
inflammation but, these neutrophils infiltrating the airway become densesitised through NSP-
cleavage of C5aR1, as previously reported by our group (van den Berg et al. 2014).  Due to 
the critical role of C5a in orchestrating inflammation, cleavage of C5aR1 renders neutrophils 
ineffective at clearing pathogens (Hunniger et al. 2015).  A vicious cycle is established 
whereby NSP release, C5a generation and inefficient pathogen clearance drives CF airway 
pathology (figure 4-28). 
 
 
Figure 4-28: Diagram of the role of NSP-generated C5a in the CF airway. 
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         Predicted cleavage sites for NE (blue) and PR3 (orange) (https://www.ebi.ac.uk/merops/ 
database). Blue asterisk is the NE-cleavage site suspected by Giles et al. (Giles et al. 2015). Red 
arrows annotate C5-cleavage site after C5 arginine-751 and green arrow is the site for subsequent 
CPB or CPB cleavage of arginine-751 to produce the inactivated form C5a-desArg.  The N-
glycosylation site at C5 Asparagine-742 (C5a-64) is annotated in yellow.  The black dashed line 
represents canonical C5/C5a cleavage, C5a from C5α chain. 
This model shows how C5a could promote neutrophilic inflammation in the CF airway may 
also be relevant for diseases where NSP-generation of C5a has also been reported such as 
rheumatoid arthritis, asthma and COPD (Robbins et al. 1991; Giles et al. 2015; Verschoor et 
al. 2016). 
 
A possible explanation of why NE and PR3-generated C5a is resistant to inactivation by CPB 
is the site where the C5a-like fragment is cleaved from the C5-alpha chain.  It has been 
speculated that the NE cleavage site is at C5 position valine-760, 9 amino acids downstream 
of the C5-convertase cleave site, arginine-751 (see figure 4-29) (Giles et al. 2015).  Despite 
this, neither C-terminal sequencing nor mass spectrometry has been performed on NE-
generated C5a to confirm this cleavage site.  Figure 4-29 demonstrates a number of NE and 
PR3 cleavage sites upstream and downstream of the C5-convertase site on C5. These have 
been predicted using a database that collates all reported cleavage site preferences for these 
proteases (https://www.ebi.ac.uk/merops/).  For instance, NE is more likely to cleave after 
leucine, valine and isoleucine. Additionally, the MEROPS website suggests that there are 
different site specificities for recombinant NE and NE purified from human blood.  NE data 
collated by MEROPS was from two separate publications (Harris et al. 2000; Wysocka et al. 
2008). 
 
Figure 4-29: Amino acid sequence of C5a and predicted preferential cleavage sites for NE and 
PR3.   
 
 
 
 
Despite no reported protein sequence data, Giles et al. observed that NE-generated C5a was 
1 kDa bigger than convertase-generated C5a therefore, a cleavage site downstream of the 
C5-convertase is plausible (Giles et al. 2015).  CPB and CPN are endopeptidases that cleave 
terminal lysine or arginine residues therefore, obstruction of the C5a C-terminal arginine by 
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Predicted cleavage sites for NE (blue) and CG (purple) (https://www.ebi.ac.uk/merops/ database). 
Red arrows annotate C3-cleavage site and green arrow is the site for subsequent CPN or CPB 
cleavage of arginine to produce the inactivated form C3a-desArg.  The black dashed line represents 
canonical C3/C3a cleavage, C3a from C3-alpha chain. 
an extension of C5a sequence would theoretically prevent cleavage and inactivation (Skidgel 
and Erdos 2007). 
 
 
 
Only CG generated detectable functional C3a-like fragments in my study; thisC3a form was 
not resistant to inactivation by porcine CPB.  Again (as for C5a), reviewing the MEROPS 
database, there are multiple predicted cleavage sites, many of which are shared with NE, but 
my data did not show that NE-generated C3a was active (figure 4-30).  These predicted sites 
are based on probability, I have selected sites with the highest probability, but because CG 
has broad specificity it is possible that CG also cleaves at the same position as C3-convertase.  
In support of the CG C3a cleavage site being the same as C3 convertase, my own resolution 
of CG-generated C3a by SDS-PAGE did suggest that the molecular weight of these fragments 
were similar to native C3a. 
 
 
Figure 4-30: Amino acid sequence C3a and predicted preferential cleavage site of CG and PR3. 
 
 
 
To my knowledge, none of the groups in table 4-1 that investigated atypical C3a or C5a-
generation also assessed whether these fragments could be inactivated by CPB or CPN.  
Despite this,  Riedemann et al. performed peptide sequencing of trypsinised C5 and observed 
that trypsin cleaved C5a-like fragments of identical length to native C5a (Riedemann et al. 
2017).  Therefore, given my hypothesis that elongated C5a-like fragments are protected from 
CPB inactivation by additional amino acids, I would predict that trypsin-generated C5a is 
inactivated similarly to nC5a.  Mass spectrometry of ß-tryptase has also confirmed the 
generation of C3a and C5a that are identical in mass to their convertase-generated 
counterparts (Fukuoka et al. 2008).  I assume, again, that these fragments are also susceptible 
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to CPB inactivation.  Therefore, although I have extensively listed (table 4-1) non-complement 
proteases that can generate functional C3a and C5a, it is possible that not all are resistant to 
inactivation, as I have shown for NE and PR3-generated C5a. 
 
 Neutrophil elastase Cathepsin G Proteinase 3 
C3a degradation degradation degradation 
nC5a Limited degradation (24hr) No degradation No degradation 
rhC5a degradation degradation degradation 
C3 C3a-like fragment 
No activity 
C3a-like fragment 
Active 
Inactivated by CPB 
C3a-like fragment 
No activity 
C5 C5a-like fragment 
Active 
Resistant to CPB inactivation 
C5a-like fragment 
Some activity 
CPB inactivation not 
tested 
C5a-like fragment 
Active 
Resistant to CPB inactivation 
Table 4-2 Summary of experiments exposing complement components to NSPs 
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 Conclusion to the chapter 
 
The complement anaphylatoxins, C3a and C5a, are elevated in the CF airway however, their 
roles in disease progression are unclear.  Over the past 40 years numerous non-complement 
proteases have been shown to generate functional C3a and C5a forms, including NSPs.  In 
this section I have investigated C5a and C3a generation by NSPs, with particular focus on 
C5a.  Most intriguingly, I have demonstrated that NE and PR3 can generate functionally 
different C5a that is resistant to inactivation by CPB.  Therefore, in the CF airway not only do 
NSPs contribute to C5a (and C3a) generation but these forms bypass regulation by 
carboxypeptidases and therefore, could potentially drive chronic neutrophilic inflammation.  
Importantly, CF represents a case of neutrophilic inflammation that is representative of other 
inflammatory diseases such as asthma, COPD, rheumatoid arthritis and sepsis. Therefore, 
mechanisms of C5a-mediated inflammation will also apply to these diseases; however, more 
investigation is required to differentiate the contribution by different C5a forms.  In the next 
section I will investigate whether therapeutic complement inhibitors that bind C5 and prevent 
the generation of C5a (and C5b) are also effective at blocking atypical generation of C5a by 
NSPs. 
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5. Generation of C5a-like fragments by neutrophil serine proteases in the 
presence of C5 cleavage inhibitors 
 
 Background to the chapter 
 
The complement system is critical for removal of pathogens and foreign bodies. Furthermore, 
complement is integral in promoting inflammation, clearing apoptotic cells and promoting 
tissue regeneration (Ricklin et al. 2010).  Despite this, the reliance on complement for the 
above mechanisms means that dysregulation can contribute to disease pathology (de 
Cordoba et al. 2012).  This is the case for numerous inflammatory and autoimmune disorders 
throughout the body such as sepsis, rheumatoid arthritis and systemic lupus erythematosus 
(de Cordoba et al. 2012). 
 
Due to the wide-reaching effects in disease, controlling complement activity has become an 
attractive therapeutic target; however, deciding how and where in the cascade is a challenge 
(Morgan and Harris 2015).  This is because simply dampening complement activity in order to 
reduce symptoms of a disease may leave a patient more susceptible to infection.  Academic 
institutions and pharmaceutical companies have developed a range of therapeutics targeting 
initiation, alternative pathway (amplification loop), MAC assembly and the anaphylatoxins 
(C3a and C5a) (figure 5-1) (Morgan and Harris 2015).  Complement based therapeutics are 
undergoing clinical trials in kidney disease (aHUS, glomerulopathy and PNH), autoimmune 
diseases (rheumatoid arthritis, lupus nephritis and myasthenia gravis), ischaemia-reperfusion 
(stroke, by-pass and organ transplantation) as well as inflammation (AMD and sepsis) 
(Morgan and Harris 2015).  The airway has also been suggested as a target for complement 
inhibition, particularly in diseases such as asthma and COPD (Marc et al. 2010; Khan et al. 
2014). 
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                                                                                                                                               , Figure 
extracted from Morgan and Harris 2015.  Complement therapeutics have been developed to target 
the three complement activation pathways as well as the anaphylatoxins.  A range of different 
inhibitory mediators have been produced such as monoclonal antibodies (white), small molecules 
(green), peptides (yellow), proteins (blue) or nucleic acids (red).  The current phase in clinical trial is 
dictated by their proximity to the centre of the target (diagram), phase I-II, preclinical and approved 
for use in clinical is labelled at the top.  
 
Figure 5-1: Complement therapeutics, their target pathway and phase in clinical trial. 
 
 
 
 
In particular, two diseases have been controlled using C5 cleavage inhibitors these are; PNH 
and aHUS.  Both diseases are rare (1-2 and 3.3 cases per million respectively), they have 
different disease mechanisms (discussed in section 1.6.5) but have been successfully 
managed by blocking the cleavage of C5 by C5 convertase using the drug Eculizumab 
(Solaris) (Hillmen et al. 2006; Zuber et al. 2012).  Following positive outcomes in PNH and 
aHUS, Eculizumab is undergoing clinical trials for numerous other diseases, these include: 
AMD, neuromyelitis optica, mild allergic asthma, refractory myasthenia gravis and Gullain-
Barre syndrome (Morgan and Harris 2015). 
 
Eculizumab is a mouse monoclonal antibody that recognises a linear epitope in the C-terminus 
of C5 between residues 884 and 890 (Thomas et al. 1996).  Eculizumab has been 
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“humanised”, meaning that the mouse complementarity-determining regions (CDR) are 
grafted onto human IgG heavy and light chains (Thomas et al. 1996).    Eculizumab does not 
bind chimpanzee or baboon C5 though the sequence is highly homologous to human C5  
(including the epitope for Eculizumab).  This discrepancy led to the discovery of an additional 
Eculizumab binding site, a hairpin loop at residues 913-922 on human C5 (Brachet et al. 
2016).  These residues are not conserved between humans and non-human primates, 
accounting for the lack of Eculizumab cross-reactivity (Brachet et al. 2016).  Interestingly, 
these interactions between Eculizumab and C5 still permits C5 to bind with C5-convertase; 
however, it prevents cleavage of C5 (into C5a and C5b) (Jore et al. 2016).  The precise 
mechanisms by which C5 cleavage inhibitors function is difficult to investigate due to the short 
half-life of C5-convertases (Jore et al. 2016). 
 
Despite its successes, Eculizumab is not perfect and several issues leave opportunities for 
additional therapeutic approaches.  One of the issues with targeting C5 is that it is expressed 
at approximately 75-100 µg/mL in serum, requiring high levels (900-1200 mg/person) of 
plasma antibody for full inhibition of C5 activity (Fukuzawa et al. 2017; Barnum and Schein 
2018).  For this reason, Eculizumab is one of the world’s most expensive drugs with a cost of 
£340,000 per patient per year (Jore et al. 2016).  A second issue is that patients with a 
mutation in C5 arginine-885 (R885H) do not respond to Eculizumab treatment (Nishimura et 
al. 2014). This is because the polymorphism lies within the linear epitope described above 
(Nishimura et al. 2014).  The R885H mutation has a prevalence of 3.5% in the healthy 
Japanese population (Nishimura et al. 2014).  Further analysis of C5 constructs found five 
more mutations that may reduce response to Eculizumab, although no PNH or aHUS patients 
bearing these alternative forms have been discovered (Volk et al. 2016). 
 
With these issues in mind, several competitor C5 cleavage inhibitors have been developed 
and are undergoing clinical trials.  As well as other monoclonal antibodies, different strategies 
include aptamers (protein-binding oligonucleotides; ARC1905) and naturally occurring 
inhibitors (Nunn et al. 2005; Ni and Hui 2009; Jore et al. 2016).  The tick C5 cleavage inhibitors, 
OmCI and RaCI, have been isolated from two different tick species, Ornithodoros moubata 
and Rhipicephalus appendiculatus respectively (Nunn et al. 2005; Jore et al. 2016).  Their 
normal role is to prevent immune activation upon ticks feeding on their hosts by inhibiting 
activation of host C5.  The mechanism by which OmCI and RaCI block C5 cleavage is that 
they bind and prevent a conformational change upon C5 interaction with C5 convertase (figure 
5-2) (Jore et al. 2016).   
227 
 
                      Adapted from Jore et al.(Jore et al. 2016)   A) Crystal structure of OmCI-C5 and RaCI3 
(RaCI variant) complexes.  Tick inhibitors bind in different locations, in both cases preventing 
conformational change of C5, particularly a flexible C345c region stopping cleavage of C5a (red). 
OmCI also binds via a CUB domain, common in complement peptidases B) Cartoon representing C5 
structure with binding sites for OmCI (cyan), RaCI (purple), SKY59 (dark green), and eculizumab 
(orange). 
 
 
Figure 5-2: Structures of OmCI and RaCI complexes and reported binding sites of Eculizumab 
and SKY59.
 
 
 
Recombinant OmCI (Coversin) is currently undergoing clinical trials in PNH and sepsis  
(https://www.akaritx.com/coversin/).  Encouraging results using OmCI were also observed in 
a porcine model of sepsis when co-administered with an anti-CD14 antibody (Skjeflo et al. 
2015).  RaCI has only recently been isolated and it has been shown that the C5 binding site 
is distinct to that of OmCI and eculizumab (figure 5-2) (Jore et al. 2016).  Due to a low 
molecular weight (<20 kDa), the authors hypothesised that the tick inhibitors will have a longer 
half-life than eculizumab and therefore require a reduced dosage and reducing the cost per 
patient.  Immunoglobulins have a short half-life of approximately 7-21 days (Wang et al. 2018). 
They are degraded following internalisation by Fc receptors and trafficking to endosomal 
compartments (Wang et al. 2018).  The neonatal Fc receptor is important for cycling 
internalised IgGs whilst facilitating the degradation of their ligands (Wang et al. 2018). Short 
half-life of IgGs is an issue for their use as a therapeutic, again this is exaggerated with 
Eculizumab because large doses are already required to overcome the high concentrations of 
C5 in serum (Fukuzawa et al. 2017).  To solve the issue of short half-life therapeutic antibodies 
in vivo, Igawa et al. have engineered antibody CDR regions to disassociate from the ligand at 
pH 6, preventing degradation in endosomal compartments and allowing cycling of antigen-
free IgG via neonatal Fc receptors (Igawa et al. 2010).   They show in mice that modification 
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of Tocilizumab (anti-IL-6R) in this manner increased concentration of the antibody in serum 
40-fold compared to the unmodified drug over a 4-day period.  The same technology has been 
integrated into a humanised rabbit-anti human C5 monoclonal antibody that has inhibitory 
activity, SKY59 (Fukuzawa et al. 2017).  SKY59 not only inhibits C5 cleavage with similar 
kinetics to eculizumab but can be recycled in vivo (Fukuzawa et al. 2017).  In addition, SKY59 
can inhibit terminal pathway activation in patients that have the R885H variant in C5 
(Fukuzawa et al. 2017).  It should be noted that a second-generation version of Eculizumab, 
Ravulizumab, engineered to enable cycling is currently undergoing phase II trials in PNH and 
aHUS (Ricklin et al. 2018). 
 
The efficacy of Eculizumab and the tick C5 cleavage inhibitors to block terminal complement 
activation has been well characterised; however, the mechanism behind SKY59-mediatied 
inhibition are not clear (Jore et al. 2016; Fukuzawa et al. 2017).   I have recently contributed 
to a report showing that SKY59 not only binds C5 but it can also bind C5b-6 preventing MAC 
formation and cell lysis (Zelek et al. 2018).  Despite characterisation of these therapeutic 
inhibitors, little is known about their capacity to prevent endogenous and exogenous protease 
generation of C5a, as investigated and discussed in the previous chapter.   Riedemann et al. 
have documented the first initial evidence that C5a can be generated by thrombin in the 
presence of Eculizumab (Riedemann et al. 2017).  Furthermore, by optimising an in-house 
C5a ELISA, the authors report elevated C5a/C5adesArg in aHUS patients undergoing 
treatment, suggesting C5 inhibition by Eculizumab is not complete.  Riedemann et al. attribute 
C5a generation to thrombin and demonstrate that their own anti-C5a therapeutic antibody, 
IFX-1, is required for full protection for immune activation. 
 
If thrombin can generate C5a in the presence of Eculizumab, is this also true for the NSP-
generated C5a-like fragments that I investigated in chapter 4?  Moreover, do other C5 
cleavage inhibitors offer any greater or lesser protection from non-canonical C5a generation?  
In attempt to answer these questions the inhibitory function of four cleavage inhibitors against 
NSP-mediated C5a generation was investigated. These include; Eculizumab, SKY59, OmCI 
and RaCI. 
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 Hypothesis 
 
I hypothesise that eculizumab is unable to prevent the generation of functionally active C5a-
like fragments by NSPs. Investigation will also include three other C5 cleavage inhibitors: 
SKY59, OmCI and, RaCI. 
 
 Aims 
 
1. Compare complement inhibition of four C5 cleavage inhibitors: Eculizumab, 
SKY59, OmCI, and RaCI. 
 
2. Investigate and compare NSP-generation of C5a-like fragments in the presence 
of the above four inhibitors using SDS-PAGE, a commercial C5a ELISA and the 
RBL-C5aR1 reporter assay. 
 
 
3. Explore mechanisms by which NSPs potentially bypass C5 cleavage inhibitor 
protection
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 Comparison of the activity of four therapeutic C5 cleavage inhibitors using a 
haemolysis assay 
 
Before investigating the main aim of this chapter, a haemolysis assay was optimised to enable 
comparison of the different inhibitors. The haemolysis assay that was used to investigate the 
different C5 cleavage inhibitors had a similar protocol to that used in section 4.7.3e.  Here I 
used C5-depleted serum as a source of complement and added back experimentally modified 
C5 to investigate effects of NSP degradation on its function. This was because serine protease 
inhibitors (such as AAT) are present in the circulation and these could have blocked NSP 
activity in my experiments.  In the following experiments, as before, 1% C5-depleted human 
serum was used.  Based on reports that C5 is approximately 100 µg/mL in normal serum 
(Barnum and Schein 2018), at 1% the C5 concentration in normal serum would be 1 µg/mL.  
From this calculation I would need to add back at least 1 µg/mL of C5 to the 1% C5-depleted 
serum to obtain physiological complement activity. 
 
To confirm the activity of the four therapeutic C5 cleavage inhibitors, 2.5 µg/mL (132 nM) C5 
was incubated with the individual therapeutic inhibitors at a range of concentrations from an 
equivalent 5-fold molar excess of therapeutic to C5 (5:1) to over a 4000-fold excess of C5 to 
therapeutic (0.006:1 therapeutic to C5).  The C5 concentration used (2.5 µg/mL) was higher 
than the physiological concentration calculated for the serum dilution used (1.0 µg/mL), this is 
because in later experiments greater C5 concentrations were required to enable visualisation 
on western blots. 
 
C5 was incubated with each therapeutic inhibitor for 15 minutes at 37°C then added to 1% C5 
depleted serum.  Sensitised sheep-erythrocytes were added, and lysis was quantified after 
incubating for 60 minutes at 37°C (figure 5-3). 
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                                                                                                                               C5 (132 nM) was 
incubated for 15 min at 37°C with each cleavage inhibitor, diluted in a 3-fold series so that the inhibitor 
to C5 ratio ranged from 5 to 0.006 (x-axis).  Each condition was diluted 1 in 10 in C5-depleted serum 
so that the final concentration of C5 was 0.25 µg.  Complement activity was measured as a percentage 
of sheep erythrocyte lysis. Data is presented as A) raw data (mean and standard deviation) B) Raw 
data from ”A” fitted with sigmoidal curves by GraphPad Prism®. R-squared > 0.99 for each condition. 
Dotted line marks 1:1 ratio. N=2. 
 
 
Figure 5-3: Comparing the activity of therapeutic C5 cleavage inhibitors. 
 
 
All inhibitors completely prevented sheep lysis at a 1:1 ratio of inhibitor to C5.  RaCI did not 
fully inhibit complement despite a plateau in activity (figure 5-3A).  Each sigmoidal curve fitted 
by GraphPad Prism® had a R-squared greater than 0.99 (figure 5-3B).  OmCI was the most 
potent C5-cleavage inhibitor, evidenced by a lower ratio required for inhibition; however, these 
data were collated from two experiments therefore, no statistical conclusions can be made. 
Despite this, the above experiments establish that all the inhibitors are active at a ratio of 1:1, 
confirming reports on their pharmokinetics that one molecule of inhibitor binds to one molecule 
of C5 (Jore et al. 2016; Fukuzawa et al. 2017).  In future assays, therapeutic C5 inhibitors 
were used in 5-fold excess of C5, this was to ensure complete inhibition. 
 
 Generation of C5a by NSPs in the presence of four C5 cleavage inhibitors 
 
The main aim of this section was to investigate whether C5 cleavage inhibitors were able to 
prevent non-canonical generation of C5a by NSPs.  To test this, a similar protocol to the 
232 
 
                                                              C5 was exposed to A) NE, PR3 and, B) CG following 
incubation with cleavage inhibitors (“-” – no inhibitor, “O” – OmCI, “R” – RaCI, “S” – SKY59, “E” – 
Eculizumab, and “4G” – 4G2).  Fragments were resolved by SDS-PAGE on 4-20% tris-glycine gels 
(non-reducing) and visualised by western blot using a monoclonal anti C5/C5a antibody and goat 
anti-mouse HRP-conjugate secondary antibody.  Following transfer blots were cut at the 56 kDa 
marker and stained identically.  For developing, the top blot was developed in low-sensitivity ECL and 
the bottom blots in high-sensitivity ECL. Bands representing the molecular weight of reference protein 
C5 (green arrows) and C5a (red arrows) have been annotated. Bands within dashed red boxes 
indicate bands of similar molecular weight to nC5a N=1 for eculizumab, n=2 for SKY59, OmCI and 
RaCI (n=3 NE generated C5a with SKY59, OmCI and RaCI). 
 
experiments performed in chapter 4 was used for generation of C5a-like fragments. In brief, 
C5 was pre-incubated with the four, individual therapeutic C5 cleavage inhibitors for 15 
minutes at room temperature.  C5, in complex with therapeutic cleavage inhibitors, was then 
exposed to either NE, PR3 or CG for 30 minutes at 37°C, NSP activity was arrested with AAT.   
Samples from the same experiments (n=3) were used to visualise any C5-proteolysis by SDS-
PAGE and western blotting, quantify C5a concentration and assess C5a activity. 
 
5.5.1. Visualising C5a-like fragments generated by NSPs 
 
The cleavage fragments of C5 that had been pre-incubated with the therapeutic inhibitors and 
subsequently exposed to NSPs were visualised by western blot using a monoclonal antibody 
that recognises the C-terminal of C5a (as used previously in chapter 4).  A fifth antibody “4G” 
was also included but was not part of my investigation (figure 5-4).    
 
 
Figure 5-4: Visualising C5a-like fragments generated by NSPs when in the presence of 
therapeutic C5 cleavage inhibitors.
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As previously shown in chapter 4, C5 exposed to each individual NSP, generated a C5a-like 
fragment that was a similar molecular weight to nC5a. Interestingly, pre-incubating C5 with 
therapeutic C5 cleavage inhibitors did not prevent the cleavage of C5 by NSPs.  Furthermore, 
C5a-like bands were generated of similar molecular weight to nC5a and C5a-like bands 
produced by NSPs from uninhibited C5.  Unfortunately, there was evidence of “smiling” in the 
gel, making absolute determination of C5a molecular weight difficult for NE and CG generated 
C5a fragments. 
 
On closer inspection neither SKY59 or Eculizumab had any obvious impact on C5a generation 
by any of the three NSPs.  RaCI did not inhibit C5a generation by PR3 or CG but the C5a-like 
band produced by NE appeared fainter than the positive control (C5 exposed to NE without 
any cleavage inhibitor, “- “).  Furthermore, when C5 was pre-incubated with RaCI, the C5a-
like bands generated by each NSP had slightly higher molecular weight (~1 kDa) than the 
other NSP-generated C5a fragments, including positive controls for each of the respective 
proteases.  As observed for RaCI, OmCI did not inhibit C5a generation by CG or PR3, but 
only a small part of a NE-generated C5a band was visible.  It is possible that a band was 
resolved but did not transfer to the nitrocellulose membrane completely, probably due to an 
air bubble between the gel and membrane.  Therefore, it is not conclusive from this blot 
whether OmCI is able to prevent C5a-like fragment generation by NE.  Despite repeating this 
set of experiments three times, a technical issue with the western blots meant that only a 
single full set of data was available. 
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                                                             C5 was exposed to A) NE, B) CG, and C) PR33 following 
incubation with cleavage inhibitors (x-axis).  C5a was quantified by commercial C5a ELISA (y-axis). 
Dashed black lines are the mean concentration of C5a when was C5 exposed to protease without 
cleavage inhibitor. Dotted black lines are the mean concentration of C5a whe (n=2). 
 
 
5.5.2. Quantifying the generation of C5a by NSPs in the presence of therapeutic C5 
cleavage inhibitors 
 
I have shown the first preliminary evidence of C5a generation by NSPs following pre-
incubation of C5 with four therapeutic C5 cleavage inhibitors; however, western blots are not 
sufficiently quantitative to detect any subtle effects of the above C5 cleavage inhibitors on 
C5a-like generation by NSPs.  A sensitive commercial C5a ELISA was performed to quantify 
C5a from the same samples as were used for western blots (Figure 5-5). 
 
 
 
Figure 5-5: Quantifying NSP-generation of C5a-like fragments when in the presence of 
therapeutic C5 cleavage inhibitors. 
 
 
 
A C5a ELISA was performed on samples from two out of three experiments and therefore 
there were not sufficient replicates to perform statistical analyses.  Despite an absence of 
235 
 
statistical evidence, these data can still provide some quantitative information about C5a 
generated by NSPs when C5 is pre-incubated with C5 cleavage inhibitors.  Data from C5a 
ELISAs reflect preliminay data from the western blot in figure 5-4, that none of the four 
therapeutic C5 cleavage inhibitors can prevent the generation of C5a-like fragments by NSPs.  
Data from the C5a ELISA show that the levels of C5a generated by NSPs are similar between 
untreated C5 and C5 that has been pre-inubated with the therapeutic inhibitors. 
 
The C5a-like fragments generated by NSPs in the presence of C5 cleavage inhibitors were 
visualised by western blot and quantified by C5a ELISA.  It was also important to establish 
whether these C5a-like fragments are functionally active. 
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                                      C5 was exposed to 420 nM A) NE, B) CG, and C) PR3 following pre-
incubation with cleavage inhibitors (x-axis).  Fragments were diluted 1 in 20 in phenol red-free media 
and added to RBL-C5aR1 cells. C5a activity was quantified by measuring ß-hexosaminidase release 
upon stimulation by known concentrations of purified nC5a (y-axis). Dashed black lines are the mean 
signal from C5 exposed to protease without cleavage inhibitor. Dotted black lines are the mean signal 
where C5 was not exposed to protease or inhibitor. Data is presented as mean ± SEM. For each 
protease a Two-way ANOVA with Tukey’s test for multiple comparisons was used to compare C5a 
generation between samples, n =3. 
 
5.5.3.  Assessing the activity of C5a-like fragments generated by NSPs in the presence 
of therapeutic C5-cleavage inhibitors 
 
Activity of C5a-like fragments was measured by stimulating ß-hexosaminidase release from 
RBL-C5aR1, as previously described for experiments in section 4.9.2.  C5a activity 
experiments were performed in parallel with the western blots and C5a ELISA and therefore 
samples from the same experiments were used (figure 5-6). 
 
 
Figure 5-6: Activity of C5a-like fragments generated by NSPs in the presence of therapeutic C5 
cleavage inhibitors.
 
 
 
 
A statistically significant increase in C5a activity, almost double, was observed for C5a-like 
fragments generated by PR3 when C5 was pre-incubated with Eculizumab (mean; 634 ng/mL) 
compared to the untreated positive control (mean; 328.4 ng/mL, p = 0.005) (figure 5-6C).  
There was no significant difference in C5a activity between all other C5a-like fragments 
generated by NE and PR3 in the presence of inhibitors, compared to when C5a was generated 
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without cleavage inhibitors present.  The C5a ELISA in figure 5-5 detected small amounts of 
C5a in the C5 preparations, this would equate to 26.9 nM C5a and therefore 3.6 % of C5 (742 
nM) at the beginning of the experiment.  However, this concentration of C5a was not reflected 
in the activity assays (mean C5a activity in C5; 6.7 ng/mL) because the activity assay is not 
sensitive enough to detect this level of activity 
 
As reported in section 4.9.4, the RBL-C5aR1 reporter assay did not detect activity from CG-
generated C5a.  C5a activity was a fifth of what would be expected from the concentrations 
measured by C5a ELISA.  For instance, NE generated 2.8 µg/mL of C5a, but this equated to 
493 ng/mL C5a activity.  Data from westerns blots, C5a ELISAs and C5a activity assays 
together suggest that neither OmCI, RaCI, SKY59, or Eculizumab prevented C5a-like 
generation by the three NSPs used.  Unfortunately, the activity of CG-generated C5a 
fragments could not be confirmed using the RBL-C5aR1 reported cell line (figure 5-6B).  I also 
investigated the mechanisms by which C5a can be generated by NSPs from C5 when in the 
presence of therapeutic inhibitors. I hypothesised that the therapeutic cleavage inhibitors 
themselves could also be susceptible to degradation by the NSPs. If so, proteolysis may 
reduce the activity of C5 cleavage inhibitors, allowing cleavage of C5a from C5 by NSPs; this 
will be addressed in the following section. 
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                                                                                                                                       Lysis of sheep 
erythrocyte was used to measure activity of A) OmCI, B) RaCI, C) SKY59 and D) Eculizumab 
following exposure to 420 nM NE for 60 minutes at 37°C prior to incubating with C5. Mean activity 
was compared to cleavage inhibitor incubated without NE over a 4-fold dilution series where C5 was 
constant, n=2. 
 Investigating inactivation of therapeutic C5 cleavage inhibitors by NE 
 
A haemolysis assay similar to that used in section 5.4 was performed to investigate whether 
NE had any impact on the activity of the therapeutic C5 cleavage inhibitors.  All four C5 
cleavage inhibitors were exposed to either NE or PBS and then incubated with C5.  AAT was 
added to arrest NE activity (figure 5-7). 
 
 
Figure 5-7: Impact of NE on the function of therapeutic C5 cleavage inhibitors. 
 
 
Data from haemolysis assays revealed that the small tick-derived inhibitors may be 
susceptible to degradation by NE (figure 5-7A and B).  At a ratio of 1:1 (OmCI to C5, there 
was a reduction in OmCI activity compared to when untreated. Despite this, at a ratio of 4:1 
inhibition of complement activity by OmCI could be maintained despite possible degradation 
by NE.  RaCI also had reduced activity at a 1:1 ratio yet, at 4:1 activity began to plateau, 
suggesting a greater concentration of RaCI is required to prevent complement activation when 
exposed to NE.  Unfortunately, due to the concentration of the RaCI stock solution the ratio of 
RaCI to C5 could not be increased beyond 5:1.  Eculizumab and SKY59 did not show any 
obvious reduction in activity, indicating that the CDRs (antigen binding domains) were not 
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       A) OmCI B) RaCI and, C) SKY59 were exposed to 2-fold serial dilutions of 420 to 52 nM NE 
(similar to NE activity in the CF airway, see chapter 3) for 60 minutes at 37°C.  Degradation was 
observed by silver stain following resolution on either 15% (OmCI and RaCI) or 12.5% (SKY59) bis-
tris gels under non-reducing conditions.  Bands were compared to NE only, cleavage inhibitor only 
and cleavage inhibitor with NE that had been inactivated by PMSF. “HC” – heavy chain, “LC” light 
chain. Representative of two experiments.  
 
affected by NE exposure at the concentrations used.  The experiments below were not 
repeated enough times to allow statistical interpretation. 
 
 Susceptibility of therapeutic C5 cleavage inhibitors to proteolysis by NE 
 
From the above experiments I have shown some preliminary data that could suggest that the 
activity of OmCI and RaCI may be affected during exposure to NE.  To explore inactivation of 
the therapeutic inhibitors by NE further I assessed their potential proteolysis by SDS-PAGE 
and silver staining.  To visualise degradation, OmCI and RaCI were exposed to a dilution 
series of NE and proteins were resolved by SDS-PAGE and stained with silver nitrate, a 
sensitive protein stain (figure 5-8).  SKY59 was also included; this was to investigate whether 
degradation of monoclonal antibody-based therapeutics was occurring despite no apparent 
impact on inhibitory activity, as shown by haemolysis assays. 
 
 
Figure 5-8: Visualising degradation of therapeutic C5 cleavage inhibitors following exposure to 
NE.  
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When separated by SDS-PAGE, RaCI resolved to approximately 14 kDa compared to the 
reported molecular weight of ~8 kDa (Jore et al. 2016).  OmCI resolved into paired bands at 
approximately 15 and 19 kDa, compared to a reported molecular weight of ~17kDa (Hepburn 
et al. 2007).  The molecular weight of NE was approximately 25 kDa, similar to the molecular 
weight specified by the manufacturer (29.5 kDa) (https://www.athensresearch.com).  Another 
band at ~15 kDa was visualised when NE was resolved by SDS-PAGE (figure 5-8 A and B) 
and could represent sample spill over from OmCI and RaCI lanes respectively. 
 
Silver staining the polyacrylamide gels provided some preliminary evidence that all the 
cleavage inhibitors in this experiment could be susceptible to degradation.  This was 
particularly evident at the maximum NE Concentration (420nM).  When OmCI was exposed 
to NE, the upper bands of the pair contained less protein, indicated by the fading bands (figure 
5-8A).  Moreover, inhibiting protease activity with PMSF prevented the loss of the upper OmCI 
band.  The reduction in OmCI band intensity was titratable with NE concentration suggesting 
that protein loss was due to proteolysis. 
 
RaCI was also susceptible to proteolysis; when RaCI was exposed to 420 nM NE there were 
lower molecular weight bands that had molecular weights of approximately 13 and 11 kDa 
(figure 5-8B).  The generation of a lower molecular weight band was titratable with NE 
concentration and inhibition of protease activity with PMSF prevented RaCI degradation.  
Proteolysis of OmCI and RaCI observed in silver stained polyacrylamide gels supports the 
reduction in inhibitory activity that was shown in haemolysis assays. 
 
Despite resolving SKY59 under non-reducing conditions, suspected IgG light (~25 kDa) and 
heavy chains (~50 kDa) were detected.  None-the-less the majority of the protein was intact 
at the expected molecular weight of ~150 kDa (measured on a gel separate to the one shown. 
Both are representative of the same data).  Interestingly, an unknown band at ~45 kDa was 
observed when SKY59 was exposed to NE.  Furthermore, generation of this unknown band 
was dependent on the concentration of NE and was not present when either NE or SKY59 
were incubated in PBS.  Incubating NE with PMSF in this experiment did not fully inhibit the 
activity of this protease. PMSF is unstable in solution and therefore, it could be that in this 
experiment that the PMSF was less effective than when used previously. 
 
In summary, in preliminary experiments I investigated the effect of NE of the activity of 
therapeutic C5 cleavage inhibitors.  In these initial experiments I some evidence that the tick 
C5 cleavage inhibitors, OmCI and RaCI, could be less active when exposed to NE. I alsoused 
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SDS-PAGE to investigatethe susceptibility of the therapeutic cleavage inhibitors to proteolysis 
by NE. 
 
 Discussion 
 
Eculizumab is one of a handful of FDA and EMA approved anti-complement therapeutics.  It 
has been successful in treating patients with PNH and aHUS over the past 10 years and is 
currently undergoing trials in other diseases (Morgan and Harris 2015).  In light of non-
canonical mechanisms of activating complement, I hypothesised that NSPs could generate 
functional C5a-like proteins in the presence of eculizumab, a monoclonal antibody-based C5-
cleavage inhibitor.  I investigated NSP-mediated generation of C5a following C5 incubation 
with Eculizumab or three other C5 cleavage inhibitors currently undergoing clinical and pre-
clinal trials. 
 
In this chapter it was shown in preliminary experiments that eculizumab and three other 
therapeutic C5 cleavage inhibitors were unable to fully inhibit C5a generation by three NSPs; 
NE, CG and PR3.  C5a-like protein generation was visualised by western blot, quantified by 
ELISA and the activity of C5a-like fragments was verified using an RBL-C5aR1 reporter assay. 
 
C5a-like fragment molecular weights were observed by western blot and their activity was 
confirmed in a ß-hexosaminidase assay.  In the absence of sequence data, I could only 
assume that the protein sequences of these fragments are the same as those generated 
without a cleavage inhibitor present.  Nevertheless, mass spectrometry or C-terminal protein 
sequencing could be performed for better characterisation and comparison of C5a-like 
fragments generated in the presence of these C5 cleavage inhibitors.  This kind of approach 
has been used to characterise C5a fragments generated by thrombin and protease released 
by A. fumigatus (Riedemann et al. 2017; Shende et al. 2018).   When C5 was pre-incubated 
with RaCI I observed that the C5a generated by each NSP was slightly larger than those C5a 
fragments generated in the presence of the other C5 cleavage inhibitors.  It is possible that 
the conformational change induced by RaCI as part of its inhibitory function alters the extent 
to which C5 exposes C5a for cleavage (Jore et al. 2016).  None the less, based on the C5a 
activity assays the increased molecular weight of C5a when generated in the presence of 
RaCI did not lead to a change in activity for NE and PR3 generated fragments. 
 
As discussed in chapter 4, there is a growing list (table 4-1) of proteases that are able to 
generate functional C5a-like fragments from degradation of C5.  Despite knowledge of non-
canonical complement activation and anaphylatoxin generation there are very few reports that 
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have investigated these alternative activation mechanisms with respect to eculizumab and 
other therapeutic C5 cleavage inhibitors. 
 
Riedemann et al. hypothesised that eculizumab interfered with commercial C5a ELISAs 
preventing detection of C5a during clinical trials and that the generation of C5a by non-
complement proteases was being masked by these issues (Riedemann et al. 2017).  The 
authors demonstrated that trypsin and thrombin were able to generate C5a-like fragments in 
the presence of eculizumab.  Furthermore, they used mass spectrometry to show that the 
fragments generated had a similar amino acid sequence to C5-convertase generated C5a 
(Riedemann et al. 2017).  They, as I have in my study, raised concern over the cross-reactivity 
of commercial C5a ELISAs with C5. Despite raising this concern, their own in-house kit was 
assessed for cross-reactivity with C3, C3a, C4 and C5b-9 but cross-reactivity with C5 was not 
reported.  Therefore, the reported C5a ELISA format may not be any more advantageous to 
what is already available on the market.  In evidence of possible cross-reactivity with C5, their 
ELISA detects 45 ng/ml (3.85 nM) C5a in purified 50 nM C5, this is equal to 7.7% cross-
reactivity (Riedemann et al. 2017).  Therefore, although Riedemann et al have shown 
generation of C5a by trypsin and thrombin in the presence of eculizumab, it is still not clear 
how important this particular mechanism is in vivo. 
 
Riedemann et al. also hypothesise that an anti-C5a antibody would be required to provide 
protection from non-complement protease-generated C5a (Riedemann et al. 2017).  Co-
incubating C5 with eculizumab and their proprietary therapeutic antibody, IFX-1, reduced C5a 
detection but not generation. None-the-less, IFX-1 inhibited C5a-mediated CD11b 
upregulation on granulocytes.  In summary of their study, C5 and C5a inhibitors may be 
required to regulate C5a activation by non-complement proteases.  An advantage of my study 
over that of Riedemann et al. is that I have compared several pre-clinical and clinical 
therapeutic C5 cleavage inhibitors.  As I have shown in figure 5-1, there are many competitive 
C5 cleavage inhibitors undergoing clinical trials that offer advantages such as lower dosage 
and better patient coverage (regarding the R885H mutation).  Therefore, although eculizumab 
is currently the only C5 cleavage inhibitor currently being used in the clinic, it is probable that 
it will be replaced (Morgan and Harris 2015).  Furthermore, it is important that new C5 cleavage 
inhibitors, undergoing clinical trials, are also assessed for their ability to block generation of 
C5a by NSPs and other non-complement proteases. 
 
Thrombin-mediated generation of C5a in the presence of OmCI has been investigated by 
Roversi et al. (Roversi et al. 2013).  Interestingly, OmCI has independent binding sites for C5 
and LTB4, a potent neutrophil chemoattractant discussed in section 1.4.4e (Roversi et al. 
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2013).  The dual-inhibitory effects of OmCI were assessed using a murine model of acute lung 
injury (Roversi et al. 2013).  The authors reported that OmCI did not prevent C5a-generation 
by thrombin in vitro, despite increasing OmCI to 100-fold excess of C5.  They showed that as 
a therapeutic, OmCI was effective against reducing lung inflammation following ovalbumin 
insult, significantly decreasing neutrophil infiltration into the airway.  Moreover, OmCI also 
significantly reduced C5a generation in BAL fluid sampled from the treated mice (Roversi et 
al. 2013).  Despite these positive results, OmCI did not completely abolish neutrophil-mediated 
injury or C5a expression implying that other chemoattractants are important.  I think that in 
light of my own work, the ineffectiveness of OmCI in reducing neutrophil mediated injury in 
their study may reflect an inability of OmCI to inhibit C5a generation by NSPs. The model used 
in the above study was for acute inflammation and therefore OmCI may be less applicable to 
chronic inflammatory airway disorders such as asthma, COPD and CF.  None-the-less, this 
model still provides useful information on the mechanisms that lead to chronic inflammation in 
the airway. 
 
An advantage to the current study was that C5a was accurately quantified by ELISA that has 
no reported cross-reactivity with C5 (https://www.quidel.com).  Despite this, I measured 3.6% 
cross-reactivity between C5 and C5a in this ELISA.  Another explanation is that the purified 
C5 is contaminated C5a; however, there was no evidence of this is western blotsIn reflection 
of western blots observing nC5a in chapter 4, I do not think that western blots would be 
sensitive enough to detect these low levels of C5a.  
 
Another advantage to this study was that I investigated proteolysis of each inhibitor by NE in 
order to try and explain why the therapeutic cleavage inhibitors are ineffective at preventing 
NSP-mediated C5a generation.  Haemolysis assays and SDS-PAGE showed that RaCI and 
OmCI were susceptible to degradation by NE.  Despite no loss of inhibitory activity, exposure 
of SKY59 to NE produced an unidentified fragment.   NE degradation of IgG has been 
previously been reported (Prince et al. 1979).  Prince et al. have shown that NE degrades IgG 
producing a 50 kDa fragment that binds protein A, a virulence factor expressed on the surface 
of Staphylococcus aureus that binds to the Fc region of IgG (Prince et al. 1979).  Therefore, it 
is also possible that the 45 kDa molecular band I observed in my own blots could also be a 
cleaved fragment of the SKY59 IgG Fc region.  Prince et al. also show that the degraded IgG 
in their experiments still bound to antigen and was able to bind FcγR on the surface of 
neutrophils (Prince et al. 1979). 
 
The degradation of IgGs by NSPs have been studied in the context of the CF airway and it 
has been hypothesised that NE burden in the inflamed airway could limit success of vaccines 
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A) NE generates C5a’ (and other products) in a two-step manner 1) degradation of the C5 cleavage 
inhibitor and 2) proteolysis of C5. B) NE generates C5a’ by bypassing the C5-cleavage inhibitor. 
 
against bacterial strains (Margaroli and Tirouvanziam 2016).  The same principle could also 
apply to IgG-derived complement therapeutics such as eculizumab and SKY59 if they are to 
be used in neutrophil driven diseases such as sepsis.  To overcome the potential for 
degradation, all inhibitors in my experiments were used in 5-fold excess of C5, ensuring 
complete inhibition of canonical complement activation even when exposed to NE.  From this, 
I concluded that C5a generation in the presence of the cleavage inhibitors was a result of 
protease bypassing the inhibitor and not sequential degradation of the inhibitor followed by C5 
(figure 5-9). 
 
 
Figure 5-9: Diagram of the mechanisms by which NE could bypass C5 cleavage inhibitors. 
 
 
C5a generation by NSP was investigated in this chapter; however, I did not explore the 
generation of functional C5b. Therefore, it is still not fully understood whether terminal pathway 
activation can be initiated by NSPs, or during inhibition by the therapeutic used in this study. 
 
In chapter 4 it was shown that proteases expressed in CF BAL fluid can generate C5a-like 
fragments that may promote disease progression.  Therapeutic inhibition of complement in 
the CF airway has not been explored, this is likely to be due a lack of understanding of how 
much complement contributes to disease progression.  Despite this, C5a and C3a generation 
have also been associated with disease progression in airway hyperresponsiveness in asthma 
(Khan et al. 2014).  As well as NSPs, dust mite proteases have been reported to generate 
C5a-like fragments in asthma (Maruo et al. 1997).  Complement inhibitors have been 
investigated as a method to reduce airway hyperresponsiveness in asthma:  A chimeric IgG 
with complement receptor related gene y (CRRY), a molecule analogous to human soluble-
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CR1 (a receptor for C3b and complement inhibitor), was used to reduce complement activation 
and consequent airway inflammation in mice exposed to ovalbumin (Taube et al. 2003).  
However, as discussed above with regards to OmCI, if C5 cleavage inhibitors were to be 
considered as a viable option to prevent C5a generation then the ability of non-complement 
proteases to bypass current C5 cleavage inhibitors needs to be investigated further.  In this 
case, inhibitors specific to C5a (IFX-1) or C5aR1 (PMX53) may be more appropriate for the 
control of C5a-mediated inflammation and smooth muscle contraction (Subramanian et al. 
2011; Sun et al. 2015). 
 
As well as in the CF airway, neutrophilic inflammation is also a pathogenic factor in sepsis.  
Patients receiving eculizumab already receive a course of antibiotics and meningitis vaccines 
to counteract reduced protection via the complement system (Wong et al. 2013).  A 
hypothetical scenario could occur whereby a patient, administered with eculizumab, upon 
contracting systemic infection could be at risk of developing sepsis mediated by C5a activation 
of neutrophils. C5a generation and neutrophil dysfunction are associated with disease severity 
in sepsis, however the contribution of NSP-generated C5a has not been investigated (Conway 
Morris et al. 2009; Xu et al. 2016). 
 
OmCI, co-administered with an anti-CD14 antibody, has been used to reduce inflammation in 
a porcine model of sepsis (Skjeflo et al. 2015).  The authors observed a significant reduction 
in complement terminal pathway components and inflammatory cytokines but C5a 
concentration was not measured. RA101295, a small peptide (2 kDa) C5 cleavage inhibitor 
has also been investigated in a non-human primate model of E. coli induced sepsis (Keshari 
et al. 2017).  It was observed that C5a levels in baboon blood were significantly reduced at 2 
and 4 hours timepoints when animals were given subcutaneous injections of the inhibitor 
(Keshari et al. 2017).  Despite this, the authors found that C5a levels continued to increase up 
to 72 hours after administration; however, no untreated animals survived past 36 hours for 
comparison of C5a concentration in serum.  As with the other inhibitors tested in my study it 
is unclear whether RA101295 is effective at preventing C5a generation by NSPs. 
 
The present study was limited to in vitro studies and therefore it would be interesting to study 
these mechanisms in vivo.  Further ex vivo and in vivo studies could be carried out to 
investigate this mechanism further.  For instance, I could have tested the ability of proteases 
in CF BAL fluid to generate C5a in the presence of these therapeutic inhibitors  As discussed 
in chapter 3, antibodies specific to NSP, thrombin and other non-complement-generated C5a 
would enhance quantification of alternative forms of C5a that are generated during disease 
manifestation. 
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 Conclusion to the chapter 
 
In addition to reports investigating thrombin and trypsin, it has been demonstrated in this study 
that NE, CG and PR3 can generate C5a-like fragments despite pre-incubation of C5 with 
eculizumab.  Furthermore, three additional C5 cleavage inhibitors were also ineffective against 
NSP-mediated C5a generation.  Expression of NSPs is upregulated during chronic 
neutrophilic inflammation and therefore, non-canonical C5a activation should be considered 
when new therapeutic inhibitors are being explored for use in inflammatory diseases.  Further 
investigation is required to determine the contribution of non-complement proteases towards 
C5a generation.
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6. Characterising interactions between C5a and glycosaminoglycans 
 
 Background to the chapter 
 
The characterisation of interactions between GAGs and pro-inflammatory molecules has 
significantly changed understanding of neutrophilic inflammation in the CF airway (Reeves et 
al. 2011a).  In testament to this enhanced understanding, therapeutics targeting GAGs (in 
particular CXCL8-GAG interactions) are being developed for use in CF clinics (Furnari et al. 
2012; McElvaney et al. 2015; Brivio et al. 2016).  The following section will give a brief overview 
of the literature that supports our current understanding how GAGs can promote CF 
pathogenesis and is the basis for the investigations in this chapter. 
 
6.1.1. Structure of GAGs and their diversity 
 
GAGs are ubiquitous. They are negatively charged, long chains of repeating disaccharides 
and important structural components of the ECM (Reeves et al. 2011a; Lindahl et al. 2015).  
There are five well-characterised GAGs; (HA, dermatan sulphate, CS, HS and heparin (figure 
6-1).  There are two categories of GAGs, these are sulphated and non-sulphated; HA is non-
sulphated whereas, heparin and other “sulphate” GAGs are sulphated (Lindahl et al. 2015).  A 
further distinction is that sulphated GAGs are synthesised in the Golgi apparatus whereas HA 
is produced at the inner surface of the cell membrane (Lindahl et al. 2015).  Synthesis of 
sulphated GAGs is catalysed by polymerisation enzymes.  For example, the carbohydrate 
transferases glucuronosyltransferase and N-acetylgalactosaminyltransferase are essential for 
the production of CS (Lindahl et al. 2015).  O-sulphation groups are added to sulphated GAGs 
by sulfotransferases which depend on the carbohydrate substrate, N-acetyl-D-glucosamine 
has a 4-O-sulphation whereas iduronic acid has a 2-Osulphation (see figure 6-1) (Lindahl et 
al. 2015). 
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                                                                            , extracted from Souza-
Fernandes et al. (Souza-Fernandes et al. 2006).   Hyaluronic acid does not interact with a protein 
core, it is composed of alternating repeats of D-glucuronic acid (GlcA) and N-Acetylglucosamine 
(GlcNAc).  Sulphated GAGs interact with protein cores through bonds between serine on the core and 
GlcA – galactose (Gal) - xylose (Xyl) on the sulphated GAG.  CS is a disaccharide repeat of N-acetyl-
D-glucosamine (GalNAc) and GlcA. Dermatan is a disaccharide repeat of GalNAc and iduronic acid 
(IdoA). HS is a disaccharide repeat of IdoA and GlcNAc.  Sulphated GAGs are differentially sulphated 
depending on carbohydrate annotated with “S” and number of carbon atom within the corresponding 
sugar.  
 
Figure 6-1: Diagram of the carbohydrate composition of GAGs. 
 
 
 
 
 
Following synthesis from the Golgi apparatus GAGs form proteoglycans, assembling around 
a protein cores that can be membrane bound, for example syndecan, or protein cores can be 
secreted, such as perlecan, an integral part of ECM assembly (figure 6-2) (Lindahl et al. 2015).  
Furthermore, not all GAGs interact with the same protein cores and moreover, HA does not 
require a protein core, and is synthesised at the cell membrane not the Golgi (Pichert et al. 
2012b).  There are three membrane-associated enzymes that generate HA. These are called 
HA synthases-1, -2 and -3, and have different functions;  HA synthase-1 and -2 generate high-
molecular weight HA and HA synthase-3 produces low-molecular weight HA (Itano et al. 
1999). 
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                                                                                           , extracted from Lindahl et al. (Lindahl et al. 
2015).   Proteoglycan cores can be membrane bound via GPI anchors (glypican) or transmembrane 
domains (syndecan).  Proteoglycans can also be secreted; secreted proteoglycan cores are important 
for extracellular matrix structure. Proteoglycans can be bound by different sulphated GAG species; 
CS and dermatan sulphate (yellow) or, HS (blue). 
 
Figure 6-2: Proteoglycan cores and associated GAGs.
 
 
The physio-chemical properties of GAGs are derived from heterogenous polysaccharides that 
have varied length as well as dynamic states of sulphation and acetylation, governed by N-
sulphotransferase and N-deacetylase, present in the Golgi (Humphries et al. 1997).  As an 
example of GAG diversity, it has been estimated that HS has 48 different disaccharide forms 
of structurally modified iduronic acid (Parish 2006). 
 
6.1.2. Functional roles of GAGs in inflammation 
 
The diverse chemical properties of GAGs mean that they have a wide-range of roles in cellular 
functions such as communication, differentiation, adhesion, antigen presentation and cell 
migration (Whitelock and Iozzo 2005; Reeves et al. 2011a).  For example, the addition of 
sulphate groups to carbon-3 of N-acetylglucuronic acid within HS produces a non-coagulant 
surface on endothelial cells facilitating free movement of cells within the vasculature 
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                                                                                     , extracted from Matuska et al. (Matuska et al. 
2016).  The heavy chain (blue box) of inter-α-inhibitor binds to HA, this facilitates TSG-6 mediated 
cross-linking.  HA matrices promote leukocyte migration and clumping, leukocytes releases enzymes 
that break down HA into smaller fragments that act as DAMPs and signal via TLR4. 
(Whitelock and Iozzo 2005).  In addition, surface-GAG expression and sulphation can be 
dynamically regulated during inflammation, this can promote leukocyte adhesion by binding 
chemoattractants (Parish 2006).  Wang et al. have shown in vivo that HS proteoglycan 
interacts with L-selectin, promoting L-selectin-mediated leukocyte adhesion to endothelial 
cells via PSGL-1 (Wang et al. 2005).  In these experiments, the authors used knockout mice 
that conditionally expressed endothelial N-sulphotransferase and showed that sulphation of 
HS was required for migration of leukocytes towards gradients of chemokines. 
 
Furthermore, although HA is not sulphated, it has been shown that HA length can alter its 
immunomodulatory function and has been shown to promote inflammation in airway disease 
(Matuska et al. 2016).  Short chain HA (150-300 kDa) has been reported to be proinflammatory 
whereas long chain HA (1000 kDa) has been demonstrated to be anti-inflammatory (Matuska 
et al. 2016).  HA is modified by the transfer of heavy chains from inter-α-inhibitor, a serine 
protease inhibitor, to carbon-6 hydroxyl groups of N-acetyl-glucosamine, that make up the 
structure of hyaluronic acid (Dyer et al. 2016a).  The above reaction is catalysed by an enzyme 
called TNF-stimulated gene 6.  This complex modification induces crosslinking of HA that 
promotes leukocyte adherence and release of enzymes that in turn degrade HA into the short, 
pro-inflammatory fragments that are recognised in a DAMP-like manner by TLR-4 (figure 6-3) 
(Matuska et al. 2016) .  
 
 
Figure 6-3: Processing of HA during inflammation.  
 
 
 
 
6.1.3. The role of GAGs in the CF airway 
 
GAGs are an important constituent of the ECM interstitium and sub-epithelial tissue that 
provide structural support, maintain hydration and facilitate migration of leukocytes during an 
inflammatory response (Souza-Fernandes et al. 2006).  The role of GAGs in the CF airway 
has an added layer of complexity compared to their normal function; degradation and 
remodelling of the ECM in CF airway by neutrophil and pathogen-derived proteases releases 
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soluble GAGs into the airway surface liquid (Reeves et al. 2011a).  In particular, three soluble 
GAGs have been reported to be elevated in the CF airway compared to healthy controls; HS, 
CS and the non-sulphated GAG, HA (Reeves et al. 2011a).  The properties and reported roles 
of these GAGs have been described in the overleaf (table 6-1). 
 
Summarising table 6-1, a diverse range of techniques has been employed to detect and 
quantify soluble GAGs in the CF airway; these include restricted digestion of GAGs using 
GAGases, immunohistochemistry and electrophoresis.  Therefore, it is difficult to compare the 
expression of soluble GAGs between different CF patient cohorts.  Furthermore, groups have 
made different observations about which GAGs are elevated, with each study suggesting one 
GAG is more important for disease progression than the other.  None the less, the studies 
summarised in table-6-1 have shown elevated soluble GAG concentrations in BAL fluid 
compared to non-CF controls, such as non-CF bronchiectasis.  The immunomodulatory role 
of GAGs is not necessarily dependent on higher expression but, the level of sulphation (HS 
and CS), length (HA) and solubilisation following degradation of the ECM.   Simply measuring 
GAGs does not inform us about their structural diversity. For instance, diversity of HA chain 
length and association with heavy chains donated by inter-α-inhibitor has been investigated in 
the CF airway (Matuska et al. 2016). 
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Table 6-1: Comparison of structure and function of GAGs expressed in the CF airway.
 Heparan Sulphate Chondroitin Sulphate Hyaluronic Acid 
Saccharide 
Components 
β-D-glucuronic acid 
N-acetyl-α- D-glucosamine 
D-galactosamine 
D-glucuronic acid 
D-Glucuronic acid 
N-acetylglucosamine 
Functions HS is a constituent part of the ECM 
scaffold by binding laminin supports 
 
HS interacts with Collagen V in the 
ECM adhering the ECM to the 
basement membrane. 
 
Cytokine interaction (CXCL8, IL-5, 
IL-6, IL-10, IL-18, TNFα and, platelet 
factor 4).  CXCL8 Interaction with 
GAGs protects CXCL8 from 
degradation by neutrophil serine 
proteases 
CS interacts with several cell-signaling molecules 
that have roles in growth and differentiation 
cytokines, chemokine and enzymes.  Binding to 
these molecules can be augmented by the degree of 
sulphation. 
Long HA form (1000 kDa) is anti-inflammatory 
and possess bacteriostatic properties 
 
HA interact with inter-α-inhibitor heavy chains, 
a reaction catalysed by TNF-stimulated gene 
6. Promotes leukocytes recruitment (see 
figure 6-3).  
 
Short HA form (150-300 kDa) cleaved from 
long by hyaluronidases. Short HA has pro-
inflammatory roles through interaction with; 
CD44 – leukocyte rolling/activation; 
RHAMM (receptor for HA-mediated motility) – 
leukocyte rolling/activation/inflammation 
 Signaling via TLR2 and TLR4 (DAMP-like) 
Expression  
in CF 
Elevated expression of intact HS 
and epithelial and endothelial 
basement membranes in CF and 
COPD compared to non-CF controls 
 
Soluble HS fragments also elevated 
in the CF airway due to degradation 
of the ECM 
Digestion by GAGases and agarose electrophoresis 
identified CS in CF and chronic bronchitis patients 
 
Expression of CS proteoglycan cores in CF and non-
CF bronchiectasis has been shown by western blot  
Crude chemical separation of saccharides in 
CF BAL fluid demonstrate that HA acid was 
the only detectable GAG.  
 
Fluorophore assisted carbohydrate 
electrophoresis demonstrated elevated heavy 
chain-hyaluronic acid complexes in CF 
sputum.   
Roles in CF Binding of CXCL8 to HS prevents 
proteolysis increasing half-life of HS 
in the airway and promoting 
neutrophilic inflammation 
 
HS can be used as an adherence 
molecule for P. aeruginosa 
(opportunistic pathogen in the CF 
airway. 
CFTR mutation alters intracellular organelle pH, 
altering activity of glycosyltransferase and may be 
responsible for increased CS polymerisation.  
 
CS increases turbidity of mucus and can induce plug 
forming. 
CFTR facilitatesHA transport across epithelial 
cell membranes, reduced function due to lack 
of CTFR could lead to accumulation in 
epithelial cells. 
References (Solic et al. 2005; Reeves et al. 
2011a) 
(Rahmoune et al. 1991; Bhaskar et al. 1998; Khatri 
et al. 2003) 
(Sahu 1980; Garantziotis et al. 2016; Matuska 
et al. 2016) 
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                                                                                           A) Chemokines establish chemotactic 
gradients using proteoglycans and hyaluronic acid (not shown).  B) Excessive neutrophilic 
degranulation releases NSPs and MMPs that breakdown ECM and structural GAGs disrupting 
chemotactic gradients, hampering pathogen clearance. 
 
6.1.4. Interaction between CXCL8 and GAGs in the CF airway 
 
Chemokine-GAG interaction is one of the most well-documented mechanisms of immune-
modulation by GAGs and, has been suggested to be a contributing factor to pathogenesis in 
the CF airway (Reeves et al. 2011a).  It has been proposed that chemokine-GAG interaction 
has multiple roles during inflammation such as ligand-receptor presentation and establishing 
chemotactic gradients within tissue (figure 6-4) (Tanino et al. 2010; Pichert et al. 2012b; Dyer 
et al. 2016b). 
 
CXCL8-GAG interaction has been studied intensely and precise binding sites for heparin, HS, 
CS, dermatan sulphate and, HA have been mapped on NMR structures (Spillmann et al. 1998; 
Krieger et al. 2004; Pichert et al. 2012a).  Interestingly, there is a core region of CXCL8 (amino 
acids 57-77) that binds strongly to all the above GAGs.  In particular, lysine-59, valine-66, 
valine-67, lysine-69, alanine-74, and glutamine-75.  The latter, glutamine, was observed to 
have the largest chemical shifts when analysed using NMR indicating strong interaction 
(Pichert et al. 2012a). 
 
 
 
 
Figure 6-4:Chemotactic role of GAGs in the airway.  
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As well as understanding the chemistry behind chemokine-GAG binding, the influence of GAG 
interaction on chemokine function has also been investigated (Kuschert et al. 1999; Culley et 
al. 2003).  Several groups have used Boyden chamber cell migration assays to investigate the 
functional consequences of CXCL8-GAG complexes, with some conflicting data. Webb et al. 
demonstrate that HS but neither heparin nor CS increased CXCL8 potency as a neutrophil 
chemoattractant (Webb et al. 1993).  Whereas, Ramdin et al. report reduced neutrophil 
migration when heparin, HS or, dextran sulphate were incubated with CXCL8, compared to 
CXCL8 without GAGs (Ramdin et al. 1998). In addition, Schlorke et al. observed reduced 
chemotaxis to CXCL8 with heparin but not CS or HS (Schlorke et al. 2012).  In the same study 
it was shown that CS and heparin induced increased oxidative burst in neutrophils when co-
incubated with CXCL8.  To add further complexity, CXCL8 forms dimers that have altered 
affinity for GAGs; the significance of oligomerisation and GAG interaction on CXCL8 function 
is not fully understood (Gangavarapu et al. 2012; Joseph et al. 2015). 
 
With greater relevance to CF, CXCL8 is susceptible to proteolysis by NE, but when in complex 
with GAGs it has been demonstrated that CXCL8 becomes resistant to degradation by NE 
(Leavell et al. 1997; Reeves et al. 2011b).  Reeves et al. use western blots to show that CXCL8 
in the CF airway is present in both native and GAG-complexed forms.  Furthermore, by 
exposing CF BAL fluid to GAG lyases the authors observe that CXCL8 can be liberated from 
GAG complexes and is consequently degraded if also exposed to NE.  The authors also show 
that degradation of CXCL8 also occurs when NaCl concentration in BAL fluid is increased.  
The mechanism behind this phenomenon is that at NaCl concentrations between 300 and 450 
nM, the ionic bonds binding CXCL8 and GAGs are disrupted, freeing and exposing CXCL8 to 
degradation by NE.  Nebulised hypertonic saline is routinely administered to CF patients to 
facilitate mucus clearance.  Reeves et al. also show that increasing NaCl concentration in CF 
BAL fluid reduces the chemotaxis of neutrophils, with the assumption that CXCL8 is freely 
degraded (Reeves et al. 2011a).  However, the authors did not speculate on any other GAG-
binding chemokines or chemotactic factors, such as C5a. 
 
6.1.5. Interactions between C5a and GAGs 
 
C5a has similar properties to CXCL8 such as low molecular weight, structure, and charge 
(isoelectric point).  C5a and CXCL8 are chemotactic for neutrophils, stimulate degranulation, 
and induce oxidative burst through interaction with their respective G-protein coupled 
receptors.  It has been observed that heparin-based sorbent and surfaces pre-coated with 
heparin reduce C5a concentration in the circulation (Mollnes et al. 1991; Sinitsyn et al. 1992).  
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These observations were made when investigating methods to reduce spontaneous 
complement activation during cardiac bypass surgery (Mollnes et al. 1991; Sinitsyn et al. 
1992).  The effect of heparin on rhC5a (recombinant) function has also been investigated; 
Culley et al. assessed the inhibitory effect of heparin on several CCL chemokines and rhC5a 
(Culley et al. 2003). They observed that when incubated with heparin, CCL11 and CCL13 but 
not rhC5a inhibited shape change, chemotaxis and oxidative burst using HL60 cells, an 
immortal cell line with neutrophil-like properties.  Despite demonstrating that heparin had no 
effect on rhC5a activity in these assays, the authors observed that rhC5a was retarded on a 
sepharose-heparin column suggesting that rhC5a does interact with heparin. 
 
In light of the above studies, C5a interaction with other GAGs, such as those expressed in the 
CF airway, has not been comprehensively characterised.   As shown in chapter 4, C5a can 
be readily generated in the CF airway by complement activation and other non-complement 
proteases such as NSPs.  
 
 
 Hypothesis  
 
I hypothesised that C5a binds ionically to soluble GAGs and that these interactions influence 
C5a activity, a mechanism that could be important for the normal roles of C5a in inflammation.  
I also hypothesise that in the CF airway, modification of C5a activity by GAGs promotes 
chronic neutrophilic inflammation. 
 
 Aims for this chapter 
 
1. Investigate the expression of GAGs in the BAL fluid from CF patients. 
 
2. Develop methods to characterise C5a-GAG binding using purified HS, CS and HA. 
 
3. Investigate the functional significance of nC5a-HS interaction on C5a activity using the 
RBL-C5aR1 reporter cell line.
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            Absorbance was measured at 570 nm. Comparison of GAGs; HS (red), CS (green), and HA 
(blue) in a 2-fold dilution series from 200 to 0.78 µg/mL.  BSA (orange) and dextran (purple) were 
used as negative controls and diluted in the same series. PBS, without GAG, is represented by the 
dotted black line, Mean of two experiments plotted.  
 
 Sulphated GAG expression in the CF airway 
 
Before investigating C5a-GAG interaction, GAG expression in the CF airway was measured 
in CF BAL fluid.  This was to confirm that there was expression of soluble GAGs in the CF 
airway and to assess whether there was any association with the concentration of C5a in those 
samples. 
 
6.4.1. Quantifying soluble GAGs in CF BAL fluid 
 
GAG expression was detected using dimethyl-methylene blue, a stain that has been described 
to bind sulphated GAGs (Stone et al. 1994).  Dimethyl-methylene blue has been used to 
measure GAG release following cartilage breakdown in response to injury (Jeffrey and Aspden 
2007).   Visually, when in suspension with GAGs, the colour of dimethyl-methylene blue shift 
from deep blue (no GAGs) to violet (GAGs present), this change in colour can be detected 
using a spectrophotometer by measuring absorbance at 570nm.  To quantify sulphated GAG 
concentration in CF BAL fluid, a reference curve was required.  A comparison of purified HS 
and CS over a 2-fold dilution demonstrated similar absorbance curves when incubated with 
dimethyl-methylene blue (figure 6-5). 
 
When GAGs were not present the optical absorbance is approximately 0.62 absorbance units, 
whereas when CS was added the optical density was reduced to a minimum of approximately 
0.2 absorbance units (figure 6-5). 
 
Figure 6-5: Dimethyl-methylene blue stain assay for quantifying sulphated GAGs in CF BAL 
fluid. 
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                                                                                                  CF BAL fluid was diluted 1 in 2 in PBS 
and incubated with dimethyl-methylene blue. Absorbance at 570 nm was read immediately using a 
spectrophotometer.  GAG concentration (y-axis) was quantified by interpolating absorbance values 
from a standard curve of purified HS (200 to 0.78µg/mL). Black bar represents cohort median for 
n=39. 
.       
 
Despite reports that dimethyl-methylene blue binds sulphated GAGs, a naturally non-
sulphated GAG, HA, was also positive for the stain (Stone et al. 1994).  To further assess the 
specificity of the dimethyl-methylene blue stain, BSA and dextran were included as generic 
examples of protein and carbohydrate respectively.  Neither BSA nor dextran stained 
positively when diluted to the same concentrations (mass/volume) as HS and CS.  Given the 
purpose of the stain was to enable quantification of GAGs in the CF airway, this assay was 
still suitable to give an indication of GAG concentration in CF BALF fluid. 
 
A standard curve of HS in 2-fold dilution series from 200 to 0.78 µg/mL was used for 
quantification of GAGs in CF BAL fluid (figure 6-6).  A preliminary experiment was performed 
to ascertain what dilution factor of CF BAL fluid samples was required for accurate 
quantification. Using CXCL8 as marker of inflammation, five CF BAL fluid samples were 
chosen that represented a range of inflammatory states.  GAG expression was detected in 
four out of five samples when BAL fluid was diluted 2-fold in PBS (not shown) therefore, a 1 
in 2 dilution factor was used for the remaining cohort samples.  GAG expression in CF BAL 
fluid samples from 39 patients was measured, in one patient quantification was below the 
detection limit (0.78 µg/mL).  The median expression was 37.2 µg/mL with a range of 0.39 to 
389 µg/mL relative to a HS curve. To my knowledge, this is the first time that soluble GAGs 
concentration in CF BAL fluid has been quantified using dimethyl-methylene blue stain. 
 
 
Figure 6-6: Soluble GAG concentration in CF BAL fluid.
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                                                        Correlations between GAGs (y-axis) and A) PMN count, B) NE 
Activity, C) CXCL8, and D) C5a (x-axis).  A “line of best fit” was plotted (black line) using linear 
regression analysis. Correlation outcomes, r and p, for each analysis are in boxes.  N=39 for each 
analysis. 
 
6.4.2. Correlations between GAGs and markers of neutrophilic inflammation in CF BAL 
fluid 
 
As discussed in the background to the study, it has been shown that GAG expression 
correlates with neutrophilic inflammation in the CF airway (Solic et al. 2005).  A correlation 
was performed on my data to assess the relationships between GAGs and markers of 
neutrophilic inflammation (neutrophil count, CXCL8 and NE activity) in CF patients (figure 6-
7). 
 
Figure 6-7: Spearman rank correlation analysis of GAGs and markers of neutrophilic 
inflammation in CF BAL fluid.
 
 
 
In this study, there was a statistically significant positive correlation with PMN count (figure 6-
7A: r = 0.666, p < 0.0001).  Soluble GAGs are liberated by degradation of ECM by neutrophil 
derived proteases such as NE.  Therefore, evidence for the liberation of soluble GAGs in the 
CF cohort was assessed by correlating GAG expression with NE activity.  There was a 
significant positive correlation between NE and GAG expression in CF BAL fluid (figure 6-7B: 
r = 0.853, p < 0.0001).  The interaction between CXCL8 and GAGs has been well 
259 
 
characterised (Pichert et al. 2012b).  In this study, there was a significant positive correlation 
between CXCL8 and GAGs (figure 6-7C: r = 0.736, p < 0.0001).  To obtain initial evidence of 
C5a-GAG interaction in the CF airway, the correlation between C5a and GAGs was tested.  
There was a significant positive correlation between C5a and GAGs (figure 6-7D: r = 0.368, p 
= 0.021). 
 
Analysis of CF BAL fluid confirmed that GAG expression correlates with markers of 
neutrophilic inflammation.  There was a correlation between C5a and GAGs in the CF airway 
and therefore this relationship required further investigation.  This is the first time GAG 
concentration has been correlated with C5a in pathological samples. Despite a significant 
positive relationship, these data are not conclusive evidence of interaction.  Therefore, in the 
following section the interaction between C5a and GAGs was investigated. 
 
 
 
 Characterisation of C5a-GAG interactions by PAGE 
 
In the literature several methods have been used to visualise and characterise GAG 
interaction with proteins; these include PAGE, affinity chromatography and solid phase plate-
based assays (Culley et al. 2003; Clark et al. 2006; Reeves et al. 2011b). 
 
6.5.1. Resolving nC5a and rhC5a by native-PAGE and BN-PAGE 
 
Reeves et al. demonstrate CXCL8-GAG interactions in CF BAL using native PAGE, a 
technique that exploits the native charge (isoelectric point, pI) of the target protein and running 
buffer pH for gel migration, rather than a charge carrier such as SDS (Fiala et al. 2011; Reeves 
et al. 2011b).  To optimise this technique for resolution of C5a and potential C5a-complexes, 
rhC5a was compared to nC5a in a dilution series (figure 6-8A).  Functional differences were 
observed between nC5a and rhC5a in chapter 4 and therefore, further differences may also 
persist in their interactions with GAGs.  This is important because previously published 
analysis of C5a-GAG interaction has been performed using rhC5a rather than nC5a (Culley 
et al. 2003; Miyabe et al. 2017). 
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Two-fold dilutions of nC5a and rhC5a in PBS were resolved by A) native-PAGE (n=1) or B) BN-PAGE 
(n=1) on 4-20% tris-glycine gels, detection by monoclonal anti-human C5/C5a antibody and goat-anti-
mouse HRP conjugated antibody. Arrow indicates C5a molecular weight. 
 
 
 
Figure 6-8: Comparing PAGE techniques for resolution of C5a and C5a-GAG complexes.
 
 
 
Recombinant C5a, but not nC5a, was visualised on SDS-free gels when resolved by native-
PAGE (figure 6-8A); however, the rhC5a band was not well-defined as SDS-PAGE in section 
4.5.  Native PAGE utilises native charge of protein for mobilisation through a polyacrylamide 
matrix. A possible explanation for the detection of rhC5a but not nC5a could be that the His-
tag incorporated into rhC5a increases the native charge allowing it to be mobilised in this 
system.   Detection of rhC5a but not nC5a continues to highlight structural differences in the 
two forms that were discussed in chapter 4. 
 
An inability to detect nC5a by native-PAGE meant that to investigate nC5a-GAG complexes 
an alternative method was required.  A compromise between native PAGE and SDS-PAGE is 
to resolve proteins by blue native PAGE (BN-PAGE) whereby coomasie blue R-250 is used 
as a charge carrier (Fiala et al. 2011).  Moreover, coomasie blue is not a detergent and 
therefore, unlike SDS-PAGE, does not alter protein structure potentially disassociating C5a-
GAG complexes. 
 
With similarities to the experiment shown in figure 6-8A, rhC5a and nC5a were diluted in series 
and resolved using a SDS-free system by adding coomasie blue into loading buffer and 
running buffers.  When visualised by western blot, both nC5a and rhC5a were detected at a 
concentration of 5 µg/mL (figure 6-8B).  A stronger signal was observed with rhC5a compared 
to nC5a, further demonstrated by the presence of a rhC5a band when 2.5 µg/mL was loaded.  
Moreover, multiple rhC5a bands could be detected at the highest concentration suggesting 
the formation of higher oligomeric structures of rhC5a; this was previously observed by SDS-
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                                                                                                              A) BN-PAGE, resolving of 5 
µg/mL nC5a incubated with 10-fold dilution series of each GAG from 5 to 500 µg/mL for 1 h at 37°C. 
Arrow indicates nC5a molecular weight. B) BN-PAGE, resolving of 5 µg/mL rhC5a incubated with 500 
µg/mL of each GAG for 1 h at °37C. In both experiments C5a-GAG complexes were separated on 4-
20% tris-glycine gels; detection by monoclonal anti-human C5/C5a antibody and goat-anti-mouse HRP 
conjugated antibody. N=1. 
PAGE (section 4.5).  The same oligomeric banding phenomenon was also observed for nC5a.  
I concluded that BN-PAGE could be suitable for visualising C5a-GAG interactions. 
 
6.5.2. Separating C5a and C5a-GAG complexes using BN-PAGE 
 
C5a-GAG interaction was investigated by incubating nC5a with a 10-fold dilution series of 
three purified GAGs; HS, CS and HA (Figure 6-9A). 
 
Figure 6-9: C5a and C5a-GAG complexes resolved by BN-PAGE.
 
 
 
As observed in Figure 6-8B, the anti-C5/C5a antibody detected multiple C5a bands indicative 
of higher oligomeric structures; however, only a single band was observed when nC5a was 
incubated with PBS, a negative control.  Interestingly, broad smeared bands were observed 
when nC5a was incubated with the 500 µg/mL CS or HA, indicating possible C5a-GAG 
interaction.  Moreover, a titratable effect was observed when nC5a was incubated with HA 
whereby the suspected nC5a-HA band intensity increased with HA concentration.  A faint 
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band, indicating nC5a-HS interaction, could only be detected when nC5a was incubated with 
5 µg/mL HS. 
 
In comparison, for rhC5a, bands indicative of GAG interaction could only be observed when 
rhC5a was incubated with 500 µg/mL HS (figure 6-9B).  Despite encouraging and original 
observations, both blots with rhC5a and nC5a could not be consistently replicated and 
therefore, no strong conclusions can be drawn from these data.  To continue this investigation 
and build on evidence from these data, an alternative method for characterising C5a-GAG 
interaction was required. 
 
 Using size exclusion chromatography to characterise C5a-GAG complexes 
 
Size exclusion chromatography was identified as a possible method for detecting C5a-GAG 
interaction; this technique has not previously been used to detect C5a-GAG interactions.  This 
method uses a glass column packed with chemically modified agarose matrix that contains 
pores that facilitate selective separation of different sized molecules under physiological 
conditions.  Separation is carried out in the fluid phase and a continuous flow is collected in 
fractions.  The different parameters in this technique could potentially enable the separation 
of C5a and larger C5a-GAGs complexes.  Continuous parameters can be measured such as 
flow rate, pressure, conductivity, and protein concentration (ultra-violet).  Due to the small 
concentrations of C5a used in the following experiments, the spectrophotometer was not 
sensitive enough to detect C5a in the fractions (not shown).   For this reason, an in-house C5a 
ELISA was developed and optimised to accurately quantify C5a. 
 
6.6.1. Optimising an in-house ELISA for detection of C5a in column eluate  
 
In this project I have used a sensitive commercial ELISA to quantify C5a in CF BAL fluid and 
in experiments where C5 is also present. The advantage of the C5a ELISA manufactured by 
Quidel is that it has no reported cross-reactivity with C5, this property is not required for 
measuring C5a in systems without C5.  The commercial C5a ELISA is expensive therefore, a 
sandwich ELISA for C5a/C5a-desArg was developed using two mouse-anti-C5a monoclonal 
antibodies (figure 6-10). 
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                                                                                                   “Capture” antibody is coated 
overnight on plastic. C5a standard or column fraction is incubated.  “Detection” antibody recognises 
capture-bound C5a. Detection antibody is quantified using HRP-conjugated “tertiary” antibody and 
TMB substrate. 
 
 
Figure 6-10: Diagram C5a ELISA and the antibodies used. 
 
 
 
The capture antibody, Hycult mouse anti-C5a/C5a desArg-neo clone 2952 (IgG1 isotype), 
binds a neo-epitope that is exposed following cleavage of C5a from C5-alpha chain by C5 
convertase.  The detection antibody, the same used for western blots in chapters 4 and 5, 
binds to the C-terminal of C5a (IgG2a isotype).  Both anti-C5a antibodies were developed by 
immunising mice therefore, for detection of binding a “tertiary” goat-anti-mouse IgG2a-HRP 
conjugated isotype specific antibody was used. 
 
To verify that there was no cross reactivity of the goat-anti-mouse IgG2a-HRP to the mouse-
anti-C5a neo-epitope capture antibody (IgG1), both capture and detection antibodies were 
coated onto a 96-well Maxisorb™ plate (figure 6-11A.).  Cross-reactivity of the goat-anti-
mouse IgG2a HRP was tested over a dilution series from 80 to 20 ng/mL.  A positive control 
of goat-anti-mouse IgG HRP conjugate, picking up all IgG was used at 80 ng/mL to show equal 
coating of capture and detection antibodies. 
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A) Wells of a 96-well plate were coated overnight with either 1 µg/mL anti-C5a neo epitope monoclonal 
antibody (Hycult clone 2952), anti-C5/C5a monoclonal antibody (Hycult clone 557) or coating buffer.  
Plates were washed and a dilution series (20 to 80 ng/mL) of goat anti-mouse IgG2a HRP-conjugate 
antibody (green shades), 80 ng/mL goat anti-mouse IgG1 HRP-conjugate antibody (red), or 1% 
milk/PBS was added and incubated for 1 h at 37°C.  Wells were washed and TMB added, colour was 
allowed to develop and stopped with HCl. Absorbance was measured at 450 nm with 570 nm 
reference filter. Mean values from duplicates in a single experiment.  B) Dilution of capture and tertiary 
antibodies to detect a dilution series from 32 to 0.1 ng/mL rhC5a, detection antibody kept constant at 
1 µg/mL. Absorbance was measured as for “A”. Mean values from duplicates in a single experiment 
 
 
Figure 6-11: Optimisation of C5a ELISA to quantify C5a in column chromatography fractions. 
 
 
 
 
 
 
There was no cross-reactivity between the goat-anti-mouse IgG2a and capture antibody, 
validating the use of these antibodies in this combination.  A dilution of the capture and tertiary 
antibodies was carried out to improve sensitivity of the C5a ELISA (figure 6-11B).  I determined 
from these data that neither increasing the capture or detection antibody concentration 
substantially improved detection of C5a.  Therefore, the capture and detection antibodies were 
to be used at 1 µg/ml.  The concentration of tertiary antibody improved detection and therefore 
the goat-anti-mouse HRP-conjugated antibody to be used at 160 ng/mL.  Having optimised a 
C5a ELISA, I could accurately detect C5a in column chromatography fractions. 
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6.6.2. Separating C5a-GAG complexes using a SD75 column 
 
C5a-GAG complexes have not previously been characterised using size exclusion 
chromatography.  A Superdex 75 10/300 GL column (SD75) was initially selected because 
the manufacturer specifies that it has a resolution range between 3 and 70 kDa.  Therefore, it 
would be able to separate unbound C5a (10.4 kDa) and GAG-bound C5a (>50 kDa).  It should 
be noted that the GAGs used in these experiments are heterogenous and the molecular weight 
was not specified by the manufacturer. 
 
In a preliminary experiment 2 µg nC5a in PBS was loaded onto the column, the first 
observation made was that total yield of C5a in the collected fractions was low, less than 5% 
of the start material (not shown).  C5a, and C3a, are “sticky” proteins due to their charge and 
can bind to plastic and other surfaces (Klos et al. 2013).  I hypothesised that the low yield was 
due to incomplete elution from the column and binding of C5a to the polystyrene fraction tubes 
after elution. 
 
6.6.3. Investigating low C5a recovery from SD75 column 
 
To investigate C5a binding non-specifically to the column, 1 column volume of 1 M NaCl in 
PBS was flowed through the column to disrupt any ionic bonds between C5a and the column 
matrix. A broad peak suspected to be C5a, large enough to be detected by the UV 
spectrometer was eluted by 1 M NaCl; this could not be quantified by C5a ELISA because the 
high salt concentration interfered with the ELISA.  I concluded for this that C5a was retarded 
on the column and was not being eluted in the column run-through.  I also hypothesised that 
C5a was binding to the collection tubes throughout the experiment; each run would typically 
take 2 hours to complete. 
 
To investigate non-specific binding of C5a to the polystyrene fraction tubes, an ELISA-style 
assay was performed using the same antibodies as the in-house C5a ELISA figure 6-12A.  
Briefly, 100 µL 2 ng/mL nC5a was incubated in two sizes of Eppendorf tubes or polystyrene 
fraction tubes for 1 h at 37°C.  Unbound C5a was removed by pipette and tubes washed with 
PBS-tween (0.05%, v/v).  The tubes were incubated with 100 µL 2 µg/mL mouse-anti-C5/C5a 
antibody for 1 h at 37°C.  Antibody bound to C5a was detected using 160 ng/mL goat-anti-
mouse HRP-conjugated antibody.  Following washes, TMB was added and colour change was 
observed.  After 5 minutes, 50 µL developed TMB solution was transferred to a 96-well plate, 
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                                                                                    A) Diagram of ELISA-style in-situ assay to 
determine whether C5a binds to plastics.  B) 2 ng/mL nC5a/PBS incubated in plastic vessels 1 h at 
room temperature, washed and 2 µg/mL mouse-anti-C5/C5a antibody added for 1 h at room 
temperature. Unbound antibody was washed, and 160 ng/mL goat-anti-mouse HRP-conjugate 
antibody added and incubated for 1 h at room temperature.  Tubes were washed, TMB added and 
allowed to develop for 5 minutes then transferred to a 96-well plate. Reaction was stopped with HCl. 
Absorbance read at 450 nm / 570 nm reference filter. C) In-house C5a ELISA comparing the use of 
tween-20 concentrations in the sample buffer.  Trouble-shooting experiments were only performed 
once (n=1). 
 
reaction stopped with an equal volume of HCl and absorbance measured at 450nm.  Signal 
was detected from all plastic tested, indicating non-specific binding of C5a (figure 6-12B). 
 
 
Figure 6-12: A tube-based ELISA to detect C5a. 
 
 
 
 
 
There was no signal from PBS coated (no C5a) vessels, verifying that there was no non-
specific binding of the antibodies.  Additionally, pre-coating the plastics with 1% milk/PBS 
reduced signal from bound C5a to similar levels to PBS for each respective vessel. 
 
To improve recovery of C5a from the chromatography column, I hypothesised that collecting 
fractions in tubes containing a PBS tween-20 buffer would prevent further binding to plastic 
however, the effect of tween-20 on the C5a ELISA needed to be validated.  A series of tween-
20 concentrations in the sample buffer (1% milk/PBS) were assessed to determine the effect 
on the ELISA (figure 6-12C).  Adding tween-20 to the sample buffer dramatically improved 
ELISA signal and therefore it was concluded that using tween-20 in collection tubes would not 
be detrimental to detecting C5a in the ELISA.  In both SDS-PAGE and ELISA I have found 
that tween-20 improves detection by the antibodies used. It is not clear why this is but this 
phenomenon could suggest that aggregated C5a (in PBS, no tween) obscures the antibody 
eptitope, reducing signal.   The following adaptions were made to the column protocol and 
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2 µg nC5a in 200 µL PBS was loaded onto a SD75 column and eluted using PBS running buffer.  0.5 
mL fractions were collected from 6 to 23 mL (x-axis), pooled in pairs to 1 mL and nC5a measured by 
C5a ELISA. C5a is plotted as a percentage of the total C5a eluted (y-axis).  Native C5a was pre-
incubated with PBS (orange) or 500 µg/ml HS (blue line) for 1 h at 37°C. On a separate run, protein 
molecular weight markers were loaded for reference (vertical dashed lines represent peak mid-points 
for each marker including respective molecular weights (kDa)). Graph is representative of n=2 for nC5a 
and nC5a + HS. 
fraction collection; future column fractions were collected in tubes pre-blocked in 1% milk/PBS 
and also contained 0.5 mL 2% milk/PBS-tween 20 (0.1% v/v). Therefore, collecting a 0.5 mL 
fraction would dilute the fraction 2-fold and give a final concentration of 1% milk/PBS-tween 
20 (0.05%). 
 
 
 
Even though the monoclonal anti-C5a antibody only detected faint nC5a-HS interaction in 
western blots (figure 6-9A), rhC5a binding to HS proteoglycan was reported as part of a larger 
study investigating the roles of C5a in promoting inflammation in rheumatoid arthritis (Miyabe 
et al. 2017).  This was published during the course of my own experiments. To further 
characterise nC5a interaction with HS, nC5a was pre-incubated with HS for 1 h at 37°C and 
loaded on to a SD75 column (figure 6-13).  Native C5a collected in each fraction was 
measured using the in-house C5a ELISA described above.  Data was calculated as a 
percentage of total eluted C5a. 
 
Figure 6-13: Separation of nC5a and nC5a-HS complexes on SD75 column.
 
 
 
 
 
Untreated nC5a eluted in two peaks: a sharp peak, containing 80% total nC5a, eluted between 
12 and 14 mL. Comparing to protein standards the molecular weight of this material was 
between 17 and 44 kDa.  The remaining material eluted in a smaller, broad peak elute between 
8 and 11 mL (>150 kDa).  Interestingly, incubating nC5a with HS reduced the sharp peak that 
previously eluted between 12 and 14 mL.  Instead, the majority of the material, presumably 
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nC5a complexed with HS, eluted in 4 mL following the void volume of the column (7mL), this 
is the volume that is not occupied by agarose matrix.  These data suggest that nC5a-HS 
complexes are heterogenous in size, demonstrated by a broad peak.  Additionally, these 
complexes are greater than 150 kDa, the maximum range of the resolution for the SD75 
column. 
 
The experiments shown in figure 6-13 provide preliminary evidence that C5a binds HS and 
that these complexes are likely to be greater than 150 kDa.  Therefore, to improve resolution 
and enable characterisation of the size C5a-GAG complexes, a column that could resolve a 
greater range molecular weights was required.  I selected a Superose 6 column because it 
has physiochemical properties that allow separation of particles that are between 5 and 5,000 
kDa.  The volume of the column is the same as SD75 and therefore the same separation 
protocol was used.
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                                                                                                                                              2 µg nC5a 
in 200 µL PBS was loaded onto a superpose 6 column and eluted using PBS running buffer.  0.5 mL 
fractions were collected from 6 to 26 mL (x-axis), pooled in pairs (1 mL) and nC5a was measured by 
C5a ELISA. C5a was plotted as a percentage of the total C5a eluted (y-axis (left)). C5a was pre-
incubated with PBS (orange), A) 500 µg/mL HS (blue) or B) 500 µg/mL CS (green) for 1 h at 37°C. 
With conditions where GAGs were incubated with nC5a, GAG concentration was also measured in 
each fraction using dimethyl methylene blue stain (y-axis (right)). Protein molecular weight markers 
were loaded separately for reference (vertical dashed lines represent peak mid-points for each 
marker and include respective molecular weights (kDa)).  Peaks of interest are annotated with arrows 
that are the colour of the respective condition.  Graphs are representative of n=2 for C5a+PBS and 
C5a + HS, n=1 for C5a + CS. 
 
 
6.6.4. Separating C5a-GAG complexes on a Superose 6 column 
 
In separate experiments nC5a, nC5a incubated with HS, and nC5a incubated with CS were 
loaded on to a Superose 6 column (figure 6-14). 
 
 
Figure 6-14: Separation of C5a and C5a-GAG complexes by a Superose 6 column.
  
 
 
 
 
 
The same experiments performed with the SD75 column (figure 6-13) were replicated on the 
Superose 6 column  and C5a concentration was quantified by C5a ELISA as before. 
Additionally, GAG concentration was also measured in the eluted fractions using the dimethyl-
methylene blue stain used for GAG quantification in the CF cohort.  GAG concentration was 
measured in fractions to investigate whether C5a and GAGs eluted in the same fractions, 
suggesting possible interaction. 
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Using the Superose 6 column, a sharp peak, suspected to be monomeric nC5a, eluted 
between 44 and 17 kDa.  In contrast to the SD75 column, the majority of C5a material eluted 
in a broad peak between elution volume 6 and 18 mL.  According to the protein reference 
makers, C5a in this broad peak could have a molecular weight between 158 and 5000 kDa 
(maximum resolution limit).  I speculated that this high molecular weight material is likely to be 
aggregated nC5a, evidence of oligomerisation was shown in western blots in a previous 
chapter (figure 4-5). 
 
Incubating nC5a with HS reduced the “monomeric C5a” peak and instead, a broad peak of 
C5a material eluted between elution volumes 9 to 22 mL (figure 6-14A).  Interestingly, this 
broad peak contained two C5a spikes, observed in fractions 12 mL and 15 mL.  Moreover, 
these increases in C5a elution at volumes 12 and 15 mL coincided with the elution of HS, as 
measured by staining samples with dimethyl methylene blue.  Therefore, I speculated that 
these two peaks represented C5a-HS complexes. 
 
In experiments where nC5a was pre-incubated with CS, a diminished “monomeric C5a” peak 
was also observed (figure 6-14B).  Large molecular weight C5a was eluted over a broad peak, 
between 6 and 17mL, additionally, a spike in eluted C5a was measured in fraction 15. The 
same peak coincided with what is suspected to be aggregated C5a but not where majority of 
CS was detected.  By measuring CS in fractions using the dimethyl-methylene blue stain, a 
peak in CS eluted between 11 and 14 mL. 
 
Separation of nC5a incubated with GAGs using the Superose 6 column has built on evidence 
of the formation of nC5a-GAG complexes established by the SD75 column. Due to the 
similarity in molecular weights between suspected nC5a aggregates and nC5a-GAG 
complexes, I decided that alternative experimental approaches were required. 
  
  Characterising C5a-GAG interaction using a heparin-sepharose affinity column. 
 
Affinity chromatography, using a sepharose-heparin column, has been previously used to 
investigate rhC5a-heparin interaction (Culley et al. 2003).  Heparin is structurally analogous 
to HS; however, heparin differs in disaccharide composition whereby N-acetylglucosamine in 
HS is substituted by α-L-iduronic acid.  Due to their physio-chemical similarities, evidence of 
C5a-heparin interactions could suggest that HS can also form complexes with C5a. 
 
To replicate data published by Culley et al., using rhC5a, 2 µg nC5a in 200 µl PBS was loaded 
onto a 1 mL heparin-sepharose affinity column.  The column was washed with five column 
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                Binding of nC5a pre-incubated with A) PBS B) HS, C) CS, or D) HA to a heparin affinity 
column. 2 µg nC5a in PBS incubated with 100 µg each GAG for 1 h at 37°C.  Bound nC5a was eluted 
with a concentration gradient of NaCl in PBS from 154 mM to 1 M (indicated by dotted lines), increase 
in gradient was observed by the increase in conductivity during elution, dashed black line (y-axis 
(right)).  0.5 mL fractions were collected from 1 to 25 mL elution volume (x-axis).  C5a in fractions was 
measured by C5a ELISA and plotted as percentage total C5a, solid bars (y-axis (left)).  Graphs 
representative of n=2 experiments (C5a + HA, n=1). 
. 
volumes (5mL) PBS, 154 mM NaCl, then NaCl concentration in PBS was increased to 1 M 
over a gradient of approximately 84.6 mM (10%) / minute; after 25 mL the NaCl concentration 
in PBS was theoretically 1 M.  The hypothesis behind this was that hypertonic solution would 
disrupt ionic bonds between nC5a and heparin.  Fractions (0.5 mL) were collected in milk 
blocked tubes to improve C5a recovery, as for size exclusion chromatography experiments. 
 
I first tested to see whether nC5a was retarded on a heparin affinity column, as reported by 
Culley et al. for rhC5a (Culley et al. 2003).  Native C5a was incubated at 37°C for 1 h and 
loaded onto a 1 mL heparin affinity column (figure 6-15A). 
 
 
Figure 6-15: Assessing binding of nC5a and nC5a-GAG complexes to a heparin affinity 
column.
 
 
 
 
When a gradient of NaCl in PBS from 154 mM to 1000 mM was applied, a sharp C5a peak 
eluted between elution volumes 15 and 20 mL.  I calculated, given the conductivity at 154 mM 
and 1000 mM NaCl, that the NaCl concentration between 15 and 20 mL would have been 
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approximately 488 mM to 670 mM NaCl.  In this first experiment I found that nC5a could be 
retarded on a heparin affinity column and eluted with a gradient of NaCl.  In the next set of 
experiments, I investigated whether pre-incubating nC5a with different GAGs could inhibit C5a 
from binding to the heparin matrix within the column.  
 
As mentioned above, the similarities in heparin and HS mean that they have been shown to 
bind similar, if not the same, residues on the target protein (CXCL8) (Pichert et al. 2012a).  
Therefore, to investigate binding of C5a to heparin and other GAGs, I hypothesised that pre-
incubating nC5a with other GAGs would inhibit anaphylatoxin binding to the heparin affinity 
column. 
 
Native C5a was incubated with either HS, CS or HA and loaded on to the heparin affinity 
column.  Interestingly, when nC5a was pre-incubated with HS (figure 6-15B) over 50% of total 
C5a material eluted in the run-through, suggesting that it was prevented from binding to 
heparin within the matrix of the column.  The remaining material, presumably nC5a not bound 
to HS, eluted with the increasing NaCl concentration between elution volumes 15 to 21 mL, 
as observed in figure 6-15A.  A similar but less pronounced shift could also be observed when 
nC5a was incubated with CS (figure 6-15C).  Approximately 20% of C5a material eluted in the 
run-through, with the remaining C5a eluting in a single peak between elution volume 15 to 21 
mL.  Incubating nC5a with HA produced a similar profile to untreated nC5a however, the sharp 
C5a peak eluted by the NaCl gradient eluted earlier than untreated C5a (figure 6-15D). 
 
Experiments using a heparin affinity column provided conclusive evidence that C5a binds to 
heparin, HS and to a lesser extent CS.  Additionally, an approximate strength of these 
interactions has been observed using a NaCl gradient.  Nevertheless, a second platform was 
sought to support these data.  
 
 Solid phase plate assay for detection of C5a-GAG binding 
 
Solid phase plate-based assays were considered as a potential platform for characterising 
C5a-GAG interaction; this technique would require coating plastic with either GAGs or C5a.  
Coating plastic plates with GAGs can be challenging due to their strong negative charge.  
Plates chemically rendered capable of binding GAGs were purchased, but initial observations 
using CXCL8 as a positive control did not reliably differentiate between binding to GAGs and 
non-specific binding to the plate (not shown).  Despite this, Miyabe et al. used HS 
proteoglycan-coated plates to investigate rhC5a interaction and to test competition using 
heparin (Miyabe et al. 2017). Binding the target protein to plastic and measuring GAG 
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                                                                                                 A) Diagram of the principle behind 
detecting C5a-GAG interaction using solid phase platform.  B)  Investigating necessity of assay buffer 
pH during biotinylated-HS incubation step. Wells were coated with PBS (blue), nC5a (green) or, rhC5a 
(red).  Assay buffer with a range of pH from 6.0 to 7.5 (dark to light shades), increasing in 0.5 
increments. Assay buffer pH was increased by additional of NaOH.  An assay buffer at pH 6.0 with 
tween-20 omitted was also compared (diagonal stripes (colour/white)), n=1. 
interaction using biotinylated-GAGs has been reported in investigations on CXCL8 and other 
chemokines (Clark et al. 2006; Dyer et al. 2016b).  Coating plates with C5a and assessing 
GAG-binding has not previously been reported therefore, the protocols for investigating 
chemokines were adapted for use with C5a. 
 
6.8.1. Optimisation of solid phase C5a-GAG binding assay 
 
In brief, a 96-well plate is coated with purified C5a overnight.  The next day, unbound C5a is 
discarded and the plate is blocked with BSA.  Following block, biotinylated-HS was added to 
each well and incubated for 3 h at 37°C.  Unbound GAGs were discarded, and bound GAGs 
were detected using streptavidin-HRP and TMB (figure 6-16A). 
 
 
Figure 6-16: Optimisation of solid phase binding assay.
 
 
 
 
In the literature, groups have reported using assay buffers containing high concentrations of 
tween-20 (up to 1%) and a lower than physiological pH (pH 6). These conditions are not 
physiological for CF airway (Schultz et al. 2017) and therefore, I investigated whether these 
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conditions were necessary for the performance of the assay.  Assay buffers with increasing 
pH and a buffer without tween-20 (at pH 6.0) were assessed during the biotinylated-HS 
incubation step of the protocol (figure 6-16B). 
 
When tween-20 was omitted from the assay buffer for all steps, absorbance measurements 
of wells coated with either PBS or nC5a were above the detection limit of the 
spectrophotometer (not shown because data could not be measured).  Additionally, omitting 
tween-20 from the buffer during the biotinylated-HS incubation step had no visible effect when 
comparing to the pH 6 assay buffer with tween (used by Clark et al. (Clark et al. 2006)). 
Therefore, tween-20 was used at 0.1% throughout the assay in future experiments. 
 
Different pH buffers were made to test the influence of pH on binding of biotinylated-HS to 
C5a.  Increasing the assay buffer pH, reduced the absorbance measured and therefore, the 
amount of biotinylated-HS bound to nC5a.  It has recently been shown that the CF airway pH 
is approximately pH 7.0 therefore, a pH 6.0 buffer is not necessarily physiological (Schultz et 
al. 2017).  Even though these conditions are not representative of the CF airway they still 
enable investigation of C5a-GAG interaction that may have a wider non-pathological role not 
just in the inflamed airway. Despite using non-physiological conditions, investigating nC5a-
GAG interaction in assays with low absorbance would reduce the ability to detect subtle effects 
and therefore, the assay buffer was kept at pH 6.0, in line with previous reports (Clark et al. 
2006).  These preliminary experiments optimised assay conditions as follows; plates were 
blocked with 1% BSA and the assay buffer used was 50 mM sodium acetate, 100 mM NaCl, 
0.1% tween-20, pH 6.0. 
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                                                                                            Wells of a 96-well plate were coated with 1 
µg/mL nC5a or PBS overnight. Biotinylated-HS binding was measured in assay buffers with increasing 
NaCl concentration from 100 to 800 mM. Representative of two experiments.   
. 
6.8.2. Characterisation of C5a-GAG binding using solid phase plate assay 
 
Characterisation of nC5a-GAG complexes using affinity chromatography revealed that nC5a-
heparin interaction can be perturbed using a NaCl gradient (figure 6-15A).  These experiments 
were replicated using the solid phase binding assay to assess whether these observations 
could be supported by a different platform. 
 
Experiments performed using the heparin affinity column revealed that nC5a could be eluted 
from the column when the NaCl concentration was greater than 450 mM (figure 6-15A).  
Dissociation of biotinylated-HS and nC5a was investigated using hypertonic assay buffers with 
NaCl at concentrations from 0.154 up to 1 M (figure 6-17).  Increasing the NaCl concentration 
to 200mM reduced absorbance of nC5a-biotinylated-HS by approximately 80%.  Further 
increase to 400 mM NaCl reduced signal to near background levels, controlled by coating 
wells with PBS only. 
 
 
Figure 6-17: Influence of NaCl on C5a-HS interaction. 
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                                                                                                                                              Wells were 
coated with 0.5 µg/mL nC5a. Coated nC5a in wells was incubated with biotinylated-HS in solution with 
A) unlabeled HS or CS at ratios (x-axis) between 0.01 and 10 (n=3). Data presented as mean±SEM.  
Two-way ANOVA with Tukey’s test for multiple comparisns was performed to compare mean binding 
at each ratio tested.    B) Unlabeled CS or HA at ratios (x-axis) between 1 and 1000, mean of two 
experiments.  In both sets of experiments absorbance was measured at 450/570 nm.  Data is 
presented a percentage of wells incubated with biotinylated-HS only (y-axis). 
. 
Experiments using the heparin affinity column also revealed that HS and to a lesser extent CS 
could compete for heparin binding sites on nC5a (figure 6-15B-C).  I hypothesised that if the 
different GAGs bound nC5a at the same amino acid residues then the relative affinity of each 
GAG for nC5a could be assessed in a competition assay.   A competition assay was developed 
using unlabelled (not biotinylated) GAGs to compete for biotinylated-HS binding sites on nC5a 
(figure 6-18). 
 
 
 
 
Figure 6-18: Competition for nC5a-bioinylated-HS binding using unlabeled GAGs.
 
 
 
In the first set of experiments unlabelled HS or CS was added in solution with biotinylated-HS 
at ratios between 0.01:1 and 10:1 (unlabelled GAG to biotinylated-HS).  The unlabelled GAGs 
and biotinylated-HS were then incubated with C5a pre-coated on the plates, the assay was 
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performed as described in section 6.8.1.  The molecular weight of the GAGs used in these 
experiments is unverified and therefore, ratios were calculated by mass rather molar 
equivalence. Due to the natural variation in absorbance between assays, data is presented as 
percentage absorbance of wells incubated with biotinylated-HS alone. 
 
An important result was that at a ratio of 1:1 unlabelled-HS to biotinylated-HS the absorbance 
was approximately 50% compared to signal of wells incubated with biotinylated-HS (figure 6-
18A).  This means that biotinylated-HS binding to nC5a can be inhibited by an equimolar 
(approximately) amount of unlabelled HS.  Additionally, there was no strong evidence to 
suggest that unlabelled-CS could compete for binding at these ratios.  At 1:1 and 10:1 ratios 
of unlabelled-GAG to biotinylated-HS there was statistically significant difference in 
biotinylated-HS binding to C5a when competing with unlabelled HS compared to unlabelled-
CS (p = 0.001 and p < 0.0001 respectively). 
 
In figure 6-18A, there was no evidence from the data to suggest that unlabelled CS competed 
with biotinylated-HS for nC5a binding, at the ratios used.  In a second set of experiments, the 
ratio of unlabelled-CS to biotinylated-HS was increased to 1000:1, HA was also compared 
(figure 6-18B).  Increasing the ratio of unlabelled-CS to biotinylated-HS to 100:1 reduced 
binding of biotinylated-HS to 50%.  Therefore, CS has approximately a 100-fold lower affinity 
(based on mass) for the binding site of biotinylated-HS; however, despite increasing HA 
concentration to 1000-fold that of biotinylated-HS there was no detectable competition for the 
HS binding site. 
  
278 
 
                                                                                                                                            Plates were 
coated with a concentration gradient of A) C3a (green, n=3) and nC5a (red, n=3), Two-way ANOVA 
with Tukey’s test for multiple comparisons was performed to compare percentage binding at each molar 
concentration tested. Data was plotted as means ± SEM  B) C3 (orange, n=2) and C5 (blue, n=2) over 
a dilution series (x-axis). Data is presented as means from two experiments.   For both A and B Solid 
phase binding assay was performed as previously described.  Data points are percentage absorbance 
at the highest concentration for each respective component (y-axis). 
6.8.3. Investigating binding of HS to other complement components 
 
Having characterised nC5a and biotinylated-HS interaction it was hypothesised that C5, with 
a 20-fold greater mass than C5a and potential for more binding sites may also bind GAGs.  
Furthermore, C3a is homologous to C5a and may also interact with GAGs, and therefore, C3 
also.  The aforementioned complement components were diluted in series and binding of 
biotinylated-HS measured (figure 4-19). 
 
Data was calculated as a percentage of the absorbance of the highest concentration of each 
respective complement component.  This was due to the variation in absorbances at the 
highest dilution, possibly owing to the affinity of each component to the plastic plate. 
 
 
 
Figure 6-19: Comparing the binding of different complement components to HS. 
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Interestingly, observations using this platform suggested that biotinylated-HS had a higher 
affinity for C3a than C5a; there was a significant difference in percentage binding at 25, 12.5 
and 6.25 nM of coated anaphylatoxin (p<0.0001, p<0.0001 and p<0.0001 respectively) (figure 
4-19A).  Additionally, biotinylated-HS also bound C5 and C3 (figure 4-19B).  Additionally, 
interactions between C3 or C5 and biotinylated-HS were stronger than their respective cleaved 
anaphylatoxins and required further dilution for a full curve to be observed.  In a visual 
comparison, there was no apparent difference between biotinylated-HS binding to C5 or C3.  
Therefore, from these data HS binds complement components in a hierarchy 
C3=C5>C3a>C5a.  Despite intriguing results, this path of investigation was not continued due 
to a lack of available time left in this project.  If this line of investigation were to be continued 
it would be interesting to perform surface plasmon resonance for more accurate quantification 
of the affinities between the above complement components and GAGs. 
 
In this section a hypothesis driven selection of different methods was used to show evidence 
that C5a interacts with GAGs, in particular, heparin and HS.  Despite this, these data do not 
provide insight into how C5a-HS interaction influences C5a function.  At the beginning of this 
chapter I hypothesised that binding of C5a to soluble GAGs in the CF airway may modify 
function, promoting neutrophilic inflammation. 
 
 Functional significance of C5a-HS interaction 
 
In the above experiments it has been consistently observed that HS has a higher affinity for 
nC5a than CS and HA.  Therefore, because there was stronger evidence for C5a-HS 
interaction, I focused my investigation on the influence of HS interaction on C5a function.  It 
has previously been shown that rhC5a incubated with heparin (analogous to HS) did not inhibit 
function of rhC5a when used to stimulate oxidative burst in HL60 cells (Culley et al. 2003).  In 
my thesis, the effect of HS binding to nC5a was investigated using the RBL-C5aR1 transfected 
cell-line (activity assay previously described in section 4.9). 
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                                                                            1 µg/mL nC5a was incubated with 500 µg/mL HS or 
PBS for up to 3 h at 37°C (x-axis). Samples were diluted 1 in 10 in phenol red-free media and added 
to cells for 30 minutes at 37°C 5% CO2.  C5a activity (y-axis) was calculated using a standard curve of 
C5a and measuring ß-hexosaminidase in supernatant following stimulation of RBL-C5aR1 cells.  One-
way ANOVA was used to test whether there was any difference in activity between the two conditions 
at each time point (n=6). 
. 
6.9.1. Effects of HS binding on C5a function 
 
Native C5a was incubated with HS for up to 3 h, mirroring the solid phase binding platform 
biotinylated-HS incubation step (figure 6-16A).  C5a activity was measured at hourly time 
points by quantifying ß-hexosaminidase release from RBL-C5aR1 following stimulation with 
samples (figure 4-20). 
 
 
Figure 6-20: Influence of HS on C5a activity.  
 
 
 
 
Reflecting data published by Culley et al. on rhC5a, there was also no significant difference in 
activity between nC5a and nC5a incubated with HS at any of the time points (Culley et al. 
2003).  As C5a activity is not affected by HS binding, this data could provide insight into the 
binding site for HS on C5a.  For instance, the C5a C-terminal is important for activity and 
therefore because C5a is still active these data suggest that the HS binding site is located 
elsewhere. 
 
6.9.2. Testing the ability of HS to protect C5a from degradation by NE. 
 
It has been reported that CXCL8 interaction with GAGs protects against degradation by NE in 
the CF airway, prolonging half-life (Reeves et al. 2011b).  The authors stated that this 
mechanism could promote neutrophilic inflammation in the CF lung.  I hypothesised that the 
same phenomenon is applicable to C5a when in complex with HS.  In chapter 4 (figure 4-6) I 
showed that C5a was susceptible to degradation by proteases in CF BAL fluid and by purified 
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                                                                                               A) C5a activity was determined by measuring 
stimulation of RBL-C5aR1. nC5a (1 µg/mL) was pre-incubated with HS (500 µg/mL) or PBS for 1 h at 37°C 
then exposed to NE (25 µg/mL) or PBS for up to 6 h (n=4).  Samples were taken at 0, 1, 2 and 6 h (x-axis).  
Samples were diluted 1 in 10 in phenol red-free media and added to cells for 30 minutes at 37°C 5% CO2.  
C5a activity was calculated using a standard curve of C5a (y-axis).  B) Data from “A” was calculated as 
percentage inactivation (y-axis, 100 – percentage of C5a without neutrophil elastase) for each respective 
time point. Data for both plots is presented as mean ± SEM, Two- way ANOVA with Tukey’s test for multiple 
comparison was used to compare means at each time point, n=4. 
NSPs.  Here, I tested the ability of HS to protect C5a from NE-mediated inactivation; C5a 
activity was measured using RBL-C5aR1 cells (figure 6-21). 
 
 
Figure 6-21: Influence of HS of C5a inactivation by NE.
 
 
 
 
In support of data from figure 6-20, there was no significant difference in activity between nC5a 
and nC5a incubated with HS.  Interestingly, there was a visible difference in activity between 
C5a and C5a incubated with HS when exposed to NE over a 6-hour time course; however, 
these observations were not statistically significant (figure 6-21A). 
 
To normalise the impact of day to day natural variation from my experiments, data was 
standardised by calculating the percentage inactivation of C5a (figure 6-21B).  Following 
standardisation, I found that nC5a incubated with HS, was significantly more susceptible to 
degradation by NE (t=1; p < 0.001, t=2; p < 0.001).  Following 6-hour exposure to NE, activity 
of nC5a, with and without HS, was completely abolished. 
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                                                                                                                                A) HS (500 µg/mL) or 
PBS for was incubated with 5 µg/mL nC5a at 1 h at 37°C then exposed to NE (25 µg/mL) or PBS for up to 
6 h (n=2).  Samples were taken at 0, 1, 2 and 6 h (x-axis). At t=0 nC5a (or nC5a with HS) and C5a incubated 
with NE gave the same measurement. B) Data from “A” was calculated as percentage degradation (y-axis, 
100 minus the percentage of C5a without NE) for each respective time point. Data for both plot are 
presented as means for two experiments. 
 
To confirm that inactivation of C5a was due to NE-mediated proteolysis, the concentration of 
nC5a from the above experiments was quantified by a sensitive commercial C5a ELISA.  This 
experiment was repeated three times; however, due to technical difficulties only two data sets 
were measured and unfortunately there was not enough time at the later stages of my project 
to repeat the experiment (figure 6-22). 
 
Figure 6-22: Quantifying NE proteolysis of C5a when in complex with HS.
 
 
 
 
Data from the C5a ELISA had visually similar trends to figure 6-21, in that nC5a incubated 
with HS was more susceptible to degradation by NE than nC5a that was not incubated with 
HS.  Interestingly, nC5a without HS was susceptible to degradation by NE, but the rate of 
nC5a concentration loss (proteolysis) appeared to be less than the rate of inactivation from 
figure 6-22A.  Moreover, when the data was calculated as percentage degradation, the 
difference between inactivation (figure 6-21B) and degradation (figure 6-22B) became more 
apparent.  The difference in the rate of concentration loss and inactivation suggested that 
there may be subtle differences in the way C5a is degraded by NE when C5a is in complex 
with HS. 
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                                                                                                       A) 1 µg/mL nC5a was incubated 
with HS (red) or PBS (blue) for 1, 2 and 3 at 37°C, samples were then either exposed to CPB or PBS 
for 1 h at 37°C.  C5a activity in samples was measured by stimulation of ß-hexosaminidase release 
from RBL-C5aR1.  Percentage inactivation was calculated by dividing the activity of C5a (or C5a-HS) 
exposed to CPB by the samples that were incubated with PBS, this value was subtracted from 1 and 
multiplied by 100 to give percentage inactivation.  Data was represented as mean ± SEM, Two-way 
ANOVA (with Tukey’s test for multiple comparisons) was performed to test whether there was any 
difference in activity between the two conditions at each time point (n=4). B) Inhibitory activity of three 
HS dilutions (x-axis) on porcine CPB was assessed using the carboxypeptidase activity assay and 
chromogenic substrate, Furylacryloyl-Ala-Lys.  Activity was calculated using a standard curve of 
porcine CPB (y-axis), n=1. 
6.9.3. Influence of HS on the inactivation of C5a by CPB 
 
In chapter 4, I showed that NSP-generated C5a is resistant to inactivation by CPB, an 
important mechanism for regulating C5a activity in circulation.  I am also interested in whether 
interaction with GAGs can also modify the activity of C5a by preventing inactivation by CPB. I 
hypothesised that HS complexed with nC5a may prevent inactivation by CPB.  The 
susceptibility of nC5a to inactivation by CPB when in complex with HS was investigated.  As 
for the above experiments, nC5a was incubated with HS over 3 h.  At 1, 2, and 3-hour time 
points nC5a was exposed to either porcine CPB or PBS for 1 h at 37°C.  C5a activity was 
quantified by measuring ß-hexosaminidase release from RBL-C5aR1 cells (figure 6-23). 
 
 
Figure 6-23: Influence of HS on inactivation of C5a by CPB.
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In chapter 4, I demonstrated that there was statistically significant inactivation of nC5a by 
porcine CPB.  To standardise the normal variability encountered in assay repeats, percentage 
inactivation was calculated for each time point for C5a incubated with and without HS (figure 
6-23A). Interestingly, a statistically significant difference in inactivation by CPB was observed 
when C5a was incubated with HS for 1 h (p = 0.039).  From these data at the 1 h time point 
nC5a-HS was 32% more active than nC5a following exposure to CPB.   There was also a 
significant difference at t = 3 (p = 0.032).  Despite a visible difference at t = 2, the difference 
in activation was not statistically significant (p = 0.071). 
 
An explanation for the above difference in nC5a inactivation by CPB, was that HS could have 
an inhibitory effect on porcine CPB activity.  In a preliminary experiment to test this hypothesis 
(n=1), HS was incubated with porcine CPB and CPB activity was measured in the 
carboxypeptidase activity assay (as used in section 4.9.1 to measure carboxypeptidase 
activity in CF BAL fluid).  HS was added to porcine CPB at the same ratios as used for C5a 
activity experiments.  Two further 10-fold dilutions of HS were made to see whether any effect 
was titratable.  Despite a small titratable effect on CPB activity, at 50 µg/mL HS, there was no 
obvious difference in porcine CPB activity (figure 6-23B).  Therefore, it is unlikely that the 
reduced inactivation of C5a in (figure 6-23A) is due an inhibitory effect of HS on the activity of 
porcine CPB.  Further replication of this experiment would be required for further assurance 
that HS does not inhibit CPB activity. 
 
In summary of these experiments investigating the influence of HS on nC5a activity, HS had 
no effect on C5a activity however, C5a was more susceptible to proteolysis by NE.  
Interestingly, there was some evidence that HS modestly reduced inactivation of nC5a by 
porcine CPB.
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 Discussion 
 
I hypothesised that in the CF airway soluble GAGs bind C5a, modifying function and promoting 
neutrophilic inflammation.  In this chapter, I have shown that the concentration of soluble 
GAGs in CF BAL fluid correlated with inflammation in the CF airway, including CXCL8, a 
chemokine that has well-characterised GAG interactions (Pichert et al. 2012a).  A correlation 
between GAGs and C5a was also observed.  As for chapter 3, data were not corrected for 
total protein, following current ERS guide lines for reporting biological factors in CF BAL fluid 
(de Blic et al. 2000).  Recombinant C5a and heparin interaction has previously been studied 
(Culley et al. 2003) however, interactions between C5a and soluble GAGs, found in the CF 
airway, have not been comprehensively characterised. 
 
Western blots and column chromatography were used to investigate C5a-GAG binding.  
Conclusive evidence of C5a interaction with HS and CS was shown using a heparin affinity 
column.  HS, CS and, HA were used to compete for heparin binding sites on nC5a, revealing 
strong inhibition of C5a-heparin binding by HS and to a lesser extent CS.  Replicating data 
from the heparin affinity columns, a solid phase binding platform showed that biotinylated-HS 
bound to nC5a.  Furthermore, unlabelled HS competed for nC5a binding at a 1:1 ratio, the 
affinity of CS for the HS binding site on nC5a was shown to be 100-fold lower.  These 
experiments confirmed C5a-heparin interaction and further characterised C5a interaction with 
GAGs found elevated in the CF airway.  My data showed that HS has affinity for nC5a and 
therefore, the influence of HS on C5a activity and regulation was investigated. HS interaction 
had no detectable effect on C5a activity, and unlike what has been reported for CXCL8, HS 
did not protect nC5a but increased susceptibility to proteolysis by NE.  Interestingly, C5a in 
complex with HS was less susceptible to inactivation by porcine CPB. 
 
Characterisation of C5a binding to a sepharose-heparin column has previously been reported 
(Culley et al. 2003), with observations that rhC5a was eluted by 422 mM NaCl in PBS.  Data 
from this chapter is similar to this finding; I have shown that nC5a could be eluted 
approximately between 488 and 680 mM NaCl.  Culley et al. also investigated the impact of 
heparin on rhC5a function with the hypothesis that heparin may reduce activity.  They found 
that incubating rhC5a with heparin did not affect shape change or oxidative burst of 
eosinophils and did not prevent migration of HL60 cells, an immortal neutrophil-like cell line 
(Gallagher et al. 1979).  In confirmation of data from their experiments, I observed nC5a 
interaction with HS, known to bind similar sites to heparin, did not affect rat basophil 
degranulation of ß-hexosaminidase. 
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                                                                                                 Amino acids with positive charge have a 
cross below. N-glycosylation site (nC5a) is marked. Histidine tag (rhC5a) is labelled in a dashed box. 
. 
 
Recombinant C5a interaction with HS proteoglycan has recently been briefly investigated as 
part of a larger study investigating the C5a/C5aR1 axis (and other chemoattractants) in 
promoting pathology in rheumatoid arthritis  (Miyabe et al. 2017).  The authors concluded that 
HS proteoglycan expression on endothelial cells was important for C5a-mediated neutrophil 
extravasion into joints.  Specifically, Miyabe et al. investigated the significance of rhC5a for 
neutrophil extravasion by demonstrating that rhC5a could bind to plates coated with HS 
proteoglycan.  Moreover, binding of rhC5a could be inhibited by pre-incubation of rhC5a with 
heparin.   Adherence of murine neutrophils to endothelial cells in vitro was also measured 
following rhC5a incubation with heparin (Miyabe et al. 2017).  They observed that pre-
incubation with heparin inhibited neutrophil adherence suggesting that C5a-HS proteoglycan 
interaction on endothelial surfaces was necessary for neutrophil adherence.  In support of the 
experiments performed by Miyabe et al, I have used HS as a competitive inhibitor of nC5a 
binding to a heparin column. 
 
Despite encouraging data from the studies by Culley et al. and Miyabe et al., I have concern 
over the use of rhC5a in those studies.  In particular, the significant structural differences 
compared to nC5a (Culley et al. 2003; Miyabe et al. 2017).  As discussed in the introduction, 
there are two major structural differences that may impact the affinity of GAGs; first is the 
positively charged N-terminal histidine-tag that is necessary for purification (figure 6-24).  
 
 
Figure 6-24: Amino acid sequence of nC5a and rhC5a.
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The second difference is that rhC5a lacks the N-glycosylation at asparagine-64, a result of 
expression in E. coli.  In chapter 4, I demonstrated that rhC5a is more susceptible to 
degradation by NSPs when compared to nC5a.  In this chapter, I observed a further difference 
between the two C5a forms; the solid phase binding assay revealed that rhC5a bound 
biotinylated-HS with greater affinity than nC5a.  It is interesting that neither report by Culley et 
al. or Miyabe et al. discussed the structural differences between the two C5a forms and how 
this might influence their data.  Figure 6-24 highlights the primary structural differences 
between nC5a and rhC5a. I hypothesise that positively charged histidine amino acids within 
the His-tag of rhC5a might confer higher affinity for GAGs explaining the higher affinity of HS 
for rhC5a than nC5a.  In support of my hypothesis, a modified recombinant form of CXCL8, 
PA401, has been engineered to have a higher affinity for GAGs (Adage et al. 2015).  PA401 
is a pre-clinical CF therapeutic developed to compete against native CXCL8 for GAG binding, 
leaving native CXCL8 susceptible to degradation by NSPs in the CF airway (Adage et al. 2015; 
McElvaney et al. 2015).  CXCL8 was modified by replacing neutrally charged amino acids with 
positively charged amino acids, such as lysine (Adage et al. 2015). 
 
Experiments using de-glycosylated nC5a, by commercially available endoglycosidases, could 
help assess the significance of the nC5a N-glycosylation site for interaction with HS (and other 
GAGs).  For example, investigating the differential glycosylation of anti-thrombin α and ß forms 
has revealed preferential heparin binding by highly glycosylated ß anti-thrombin (Pol-Fachin 
et al. 2011).  Interaction with heparin modulates anti-thrombin activity and is important for 
function (Pol-Fachin et al. 2011). 
 
A further advantage of this study to those previously reporting C5a-GAG interactions was that 
I quantified soluble GAG concentration in the CF airway, giving additional confidence in the 
GAG to C5a ratio used in my experiments.  The GAG to nC5a ratio used in my experiments 
was less than what I observed in CF BAL fluid.  For instance, for chromatography, 100 µg 
GAG was incubated with 2 µg C5a (50:1).  In chapter 3, the greatest expression of C5a in CF 
BAL fluid was 807 pg/mL and, in this chapter lowest detectable GAG expression was 3.8 
µg/mL, a ratio of over 4700:1.  Therefore, any observed effects in vitro, are underestimates of 
a in vivo CF lung environment.  In order to make my experiments more physiologically 
representative of the CF airway I would need to either decrease the C5a concentration or 
increase GAG concentration.  The platforms used in this chapter would not be able to detect 
significantly lower concentrations of C5a. Furthermore, the GAGs used in these experiments 
are not soluble in aqueous solution at concentrations greater than 3 mg/ml and therefore, 
increasing GAG concentration in my experiments may not have been possible. 
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Despite previous reports of C5a-heparin interaction, observations made in this chapter more 
comprehensively characterise nC5a-GAG binding (Mollnes et al. 1991; Culley et al. 2003; 
Miyabe et al. 2017).  The hypotheses for this investigation were initially made following reports 
of an in-depth characterisation of CXCL8-GAG interaction and the functional implications, 
particularly for neutrophilic inflammation in the CF airway (Reeves et al. 2011a; Reeves et al. 
2011b).  Like C5a, CXCL8 is small and chemotactic for neutrophils and therefore, I 
hypothesised that similar modifications of CXCL8, through interaction with GAGs, may also 
apply to C5a. 
 
In comparison to C5a, it has been shown that CXCL8 eluted from a sepharose-heparin column 
at 510 mM NaCl (Webb et al. 1993). Therefore because higher concentrations of NaCl are 
required to disrupt these ionic interactions, CXCL8 has a higher affinity for this GAG than nC5a 
(488 to 680 mM NaCl (my data), 422 mM NaCl(Culley et al 2003.) .   Unlike nC5a, CXCL8 has 
also been observed to bind HA however, methods used in my study could not detect C5a-HA 
complexes and therefore, C5a affinity cannot be ruled out.  It should be noted that in the 
current study both the heparin column and solid phase platform can only test C5a binding of 
heparin or HS binding sites.  This is because, in both the competition assays performed using 
these platforms, GAGs competed for heparin/HS binding of C5a    However, biotinylation of 
CS or HA would enable analysis of possible alternative binding sites for these GAGs.  In 
explanation, it has been shown that that HA preferentially binds alternative sites on CXCL8 
compared to HS and heparin (Pichert et al. 2012a).  Therefore, HA might not compete against 
HS for binding as tested for C5a in the present study. 
 
An important consequence of CXCL8 interaction with GAGs is protection of this chemokine 
from degradation and inactivation by NSPs (Reeves et al. 2011a).  However, in my study nC5a 
incubated with HS was more susceptible to proteolysis by NE.  Myself and others have shown 
that C5a can be degraded by NE (Brozna et al. 1977; Huber-Lang et al. 2006).  I can only 
speculate on the mechanism that increases C5a proteolysis when in complex with HS.  A 
possible mechanism is that HS induces a conformational change in C5a tertiary structure 
further exposing the c-terminal signalling domain to degradation.  In support of my hypothesis, 
binding of heparin to anti-thrombin has been reported to induce conformation changes in 
constituent α-helices that increase activity (Pol-Fachin et al. 2011). 
 
Despite revealing increased susceptibility to degradation by NE, another important result was 
that nC5a in complex with HS was less susceptible to inactivation by porcine CPB; this is the 
first time it has been shown that GAGs may modify C5a activity.  As tested for NE, this 
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phenomenon did not appear to be due to modified activity of CPB by HS.  In blood, regulation 
of C5a, and other proteins, by CPN and CPB is a crucial mechanism for preventing over-
activation of neutrophils and other C5aR1 expressing cells (Matthews et al. 2004).  In chapter 
4, I measured CPN and CPB activity in the CF airway and therefore, interaction of C5a with 
soluble HS may prevent anaphylatoxin inactivation and promote neutrophilic inflammation.  
Furthermore, this mechanism may be important for maintaining the normal functional of C5a 
in inflammation.  C5a is a potent chemoattractant and critical for orchestrating the 
inflammatory response towards pathogens by upregulating opsonic receptors (Hunniger et al. 
2015). 
 
In this chapter I have built on evidence that C5a interacts with GAGs.  A potential weakness 
to this study is the source and heterogeneity of the GAGs used in the experiments.  All GAGs 
were sourced from Sigma however, this manufacturer does not disclose any information on 
the size or degree of sulphation of these GAGs. None the less, other published studies 
discussed in this chapter have also reported on GAG characterisation using GAGs sourced 
from Sigma (Culley et al. 2003).  Purity, size and sulphation have a strong influence on GAG 
binding to the target protein (Pichert et al. 2012a).  An off-shoot company from the University 
of Manchester, Iduron, specialises in producing pure GAGs with known levels of sulphation 
(http://iduron.co.uk/).  To characterise nC5a-GAG interaction further, de-sulphated HS and CS 
could be investigated.  It has been shown for CXCL8 that the level of sulphation alters GAG 
binding (Pichert et al. 2012a).   In light of data from chapter 4, it would also be interesting to 
investigate the differences in the affinity for GAGs between nC5a and the C5a-like fragments 
that are readily generated by NSPs.  In section 4.9.4; I reported for the first time that, C5a-like 
fragments generated by NE and PR3 are resistant to inactivation by porcine CPB. Therefore, 
are the functional differences between nC5a and the NSP-generated C5a-like fragments 
observed in this study further modified through interaction with GAGs? 
 
Binding of HS to other complement components was also investigated using the solid phase 
binding platform.  Interestingly, C5, C3 and, C3a all bound HS with greater affinity than nC5a.  
Despite coating plates with equivalent molar concentrations of complement components, the 
actual concentration of each component bound to the plastic was not determined.  Therefore, 
further investigation is required for a more conclusive comparison at equimolar concentrations.  
With similarities to C5a, Sinitsyn et al. also showed that C3a could be retarded on a heparin- 
based sorbent suggesting C3a-heparin interaction (Sinitsyn et al. 1992).  HA and HA subjected 
to heat treatment and freeze-thawing to alter conformation has also been reported to bind 
several complement components including C3 and C5 (Hong et al. 2007).  Interestingly, the 
authors give evidence that treating HA modifies how it binds and, that these chemically-altered 
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GAGs inhibit sheep erythrocyte haemolysis by binding C1 and C3.  The functional impact of 
HS on C3a, C3, and C5 was not investigated in the present study. 
 
 Conclusion to the chapter 
 
In summary, the ECM is degraded during neutrophilic inflammation of the CF airway liberating 
soluble GAGs that disrupt neutrophil function through interaction with chemokines.  To date, 
most interest in GAG-chemokine interaction has been placed on CXCL8, well-documented as 
a major contributor towards neutrophilic inflammation in the CF airway.  CXCL8-mediated 
neutrophilic inflammation has been reported to be accelerated through interaction with soluble 
GAGs.  I have shown that C5a also binds heparin and HS, with the latter interaction reducing 
inactivation by carboxypeptidases.     Modulation of C5a activity in this manner could contribute 
towards neutrophilic inflammation and has, until more recently, been overlooked.  C5a is a 
highly potent chemoattractant; moreover, it is crucial for orchestrating the inflammatory 
response by upregulating opsonic receptors and the release of pro-inflammatory factors.  In 
this chapter I have mainly focused on the pathogenic implications of C5a-GAG interactions; 
however, these experiments also show that these interactions may play a normal role in the 
function of C5a by maintaining activity in the presence of carboxypeptidases.    
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7. Final summary 
 
In this project I have used a cohort of CF patients to investigate the role of the complement 
anaphylatoxins in promoting chronic neutrophilic inflammation in the CF airway.  I found that 
C5a and C3a positively correlated with makers of neutrophilic inflammation in CF BAL fluid.  I 
used CF BAL fluid to explore the mechanisms by which C5a and C3a promote neutrophilic 
inflammation.  Serine proteases within BAL fluid were able to generate C5a-like and C3a-like 
fragments of similar molecular weight to convertase-generated C5a and C3a.  I characterised 
the generation of functionally active C5a-like and C3a-like fragments using purified NSPs.  I 
also assessed whether NSP-generated C5a and C3a could be inactivated by 
carboxypeptidases, a critical mechanism for regulating native C5a and C3a activity.  An 
important outcome of these experiments was that NE and PR3-generated C5a was resistant 
to activation. I suggest that this mechanism of generating alternatively functioning C5a-like 
fragments could contribute to neutrophilic inflammation and the CF airway and in other 
diseases that are characterised by chronic inflammation, such as COPD, rheumatoid arthritis 
and sepsis. 
 
I also investigated mechanisms by which C5a is influenced by the local lung environment in 
CF.  In particular, I explored the influence of GAGs interaction on C5a function.  I found that 
nC5a interacted with heparin and HS and that these interactions had two consequences for 
C5a activity.  The first is that when C5a was incubated with HS it was more susceptible to NE-
mediated proteolysis.  The second consequence of C5a interaction with HS was that C5a was 
more resistant to inactivation by CPB.  The interactions between C5a and GAGs may be 
important for the normal roles of C5a in inflammation such as; neutrophil recruitment, 
degranulation and the up regulation of opsonic receptors (Hunniger et al. 2015).  The 
abundance of soluble GAGs in the CF airway mean that these mechanisms by which GAGs 
modify C5a activity may also be a contributor towards chronic neutrophilic inflammation in CF.   
 
7.1. Limitations to the study 
 
In this study I used BAL fluid from CF patients to explore the mechanism by which C5a (and 
C3a) promote chronic neutrophilic inflammation.  As previously mentioned BAL fluid sampling 
is the gold standard for identifying pathogens during pulmonary exacerbation and during 
routine surveillance (Ronchetti et al. 2018).  Analysis of BAL fluid rather than sputum is also 
more advantageous when reporting on immunomodulatory factors (cytokines, lipids etc.)  
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within the airway due the way these samples are processed (McElvaney et al. 2018).  Despite 
this, there are limitations to using BAL fluid for studying pathogenic factors in CF.  For instance, 
BAL requires sedation and is invasive and therefore the ERS considers it unethical to perform 
BAL on healthy volunteers (Brennan et al. 2008). Consequently, because BAL cannot be 
performed on healthy volunteers other non-CF disease controls are sometimes used for 
healthy controls (Brennan et al. 2008).  These include asthma, ciliary dyskinesia, tonsillectomy 
surgery and non-CF bronchiectasis (Brennan et al. 2008).  In my study I did not have access 
to a control population however, in chapter 3 I stratified my patient cohort by reasons for 
performing BAL to separate well and unwell patients.  This was successful when comparing 
neutrophil count and levels of CXCL8. 
 
Another limitation to analysing BAL fluid is that it is from a single site, a ERS consensus 
recommends that the first sample site is the right middle lobe of the lungs (de Blic et al. 2000).  
An issue here could be that, if inflammation is localised in the airway then analytes from this 
single site may not correlate with disease scores (McNally et al. 2017).  The consensus for 
surveillance of pathogens in the CF airway using BAL is to sample from the right middle lobe 
followed by the left lower lobe or most infected lobe as identified by chest X-ray (Brennan et 
al. 2008).  A pool of these two sites is also analysed.  A recent report was the first to compare 
inflammation (CXCL8) in a single site with a pool of two sites (McNally et al. 2017).  McNally 
et al. report using a cohort of 32 CF patients showed that there was no statistical difference 
between a single site and a pooled sample.  In my study, three samples were collected: right 
middle lobe, left lower lobe and a pool of the two sites.  All analyses in my study were 
performed on the samples from the right middle lobe.  Measuring and comparing inflammation 
and complement in the other sites would have been interesting to investigate but there was 
not enough time to perform these experiments.  Although I have discussed BAL sampling from 
a single site as a limitation, I have also described it as an advantage over sputum sampling 
therefore, all factors should be considered when weighing up advantages and disadvantages 
of reporting on airway fluid samples. 
 
In this study I have used immortal cell lines such as U937 and RBL-2H3.  These were 
transfected with C3aR or C5aR1 to investigate functional activity of C3a-like and C5a-like 
fragments generated by NSPs.  These cell lines were informative about the activity of these 
fragments; however, I did not assess C5a and C3a-like fragments in primary neutrophils.  
Neutrophils are notoriously difficult to work with as they have a short life-span in vitro and they 
are sensitive to stimulation by non-specific factors.  Despite these difficulties it is still possible 
to work with primary neutrophils and our group has previously reported on C5a signaling in 
these cells (van den Berg et al. 2014).  In my study I investigated the molecular characteristics 
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of C5a (and C3a) and therefore it was more appropriate to use stably transfected cell lines, 
rather than primary cells.  As a compromise to working with blood neutrophils some groups 
use HL60 cells, a leukemia cell line that displays a neutrophil-like morphology. HL60 cells 
have been used to study the influence of heparin interaction with chemokines or C5a (Culley 
et al. 2003).  A disadvantage of using HL60 cell lines to study the normal function of neutrophils 
is that due to disruption of granulopoiesis they do not produce secondary granules and 
therefore, they do not truly reflect neutrophils (Gallagher et al. 1979).  A second cell line NB-
4 also has a neutrophil-like phenotype, and has similar disadvantages to HL60 as these also 
not possess secondary granules (Pass et al. 2007).  Therefore, HL60 and NB4 cell lines are 
acceptable for investigating neutrophil chemotaxis and ROS production but not suitable for 
studying neutrophil maturation (Pass et al. 2007). 
 
I have investigated the role of C5a (and C3a) in promoting neutrophilic inflammation in the CF 
airway. Despite intriguing results, experiments investigating C5a and C3a were performed in 
simple ex vivo or in vitro systems.  This does not invalidate my data, but the CF airway is a 
complex environment containing a plethora of self and pathogen-derived factors and 
therefore, we must be careful when translating findings from in vitro experiments.  None the 
less, models of CF are not straightforward, particularly as neutrophils are terminally 
differentiated cells with a short life-span.   A promyelocytic immortal cell line (PLB-985) that 
can be differentiated into neutrophil-like phenotypes with ΔF508Del cftr have been used to 
investigate defective phagosome function in neutrophils (Zhou et al. 2013b).  PLB-985, like 
HL-60 and NB-4, are immature in terms of granulopoiesis and do not fully reflect the 
morphology of mature neutrophils (Tucker et al. 1987). 
 
Animal models of the CF airway are also not straightforward.  Mice models with mutations in 
cftr, that reflect mutations characterised in humans, do not develop severe airway disease; 
this is because of physiological differences between mice and humans (Lavelle et al. 2016).  
At the tissue level, the murine upper airways are representative of humans; however, there 
are fewer mucus-producing goblet cells in the mouse lower airway meaning that they do not 
spontaneously develop lung obstruction when lacking the CFTR (Lavelle et al. 2016).  Porcine 
models of CF have been more successful in replicating human CF airway pathology (Lavelle 
et al. 2016).   Pigs with the ΔF508del cftr genotype had similar neutrophil influx and CXCL8 
levels observed in the human disease (Rogers et al. 2008).  Furthermore, the porcine airway 
had recurrent S. aureus infections, mimicking early microbiology in paediatric CF patients 
(Stoltz et al. 2010).  A disadvantage to porcine CF models is the majority of newborn piglets 
are born with obstructive meconium ileum, a blockage of the GI tract that requires surgical 
intervention, which increases the cost of maintaining this animal model (Lavelle et al. 2016).  
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A more suitable but unusual animal used to model CF airway disease is ferrets. Cftr -/- ferrets 
have a phenotype that is representative of CF in humans however, pathology in the GI tract is 
much more severe with 75% of developing meconium ileum (Lavelle et al. 2016).  In summary, 
modelling CF disease in cell lines and animals is difficult and reflects the importance of CFTR 
in homeostasis.  
 
7.2. What does my research mean for CF? 
 
The fact that we are still unable to control neutrophilic inflammation in the CF airway suggests 
that there are fundamental aspects of disease pathogenesis that we do not understand.  In 
this study, I investigated how C5a and mechanisms of C5a generation could promote 
neutrophilic inflammation.  One of the key papers behind this rationale was written by 
Mackerness et al. who identified that in CF sputum, C5a (as well as other factors) was an 
important neutrophil chemotactic factor (Mackerness et al. 2008).  The aim of this project was 
not to pursue C5a as a therapeutic target, but to improve understanding of another factor in 
the CF airway, beyond CXCL8, that contributes to neutrophilic inflammation.  I do not doubt 
that CXCL8 is a major contributor to neutrophilic inflammation in the airway; however, I do feel 
that other factors such as LTB4, fMLP and C5a are overlooked, given their potency and roles 
in neutrophil stimulation (Brink et al. 2003; Ye et al. 2009; Klos et al. 2013).  I do not think that 
C5a is any more or less pathogenic in the CF airway than CXCL8; however, C5a has many 
functions that are important for orchestrating inflammation and clearance of pathogens.  These 
include neutrophil priming and upregulation of opsonic receptors (Hunniger et al. 2015).  
Furthermore, CXCL8 and C5a have distinctive roles. For instance, CXCL8 may be more 
important for neutrophil recruitment to the airway lumen but C5a may be more critical for the 
over-activation of neutrophils by promoting degranulation and ROS production (Kim and 
Haynes 2012; Hunniger et al. 2015).  CF is not the only disease where C5a has been identified 
as a pathogenic factor.  Other airway diseases include COPD and asthma but C5a has also 
been identified as a pathogenic factor in sepsis. Consequently, C5a has been suggested to 
be an appropriate therapeutic target in these diseases (Khan et al. 2013; Huber-Lang et al. 
2014; Khan et al. 2014). 
 
Would C5a be an appropriate target in CF? Sass et al. used a C1 inhibitor as part of their 
study to investigate atypical generation of C5a in CF sputum (Sass et al. 2015).  From their 
data they suggest that C5a generation is predominantly through complement activation and 
not mediated by non-complement proteases.  Their single ex vivo study does not conclusively 
mean that non-canonical generation of C5a in the airway is not a significant mechanism for 
promoting pathogenesis.  Specifically targeting C5a in the CF airway could be achieved by 
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directly blocking C5a by antibody such as IFX-1 developed by inflaRx GmbH (Riedemann et 
al. 2017).  C5a function could also be abrogated by PMX53, a hexapeptide antagonist of 
C5aR1 (Tamamis et al. 2014).  As well as considering the methods of inhibiting C5a function, 
when to block C5a should be carefully thought out.  It has been reported that C5a has both 
protective and pathogenic roles in developing hyperallergenic asthma and therefore, the 
protective roles of C5a, as mediator of normal inflammation should be considered (Kohl et al. 
2006).  Particularly in light of BIIL284, a BLT1R antagonist that had serious adverse effects 
when administered in a CF trial (Konstan et al. 2014). In this case, BLT1R inhibition reduced 
neutrophil recruitment but increased susceptibility to infection by P. aeruginosa.   I think that 
blocking C5a (or C5aR1) would be more appropriate during pulmonary exacerbation; this is 
because C5a has been reported to spike during pulmonary exacerbation in CF patients (Hair 
et al. 2017).  If C5a is pathogenic during these episodes, then inhibition may prevent airway 
remodeling and irreversible loss of lung function.  I would also advocate further research into 
NSP-generated C5a and the effectiveness of the above C5a/C5aR1 inhibitors in reducing the 
activity of alternative C5a forms that I have investigated in this project. 
 
In chapter 5, I investigated the generation of C5a by NSPs in the presence of C5 cleavage 
inhibitors.  I reported that three pre-clinical therapeutics and eculizumab, a successful clinical 
complement inhibitor, were ineffective against NSP-mediated C5a generation.  As I discussed 
in chapter 5, given these data, I do not think these C5 cleavage inhibitors would be appropriate 
for use in CF and, I have concerns over their use in diseases characterised by neutrophilic 
inflammation.  This is because my research has shown that during neutrophilic inflammation 
the inhibitory function of these therapies can be bypassed by NSPs.  Therefore, they might 
only be effective against terminal complement activation and MAC formation but not the 
generation of C5a.  Furthermore, MAC mediated lysis is an important mechanism for the 
elimination of pathogens that you may not want to attenuate during pulmonary exacerbation 
(Savoia et al. 2008).   
 
In summary, I think that this research could continue to raise awareness of other important 
neutrophil stimulants in the CF airway as well as CXCL8.  C5a, is a multi-faceted pro-
inflammatory molecule as well as a potent neutrophil chemoattractant; furthermore, these 
functions are crucial for orchestrating a normal inflammatory response as well as contributing 
to pathogenesis in chronic conditions.  Further understanding is needed of how each of these 
C5a-mediated functions contributes to chronic neutrophil inflammation before therapeutic 
intervention is considered.   
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7.3. CF therapeutics – what is the future? 
 
For CF patients, the greatest gains in life expectancy over the last couple of decades have 
been through disease management and improvements in pathogen surveillance (Elborn 
2016).  An issue with testing many new CF therapeutics is that they may have long-term 
benefits that are not detected in short-term trials.  Furthermore, trials are often performed in 
older patients (Mayer-Hamblett et al. 2016).  Therapeutics that correct CFTR function would 
be more beneficial in paediatric patients, to prevent lung function decline in the earlier stages 
of the disease before chronic neutrophilic inflammation is established.  The issue with long 
term trials in paediatric cohorts is that given the short life expectancy of CF patients, it is 
unethical to have a placebo control group for such a long period.  The other ethical 
consideration is the desire to stop other medications so that the effect size of the therapeutic 
under trial can be accurately measured. 
 
Currently CF disease is managed by regular physiotherapy and inhalation of nebulized 
hypertonic saline as well as corticosteroids and administration of antibiotics upon contracting 
pulmonary infection (Elborn 2016).  There have been several different therapeutic approaches 
to preserve lung function and improve life expectancy in CF.  Two clinically approved 
therapeutics, Ivacaftor and Lumacaftor have been developed to increase CFTR activity 
(G551D cftr patients) and facilitate intracellular trafficking (Δ508Del cftr patients)(Wainwright 
et al. 2015).  A combined therapy using both drugs, Orkambi, has been shown to marginally 
reduce the decline in lung function in CF patients (Wainwright et al. 2015).  Despite modest 
improvements, these drugs are one of the most successful approaches to preserving lung 
function.  It is likely that the long-term benefits, not observed in short 2-year trials, will become 
more apparent in the next few years.  Furthermore, in paediatric CF patients these drugs will 
maintain healthy lung function prior to the decline in lung function that is observed as CF 
patients age.  Despite this potential, Orkambi is expensive (over £140,000/patient/year) and 
the National Health Service has restricted its availability, a controversial issue that has recently 
been reported in the national news https://www.bbc.co.uk/news/uk-wales-45215134).   
 
Gene therapy using liposomal delivery of wild type CFTR (rather than correcting gene 
mutation) to the airway epithelium has been trialed in CF patients and was found to modestly 
stabilise lung function (Alton et al. 2015).  More specifically, a double blind, placebo-controlled 
phase IIb trial was conducted with 140 patients over a 12-month period.  Absolute change in 
lung function over this period was 3.7% (0.1-7.3), greater than placebo control (Alton et al. 
2015).  Gene therapy has long been thought to be the “gold bullet” for CF; however, issues 
such as delivery vector (viral or liposomal in a complex environment) and epithelial turn-over 
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has slowed development of therapeutics correcting cftr mutation (Fajac and De Boeck 2017).  
None-the-less, other mechanisms of genetically correcting cftr mutation are being developed 
such as mRNA repair, whereby single-stranded anti-sense RNA is used to guide the repair of 
abnormal mRNA prior to translation (Zamecnik et al. 2004).   
 
The limited success of gene therapy and benefits of potentiators/activators does not mean 
that gene therapy will not be an important therapeutic in the future.  One of the first CF 
therapeutics was the supplementation of pancreatic enzymes that are deficient in CF patients 
due to blockage of bile ducts (Somaraju and Solis-Moya 2015).  Before this, most people with 
mutations in cftr did not live through childhood, before airway chronic inflammation became 
established (Somaraju and Solis-Moya 2015).  Only after intervention did airway inflammation 
become the predominant factor in mortality.  Therefore, if drugs like Orkambi restore airway 
function, CF patients will live longer but another aspect of the disease could manifest; for 
instance, CF-related diabetes, osteopenia and distal intestinal obstruction syndrome (Elborn 
2016).  Gene therapy could be a more appropriate therapeutic approach for correcting CF 
pathology not just in the airway.      
 
Neutrophilic inflammation of the airway is a major characteristic of CF pathology yet, 
therapeutic approaches to reduce inflammation have been largely unsuccessful. In some 
cases, anti-inflammatory drugs have been detrimental, particularly in the case of BIIL284, a 
BLT1R antagonist (Konstan et al. 2014).  Ibuprofen remains one of the only modestly effective 
anti-inflammatory drugs prescribed to CF patients (Konstan et al. 2007).  Targeting CXCL8-
mediated neutrophilic inflammation in the CF airway has also been approached.  As previously 
mentioned, a decoy CXCL8, PA401, has been developed that has no activity but has greater 
affinity for GAGs (McElvaney et al. 2015).  The mechanism of PA401 in reducing CXCL8 levels 
in the CF airway, is that PA401 competes with CXCL8 for GAG binding sites (McElvaney et 
al. 2015).  GAGs have been shown to protect CXCL8 from degradation by NSPs and therefore, 
preventing CXCL8-GAG interaction would leave CXCL8 susceptible to inactivation 
(McElvaney et al. 2015; Reeves et al. 2015).  PA401 is currently undergoing pre-clinical trials 
(McElvaney et al. 2015). 
 
7.4. Do we need to research the roles C5a (and C3a) in CF pathogenesis? 
 
Above I briefly discussed the different therapeutic approaches to restoring CFTR function in 
the CF airway.  Given that these therapeutics are being improved and the benefits of taking 
them are becoming more apparent, why do we need to investigate C5a (and C3a) in the CF 
airway?  Chronic neutrophilic inflammation is not unique to the CF airway and is a 
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characteristic of other airway diseases such as COPD and neutrophilic asthmas (Hoenderdos 
and Condliffe 2013; Lambrecht and Hammad 2015). Neutrophilic inflammation is also a 
pathogenic factor in sepsis and rheumatoid arthritis (Delano and Ward 2016; Sadik et al. 
2018).  Despite differences in the way these diseases manifest and progress, neutrophils and 
neutrophil dysfunction contribute to their pathogenesis.  Furthermore, complement and in 
particular the C5a-C5aR1 axis, has been reported to be significant in promoting neutrophilic 
inflammation in these diseases (Conway Morris et al. 2009; Marc et al. 2010; Khan et al. 2015; 
Miyabe et al. 2017).  Therefore, as well as investigating new mechanisms that promote 
neutrophilic inflammation in CF, this disease can be used as a case study of extreme 
neutrophilic inflammation.  This means that the mechanisms that I have investigated in this 
project could also be translated to other inflammatory diseases. 
 
The generation of C5a-like forms by non-complement proteases such as NSPs as a 
mechanism of promoting pathogenesis has previously been reported in pathologies including 
rheumatoid arthritis, COPD and asthma (Robbins et al. 1991; Giles et al. 2015; Verschoor et 
al. 2016).  Therefore, the NSP-generated C5a that I found to be resistant to inactivation by 
carboxypeptidases could also be an important for driving neutrophilic inflammation in these 
other diseases. 
 
7.5. The importance of Complement 
 
Complement contributes to a variety of different diseases: however, there are less than 
handful that are directly linked to complement dysregulation or deficiency.  Does this mean 
that complement is not an important aspect of our immune system?  Persons deficient in C3, 
a component central to complement activity, are susceptible to recurrent bacterial infections 
(Botto et al. 2009).  C5 deficient persons are also susceptible to meningococcal infection, 
further demonstrating a central role for complement in preventing infection (Arnaout et al. 
2013).  Despite these case studies, complement deficiencies are rare (1-5 cases per million), 
but they are more prevalent in communities where there is consanguineous marriage (Arnaout 
et al. 2013; Nanthapisal et al. 2018).   
 
Beyond immunity, complement has also been hypothesised to have roles in fertilization, 
embryogenesis and neural development (Hawksworth et al. 2018);  protecting sperm from 
elimination by complement, guiding stem cells into the appropriate areas and pruning 
redundant neurons (Hawksworth et al. 2018).  Do these critical roles in reproduction and 
development explain the rarity of complement deficiency?  Particularly with development, the 
discrepancy between the reported developmental functions of complement and what we 
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observed in the population are intriguing; however, these discrepancies may highlight that 
animal models do not completely reflect the human complement system (Hawksworth et al. 
2018). 
 
Complement is ancient, and pre-dates adaptive immunity.  Furthermore, complement C3 
genes have been discovered in primitive organisms such as ascidians (sea squirts) and sea 
anemones (Nonaka and Yoshizaki 2004; Hawksworth et al. 2018).  Injecting LPS into the 
pharynx of Ciona intestinalis (sea squirt), has demonstrated that C3 and its cleavage 
fragments are part of this organism’s immune defense (Giacomelli et al. 2012).  None the less, 
if complement was sufficient for immune protection in complex mammals then the adaptive 
immune system may not have evolved.  Interestingly, C3 deficient individuals are particularly 
vulnerable to bacterial infections during childhood, as adaptive immunity is developing its 
antigen repertoire (Botto et al. 2009).  Therefore, the complement system provides vital 
protection whilst the adaptive immune system matures. 
 
I have discussed the necessity of complement in immunity using examples of complete 
complement deficiency for justification.  In an era of GWAS (genome-wide association studies) 
to search for genetic evidence of an individual’s susceptibility to disease, mutations in 
complement genes have been identified as risk factors (Harris et al. 2012).  Examples of 
diseases where complement genes are risk factors are AMD, rheumatoid arthritis and aHUS 
(Harris et al. 2012).  Combining all the identified single nucleotide polymorphisms in C3, factor 
B and factor I in a Spanish population Harris et al. have developed a “complotype” (Harris et 
al. 2012). An individual’s complotype could indicate that they are more at risk from infection 
due to single nucleotide polymorphisms that reduce complement activity. Or, at the other end 
of the scale, a patient may be at risk of inflammation as a consequence of increased 
complement activity (Harris et al. 2012). 
 
Given the developmental and protective role of complement how important is it for immunity 
and pathogen clearance in the airway?  In asthma the C5a/C5aR1 axis has been reported to 
have both protective or pathogenic roles during sensitisation and hyperresponsiveness 
respectively (Laumonnier et al. 2017).  Polymorphisms in C3, C5 and C5aR1 genes have also 
been associated with different levels of risk for developing bronchial asthma (Hasegawa et al. 
2004). In particular, the authors found that a C4896T mutation in C3 was associated with 
developing bronchial asthma in adults. A C1632T polymorphism in C5 was found to be 
protective against developing asthma in adults. Despite identification of these polymorphisms, 
no mechanisms were explored in their study.  Complement is important for eliminating 
pathogens in the airway.  It has been demonstrated that airways infected with P. aeruginosa 
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and B. cepacia had high levels of pathogen-specific IgG; furthermore, antibacterial activity was 
complement mediated (Savoia et al. 2008). Therefore, complement in the airway is important 
for responding to allergens and pathogens. 
 
7.6.  Immune modulation by NSPs 
 
In section 1.4.7, I discussed the reported roles that NSPs have in immune modulation, such 
as proteolytic activation of PARs, pro-IL-1ß and CXCL8-77 (Joosten et al. 2009; Chakraborty 
et al. 2014; Mercer et al. 2014).  As part of this project, I have characterised the alternative 
generation of functionally different C5a (and C3a).  With the above diverse mechanisms in 
mind, are these functions coincidental or a result of intricate evolution between NSPs and the 
innate immune system? 
 
My first thought is that many of the reported mechanisms of immune modulation by NSPs are 
coincidental and, are a result of the broad specificity of NSPs.  A database of NSPs substrates 
(recombinant and native) can be viewed on the MEROPs website 
(https://merops.sanger.ac.uk/).  In response to the broad specificity of NSPs, our immune 
system has evolved to regulate the activity of these proteases through the production of serine 
protease inhibitors, such as; AAT, SLPI and elafin (Korkmaz et al. 2010).  These inhibitors 
prevent excessive tissue damage or remodeling as a result of neutrophilic inflammation 
(Korkmaz et al. 2010).  Therefore, NSP-mediated immunomodulation would need to occur in 
close proximity to neutrophils, where proteases activity is highest.  Immune modulation by 
NSPs may also be more prevalent is diseases where there is chronic neutrophilic inflammation 
that overwhelms their regulation, such as the CF airway (Hentschel et al. 2015).  Taking this 
all into account, do these NSP-mediated functions offer a great enough selective advantages 
to suggest that these mechanisms evolved? 
 
Another reason why I suggest these mechanisms are coincidental is that the canonical 
activation of these immune functions is mediated by serine proteases.  The normal reported 
activation mechanism of PAR-1 is through cleavage by thrombin  (Mercer et al. 2014), a serine 
protease.  Furthermore C5 convertase is a proteolytic complex of serine proteases C4bC2b 
(C3 convertase), that has cleavage site specificity modified by binding of C3b (Barnum and 
Schein 2018).  Although the serine protease family is large, it is not inconceivable that these 
proteases share site specificity.  In support of this statement, cleavage of identical C5a 
fragments to native C5a has be reported by thrombin and trypsin (Riedemann et al. 2017).  
Therefore, C5 convertase and thrombin share the same cleavage site on C5.  I have 
hypothesised that the cleavage of NE-generated C5a is not the same as C5 convertase 
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generated C5a. Furthermore Giles et al. speculated that the NE cleavage site is 10-amino 
acids downstream and therefore a similar sized C5a fragments produced (Giles et al. 2015). 
If serine proteases share some degree of site-specificity, then we might expect to see more 
cases of immunomodulation, where there is atypical activation of protease-activated immune 
functions by NSPs. Although, many NSP mediated immunomodulatory functions have been 
reported, there could be many more that have not been discovered.   
 
My approach to the question of whether NSP-mediated immune modulation is coincidence 
has been binary.  I think that it is more likely that some of these NSP-mediated functions have 
evolved and others are coincidence.  Furthermore, some of these mechanisms may only be 
applicable to cases where there is extreme neutrophilic inflammation (such as CF), and others 
may be “normal” roles for these proteases.  For instance, until the 1930s CF patients did not 
live to a reproductive age (Somaraju and Solis-Moya 2015); therefore, the selective pressure 
for NSP-mediated immune modulation in CF may not be very high.  In summary, it seems 
unlikely that the generation of C5a-like (and C3a-like) fragments by NSPs in the CF airway 
has been driven by evolution.  On the other hand, the pathogenic role that these mechanisms 
of C5a (and C3a) generation may not be a large enough negative selective pressure for them 
to be more tightly regulated.  
 
7.7. Conclusion to the chapter 
 
From my data I think that the generation of alternatively functioning C5a by NSPs could be an 
important mechanism for promoting neutrophilic inflammation in the CF airway.  Interactions 
between GAGs that modify the regulation of C5a could also be significant for the normal roles 
of C5a in inflammation and its pathogenic roles during chronic inflammation.  CF is an extreme 
case of neutrophilic inflammation that can be used to study the molecular characteristics of 
C5a (and C3a).  Further understanding of the pathogenic roles of complement anaphylatoxins 
in CF can be translated to other diseases characterised by neutrophilic inflammation. 
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7.8. Key findings from my study 
 
1. C5a and C3a positively correlate with markers of neutrophilic inflammation in CF BAL 
fluid. 
 
2. C5a-like and C3a-like fragments are generated by proteases present in CF BAL fluid. 
 
3. NE and PR3 generate functionally alternative C5a that is resistant to inactivation by 
CPB. 
 
4. Complement therapeutics that inhibit cleavage of C5 by C5 convertase are ineffective 
against NSP-mediated C5a generation.  
 
5. C5a binds heparin, HS and CS. C5a-HS interaction protects C5a from inactivation by 
CPB 
 
 
7.9. Future Work 
 
➢ Comprehensively characterise NSP-generated C5a-like and C3a-like fragments 
using mass spectrometry. 
 
➢ Develop a specific antibody to quantify generation of C5a-like and C3a-like fragments 
in CF BAL fluid (and other samples from diseases characterised by neutrophilic 
inflammation). 
 
➢ Investigate other proteases (as well as NSPs) that can generate C5a-like fragments 
in the presence of therapeutic C5 cleavage inhibitors. 
 
➢ Use purified GAG species and surface plasmon resonance to measure C5a affinity 
for different GAGs. 
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